Date,Articles
2007-01-12,"{""abstract"": ""Employment contracts have been blamed for virtually guaranteeing huge payouts even when an executive fails."", ""web_url"": ""https://www.nytimes.com/2007/01/12/business/12pay.html"", ""snippet"": ""Employment contracts have been blamed for virtually guaranteeing huge payouts even when an executive fails."", ""lead_paragraph"": ""The new heads of Exxon Mobil, PepsiCo and Pfizer don\u2019t have one. Nor do the chief executives at Citigroup, General Electric and Procter & Gamble. And some corporate governance experts say shareholders are better off as a result."", ""print_section"": ""C"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Hire by the Contract Now, Risk a Big Regret Later"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Hire by the Contract Now, Risk a Big Regret Later"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Hiring and Promotion"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Appointments and Executive Changes"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Nardelli, Robert L"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Home Depot Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Executives and Management"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Wages and Salaries"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2007-01-12T05:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Eric Dash"", ""person"": [{""firstname"": ""Eric"", ""middlename"": null, ""lastname"": ""Dash"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/909a4810-d719-5079-8bd8-6cf0023ea3be"", ""word_count"": 1563, ""uri"": ""nyt://article/909a4810-d719-5079-8bd8-6cf0023ea3be""}"
2007-01-22,"{""abstract"": ""The world\u2019s largest drugmaker is seeking to cut costs by up to $2 billion a year amid fierce competition."", ""web_url"": ""https://www.nytimes.com/2007/01/22/business/22cnd-pfizer.html"", ""snippet"": ""The world\u2019s largest drugmaker is seeking to cut costs by up to $2 billion a year amid fierce competition."", ""lead_paragraph"": ""The drug giant Pfizer said today that it would lay off 10,000 workers and close several manufacturing and research sites in an effort to bolster earnings hurt by the loss of patent protection on certain drugs and setbacks in developing new products. "", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2007/01/22/business/pfizerspan.jpg"", ""height"": 250, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2007/01/22/business/pfizerspan.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 250}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2007/01/22/business/pfizer75.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2007/01/22/business/pfizer75.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Pfizer to Lay Off 10,000 Workers"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer to Lay Off 10,000 Workers to Cut Costs"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Company Reports"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Layoffs and Job Reductions"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2007-01-22T05:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""ContinuousNews"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/1c7e6e5e-8115-52e6-af10-7f37bd534364"", ""word_count"": 836, ""uri"": ""nyt://article/1c7e6e5e-8115-52e6-af10-7f37bd534364""}"
2007-01-23,"[{""abstract"": ""Pfizer will reorganize its businesses and close several manufacturing and research sites, including a plant in Brooklyn, the borough where the drug company began."", ""web_url"": ""https://www.nytimes.com/2007/01/23/business/23pfizer.html"", ""snippet"": ""Pfizer will reorganize its businesses and close several manufacturing and research sites, including a plant in Brooklyn, the borough where the drug company began."", ""lead_paragraph"": ""Pfizer said yesterday that it would cut 7,800 workers, close several manufacturing and research sites and overhaul its business practices in hopes of coping with competition from cheaper generic drugs and setbacks in developing new products. "", ""print_section"": ""C"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2007/01/22/business/pfizerspan.jpg"", ""height"": 250, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2007/01/22/business/pfizerspan.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 250}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2007/01/22/business/pfizer75.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2007/01/22/business/pfizer75.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Pfizer, Hurt by Rival Drugs, Will Lay Off 7,800"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer, Hurt by Rival Generic Drugs, Will Lay Off 7,800"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Layoffs and Job Reductions"", ""rank"": 3, ""major"": ""N""}], ""pub_date"": ""2007-01-23T05:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/5be89693-65a5-5dd2-bec4-2033a87011f2"", ""word_count"": 999, ""uri"": ""nyt://article/5be89693-65a5-5dd2-bec4-2033a87011f2""}, {""abstract"": ""Pfizer is phasing out its manufacturing plant in Brooklyn, on the same Flushing Avenue site where the company was founded in 1849."", ""web_url"": ""https://www.nytimes.com/2007/01/23/business/23react.html"", ""snippet"": ""Pfizer is phasing out its manufacturing plant in Brooklyn, on the same Flushing Avenue site where the company was founded in 1849."", ""lead_paragraph"": ""Pfizer is closing the plant in the borough where it was born."", ""print_section"": ""C"", ""print_page"": ""6"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Shutting Doors Where a Drug-Making Giant Began"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Shutting Doors Where a Drug-Making Giant Began"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Brooklyn (NYC)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Layoffs and Job Reductions"", ""rank"": 3, ""major"": ""N""}], ""pub_date"": ""2007-01-23T05:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Ann Farmer and Nick Bunkley"", ""person"": [{""firstname"": ""Ann"", ""middlename"": null, ""lastname"": ""Farmer"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Nick"", ""middlename"": null, ""lastname"": ""Bunkley"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/6c66842b-9cfc-5d94-a70f-2b3c08ae00bc"", ""word_count"": 979, ""uri"": ""nyt://article/6c66842b-9cfc-5d94-a70f-2b3c08ae00bc""}]"
2007-01-27,"{""abstract"": ""That era when Pfizer was the king of the hill wasn\u2019t some distant age \u2014 it was just maybe three or four years ago. Oh, how the mighty have fallen!"", ""web_url"": ""https://www.nytimes.com/2007/01/27/business/27nocera.html"", ""snippet"": ""That era when Pfizer was the king of the hill wasn\u2019t some distant age \u2014 it was just maybe three or four years ago. Oh, how the mighty have fallen!"", ""lead_paragraph"": ""There was once a pharmaceutical company that could do no wrong. It had the best-selling drug in the world. It saturated the airwaves with its ads, and swarmed doctors\u2019 offices with its army of good-looking sales representatives. It had mastered the art of turning drugs into blockbusters. It made many billions in profits. Wall Street analysts loved it."", ""print_section"": ""C"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2007/01/27/business/75_pfizer.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2007/01/27/business/75_pfizer.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""The Dangers of Swinging for the Fences"", ""kicker"": ""Talking Business"", ""content_kicker"": null, ""print_headline"": ""The Dangers Of Swinging For the Fences"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}], ""pub_date"": ""2007-01-27T05:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Joe Nocera"", ""person"": [{""firstname"": ""Joe"", ""middlename"": null, ""lastname"": ""Nocera"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/3944bfb1-42b1-5ab7-8cdb-bd377f8dce6d"", ""word_count"": 1684, ""uri"": ""nyt://article/3944bfb1-42b1-5ab7-8cdb-bd377f8dce6d""}"
2007-02-02,"{""abstract"": ""Pfizer is acquiring a small Pennsylvania start-up developing experimental treatments for Type 2 diabetes. Pfizer said yesterday that it would buy BioRexis Pharmaceutical, which has 50 employees and two key drug compounds in early testing, for an undisclosed amount."", ""web_url"": ""https://dealbook.nytimes.com/2007/02/02/pfizer-buys-experimental-drug-start-up/"", ""snippet"": """", ""lead_paragraph"": ""Pfizer is acquiring a small Pennsylvania start-up developing experimental treatments for Type 2 diabetes. Pfizer said yesterday that it would buy BioRexis Pharmaceutical, which has 50 employees and two key drug compounds in early testing, for an undisclosed amount."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer Buys Experimental Drug Start-Up"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2007-02-02T12:27:22+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/4a287a12-ea7b-554f-9268-4d3d9e2a3c82"", ""word_count"": 45, ""uri"": ""nyt://article/4a287a12-ea7b-554f-9268-4d3d9e2a3c82""}"
2007-03-21,"{""abstract"": ""Pfizer, the drug maker, won a court ruling yesterday blocking a rival company, Teva Pharmaceutical Industries, from marketing a generic version of the painkiller Celebrex, the world\u2019s top-selling arthritis drug, until 2015."", ""web_url"": ""https://www.nytimes.com/2007/03/21/business/21generic.html"", ""snippet"": ""Pfizer, the drug maker, won a court ruling yesterday blocking a rival company, Teva Pharmaceutical Industries, from marketing a generic version of the painkiller Celebrex, the world\u2019s top-selling arthritis drug, until 2015."", ""lead_paragraph"": ""Pfizer, the drug maker, won a court ruling yesterday blocking a rival company, Teva Pharmaceutical Industries, from marketing a generic version of the painkiller Celebrex, the world\u2019s top-selling arthritis drug, until 2015."", ""print_section"": ""C"", ""print_page"": ""5"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer Painkiller\u2019s Patent Upheld"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer Painkiller\u2019s Patent Upheld"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}], ""pub_date"": ""2007-03-21T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Bloomberg News"", ""person"": [{""firstname"": ""Bloomberg"", ""middlename"": null, ""lastname"": ""News"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/64478e15-f59f-51cf-8569-19706e8252a7"", ""word_count"": 289, ""uri"": ""nyt://article/64478e15-f59f-51cf-8569-19706e8252a7""}"
2007-04-10,"[{""abstract"": ""Wall Street analysts are cutting their sales estimates for Exubera, which has been dogged by questions about its safety, cost and convenience."", ""web_url"": ""https://www.nytimes.com/2007/04/10/business/10drug.html"", ""snippet"": ""Wall Street analysts are cutting their sales estimates for Exubera, which has been dogged by questions about its safety, cost and convenience."", ""lead_paragraph"": ""Exubera, the first and so far only commercially available inhaled-insulin diabetes treatment, is on the verge of turning into an expensive failure for its maker, Pfizer. "", ""print_section"": ""C"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2007/04/10/business/10drug.75.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2007/04/10/business/10drug.75.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Pfizer Drug for Diabetes Is Lagging"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer Drug For Diabetes Is Lagging"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Exubera (Drug)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Sales"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Diabetes"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2007-04-10T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Alex Berenson"", ""person"": [{""firstname"": ""Alex"", ""middlename"": null, ""lastname"": ""Berenson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/251419c4-dce1-5b69-b68f-260005513c63"", ""word_count"": 1063, ""uri"": ""nyt://article/251419c4-dce1-5b69-b68f-260005513c63""}, {""abstract"": ""A consumer group has asked the F.D.A. to ban the long and unconventional ad, saying it gives a false impression."", ""web_url"": ""https://www.nytimes.com/2007/04/10/business/media/10celebrex.web.html"", ""snippet"": ""A consumer group has asked the F.D.A. to ban the long and unconventional ad, saying it gives a false impression."", ""lead_paragraph"": ""A new television advertisement for Pfizer\u2019s painkiller Celebrex that has attracted attention for both its length and innovative marketing approach is now also the target of criticism for its message."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Celebrex Commercial Draws Criticism"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""</hl1> <hl2 class="", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Celebrex (Drug)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""ADVERTISING AND MARKETING"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2007-04-10T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""Media"", ""byline"": {""original"": ""By Stephanie Saul"", ""person"": [{""firstname"": ""Stephanie"", ""middlename"": null, ""lastname"": ""Saul"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/fb7510d6-dfa5-505a-ad6e-c827d76cf9d7"", ""word_count"": 828, ""uri"": ""nyt://article/fb7510d6-dfa5-505a-ad6e-c827d76cf9d7""}]"
2007-04-30,"{""abstract"": ""Pfizer has always straddled a line marketing Viagra, insisting that the drug treats a serious medical condition while promoting it with wink-and-a-nod ads."", ""web_url"": ""https://www.nytimes.com/2007/04/30/business/media/30viagra.html"", ""snippet"": ""Pfizer has always straddled a line marketing Viagra, insisting that the drug treats a serious medical condition while promoting it with wink-and-a-nod ads."", ""lead_paragraph"": ""How much sexual innuendo can an advertiser pack into 15 seconds?"", ""print_section"": ""C"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2007/04/30/business/30viagra.75.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2007/04/30/business/30viagra.75.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Minky Viagra? Pfizer Doesn\u2019t Want You to Understand It, Just Buy It"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Minky Viagra? Pfizer Doesn\u2019t Want You to Understand It, Just Buy It"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Viagra (Drug)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""ADVERTISING AND MARKETING"", ""rank"": 3, ""major"": ""N""}], ""pub_date"": ""2007-04-30T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""Media"", ""byline"": {""original"": ""By Alex Berenson"", ""person"": [{""firstname"": ""Alex"", ""middlename"": null, ""lastname"": ""Berenson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/32b4f49a-f6df-5ba3-9768-a96c7b8cc6f6"", ""word_count"": 352, ""uri"": ""nyt://article/32b4f49a-f6df-5ba3-9768-a96c7b8cc6f6""}"
2007-05-21,"{""abstract"": ""John L. LaMattina said he was leaving the company, five months after Pfizer was forced to cancel development of its highest-profile drug candidate."", ""web_url"": ""https://www.nytimes.com/2007/05/21/business/21pfizer.html"", ""snippet"": ""John L. LaMattina said he was leaving the company, five months after Pfizer was forced to cancel development of its highest-profile drug candidate."", ""lead_paragraph"": ""Pfizer\u2019s head of research, John L. LaMattina, said yesterday that he was leaving the company, five months after Pfizer was abruptly forced to cancel development of torcetrapib, a heart medicine that was its highest-profile drug candidate."", ""print_section"": ""C"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer\u2019s Head of Research Is Departing"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer\u2019s Head Of Research Is Departing"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Executives and Management"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2007-05-21T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Alex Berenson"", ""person"": [{""firstname"": ""Alex"", ""middlename"": null, ""lastname"": ""Berenson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/17d2e194-da98-56ee-a162-ec40115de18e"", ""word_count"": 392, ""uri"": ""nyt://article/17d2e194-da98-56ee-a162-ec40115de18e""}"
2007-07-06,"{""abstract"": ""Pfizer settled a lawsuit against a rival drug maker, Novartis, for alleged infringement of a United States patent for the antibiotic medicine Zithromax. Pfizer sued Novartis and Sandoz, a unit operating in the United States, in February 2006 in federal court in Wilmington, Del., saying it would be irreparably harmed by the rival companies\u2019 use of the invention for forms of crystal azithromycin; Pfizer sought unspecified damages. The parties have agreed to settle all claims over the 2005 drug patent, and the suit was dismissed June 25, according to court papers. Pfizer is based in New York, and Novartis is based in Basel, Switzerland."", ""web_url"": ""https://www.nytimes.com/2007/07/06/business/worldbusiness/06fobriefs-DRUGSUITSETT_BRF.html"", ""snippet"": ""Pfizer settled a lawsuit against a rival drug maker, Novartis, for alleged infringement of a United States patent for the antibiotic medicine Zithromax. Pfizer sued Novartis and Sandoz, a unit operating in the United States, in February 2006 in fe..."", ""lead_paragraph"": ""Pfizer settled a lawsuit against a rival drug maker, Novartis, for alleged infringement of a United States patent for the antibiotic medicine Zithromax. Pfizer sued Novartis and Sandoz, a unit operating in the United States, in February 2006 in federal court in Wilmington, Del., saying it would be irreparably harmed by the rival companies\u2019 use of the invention for forms of crystal azithromycin; Pfizer sought unspecified damages. The parties have agreed to settle all claims over the 2005 drug patent, and the suit was dismissed June 25, according to court papers. Pfizer is based in New York, and Novartis is based in Basel, Switzerland."", ""print_section"": ""C"", ""print_page"": ""6"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Switzerland: Drug Suit Settled"", ""kicker"": ""World Business Briefing"", ""content_kicker"": null, ""print_headline"": ""Switzerland: Drug Suit Settled"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""NOVARTIS"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Switzerland"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Suits and Litigation"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2007-07-06T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""World Business"", ""byline"": {""original"": ""By Bloomberg News"", ""person"": [{""firstname"": ""Bloomberg"", ""middlename"": null, ""lastname"": ""News"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""Brief"", ""_id"": ""nyt://article/1b816873-7671-5534-8939-b62d4786ce5f"", ""word_count"": 108, ""uri"": ""nyt://article/1b816873-7671-5534-8939-b62d4786ce5f""}"
2007-07-14,"{""abstract"": ""Drug makers are exploring the possibility of tying pharmaceutical prices to performance."", ""web_url"": ""https://www.nytimes.com/2007/07/14/business/14drugprice.html"", ""snippet"": ""Drug makers are exploring the possibility of tying pharmaceutical prices to performance."", ""lead_paragraph"": ""Drug companies like to say that their most expensive products are fully worth their breathtaking prices. Now one company is putting its money where its mouth is \u2014 by offering a money-back guarantee."", ""print_section"": ""C"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2007/07/13/business/14drugprice-600.jpg"", ""height"": 312, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2007/07/13/business/14drugprice-600.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 312}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2007/07/13/business/14drugprices-75a.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2007/07/13/business/14drugprices-75a.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Pricing Pills by the Results"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pricing Pills by the Results"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Biogen Idec Incorporated"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""United Healthcare Insurance Co"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""United States"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Johnson & Johnson Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""GLAXOSMITHKLINE"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicare"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Millennium Pharmaceuticals Incorporated"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Genomic Health Incorporated"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Dana-Farber Cancer Institute"", ""rank"": 11, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Cigna Corp"", ""rank"": 12, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Genentech Inc"", ""rank"": 13, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Great Britain"", ""rank"": 14, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Prices (Fares, Fees and Rates)"", ""rank"": 15, ""major"": ""N""}], ""pub_date"": ""2007-07-14T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/f1e1c445-4163-527c-a39a-2c7a0b83f481"", ""word_count"": 1621, ""uri"": ""nyt://article/f1e1c445-4163-527c-a39a-2c7a0b83f481""}"
2007-07-16,"{""abstract"": ""COMPANY REPORTS Earnings season gets into full swing, particularly for technology, financial and drug companies. Reports will come from Charles Schwab and Mattel (Monday); Coca-Cola, I.B.M., Intel, Johnson & Johnson, Merrill Lynch, Novartis, Wells Fargo and Yahoo (Tuesday); Abbott Laboratories, Altria, AMR, Delta Air Lines, eBay, JPMorgan Chase, Pfizer, Southwest Airlines and United Technologies (Wednesday); Advanced Micro Devices, Bank of America, Bank of New York Mellon, Continental Airlines, Dow Jones, First Data, Google, Honeywell, Microsoft, Motorola and Wyeth (Thursday); and Boston Scientific, Caterpillar and Citigroup (Friday)."", ""web_url"": ""https://www.nytimes.com/2007/07/16/business/16ahead.html"", ""snippet"": ""COMPANY REPORTS Earnings season gets into full swing, particularly for technology, financial and drug companies. Reports will come from Charles Schwab and Mattel (Monday); Coca-Cola, I.B.M., Intel, Johnson & Johnson, Merrill Lynch, Novartis, Wells..."", ""lead_paragraph"": ""COMPANY REPORTS Earnings season gets into full swing, particularly for technology, financial and drug companies. Reports will come from Charles Schwab and Mattel (Monday); Coca-Cola, I.B.M., Intel, Johnson & Johnson, Merrill Lynch, Novartis, Wells Fargo and Yahoo (Tuesday); Abbott Laboratories, Altria, AMR, Delta Air Lines, eBay, JPMorgan Chase, Pfizer, Southwest Airlines and United Technologies (Wednesday); Advanced Micro Devices, Bank of America, Bank of New York Mellon, Continental Airlines, Dow Jones, First Data, Google, Honeywell, Microsoft, Motorola and Wyeth (Thursday); and Boston Scientific, Caterpillar and Citigroup (Friday)."", ""print_section"": ""C"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Looking Ahead"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Looking Ahead"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""International Business Machines Corp"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""United States Politics and Government"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Intel Corp"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""AIRLINES AND AIRPLANES"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Computers and the Internet"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2007-07-16T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": """", ""person"": [], ""organization"": null}, ""type_of_material"": ""Schedule"", ""_id"": ""nyt://article/0c6441f0-3edd-5f25-a4c5-05cc77f53064"", ""word_count"": 287, ""uri"": ""nyt://article/0c6441f0-3edd-5f25-a4c5-05cc77f53064""}"
2007-10-05,"{""abstract"": ""The hirings are aimed at rejuvenating the drug maker\u2019s lagging research operations."", ""web_url"": ""https://www.nytimes.com/2007/10/05/business/05pfizer.html"", ""snippet"": ""The hirings are aimed at rejuvenating the drug maker\u2019s lagging research operations."", ""lead_paragraph"": ""Pfizer, the world\u2019s largest drug maker, said yesterday that it had hired two senior scientists and promoted a third to rejuvenate its lagging research operations."", ""print_section"": ""C"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer Hires 2 Top Scientists to Expand Drug Pipeline"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer Hires 2 Top Scientists to Expand Drug Pipeline"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Appointments and Executive Changes"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Kindler, Jeffrey B"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2007-10-05T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Alex Berenson"", ""person"": [{""firstname"": ""Alex"", ""middlename"": null, ""lastname"": ""Berenson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/dee511ba-22b9-5053-a9b9-6f4464807d07"", ""word_count"": 686, ""uri"": ""nyt://article/dee511ba-22b9-5053-a9b9-6f4464807d07""}"
2007-10-13,"{""abstract"": ""Pfizer\u2019s most recent compensation report, the basis for an attempt to revamp the format of such reports, is now under S.E.C. review for inadequate disclosure."", ""web_url"": ""https://www.nytimes.com/2007/10/13/business/13proxy.html"", ""snippet"": ""Pfizer\u2019s most recent compensation report, the basis for an attempt to revamp the format of such reports, is now under S.E.C. review for inadequate disclosure."", ""lead_paragraph"": ""Regulators and investors have complained for years that corporate compensation reports are too long, too dense, too jargony and too opaque. "", ""print_section"": ""C"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2007/10/13/business/13proxy.75.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2007/10/13/business/13proxy.75.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Pfizer\u2019s Attempt at Financial Clarity Gets Blurred"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer\u2019s Attempt at Financial Clarity Gets Blurred"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Securities and Exchange Commission"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Executives and Management"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Wages and Salaries"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Design"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2007-10-13T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Eric Dash"", ""person"": [{""firstname"": ""Eric"", ""middlename"": null, ""lastname"": ""Dash"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/ecbcf496-bd83-5419-9757-8a6834d59a41"", ""word_count"": 926, ""uri"": ""nyt://article/ecbcf496-bd83-5419-9757-8a6834d59a41""}"
2007-10-18,"{""abstract"": ""Pfizer will take a charge of $2.8 billion for costs associated with Exubera, making it one of the most expensive flops in the history of the pharmaceutical industry."", ""web_url"": ""https://www.nytimes.com/2007/10/18/business/18cnd-exubera.html"", ""snippet"": ""Pfizer will take a charge of $2.8 billion for costs associated with Exubera, making it one of the most expensive flops in the history of the pharmaceutical industry."", ""lead_paragraph"": ""Pfizer said today that it would stop selling Exubera, its inhaled insulin, less than two years after introducing the drug. Despite Pfizer\u2019s heavy promotion, Exubera\u2019s sales had been miniscule, with prescriptions amounting to less than 1 percent of the insulin market. "", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Weak Sales Prompt Pfizer to Cancel Diabetes Drug"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Exubera (Drug)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Insulin"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2007-10-18T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Alex Berenson"", ""person"": [{""firstname"": ""Alex"", ""middlename"": null, ""lastname"": ""Berenson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/7e908ab2-a313-55f2-9383-85d41b0254e2"", ""word_count"": 984, ""uri"": ""nyt://article/7e908ab2-a313-55f2-9383-85d41b0254e2""}"
2007-10-19,"{""abstract"": ""The discontinuation of Exubera, an inhaled insulin, is another black eye for Pfizer, the world\u2019s biggest drug company, which has recently sustained a series of reversals."", ""web_url"": ""https://www.nytimes.com/2007/10/19/business/19pfizer.html"", ""snippet"": ""The discontinuation of Exubera, an inhaled insulin, is another black eye for Pfizer, the world\u2019s biggest drug company, which has recently sustained a series of reversals."", ""lead_paragraph"": ""Pfizer said yesterday that it would stop selling Exubera, its inhaled insulin, less than two years after introducing the drug. Despite Pfizer\u2019s heavy promotion, Exubera\u2019s sales were minuscule, with prescriptions amounting to less than 1 percent of the insulin market. "", ""print_section"": ""C"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2007/10/19/business/19pfizer.751.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2007/10/19/business/19pfizer.751.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Weak Sales Prompt Pfizer to Cancel Diabetes Drug"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer to Stop Selling Diabetes Drug"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Exubera (Drug)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Insulin"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Diabetes"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2007-10-19T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Alex Berenson"", ""person"": [{""firstname"": ""Alex"", ""middlename"": null, ""lastname"": ""Berenson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/8b468b7f-3c55-5b73-8978-806e3cf62521"", ""word_count"": 958, ""uri"": ""nyt://article/8b468b7f-3c55-5b73-8978-806e3cf62521""}"
2007-11-03,"{""abstract"": ""Many patients on the cholesterol drug are switching to a cheaper alternative, but Pfizer is not letting its flagship product go down without a fight."", ""web_url"": ""https://www.nytimes.com/2007/11/03/business/03generic.html"", ""snippet"": ""Many patients on the cholesterol drug are switching to a cheaper alternative, but Pfizer is not letting its flagship product go down without a fight."", ""lead_paragraph"": ""It is shaping up to be the biggest shift yet to a generic drug, potentially saving the nation $2 billion a year or more in prescription costs. "", ""print_section"": ""A"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Maker of Lipitor Digs in to Fight Generic Rival"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Lipitor Maker Digs In to Fight Generic Rival"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Statins (Cholesterol-Lowering Drugs)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""ADVERTISING AND MARKETING"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cholesterol"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Health Insurance and Managed Care"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Generic and Brand Name Products"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2007-11-03T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Stephanie Saul and Alex Berenson"", ""person"": [{""firstname"": ""Stephanie"", ""middlename"": null, ""lastname"": ""Saul"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Alex"", ""middlename"": null, ""lastname"": ""Berenson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/8bfa5295-d6cd-525e-9ce8-4733665c60fe"", ""word_count"": 1461, ""uri"": ""nyt://article/8bfa5295-d6cd-525e-9ce8-4733665c60fe""}"
2007-11-05,"{""abstract"": ""Drugs to raise so-called good cholesterol may still have a future despite the failure last year of an experimental treatment from Pfizer, researchers said."", ""web_url"": ""https://www.nytimes.com/2007/11/05/business/05cnd-drug.html"", ""snippet"": ""Drugs to raise so-called good cholesterol may still have a future despite the failure last year of an experimental treatment from Pfizer, researchers said."", ""lead_paragraph"": ""ORLANDO, Fla., Nov. 5 \u2014 Drugs to raise so-called good cholesterol may still have a future despite the widely publicized failure last year of an experimental cholesterol treatment from Pfizer, researchers said at a heart conference here."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Hunt for Cholesterol Drug Is Not Over"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cholesterol"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AMERICAN HEART ASSN"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2007-11-05T05:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Alex Berenson"", ""person"": [{""firstname"": ""Alex"", ""middlename"": null, ""lastname"": ""Berenson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/d7a178a4-2087-554c-ad48-15db9ed52f24"", ""word_count"": 873, ""uri"": ""nyt://article/d7a178a4-2087-554c-ad48-15db9ed52f24""}"
2007-11-16,"[{""abstract"": ""Alfred E. Mann is betting nearly $1 billion of his own money that he can succeed where Pfizer failed."", ""web_url"": ""https://www.nytimes.com/2007/11/16/business/16mannkind.html"", ""snippet"": ""Alfred E. Mann is betting nearly $1 billion of his own money that he can succeed where Pfizer failed."", ""lead_paragraph"": ""LOS ANGELES, Nov. 15 \u2014 Pfizer, the world\u2019s biggest drug company, flopped miserably with a seemingly can\u2019t-miss idea. But Alfred E. Mann is so certain he can succeed that he is betting nearly $1 billion of his own money on the effort. "", ""print_section"": ""C"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2007/11/16/business/16mannkind.75.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2007/11/16/business/16mannkind.75.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Betting an Estate on Inhaled Insulin"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Betting an Estate on Inhaled Insulin"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""MannKind Corporation"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Diabetes"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Mann, Alfred E"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Insulin"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2007-11-16T05:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/176ad46d-b6f1-538b-92b5-fad83fca9bf7"", ""word_count"": 1628, ""uri"": ""nyt://article/176ad46d-b6f1-538b-92b5-fad83fca9bf7""}, {""abstract"": ""Pfizer, the world\u2019s biggest drug company, flopped miserably with a seemingly can\u2019t-miss idea. But Alfred E. Mann is so certain he can succeed that he is betting nearly $1 billion of his own money on the effort."", ""web_url"": ""https://dealbook.nytimes.com/2007/11/16/betting-an-estate-on-inhaled-insulin/"", ""snippet"": """", ""lead_paragraph"": ""Pfizer, the world\u2019s biggest drug company, flopped miserably with a seemingly can\u2019t-miss idea. But Alfred E. Mann is so certain he can succeed that he is betting nearly $1 billion of his own money on the effort."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Betting an Estate on Inhaled Insulin"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2007-11-16T12:22:35+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/1bdf04c1-9c9d-550b-9b6e-e3c1b0791a51"", ""word_count"": 413, ""uri"": ""nyt://article/1bdf04c1-9c9d-550b-9b6e-e3c1b0791a51""}]"
2007-12-27,"[{""abstract"": ""Pfizer said it would fight a Nigerian court order that could jail three employees."", ""web_url"": ""https://www.nytimes.com/2007/12/27/business/worldbusiness/27fobriefs-PFIZERFIGHTS_BRF.html"", ""snippet"": ""Pfizer said it would fight a Nigerian court order that could jail three employees."", ""lead_paragraph"": ""Pfizer said it would fight a Nigerian court order that could jail three employees who had failed to appear at a trial over whether the company had improperly tested an experimental drug on Nigerian children. The employees did not receive summonses to appear at last month\u2019s trial, Pfizer said. The state of Kano is demanding $2.75 billion from Pfizer, which it says used an untested meningitis drug in a 1996 outbreak. Pfizer has said its use of the drug obeyed government rules and saved lives."", ""print_section"": ""C"", ""print_page"": ""5"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""WORLD BUSINESS BRIEFING: Nigeria: Pfizer Fights Jailings"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""WORLD BUSINESS BRIEFING: Nigeria: Pfizer Fights Jailings"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Nigeria"", ""rank"": 3, ""major"": ""N""}], ""pub_date"": ""2007-12-27T05:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""World Business"", ""byline"": {""original"": ""By Bloomberg News"", ""person"": [{""firstname"": ""Bloomberg"", ""middlename"": null, ""lastname"": ""News"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""Brief"", ""_id"": ""nyt://article/2a4878e8-c9f8-5da9-b015-6ba64479e5ba"", ""word_count"": 85, ""uri"": ""nyt://article/2a4878e8-c9f8-5da9-b015-6ba64479e5ba""}, {""abstract"": ""AMERICAS."", ""web_url"": ""https://www.nytimes.com/2007/12/27/business/worldbusiness/27fobriefs.html"", ""snippet"": ""AMERICAS."", ""lead_paragraph"": ""AMERICAS"", ""print_section"": ""C"", ""print_page"": ""5"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""World Business Briefs"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""International Business Machines Corp"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Company Reports"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Semiconductor Manufacturing International Corporation"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Wireless Communications"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""International Trade and World Market"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AIRBUS INDUSTRIE"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 8, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 9, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Mexico"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""BAE Systems PLC"", ""rank"": 11, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Computer Chips"", ""rank"": 12, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Japan"", ""rank"": 13, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Canal Plus"", ""rank"": 14, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""AIRLINES AND AIRPLANES"", ""rank"": 15, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Boeing Co"", ""rank"": 16, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Computers and the Internet"", ""rank"": 17, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""China"", ""rank"": 18, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""France"", ""rank"": 19, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Nigeria"", ""rank"": 20, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Kazakhstan"", ""rank"": 21, ""major"": ""N""}], ""pub_date"": ""2007-12-27T05:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""World Business"", ""byline"": {""original"": ""By Bloomberg News"", ""person"": [{""firstname"": ""Bloomberg"", ""middlename"": null, ""lastname"": ""News"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""Brief"", ""_id"": ""nyt://article/875ea4ad-da4f-51db-98a9-5a79f611e041"", ""word_count"": 462, ""uri"": ""nyt://article/875ea4ad-da4f-51db-98a9-5a79f611e041""}]"
2008-01-17,"{""abstract"": ""European regulators raided some of the Continent\u2019s biggest drug makers in an inquiry over whether patent disputes and lawsuits are keeping generic products off the market."", ""web_url"": ""https://www.nytimes.com/2008/01/17/business/worldbusiness/17compete.html"", ""snippet"": ""European regulators raided some of the Continent\u2019s biggest drug makers in an inquiry over whether patent disputes and lawsuits are keeping generic products off the market."", ""lead_paragraph"": ""Antitrust regulators on Wednesday raided big European drug makers as part of an investigation into whether patents and lawsuit settlements are being manipulated to keep generic products off the market."", ""print_section"": ""C"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""European Antitrust Regulators Raid Large Drug Makers"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""European Antitrust Regulators Raid Large Drug Makers"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Teva Pharmaceutical Industries Limited"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""ANTITRUST ACTIONS AND LAWS"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Wyeth"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""European Union"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ASTRAZENECA"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""European Commission"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Sanofi-Aventis"", ""rank"": 9, ""major"": ""N""}], ""pub_date"": ""2008-01-17T05:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""World Business"", ""byline"": {""original"": ""By Stephen Castle and James Kanter"", ""person"": [{""firstname"": ""Stephen"", ""middlename"": null, ""lastname"": ""Castle"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""James"", ""middlename"": null, ""lastname"": ""Kanter"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/5ae300ef-d857-5435-8378-18ff179eccf0"", ""word_count"": 565, ""uri"": ""nyt://article/5ae300ef-d857-5435-8378-18ff179eccf0""}"
2008-02-07,"{""abstract"": ""Dr. Robert Jarvik\u2019s appearance in television ads for Lipitor has helped rekindle a smoldering debate."", ""web_url"": ""https://www.nytimes.com/2008/02/07/business/media/07jarvik.html"", ""snippet"": ""Dr. Robert Jarvik\u2019s appearance in television ads for Lipitor has helped rekindle a smoldering debate."", ""lead_paragraph"": ""Dr. Robert Jarvik is best known for the artificial heart he pioneered more than a quarter-century ago. Since then he had toiled in relative obscurity \u0097 until he began appearing in television ads two years ago for the Pfizer cholesterol drug Lipitor."", ""print_section"": ""A"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2008/02/07/business/07jarvik.75.1.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2008/02/07/business/07jarvik.75.1.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Drug Ads Raise Questions for Heart Pioneer"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""For Jarvik Heart Pioneer, Drug Ads Raise Profile and Questions"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Lipitor (Drug)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""ADVERTISING AND MARKETING"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2008-02-07T05:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""Media"", ""byline"": {""original"": ""By Stephanie Saul"", ""person"": [{""firstname"": ""Stephanie"", ""middlename"": null, ""lastname"": ""Saul"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/e97c1a8c-347e-5549-99e3-1639087714d6"", ""word_count"": 1272, ""uri"": ""nyt://article/e97c1a8c-347e-5549-99e3-1639087714d6""}"
2008-02-08,"{""abstract"": ""A Congressional committee wants information about people who might have served as stunt doubles for Dr. Robert Jarvik in televised ads."", ""web_url"": ""https://www.nytimes.com/2008/02/08/business/media/08jarvik.html"", ""snippet"": ""A Congressional committee wants information about people who might have served as stunt doubles for Dr. Robert Jarvik in televised ads."", ""lead_paragraph"": ""A Congressional committee investigating the Lipitor advertising campaign featuring Dr. Robert Jarvik wants information about payments to people who might have served as stunt doubles for the doctor in televised ads. "", ""print_section"": ""C"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2008/02/08/business/lipitor.75.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2008/02/08/business/lipitor.75.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Committee Investigates Ad Tactics for Lipitor"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Committee Investigates Ad Tactics For Lipitor"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""ADVERTISING AND MARKETING"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Lipitor (Drug)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Washington (DC)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Television"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2008-02-08T05:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""Media"", ""byline"": {""original"": ""By Stephanie Saul"", ""person"": [{""firstname"": ""Stephanie"", ""middlename"": null, ""lastname"": ""Saul"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/e8474053-d374-5229-a728-b470f9653154"", ""word_count"": 326, ""uri"": ""nyt://article/e8474053-d374-5229-a728-b470f9653154""}"
2008-02-21,"{""abstract"": ""In the search for a new money-maker Pfizer paid $195 million for Houston-based Encysive Pharmaceuticals, a small outfit with big hopes for a breakthrough drug that, so far, the Food and Drug Administration has snubbed."", ""web_url"": ""https://dealbook.nytimes.com/2008/02/21/looking-for-next-big-hit-pfizer-spends-195-million-on-encysive/"", ""snippet"": """", ""lead_paragraph"": ""In the search for a new money-maker Pfizer paid $195 million for Houston-based Encysive Pharmaceuticals, a small outfit with big hopes for a breakthrough drug that, so far, the Food and Drug Administration has snubbed."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Looking for Next Big Hit, Pfizer Spends $195 Million on Encysive"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2008-02-21T11:42:41+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/92c051f1-43a5-5cc8-aad4-7d4e34e20323"", ""word_count"": 154, ""uri"": ""nyt://article/92c051f1-43a5-5cc8-aad4-7d4e34e20323""}"
2008-02-25,"{""abstract"": ""The ads featuring Dr. Robert Jarvik, a pioneer in artificial hearts, created false impressions, the company said."", ""web_url"": ""https://www.nytimes.com/2008/02/25/business/25cnd-pfizer.html"", ""snippet"": ""The ads featuring Dr. Robert Jarvik, a pioneer in artificial hearts, created false impressions, the company said."", ""lead_paragraph"": ""Under criticism that its ads are misleading, Pfizer said Monday it would cancel a long-running advertising campaign using the artificial heart pioneer Dr. Robert Jarvik as a spokesman for its cholesterol drug Lipitor."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2008/02/07/business/07jarvik.75.1.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2008/02/07/business/07jarvik.75.1.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Pfizer to End Lipitor Campaign by Jarvik"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Jarvik, Robert K"", ""rank"": 3, ""major"": ""N""}], ""pub_date"": ""2008-02-25T05:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Stephanie Saul"", ""person"": [{""firstname"": ""Stephanie"", ""middlename"": null, ""lastname"": ""Saul"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/460202a1-4b37-56ba-8e0e-4a0634a54dc4"", ""word_count"": 808, ""uri"": ""nyt://article/460202a1-4b37-56ba-8e0e-4a0634a54dc4""}"
2008-02-26,"{""abstract"": ""Criticized that its ads are misleading, Pfizer said it would end a campaign using the artificial heart pioneer Robert Jarvik as a spokesman for its cholesterol drug Lipitor."", ""web_url"": ""https://www.nytimes.com/2008/02/26/business/26pfizer.html"", ""snippet"": ""Criticized that its ads are misleading, Pfizer said it would end a campaign using the artificial heart pioneer Robert Jarvik as a spokesman for its cholesterol drug Lipitor."", ""lead_paragraph"": ""Under criticism that its ads are misleading, Pfizer said Monday that it would cancel a long-running advertising campaign using the artificial heart pioneer Robert Jarvik as a spokesman for its cholesterol drug Lipitor."", ""print_section"": ""C"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2008/02/07/business/07jarvik.75.1.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2008/02/07/business/07jarvik.75.1.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Pfizer to End Lipitor Ads by Jarvik"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer to End Lipitor Ads With Jarvik"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""ADVERTISING AND MARKETING"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Jarvik, Robert K"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Lipitor (Drug)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cholesterol"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2008-02-26T05:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Stephanie Saul"", ""person"": [{""firstname"": ""Stephanie"", ""middlename"": null, ""lastname"": ""Saul"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/1470f649-a6e5-5247-abc7-c079d400b6ea"", ""word_count"": 810, ""uri"": ""nyt://article/1470f649-a6e5-5247-abc7-c079d400b6ea""}"
2008-03-02,"{""abstract"": ""Improv actors know a thing or two about flexibility and creativity."", ""web_url"": ""https://www.nytimes.com/2008/03/02/business/02unbox.html"", ""snippet"": ""Improv actors know a thing or two about flexibility and creativity."", ""lead_paragraph"": ""MANAGERS striving to foster creativity often use the time-worn phrase \u201cthinking outside the box\u201d to encourage workers to come up with something nobody else in the room is thinking. But the improvisational actress Patricia Ryan Madson has a better idea: Look inside the box and take a fresh look at what\u2019s already there."", ""print_section"": ""BU"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2008/03/02/business/02unbox.xlarge1.jpg"", ""height"": 360, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2008/03/02/business/02unbox.xlarge1.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 360}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2008/03/02/business/02unbox.751.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2008/03/02/business/02unbox.751.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Can Executives Learn to Ignore the Script?"", ""kicker"": ""Unboxed"", ""content_kicker"": null, ""print_headline"": ""Can Executives Learn to Ignore the Script?"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Ryan, Patricia"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Executives and Management"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""ADVERTISING AND MARKETING"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Books and Literature"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2008-03-02T05:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""SundayBusiness"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Janet Rae-Dupree"", ""person"": [{""firstname"": ""Janet"", ""middlename"": null, ""lastname"": ""Rae-Dupree"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/d043a9e3-3672-51ea-927f-c5713d6f3d12"", ""word_count"": 1172, ""uri"": ""nyt://article/d043a9e3-3672-51ea-927f-c5713d6f3d12""}"
2008-05-02,"{""abstract"": ""Four years after purchasing Esperion Therapeutics, a company focused on the discovery and development of compounds for cardiovascular and metabolic disease, Pfizer is selling the Ann Arbor, Mich.-based firm to an entity funded by a group of investors."", ""web_url"": ""https://dealbook.nytimes.com/2008/05/02/esperion-raises-228-million-after-pfizer-spin-out/"", ""snippet"": """", ""lead_paragraph"": ""Four years after purchasing Esperion Therapeutics, a company focused on the discovery and development of compounds for cardiovascular and metabolic disease, Pfizer is selling the Ann Arbor, Mich.-based firm to an entity funded by a group of investors."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Esperion Raises $22.8 Million After Pfizer Spin-Out"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2008-05-02T10:44:01+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/f54f567a-73ea-53fe-8389-536067a13b80"", ""word_count"": 100, ""uri"": ""nyt://article/f54f567a-73ea-53fe-8389-536067a13b80""}"
2008-05-03,"{""abstract"": ""Pfizer has begun negotiating settlements with individual plaintiff\u2019s firms over its Celebrex and Bextra painkillers, a New York lawyer said."", ""web_url"": ""https://www.nytimes.com/2008/05/03/business/03pfizer.html"", ""snippet"": ""Pfizer has begun negotiating settlements with individual plaintiff\u2019s firms over its Celebrex and Bextra painkillers, a New York lawyer said."", ""lead_paragraph"": ""Pfizer has started settling cases over its Celebrex and Bextra painkillers, a New York lawyer said on Friday."", ""print_section"": ""C"", ""print_page"": ""8"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer Begins Settling Painkiller Cases"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer Begins Settling Painkiller Cases"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Celebrex (Drug)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Bextra (Drug)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Pain"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Suits and Litigation"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2008-05-03T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Bloomberg News"", ""person"": [{""firstname"": ""Bloomberg"", ""middlename"": null, ""lastname"": ""News"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/94a4f634-1b75-5a53-b3b9-bc9cb7f35521"", ""word_count"": 241, ""uri"": ""nyt://article/94a4f634-1b75-5a53-b3b9-bc9cb7f35521""}"
2008-06-13,"{""abstract"": ""Pfizer may bid for Ranbaxy Laboratories, countering a $4.6 billion offer by Japan\u2019s Daiichi Sankyo for the Indian generic drug maker, the Business Standard newspaper said."", ""web_url"": ""https://dealbook.nytimes.com/2008/06/13/pfizer-may-table-counter-bid-for-indias-ranbaxy-report-says/"", ""snippet"": """", ""lead_paragraph"": ""Pfizer may bid for Ranbaxy Laboratories, countering a $4.6 billion offer by Japan\u2019s Daiichi Sankyo for the Indian generic drug maker, the Business Standard newspaper said."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer May Table Counter-Bid for India\u2019s Ranbaxy, Report Says"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2008-06-13T10:59:18+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/3e325273-4183-5548-a4da-f638438a1578"", ""word_count"": 191, ""uri"": ""nyt://article/3e325273-4183-5548-a4da-f638438a1578""}"
2008-06-19,"{""abstract"": ""The settlement of a patent dispute over the blockbuster cholesterol drug will delay the release of generic versions in the United States until 2011."", ""web_url"": ""https://www.nytimes.com/2008/06/19/business/19drug.html"", ""snippet"": ""The settlement of a patent dispute over the blockbuster cholesterol drug will delay the release of generic versions in the United States until 2011."", ""lead_paragraph"": ""For people with high cholesterol, the wait for a cheaper version of Lipitor just got longer. Pfizer announced an agreement Wednesday to head off generic competition for its flagship drug until November 2011 \u0097 up to 20 months later than many analysts had been expecting. "", ""print_section"": ""C"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2008/06/19/business/19drug.75.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2008/06/19/business/19drug.75.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Release of Generic Lipitor Is Delayed"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Settlement Delays a Generic Lipitor For Many Months, a Boon to Pfizer"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Inventions and Patents"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Ranbaxy Laboratories"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Lipitor (Drug)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cholesterol"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Generic and Brand Name Products"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2008-06-19T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Stephanie Saul"", ""person"": [{""firstname"": ""Stephanie"", ""middlename"": null, ""lastname"": ""Saul"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/e9f1b78e-6519-529a-9bb4-835f6a829914"", ""word_count"": 987, ""uri"": ""nyt://article/e9f1b78e-6519-529a-9bb4-835f6a829914""}"
2008-07-13,"{""abstract"": ""Social scientists have learned that there is power in tying certain behaviors to habitual cues through relentless advertising."", ""web_url"": ""https://www.nytimes.com/2008/07/13/business/13habit.html"", ""snippet"": ""Social scientists have learned that there is power in tying certain behaviors to habitual cues through relentless advertising."", ""lead_paragraph"": ""A FEW years ago, a self-described \u201cmilitant liberal\u201d named Val Curtis decided that it was time to save millions of children from death and disease. So Dr. Curtis, an anthropologist then living in the African nation of Burkina Faso, contacted some of the largest multinational corporations and asked them, in effect, to teach her how to manipulate consumer habits worldwide."", ""print_section"": ""BU"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2008/07/13/business/13hand.xlarge1.jpg"", ""height"": 350, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2008/07/13/business/13hand.xlarge1.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 350}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2008/07/13/business/13hands.751.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2008/07/13/business/13hands.751.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Warning: Habits May Be Good for You"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Warning: Habits May Be Good for You"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""ADVERTISING AND MARKETING"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Procter & Gamble Co"", ""rank"": 3, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Ghana"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Research"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Vanderbilt University"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Colgate-Palmolive Company"", ""rank"": 8, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Burkina Faso"", ""rank"": 9, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cleansers, Detergents and Soaps"", ""rank"": 10, ""major"": ""N""}], ""pub_date"": ""2008-07-13T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""SundayBusiness"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Charles Duhigg"", ""person"": [{""firstname"": ""Charles"", ""middlename"": null, ""lastname"": ""Duhigg"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/e3168531-2ae3-5b02-8031-69311dfedb79"", ""word_count"": 2526, ""uri"": ""nyt://article/e3168531-2ae3-5b02-8031-69311dfedb79""}"
2008-09-09,"{""abstract"": ""Shares in German drugs and chemicals group Bayer rose on market talk of takeover interest from U.S. rival Pfizer, traders told Reuters Tuesday."", ""web_url"": ""https://dealbook.nytimes.com/2008/09/09/rumors-of-a-pfizer-deal-lift-bayer-shares/"", ""snippet"": """", ""lead_paragraph"": ""Shares in German drugs and chemicals group Bayer rose on market talk of takeover interest from U.S. rival Pfizer, traders told Reuters Tuesday."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Rumors of a Pfizer Deal Lift Bayer Shares"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2008-09-09T10:55:52+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/d722c277-8c29-5520-9668-2a3d0ec81c1a"", ""word_count"": 253, ""uri"": ""nyt://article/d722c277-8c29-5520-9668-2a3d0ec81c1a""}"
2008-10-08,"{""abstract"": ""The drug maker manipulated the publication of studies to bolster use of its epilepsy drug Neurontin, according to expert witnesses in a lawsuit against the company."", ""web_url"": ""https://www.nytimes.com/2008/10/08/health/research/08drug.html"", ""snippet"": ""The drug maker manipulated the publication of studies to bolster use of its epilepsy drug Neurontin, according to expert witnesses in a lawsuit against the company."", ""lead_paragraph"": ""The drug maker Pfizer earlier this decade manipulated the publication of scientific studies to bolster the use of its epilepsy drug Neurontin for other disorders, while suppressing research that did not support those uses, according to experts who reviewed thousands of company documents for plaintiffs in a lawsuit against the company. "", ""print_section"": ""B"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Experts Conclude Pfizer Manipulated Studies"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Experts Conclude Pfizer Manipulated Studies"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Frauds and Swindling"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""ADVERTISING AND MARKETING"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Epilepsy"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Research"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Neurontin (Drug)"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2008-10-08T05:00:13+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Health"", ""subsection_name"": ""Research"", ""byline"": {""original"": ""By Stephanie Saul"", ""person"": [{""firstname"": ""Stephanie"", ""middlename"": null, ""lastname"": ""Saul"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/f3babf78-06ea-5415-bc5c-65783afb44da"", ""word_count"": 944, ""uri"": ""nyt://article/f3babf78-06ea-5415-bc5c-65783afb44da""}"
2008-10-17,"{""abstract"": ""Pfizer said that it had an $894 million deal to end more than 90 percent of personal injury suits brought by people claiming the drugs caused heart attacks, strokes or other harm."", ""web_url"": ""https://www.nytimes.com/2008/10/18/business/18drug.html"", ""snippet"": ""Pfizer said that it had an $894 million deal to end more than 90 percent of personal injury suits brought by people claiming the drugs caused heart attacks, strokes or other harm."", ""lead_paragraph"": ""Pfizer said Friday it had agreed to set aside $894 million to settle virtually all the lawsuits related to its withdrawn painkiller Bextra as well as a similar drug that remains on the market, Celebrex, four years after concerns about cardiovascular risks of such drugs became widely publicized."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2008/10/18/business/18drug.75.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2008/10/18/business/18drug.75.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Pfizer to Settle Claims Over Bextra and Celebrex"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer in $894 Million Drug Settlement"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Bextra (Drug)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Celebrex (Drug)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Suits and Litigation"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2008-10-17T12:29:22+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Stephanie Saul"", ""person"": [{""firstname"": ""Stephanie"", ""middlename"": null, ""lastname"": ""Saul"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/94fe5dd2-0677-58f6-adb6-cc723f0ac27a"", ""word_count"": 843, ""uri"": ""nyt://article/94fe5dd2-0677-58f6-adb6-cc723f0ac27a""}"
2008-10-23,"{""abstract"": ""Bayer shares jumped Wednesday amid market chatter that Pfizer may be interested in taking over its rival German drugs and chemicals maker."", ""web_url"": ""https://dealbook.nytimes.com/2008/10/23/rumors-of-a-pfizer-bid-push-bayer-shares-up/"", ""snippet"": """", ""lead_paragraph"": ""Bayer shares jumped Wednesday amid market chatter that Pfizer may be interested in taking over its rival German drugs and chemicals maker."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Rumors of a Pfizer Bid Push Bayer Shares Up"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2008-10-23T11:03:36+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/9bbffb27-3031-58d2-8ad5-1fd28b579160"", ""word_count"": 208, ""uri"": ""nyt://article/9bbffb27-3031-58d2-8ad5-1fd28b579160""}"
2008-11-28,"{""abstract"": ""Critics say drug firms worked to discredit a clinical trial that found that inexpensive pills for hypertension worked better than newer drugs."", ""web_url"": ""https://www.nytimes.com/2008/11/28/business/28govtest.html"", ""snippet"": ""Critics say drug firms worked to discredit a clinical trial that found that inexpensive pills for hypertension worked better than newer drugs."", ""lead_paragraph"": ""The surprising news made headlines in December 2002. Generic pills for high blood pressure, which had been in use since the 1950s and cost only pennies a day, worked better than newer drugs that were up to 20 times as expensive. "", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""The Minimal Impact of a Big Hypertension Study"", ""kicker"": ""The Evidence Gap"", ""content_kicker"": null, ""print_headline"": ""A Big Blood Pressure Study, and Its Minimal Impact on Drug Use"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Generic and Brand Name Products"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Hypertension"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Prices (Fares, Fees and Rates)"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2008-11-28T02:06:57+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""Series"", ""_id"": ""nyt://article/0a53c4c5-4c8b-54d3-8742-2b26941bf0b6"", ""word_count"": 2755, ""uri"": ""nyt://article/0a53c4c5-4c8b-54d3-8742-2b26941bf0b6""}"
2009-01-05,"{""abstract"": ""Pfizer, the world\u2019s biggest pharmaceutical group, is open to to doing some dealmaking, The Financial Times reported."", ""web_url"": ""https://dealbook.nytimes.com/2009/01/05/pfizer-said-to-be-on-the-lookout-for-takeover-targets/"", ""snippet"": """", ""lead_paragraph"": ""Pfizer, the world\u2019s biggest pharmaceutical group, is open to to doing some dealmaking, The Financial Times reported."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer Said to Be on the Lookout for Takeover Targets"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2009-01-05T12:18:45+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/1c7bf102-9b85-573b-86f3-5b42abe27e32"", ""word_count"": 150, ""uri"": ""nyt://article/1c7bf102-9b85-573b-86f3-5b42abe27e32""}"
2009-01-13,"{""abstract"": ""The drug company plans to reduce its global research staff by 5 percent to 8 percent in an effort to refocus disappointing research efforts and cut its overhead."", ""web_url"": ""https://www.nytimes.com/2009/01/14/business/14pfizer.html"", ""snippet"": ""The drug company plans to reduce its global research staff by 5 percent to 8 percent in an effort to refocus disappointing research efforts and cut its overhead."", ""lead_paragraph"": ""The pharmaceutical giant Pfizer is cutting up to 800 research jobs this year, the company said on Tuesday, pruning positions not involved in the six disease areas that are its current focus. "", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer to Cut Researchers as It Hones Its Focus"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer to Cut Researchers As It Hones Its Focus"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Layoffs and Job Reductions"", ""rank"": 2, ""major"": ""N""}], ""pub_date"": ""2009-01-13T17:44:19+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Duff Wilson"", ""person"": [{""firstname"": ""Duff"", ""middlename"": null, ""lastname"": ""Wilson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/e777142c-0614-5d04-95df-40869e1c7ff2"", ""word_count"": 616, ""uri"": ""nyt://article/e777142c-0614-5d04-95df-40869e1c7ff2""}"
2009-01-23,"[{""abstract"": ""Wyeth\u2018s shares rose as much as 15 percent in German trading Friday, as investors reacted to a report in the Wall Street Journal that Pfizer was in in talks about potentially buying the drugmaker. Discussions have been going on for months and a deal wasn\u2019t imminent, the report said."", ""web_url"": ""https://dealbook.nytimes.com/2009/01/23/pfizer-in-talks-to-buy-wyeth-for-60-billion-report-says/"", ""snippet"": """", ""lead_paragraph"": ""Wyeth\u2018s shares rose as much as 15 percent in German trading Friday, as investors reacted to a report in the Wall Street Journal that Pfizer was in in talks about potentially buying the drugmaker. Discussions have been going on for months and a deal wasn\u2019t imminent, the report said."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Wyeth Shares Rise on Report of Takeover Talks"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2009-01-23T13:37:29+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/008a45bb-84e8-5de5-800d-1e1ab5804e65"", ""word_count"": 156, ""uri"": ""nyt://article/008a45bb-84e8-5de5-800d-1e1ab5804e65""}, {""abstract"": ""Reports that drug giant Pfizer is in talks to acquire rival Wyeth in a deal that could be worth more than $60 billion are having a treacherous effect on shares of Crucell, a Dutch biotech company."", ""web_url"": ""https://dealbook.nytimes.com/2009/01/23/do-pfizer-wyeth-talks-leave-crucell-in-the-cold/"", ""snippet"": ""Reports that drug giant Pfizer is in talks to acquire rival Wyeth in a deal that could be worth more than $60 billion are having a treacherous effect on shares of Crucell, a Dutch biotech company."", ""lead_paragraph"": ""Reports that drug giant Pfizer is in talks to acquire rival Wyeth in a deal that could be worth more than $60 billion are having a treacherous effect on shares of Crucell, a Dutch biotech company."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Do Pfizer-Wyeth Talks Leave Crucell Out in the Cold?"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2009-01-23T18:11:13+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/92dc8344-87c8-5895-8d7f-d7d782cded57"", ""word_count"": 183, ""uri"": ""nyt://article/92dc8344-87c8-5895-8d7f-d7d782cded57""}]"
2009-01-24,"{""abstract"": ""The purchase of Wyeth by Pfizer for more than $60 billion could be completed over the weekend."", ""web_url"": ""https://www.nytimes.com/2009/01/24/business/24drug.html"", ""snippet"": ""The purchase of Wyeth by Pfizer for more than $60 billion could be completed over the weekend."", ""lead_paragraph"": ""This article was reported by Duff Wilson, Natasha Singer and Andrew Ross Sorkin and written by Mr. Sorkin."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2009/01/24/business/24drug01-75.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2009/01/24/business/24drug01-75.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Pfizer Said to Be Closing In on Deal for Wyeth"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer Said to Be Closing In On Deal for a Rival, Wyeth"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Wyeth"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2009-01-24T02:52:58+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Ross Sorkin"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": ""Ross"", ""lastname"": ""Sorkin"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/195a153e-a21e-57a5-9e4b-6db539f8f18d"", ""word_count"": 991, ""uri"": ""nyt://article/195a153e-a21e-57a5-9e4b-6db539f8f18d""}"
2009-01-26,"[{""abstract"": ""The deal creating a pharmaceutical giant is the first big merger backed by Wall Street in months."", ""web_url"": ""https://www.nytimes.com/2009/01/26/business/26drug.html"", ""snippet"": ""The deal creating a pharmaceutical giant is the first big merger backed by Wall Street in months."", ""lead_paragraph"": ""The board of Pfizer, the world\u2019s largest drug maker, agreed to acquire a rival, Wyeth, for $68 billion, the companies announced Monday. "", ""print_section"": ""A"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2009/01/26/business/27pfizer600.jpg"", ""height"": 362, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2009/01/26/business/27pfizer600.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 362}}], ""headline"": {""main"": ""Pfizer Agrees to Pay $68 Billion for Rival Drug Maker Wyeth"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""In Tight Market, Pfizer Agrees to Pay $68 Billion for Rival Wyeth"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Wyeth"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2009-01-26T02:10:39+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Ross Sorkin and Duff Wilson"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": ""Ross"", ""lastname"": ""Sorkin"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Duff"", ""middlename"": null, ""lastname"": ""Wilson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/57da4773-4e6d-572a-88c4-9fe149316688"", ""word_count"": 1565, ""uri"": ""nyt://article/57da4773-4e6d-572a-88c4-9fe149316688""}, {""abstract"": ""Pfizer will acquire Wyeth in a cash and stock deal valued at $68 billion, the companies said in a statement Monday morning."", ""web_url"": ""https://dealbook.nytimes.com/2009/01/26/pfizer-to-buy-wyeth-in-68-billion-deal/"", ""snippet"": ""Pfizer will acquire Wyeth in a cash and stock deal valued at $68 billion, the companies said in a statement Monday morning."", ""lead_paragraph"": ""Pfizer will acquire Wyeth in a cash and stock deal valued at $68 billion, the companies said in a statement Monday morning. "", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer to Buy Wyeth in $68 Billion Deal"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2009-01-26T12:14:04+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/188b884c-ccc1-549e-a546-e38bb34166e3"", ""word_count"": 1021, ""uri"": ""nyt://article/188b884c-ccc1-549e-a546-e38bb34166e3""}, {""abstract"": ""Matthew Nugen, who became national political director for Barack Obama\u2019s presidential campaign in early 2007, has started a new job as a strategic adviser for  Ogilvy Government Relations, a powerful lobbying firm whose clients include corporate giants such as Pfizer and big financial firms such as Blackstone."", ""web_url"": ""https://dealbook.nytimes.com/2009/01/26/obama-aide-joins-ogilvy-as-adviser/"", ""snippet"": ""Matthew Nugen, who became national political director for Barack Obama\u2019s presidential campaign in early 2007, has started a new job as a strategic adviser for  Ogilvy Government Relations, a powerful lobbying firm whose clients include corporate g..."", ""lead_paragraph"": ""Matthew Nugen signed on as national political director for Barack Obama\u2019s presidential campaign in early 2007, giving him an important role in what even some of Mr. Obama\u2019s rivals have described as a remarkably well-run presidential bid. "", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Obama Aide Joins Ogilvy as Adviser"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2009-01-26T13:15:40+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/438b4a2a-63a1-5ef7-ba4a-20db6cee856a"", ""word_count"": 504, ""uri"": ""nyt://article/438b4a2a-63a1-5ef7-ba4a-20db6cee856a""}, {""abstract"": ""The price tag isn\u2019t the only big thing about Pfizer\u2018s deal to buy rival drug maker Wyeth. Pfizer is also aiming for big synergies from the $68 billion acquisition."", ""web_url"": ""https://dealbook.nytimes.com/2009/01/26/pfizer-deal-calls-for-ambitious-cost-cuts/"", ""snippet"": ""The price tag isn\u2019t the only big thing about Pfizer\u2018s deal to buy rival drug maker Wyeth. Pfizer is also aiming for big synergies from the $68 billion acquisition."", ""lead_paragraph"": ""The price tag isn\u2019t the only big thing about Pfizer\u2018s deal to buy the rival drug maker Wyeth. Pfizer is also aiming for big synergies from the $68 billion acquisition, announced Monday morning after days of speculation in the news media. That implies some serious cost cuts are in order."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer Deal Calls for Ambitious Cost Cuts"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2009-01-26T16:11:12+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By"", ""person"": [], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/e0a2dc34-2e07-5e02-ba83-e5fa413c3c46"", ""word_count"": 474, ""uri"": ""nyt://article/e0a2dc34-2e07-5e02-ba83-e5fa413c3c46""}, {""abstract"": ""Monday\u2019s toll included 20,000 cuts at Caterpillar, 8,000 at Sprint Nextel, 7,000 at Home Depot and 8,000 from the expected merger of Pfizer and Wyeth."", ""web_url"": ""https://www.nytimes.com/2009/01/27/business/economy/27jobcuts.html"", ""snippet"": ""Monday\u2019s toll included 20,000 cuts at Caterpillar, 8,000 at Sprint Nextel, 7,000 at Home Depot and 8,000 from the expected merger of Pfizer and Wyeth."", ""lead_paragraph"": ""Employers have tried to nip and tuck their labor costs by reducing overtime, shortening the workweek and freezing wages, but now, they are reaching for the saw."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""62,000 Jobs Are Cut by U.S. and Foreign Companies"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""A Day of Layoffs, Across Industries and Continents"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Sprint Nextel Corporation"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Layoffs and Job Reductions"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Sprint Nextel Corp"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Home Depot Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Subprime Mortgage Crisis"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Wyeth"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2009-01-26T16:36:58+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""Economy"", ""byline"": {""original"": ""By Jack Healy"", ""person"": [{""firstname"": ""Jack"", ""middlename"": null, ""lastname"": ""Healy"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/6eed67f5-70cb-526c-b179-d4d28f51ede7"", ""word_count"": 1071, ""uri"": ""nyt://article/6eed67f5-70cb-526c-b179-d4d28f51ede7""}, {""abstract"": ""Pfizer\u2018s $68 billion deal to buy the rival drug maker Wyeth ranks among the largest pharmaceutical deals of all time. The acquisition, which is being paid for in cash and Pfizer stock, also breaks a long-running drought in the merger world, which hasn\u2019t seen such a large transaction (excluding spinoffs) since a group of banks bid nearly $96 billion for ABN Amro in April 2007."", ""web_url"": ""https://dealbook.nytimes.com/2009/01/26/pfizers-prescription-for-growth-big-deals/"", ""snippet"": """", ""lead_paragraph"": ""Pfizer\u2018s $68 billion deal to buy the rival drug maker Wyeth ranks among the largest pharmaceutical deals of all time. The acquisition, which is being paid for in cash and Pfizer stock, also breaks a long-running drought in the merger world, which hasn\u2019t seen such a large transaction (excluding spinoffs) since a group of banks bid nearly $96 billion for ABN Amro in April 2007."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer\u2019s Prescription for Growth: Big Deals"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2009-01-26T17:27:45+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/2e7b3cec-323d-5a31-a9f7-ca9555ebfcd5"", ""word_count"": 287, ""uri"": ""nyt://article/2e7b3cec-323d-5a31-a9f7-ca9555ebfcd5""}, {""abstract"": ""Pfizer\u2019s planned acquisition of Wyeth is a validation of Wyeth\u2019s decision to reduce its reliance on small-molecule drugs."", ""web_url"": ""https://www.nytimes.com/2009/01/27/business/27wyeth.html"", ""snippet"": ""Pfizer\u2019s planned acquisition of Wyeth is a validation of Wyeth\u2019s decision to reduce its reliance on small-molecule drugs."", ""lead_paragraph"": ""Molecules."", ""print_section"": ""B"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2009/01/27/business/27pfizer.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2009/01/27/business/27pfizer.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""In Wyeth, Pfizer Sees a Drug Pipeline"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""In Pursuit of a Pipeline of Biological Treatments"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Biotechnology"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Wyeth"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2009-01-26T19:21:15+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Natasha Singer"", ""person"": [{""firstname"": ""Natasha"", ""middlename"": null, ""lastname"": ""Singer"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/62c902a8-ddbe-56fe-9f2e-11f63f134818"", ""word_count"": 1104, ""uri"": ""nyt://article/62c902a8-ddbe-56fe-9f2e-11f63f134818""}]"
2009-01-27,"[{""abstract"": ""Layoffs, falling stock and slim dividends leave Pfizer little to cheer about one day after the $68 billion megamerger with Wyeth."", ""web_url"": ""https://www.nytimes.com/2009/01/27/business/27chief.html"", ""snippet"": ""Layoffs, falling stock and slim dividends leave Pfizer little to cheer about one day after the $68 billion megamerger with Wyeth."", ""lead_paragraph"": ""After announcing the $68 billion megamerger with Wyeth on Monday morning, Pfizer\u2019s chief executive, Jeffrey B. Kindler, did not have much time to celebrate."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""For Pfizer, a Big Deal and a Test"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""For Pfizer, A Big Deal And a Test"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Company Reports"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Layoffs and Job Reductions"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 5, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Kindler, Jeffrey B"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Wyeth"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2009-01-27T03:06:55+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Duff Wilson"", ""person"": [{""firstname"": ""Duff"", ""middlename"": null, ""lastname"": ""Wilson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/ff168fe6-4a32-5e1d-992e-6558e8108857"", ""word_count"": 1248, ""uri"": ""nyt://article/ff168fe6-4a32-5e1d-992e-6558e8108857""}, {""abstract"": ""Pfizer\u2019s move to buy Wyeth dims the hopes of struggling small biotechnology companies that wanted to sell themselves or their products to larger businesses."", ""web_url"": ""https://www.nytimes.com/2009/01/27/business/27biotech.html"", ""snippet"": ""Pfizer\u2019s move to buy Wyeth dims the hopes of struggling small biotechnology companies that wanted to sell themselves or their products to larger businesses."", ""lead_paragraph"": ""This month Pfizer\u2019s chief executive, Jeffrey B. Kindler, held a breakfast for venture capitalists atop a hotel in San Francisco. Some guests took it as a sign that Pfizer was serious about buying young biotechnology companies or licensing their technology. "", ""print_section"": ""B"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Wyeth Deal May Slow Pfizer Biotech Acquisitions"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Purchase of Wyeth May Blunt Pfizer\u2019s Appetite for Small Biotech Companies"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Biogen Idec Incorporated"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AMGEN INC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Wyeth"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Biotechnology"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2009-01-27T03:11:40+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/29a4957d-5eb7-5270-bff9-2bfccdfaa96a"", ""word_count"": 872, ""uri"": ""nyt://article/29a4957d-5eb7-5270-bff9-2bfccdfaa96a""}, {""abstract"": ""Molecules."", ""web_url"": ""https://dealbook.nytimes.com/2009/01/27/in-wyeth-pfizer-sees-a-drug-pipeline/"", ""snippet"": """", ""lead_paragraph"": ""Molecules."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""In Wyeth, Pfizer Sees a Drug Pipeline"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2009-01-27T11:59:48+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/b010c051-b9a4-5e3b-9e87-bf571e1974bb"", ""word_count"": 1093, ""uri"": ""nyt://article/b010c051-b9a4-5e3b-9e87-bf571e1974bb""}, {""abstract"": ""After announcing the $68 billion megamerger with Wyeth on Monday morning, Pfizer\u2019s chief executive, Jeffrey B. Kindler, did not have much time to celebrate."", ""web_url"": ""https://dealbook.nytimes.com/2009/01/27/for-pfizer-a-big-deal-and-a-test/"", ""snippet"": """", ""lead_paragraph"": ""After announcing the $68 billion megamerger with Wyeth on Monday morning, Pfizer\u2019s chief executive, Jeffrey B. Kindler, did not have much time to celebrate."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""For Pfizer, a Big Deal and a Test"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2009-01-27T12:01:05+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/4ab64c82-ca65-5044-ac9e-9d1043e93d36"", ""word_count"": 1222, ""uri"": ""nyt://article/4ab64c82-ca65-5044-ac9e-9d1043e93d36""}, {""abstract"": ""This month Pfizer\u2019s chief executive, Jeffrey B. Kindler, held a breakfast for venture capitalists atop a hotel in San Francisco. Some guests took it as a sign that Pfizer was serious about buying young biotechnology companies or licensing their technology."", ""web_url"": ""https://dealbook.nytimes.com/2009/01/27/wyeth-deal-may-slow-pfizer-biotech-acquisitions/"", ""snippet"": """", ""lead_paragraph"": ""This month Pfizer\u2019s chief executive, Jeffrey B. Kindler, held a breakfast for venture capitalists atop a hotel in San Francisco. Some guests took it as a sign that Pfizer was serious about buying young biotechnology companies or licensing their technology."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Wyeth Deal May Slow Pfizer Biotech Acquisitions"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2009-01-27T12:10:58+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/1fc7fe3f-c92e-5298-9a5f-e1602e186ea5"", ""word_count"": 869, ""uri"": ""nyt://article/1fc7fe3f-c92e-5298-9a5f-e1602e186ea5""}]"
2009-01-28,"[{""abstract"": ""An article on Tuesday about Pfizer\u2019s $68 billion acquisition of a rival drug maker, Wyeth, misstated the price of two previous Pfizer acquisitions. The company paid $90 billion, not million, for Warner-Lambert in 2000, and $60 billion, not million, for Pharmacia in 2003."", ""web_url"": ""https://www.nytimes.com/2009/01/28/business/28correx-03.html"", ""snippet"": ""An article on Tuesday about Pfizer\u2019s $68 billion acquisition of a rival drug maker, Wyeth, misstated the price of two previous Pfizer acquisitions. The company paid $90 billion, not million, for Warner-Lambert in 2000, and $60 billion, not million..."", ""lead_paragraph"": ""An article on Tuesday about Pfizer\u2019s $68 billion acquisition of a rival drug maker, Wyeth, misstated the price of two previous Pfizer acquisitions. The company paid $90 billion, not million, for Warner-Lambert in 2000, and $60 billion, not million, for Pharmacia in 2003."", ""print_section"": ""A"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Correction"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Corrections"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2009-01-28T04:02:24+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": """", ""person"": [], ""organization"": null}, ""type_of_material"": ""Correction"", ""_id"": ""nyt://article/5d0609b8-412c-5d06-a171-858b4435d8d9"", ""word_count"": 43, ""uri"": ""nyt://article/5d0609b8-412c-5d06-a171-858b4435d8d9""}, {""abstract"": "" Pfizer\u2018s mammoth bid for Wyeth is already reverberating through the pharmaceutical world."", ""web_url"": ""https://dealbook.nytimes.com/2009/01/28/pfizer-bid-for-wyeth-bodes-well-for-roche-deal/"", ""snippet"": """", ""lead_paragraph"": "" Pfizer\u2018s mammoth bid for Wyeth is already reverberating through the pharmaceutical world."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer Bid for Wyeth Bodes Well for Roche Deal"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2009-01-28T11:56:25+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/9161fd5b-474a-5e6c-b60c-5efb54cca77d"", ""word_count"": 722, ""uri"": ""nyt://article/9161fd5b-474a-5e6c-b60c-5efb54cca77d""}]"
2009-01-30,"[{""abstract"": ""Drug giant Pfizer\u2018s agreement to acquire rival Wyeth would give Wyeth directors a voice on Pfizer\u2019s board and includes hefty penalties aimed at preventing the deal from collapsing, The Associated Press reports citing a regulatory filing made Thursday."", ""web_url"": ""https://dealbook.nytimes.com/2009/01/30/pfizer-deal-gives-wyeth-say-on-board-breakup-fee/"", ""snippet"": """", ""lead_paragraph"": ""Drug giant Pfizer\u2018s agreement to acquire rival Wyeth would give Wyeth directors a voice on Pfizer\u2019s board and includes hefty penalties aimed at preventing the deal from collapsing, The Associated Press reports citing a regulatory filing made Thursday."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer Deal Gives Wyeth Say on Board, Breakup Fee"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2009-01-30T12:24:22+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/785b4669-4a4c-5662-9c30-d72ddd0ba8e7"", ""word_count"": 658, ""uri"": ""nyt://article/785b4669-4a4c-5662-9c30-d72ddd0ba8e7""}, {""abstract"": ""On Thursday evening, Wyeth filed the agreement for its $68 billion takeover by Pfizer. As the press release on Monday hinted, the Wyeth-Pfizer deal offers a new model for strategic transactions."", ""web_url"": ""https://dealbook.nytimes.com/2009/01/30/wyeths-deal-contract-shows-a-new-path/"", ""snippet"": """", ""lead_paragraph"": ""On Thursday evening, Wyeth filed the agreement for its $68 billion takeover by Pfizer. As the press release on Monday hinted, the Wyeth-Pfizer deal offers a new model for strategic transactions."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer\u2019s New Deal Model"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2009-01-30T14:20:43+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/413b4dde-c1f5-5111-ac14-73177071b11b"", ""word_count"": 1306, ""uri"": ""nyt://article/413b4dde-c1f5-5111-ac14-73177071b11b""}]"
2009-02-02,"{""abstract"": ""Pfizer\u2018s $68 billion acquisition of rival pharmaceutical maker Wyeth is drawing criticism over the $22.5 billion in loans Pfizer received from major Wall Street banks to help close the deal."", ""web_url"": ""https://dealbook.nytimes.com/2009/02/02/policy-group-questions-loans-for-pfizer-deal/"", ""snippet"": """", ""lead_paragraph"": ""Pfizer\u2018s $68 billion acquisition of rival pharmaceutical maker Wyeth is drawing criticism over the $22.5 billion in loans Pfizer received from major Wall Street banks to help close the deal."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Policy Group Questions Loans for Pfizer Deal"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2009-02-02T15:38:35+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/37756582-4b7e-51a4-8925-b4ae0cda3d52"", ""word_count"": 338, ""uri"": ""nyt://article/37756582-4b7e-51a4-8925-b4ae0cda3d52""}"
2009-02-10,"{""abstract"": ""Deals aren\u2019t dead \u2014 just ask Pfizer or Live Nation \u2014 but they did seem to go into a coma last week."", ""web_url"": ""https://dealbook.nytimes.com/2009/02/10/the-week-that-deals-almost-dried-up/"", ""snippet"": """", ""lead_paragraph"": ""Deals aren\u2019t dead \u2014 just ask Pfizer or Live Nation \u2014 but they did seem to go into a coma last week."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""The Week That Deals (Almost) Dried Up"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2009-02-10T19:43:20+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/29c4d5b7-fc36-5a62-9bd0-2f86ce11dade"", ""word_count"": 245, ""uri"": ""nyt://article/29c4d5b7-fc36-5a62-9bd0-2f86ce11dade""}"
2009-02-21,"{""abstract"": ""Pfizer, the world\u2019s biggest drug maker, is significantly reducing the value of the severance packages for top managers in a nod to public pressure to reduce executive pay."", ""web_url"": ""https://www.nytimes.com/2009/02/21/business/economy/21bizbriefs-PFIZERREDUCE_BRF.html"", ""snippet"": ""Pfizer, the world\u2019s biggest drug maker, is significantly reducing the value of the severance packages for top managers in a nod to public pressure to reduce executive pay."", ""lead_paragraph"": ""Pfizer, the world\u2019s biggest drug maker, is significantly reducing the value of the severance packages for top managers in a nod to public pressure to reduce executive pay. The new executive severance plan took effect Monday, according to a filing with the Securities and Exchange Commission. Pfizer\u2019s new plan would provide top officers terminated without cause with benefits including a severance payment equaling one to two times the total of their annual base salary and target bonus. That still amounts to at least a few million dollars for some officers and nearly $10 million for the chief executive, Jeffrey B. Kindler."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer Reduces Executive Severance Pay"", ""kicker"": ""Business Briefing | Company News"", ""content_kicker"": null, ""print_headline"": ""Pfizer Reduces Executive Severance Pay"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Executives and Management"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Wages and Salaries"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2009-02-21T04:39:22+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""Economy"", ""byline"": {""original"": ""By ASSOCIATED PRESS"", ""person"": [], ""organization"": ""ASSOCIATED PRESS""}, ""type_of_material"": ""Brief"", ""_id"": ""nyt://article/d11bdc2a-3bc5-5354-b502-d017aab20e27"", ""word_count"": 104, ""uri"": ""nyt://article/d11bdc2a-3bc5-5354-b502-d017aab20e27""}"
2009-03-02,"{""abstract"": ""Taking a photo of opponents of drug industry influence on campus appeared to violate medical school rules."", ""web_url"": ""https://www.nytimes.com/2009/03/03/business/03pfizer.html"", ""snippet"": ""Taking a photo of opponents of drug industry influence on campus appeared to violate medical school rules."", ""lead_paragraph"": ""Harvard Medical School\u2019s rules say that students on campus are supposed to be off-limits to drug company representatives. "", ""print_section"": ""B"", ""print_page"": ""6"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2009/03/03/business/03pfizer.75.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2009/03/03/business/03pfizer.75.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Pfizer Worker Photographed Protesters at Harvard"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer Worker Photographed Student Protest at Harvard"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medical Schools"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Conflicts of Interest"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Harvard Medical School"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2009-03-02T22:53:11+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Duff Wilson"", ""person"": [{""firstname"": ""Duff"", ""middlename"": null, ""lastname"": ""Wilson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/494968bf-0baa-5cba-8d4e-e7bf00ad6dda"", ""word_count"": 296, ""uri"": ""nyt://article/494968bf-0baa-5cba-8d4e-e7bf00ad6dda""}"
2009-03-03,"[{""abstract"": ""More than 200 Harvard Medical School students and sympathetic faculty are intent on exposing and curtailing the industry influence in their classrooms and laboratories."", ""web_url"": ""https://www.nytimes.com/2009/03/03/business/03medschool.html"", ""snippet"": ""More than 200 Harvard Medical School students and sympathetic faculty are intent on exposing and curtailing the industry influence in their classrooms and laboratories."", ""lead_paragraph"": ""BOSTON \u0097 In a first-year pharmacology class at Harvard Medical School, Matt Zerden grew wary as the professor promoted the benefits of cholesterol drugs and seemed to belittle a student who asked about side effects."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2009/03/03/business/03medschool.1.600.jpg"", ""height"": 337, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2009/03/03/business/03medschool.1.600.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 337}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2009/03/03/business/03medschool.1.75.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2009/03/03/business/03medschool.1.75.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Harvard Medical School in Ethics Quandary"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Patching a Wound"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Conflicts of Interest"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Harvard Medical School"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Bristol-Myers Squibb Co"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Harvard University"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medical Schools"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Baxter International Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Ethics"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2009-03-03T01:28:30+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Duff Wilson"", ""person"": [{""firstname"": ""Duff"", ""middlename"": null, ""lastname"": ""Wilson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/2dabdb4e-b32b-55cf-b9eb-3d5e53dd6af8"", ""word_count"": 1533, ""uri"": ""nyt://article/2dabdb4e-b32b-55cf-b9eb-3d5e53dd6af8""}, {""abstract"": ""The drug maker has been asked to provide details of its payments to faculty members at Harvard Medical School."", ""web_url"": ""https://www.nytimes.com/2009/03/04/business/04pfizer.html"", ""snippet"": ""The drug maker has been asked to provide details of its payments to faculty members at Harvard Medical School."", ""lead_paragraph"": ""Senator Charles E. Grassley on Tuesday asked the drug maker Pfizer to provide details of its payments to at least 149 faculty members at Harvard Medical School."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Senator Asks Pfizer About Harvard Payments"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Senator Asks Pfizer To Detail Pay To Harvard"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Harvard University"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Conflicts of Interest"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2009-03-03T22:51:38+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Duff Wilson"", ""person"": [{""firstname"": ""Duff"", ""middlename"": null, ""lastname"": ""Wilson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/fe5bedd0-a2af-598e-b552-3e0e0225940e"", ""word_count"": 610, ""uri"": ""nyt://article/fe5bedd0-a2af-598e-b552-3e0e0225940e""}]"
2009-03-18,"{""abstract"": ""Pfizer, the giant drug maker, has sold $13.5 billion worth of bonds to replace short-term loans covering about one-third of the cost of its planned acquisition of its rival Wyeth, The Associated Press said."", ""web_url"": ""https://dealbook.nytimes.com/2009/03/18/pfizer-sells-135b-in-bonds-as-part-of-wyeth-deal/"", ""snippet"": """", ""lead_paragraph"": ""Pfizer, the giant drug maker, has sold $13.5 billion worth of bonds to replace short-term loans covering about one-third of the cost of its planned acquisition of its rival Wyeth, The Associated Press said."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer Sells $13.5 Billion in Bonds for Wyeth Deal"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2009-03-18T11:45:07+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/dce07291-cfee-51e6-8353-43a88f5e3274"", ""word_count"": 443, ""uri"": ""nyt://article/dce07291-cfee-51e6-8353-43a88f5e3274""}"
2009-04-16,"{""abstract"": ""The pharmaceutical giants GlaxoSmithKline and Pfizer said they would form a specialty company to research, develop and market treatments for H.I.V."", ""web_url"": ""https://www.nytimes.com/2009/04/17/business/17drug.html"", ""snippet"": ""The pharmaceutical giants GlaxoSmithKline and Pfizer said they would form a specialty company to research, develop and market treatments for H.I.V."", ""lead_paragraph"": ""Hoping to challenge Gilead Sciences, the leader in H.I.V. drugs, the pharmaceutical giants GlaxoSmithKline and Pfizer said Thursday that they would form a specialty company to research, develop and market treatments for H.I.V., the virus that causes AIDS. "", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Glaxo and Pfizer Join Forces to Develop and Market H.I.V. Drugs"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Glaxo and Pfizer Join Forces to Develop and Market H.I.V. Drugs"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""GlaxoSmithKline PLC"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Acquired Immune Deficiency Syndrome"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2009-04-16T18:00:34+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Natasha Singer"", ""person"": [{""firstname"": ""Natasha"", ""middlename"": null, ""lastname"": ""Singer"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/54388f8b-ca16-5e0c-b49a-135b3d3e4342"", ""word_count"": 598, ""uri"": ""nyt://article/54388f8b-ca16-5e0c-b49a-135b3d3e4342""}"
2009-04-17,"{""abstract"": ""GlaxoSmithKline and Pfizer plan to spin out and combine their H.I.V. research units, choosing an alternative to the big mergers that have been transforming the industry."", ""web_url"": ""https://dealbook.nytimes.com/2009/04/17/a-different-kind-of-drug-deal/"", ""snippet"": ""GlaxoSmithKline and Pfizer plan to spin out and combine their H.I.V. research units, choosing an alternative to the big mergers that have been transforming the industry."", ""lead_paragraph"": ""The rapid consolidation in the pharmaceutical industry continued Thursday as GlaxoSmithKline and Pfizer, two rival drug makers, agreed to spin out and combine their H.I.V. research units into a new company."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""A Different Kind of Drug Deal"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2009-04-17T11:10:40+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/4770809a-fbb3-5940-b0a5-16714cfac3bc"", ""word_count"": 342, ""uri"": ""nyt://article/4770809a-fbb3-5940-b0a5-16714cfac3bc""}"
2009-04-28,"{""abstract"": ""As Pfizer sails toward its merger with Wyeth, it is hitting headwinds from patent expirations and weakening in sales in some key products, including Lipitor."", ""web_url"": ""https://www.nytimes.com/2009/04/29/business/29pfizer.html"", ""snippet"": ""As Pfizer sails toward its merger with Wyeth, it is hitting headwinds from patent expirations and weakening in sales in some key products, including Lipitor."", ""lead_paragraph"": ""As the drug giant Pfizer sails toward its merger with Wyeth, the company is hitting headwinds in the form of patent expirations and weakening sales in some important products, including Lipitor. "", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2009/04/29/business/29pfizer.75.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2009/04/29/business/29pfizer.75.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Pfizer Profit Dips on Ease in Demand for Lipitor"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer Profit Dips 2% as Demand for Lipitor Declines"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Company Reports"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Lipitor (Drug)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Wyeth"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2009-04-28T19:03:39+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Duff Wilson"", ""person"": [{""firstname"": ""Duff"", ""middlename"": null, ""lastname"": ""Wilson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/155c22d3-534f-5372-80ee-25cbd380c692"", ""word_count"": 671, ""uri"": ""nyt://article/155c22d3-534f-5372-80ee-25cbd380c692""}"
2009-05-04,"{""abstract"": ""The proposed tax overhaul, aimed at benefits enjoyed by those harboring cash in offshore accounts, could help raise $210 billion, the administration estimates."", ""web_url"": ""https://www.nytimes.com/2009/05/05/business/05tax.html"", ""snippet"": ""The proposed tax overhaul, aimed at benefits enjoyed by those harboring cash in offshore accounts, could help raise $210 billion, the administration estimates."", ""lead_paragraph"": ""WASHINGTON \u2014 President Obama on Monday called for curbing offshore tax havens and corporate tax breaks to collect billions of dollars more from multinational companies and wealthy individuals. "", ""print_section"": ""A"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2009/05/05/business/05tax01-75.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2009/05/05/business/05tax01-75.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Obama Calls for Curbs on Offshore Tax Havens"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""OBAMA ASKS CURB ON USE OF HAVENS TO REDUCE TAXES"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Corporations"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Internal Revenue Service"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Microsoft Corp"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""High Net Worth Individuals"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""United States Politics and Government"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tax Shelters"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Goldman Sachs Group"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Procter & Gamble Co"", ""rank"": 9, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Obama, Barack"", ""rank"": 10, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""United States Economy"", ""rank"": 11, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tax Evasion"", ""rank"": 12, ""major"": ""N""}], ""pub_date"": ""2009-05-04T16:34:44+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Jackie Calmes and Edmund L. Andrews"", ""person"": [{""firstname"": ""Jackie"", ""middlename"": null, ""lastname"": ""Calmes"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Edmund"", ""middlename"": ""L."", ""lastname"": ""Andrews"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/46f7fa73-6e04-5689-8bed-a0865866e6e2"", ""word_count"": 1108, ""uri"": ""nyt://article/46f7fa73-6e04-5689-8bed-a0865866e6e2""}"
2009-06-15,"{""abstract"": ""Pfizer is looking to conclude deals in emerging markets over \u201cfew months\u201d to raise its share in a market estimated at $80 billion, a Pfizer executive told Reuters."", ""web_url"": ""https://dealbook.nytimes.com/2009/06/15/pfizer-looks-to-raise-presence-in-emerging-markets/"", ""snippet"": ""Pfizer is looking to conclude deals in emerging markets over \u201cfew months\u201d to raise its share in a market estimated at $80 billion, a Pfizer executive told Reuters."", ""lead_paragraph"": ""Pfizer, the world\u2019s largest drugmaker, is looking to conclude deals in emerging markets over \u201cfew months\u201d to raise its share of a market estimated at about $80 billion, an executive told Reuters."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer Looks to Raise Presence in Emerging Markets"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2009-06-15T10:37:33+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/febb7c54-cd52-5bd7-b449-15023a58e171"", ""word_count"": 407, ""uri"": ""nyt://article/febb7c54-cd52-5bd7-b449-15023a58e171""}"
2009-06-18,"{""abstract"": ""Wyeth has scheduled a meeting for its shareholders to vote on whether to approve its pending acquisition by Pfizer."", ""web_url"": ""https://dealbook.nytimes.com/2009/06/18/wyeth-sets-meeting-for-shareholders-merger-vote/"", ""snippet"": ""Wyeth has scheduled a meeting for its shareholders to vote on whether to approve its pending acquisition by Pfizer."", ""lead_paragraph"": ""The drug maker Wyeth has scheduled a meeting for its shareholders to vote on whether to approve the company\u2019s pending acquisition by Pfizer, The Associated Press said."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Wyeth Sets Meeting for Shareholders\u2019 Merger Vote"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2009-06-18T09:59:47+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/1080f593-ceb9-53c8-b105-f2e1e2c02dc7"", ""word_count"": 140, ""uri"": ""nyt://article/1080f593-ceb9-53c8-b105-f2e1e2c02dc7""}"
2009-09-02,"[{""abstract"": ""Companies are pouring billions into developing cancer drugs, lured by the high prices such drugs can command."", ""web_url"": ""https://www.nytimes.com/2009/09/02/health/research/02cancerdrug.html"", ""snippet"": ""Companies are pouring billions into developing cancer drugs, lured by the high prices such drugs can command."", ""lead_paragraph"": ""SAN DIEGO \u0097 Pfizer\u2019s fortunes in the past were built on cardiovascular drugs, like the cholesterol buster Lipitor and the blood pressure pill Norvasc. "", ""print_section"": ""A"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2009/09/02/business/02cancerdrug_75.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2009/09/02/business/02cancerdrug_75.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""For Profit, Industry Seeks Cancer Drugs"", ""kicker"": ""Forty Years' War"", ""content_kicker"": null, ""print_headline"": ""Taking Big Risk for Big Payoff, Industry Seeks Cancer Drugs"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Cancer"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Research"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Exelixis Incorporated"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Prices (Fares, Fees and Rates)"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2009-09-02T01:21:49+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Health"", ""subsection_name"": ""Research"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""Series"", ""_id"": ""nyt://article/2ff2563b-109d-52dd-b90c-4e5c3914ff77"", ""word_count"": 1832, ""uri"": ""nyt://article/2ff2563b-109d-52dd-b90c-4e5c3914ff77""}, {""abstract"": ""The government charged that executives throughout the company planned schemes to illegally market Bextra and other drugs."", ""web_url"": ""https://www.nytimes.com/2009/09/03/business/03health.html"", ""snippet"": ""The government charged that executives throughout the company planned schemes to illegally market Bextra and other drugs."", ""lead_paragraph"": ""WASHINGTON \u0097 The pharmaceutical giant Pfizer agreed to pay $2.3 billion to settle civil and criminal allegations that it had illegally marketed its painkiller Bextra, which has been withdrawn."", ""print_section"": ""B"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer Pays $2.3 Billion to Settle Marketing Case"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer to Pay $2.3 Billion to Settle Inquiry Over Marketing"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Bextra (Drug)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Frauds and Swindling"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""ADVERTISING AND MARKETING"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2009-09-02T14:38:10+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Gardiner Harris"", ""person"": [{""firstname"": ""Gardiner"", ""middlename"": null, ""lastname"": ""Harris"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/cae7074f-c51e-539c-9e67-86c73465a47e"", ""word_count"": 1075, ""uri"": ""nyt://article/cae7074f-c51e-539c-9e67-86c73465a47e""}]"
2009-09-03,"{""abstract"": ""Pfizer agreed to pay $2.3 billion to settle civil and criminal allegations that it had illegally marketed its painkiller Bextra, which has been withdrawn."", ""web_url"": ""https://dealbook.nytimes.com/2009/09/03/pfizer-pays-23-billion-to-settle-marketing-case/"", ""snippet"": ""Pfizer agreed to pay $2.3 billion to settle civil and criminal allegations that it had illegally marketed its painkiller Bextra, which has been withdrawn."", ""lead_paragraph"": ""The pharmaceutical giant Pfizer agreed to pay $2.3 billion to settle civil and criminal allegations that it had illegally marketed its painkiller Bextra, which has been withdrawn, The New York Times\u2019s Gardiner Harris reported."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer Pays $2.3 Billion to Settle Marketing Case"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2009-09-03T08:31:17+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/c692b2ed-78cf-53d0-843e-c1422a51bb39"", ""word_count"": 522, ""uri"": ""nyt://article/c692b2ed-78cf-53d0-843e-c1422a51bb39""}"
2009-09-30,"{""abstract"": ""The drug maker still needs approval from the United States and Candada for its $68 billion buyout of a rival."", ""web_url"": ""https://dealbook.nytimes.com/2009/09/30/pfizer-gets-ok-from-china-and-australia-for-wyeth-deal/"", ""snippet"": ""The drug maker still needs approval from the United States and Candada for its $68 billion buyout of a rival."", ""lead_paragraph"": ""Pfizer, the drug maker, has received regulatory approval from both Chinese and Australian antitrust authorities for its $68 billion buyout of a rival, Wyeth."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer Gets Approval From China and Australia for Wyeth Deal"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2009-09-30T10:19:22+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/06003243-1426-5c80-82e8-65ad9cc1c818"", ""word_count"": 136, ""uri"": ""nyt://article/06003243-1426-5c80-82e8-65ad9cc1c818""}"
2009-10-15,"{""abstract"": ""Pfizer\u2019s $68 billion purchase of Wyeth will close Thursday after antitrust regulators in the U.S. and Canada cleared the deal, which will make Pfizer the world\u2019s largest drugmaker by revenue."", ""web_url"": ""https://dealbook.nytimes.com/2009/10/15/us-and-canada-approve-pfizer-wyeth-deal/"", ""snippet"": ""Pfizer\u2019s $68 billion purchase of Wyeth will close Thursday after antitrust regulators in the U.S. and Canada cleared the deal, which will make Pfizer the world\u2019s largest drugmaker by revenue."", ""lead_paragraph"": ""Pfizer\u2018s $68 billion purchase of Wyeth will close Thursday after antitrust regulators in the United States and Canada cleared the deal, which will make Pfizer the world\u2019s largest drugmaker by revenue, The Associated Press reported."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""U.S. and Canada Approve Pfizer-Wyeth Deal"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2009-10-15T07:58:30+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/30396b59-e782-5766-b744-b59e2924744d"", ""word_count"": 191, ""uri"": ""nyt://article/30396b59-e782-5766-b744-b59e2924744d""}"
2009-10-28,"{""abstract"": ""Pfizer just announced it is giving two senior vice presidents bonuses of $1 million and $1.2 million for their deft handling of the $68 billion Wyeth buyout in the midst of the global financial crisis."", ""web_url"": ""https://dealbook.nytimes.com/2009/10/28/for-closing-wyeth-deal-pfizer-doles-out-rewards/"", ""snippet"": ""Pfizer just announced it is giving two senior vice presidents bonuses of $1 million and $1.2 million for their deft handling of the $68 billion Wyeth buyout in the midst of the global financial crisis."", ""lead_paragraph"": ""From Duff Wilson, a DealBook colleague:"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""For Closing Wyeth Deal, Pfizer Doles Out Rewards"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2009-10-28T20:21:49+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Duff Wilson"", ""person"": [{""firstname"": ""Duff"", ""middlename"": null, ""lastname"": ""Wilson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/2d1b70ee-ede8-570a-a673-b7881bc031da"", ""word_count"": 275, ""uri"": ""nyt://article/2d1b70ee-ede8-570a-a673-b7881bc031da""}"
2009-11-05,"[{""abstract"": ""At their worst, bonuses for acquisitions encourage empire-building and widen the gap between the interests of management and those of shareholders."", ""web_url"": ""https://www.nytimes.com/2009/11/05/business/05views.html"", ""snippet"": ""At their worst, bonuses for acquisitions encourage empire-building and widen the gap between the interests of management and those of shareholders."", ""lead_paragraph"": ""Frank A. D\u2019Amelio may be worth the $6 million of compensation he received last year as chief financial officer for Pfizer. But it\u2019s questionable for the drug company to also pay him a $1.2 million bonus \u0097 half in cash and half in stock \u0097 for his role in acquiring its rival Wyeth. Rewarding executives for going shopping is daft."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Offer Incentives, but Carefully"", ""kicker"": ""Breakingviews.com"", ""content_kicker"": null, ""print_headline"": ""Offer Incentives, but Carefully"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Bonuses"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Executives and Management"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Executive Compensation"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2009-11-05T04:49:42+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Robert Cyran and Aliza Rosenbaum"", ""person"": [{""firstname"": ""Robert"", ""middlename"": null, ""lastname"": ""Cyran"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Aliza"", ""middlename"": null, ""lastname"": ""Rosenbaum"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/88f48f75-f2de-5c84-aac3-e480e726411b"", ""word_count"": 740, ""uri"": ""nyt://article/88f48f75-f2de-5c84-aac3-e480e726411b""}, {""abstract"": ""If not carefully handled, bonuses awarded to chief executives for selling their company can widen the gap between the interests of management and those of shareholders, Breakingviews argues."", ""web_url"": ""https://dealbook.nytimes.com/2009/11/05/rewarding-ceos-for-dealmaking/"", ""snippet"": ""If not carefully handled, bonuses awarded to chief executives for selling their company can widen the gap between the interests of management and those of shareholders, Breakingviews argues."", ""lead_paragraph"": ""Frank A. D\u2019Amelio may be worth the $6 million of compensation he received last year as chief financial officer for Pfizer. But, Breakingviews says, it\u2019s questionable for the drug company to also pay him a $1.2 million bonus \u2014 half in cash and half in stock \u2014 for his role in acquiring its rival Wyeth. Rewarding executives for going shopping is crazy, the publication suggests."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Should C.E.O.s Be Rewarded for Dealmaking?"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2009-11-05T09:12:51+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/ea8a543a-8fb6-537d-8359-96ee108b61b5"", ""word_count"": 414, ""uri"": ""nyt://article/ea8a543a-8fb6-537d-8359-96ee108b61b5""}]"
2009-11-24,"{""abstract"": ""The drug maker has been ordered to pay punitive damages to two women whose breast cancer was diagnosed after they used hormone drugs."", ""web_url"": ""https://www.nytimes.com/2009/11/24/business/24wyeth.html"", ""snippet"": ""The drug maker has been ordered to pay punitive damages to two women whose breast cancer was diagnosed after they used hormone drugs."", ""lead_paragraph"": "" Pfizer has been ordered to pay a total of $103 million in punitive damages to two women who were found to have breast cancer after they used hormonal drugs, state court officials in Philadelphia said Monday."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2009/11/24/business/24wyeth_CA0/thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2009/11/24/business/24wyeth_CA0/thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Another Loss for Pfizer in Drug Suits"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer Loses Again in Suit Over Drugs"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Cancer"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Suits and Litigation"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Estrogen"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Hormones"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Wyeth"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2009-11-24T02:02:43+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Duff Wilson"", ""person"": [{""firstname"": ""Duff"", ""middlename"": null, ""lastname"": ""Wilson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/c4096033-8017-5fd3-af9b-1471290eb2ab"", ""word_count"": 991, ""uri"": ""nyt://article/c4096033-8017-5fd3-af9b-1471290eb2ab""}"
2009-12-01,"{""abstract"": ""Pfizer said that it had licensed the worldwide rights to a treatment for Gaucher disease, a genetic disorder, putting Pfizer into competition with Genzyme."", ""web_url"": ""https://www.nytimes.com/2009/12/02/business/02drug.html"", ""snippet"": ""Pfizer said that it had licensed the worldwide rights to a treatment for Gaucher disease, a genetic disorder, putting Pfizer into competition with Genzyme."", ""lead_paragraph"": ""The world\u2019s largest drug company is thinking small. "", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer Deal Signals a Move Into Treating Rare Diseases"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer Deal Signals a Move Into Treating Rare Diseases"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Genzyme Corp"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Gaucher's Disease"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2009-12-01T12:05:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/39cdcd29-84bb-5035-8d10-97a1e977c911"", ""word_count"": 703, ""uri"": ""nyt://article/39cdcd29-84bb-5035-8d10-97a1e977c911""}"
2009-12-02,"{""abstract"": ""Pfizer said Tuesday that it had licensed the worldwide rights to a treatment for Gaucher disease, a rare genetic disorder, from Protalix Biotherapeutics, an Israeli biotechnology company."", ""web_url"": ""https://dealbook.nytimes.com/2009/12/02/pfizer-deal-signals-a-move-into-treating-rare-diseases/"", ""snippet"": ""Pfizer said Tuesday that it had licensed the worldwide rights to a treatment for Gaucher disease, a rare genetic disorder, from Protalix Biotherapeutics, an Israeli biotechnology company."", ""lead_paragraph"": ""The world\u2019s largest drug company is thinking small. Pfizer said Tuesday that it had licensed the worldwide rights to a treatment for Gaucher disease, a rare genetic disorder, from Protalix Biotherapeutics, an Israeli biotechnology company, The New York Times\u2019s Andrew Pollack writes."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer Deal Signals Move Into Rare Diseases"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2009-12-02T10:01:02+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/ca56c731-9f02-5806-bbe7-a378b35b06da"", ""word_count"": 700, ""uri"": ""nyt://article/ca56c731-9f02-5806-bbe7-a378b35b06da""}"
2009-12-12,"[{""abstract"": ""Two pharmaceutical companies have developed drugs to fight premature ejaculation, and hope they will become blockbusters like drugs for erectile dysfunction."", ""web_url"": ""https://www.nytimes.com/2009/12/13/business/13stream.html"", ""snippet"": ""Two pharmaceutical companies have developed drugs to fight premature ejaculation, and hope they will become blockbusters like drugs for erectile dysfunction."", ""lead_paragraph"": ""VIAGRA and its pitchman, Bob Dole, turned erectile dysfunction into a modern man\u2019s malady."", ""print_section"": ""BU"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2009/12/12/business/13stream1/articleLarge.jpg"", ""height"": 363, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2009/12/12/business/13stream1/articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 363}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2009/12/12/business/13stream1/thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2009/12/12/business/13stream1/thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Sure, It\u2019s Treatable. But Is It a Disorder?"", ""kicker"": ""Slipstream"", ""content_kicker"": null, ""print_headline"": ""Sure, It\u2019s Treatable. But Is It a Disorder?"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Viagra (Drug)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Johnson & Johnson Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Dole, Bob"", ""rank"": 4, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Cassels, Alan"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Sex"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Doctors"", ""rank"": 8, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 10, ""major"": ""N""}], ""pub_date"": ""2009-12-12T18:13:02+0000"", ""document_type"": ""article"", ""news_desk"": ""SundayBusiness"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Natasha Singer"", ""person"": [{""firstname"": ""Natasha"", ""middlename"": null, ""lastname"": ""Singer"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/d50101df-db6b-5c0e-9793-8224f6c13cd0"", ""word_count"": 1042, ""uri"": ""nyt://article/d50101df-db6b-5c0e-9793-8224f6c13cd0""}, {""abstract"": ""Lawsuits and internal documents show how Pfizer and its predecessors promoted the idea of taking hormone drugs."", ""web_url"": ""https://www.nytimes.com/2009/12/13/business/13drug.html"", ""snippet"": ""Lawsuits and internal documents show how Pfizer and its predecessors promoted the idea of taking hormone drugs."", ""lead_paragraph"": ""MILLIONS of American women in the 1990s were told they could help their bodies ward off major illness by taking menopausal hormone drugs. Some medical associations said so. Many gynecologists and physicians said so. Respected medical journals said so, too. "", ""print_section"": ""BU"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2009/12/13/business/13drug1a/thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2009/12/13/business/13drug1a/thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Menopause, as Brought to You by Big Pharma"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Menopause, as Brought To You by Big Pharma"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""New England Journal of Medicine"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Women and Girls"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Hormones"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Journal of the American Medical Assn"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Breasts"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Menopause"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""National Institutes of Health"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""American Journal of Medicine"", ""rank"": 10, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Suits and Litigation"", ""rank"": 11, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Estrogen"", ""rank"": 12, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cancer"", ""rank"": 13, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 14, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Wyeth"", ""rank"": 15, ""major"": ""N""}], ""pub_date"": ""2009-12-12T19:25:52+0000"", ""document_type"": ""article"", ""news_desk"": ""SundayBusiness"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Natasha Singer and Duff Wilson"", ""person"": [{""firstname"": ""Natasha"", ""middlename"": null, ""lastname"": ""Singer"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Duff"", ""middlename"": null, ""lastname"": ""Wilson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/07396369-54c4-535a-bcc8-08fc46f6d29b"", ""word_count"": 3159, ""uri"": ""nyt://article/07396369-54c4-535a-bcc8-08fc46f6d29b""}]"
2009-12-21,"[{""abstract"": ""Pfizer will have the rights to develop Athersys\u2019s cells to treat inflammatory bowel disease, which is in early human testing."", ""web_url"": ""https://www.nytimes.com/2009/12/21/business/21pfizer.html"", ""snippet"": ""Pfizer will have the rights to develop Athersys\u2019s cells to treat inflammatory bowel disease, which is in early human testing."", ""lead_paragraph"": ""Pfizer said Sunday that it was buying the rights to a somewhat controversial cell therapy from Athersys, a biotechnology company \u0097 a sign of big pharmaceutical companies\u2019 growing interest in stem cells. "", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer Acquires a Stem-Cell Therapy"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer Acquires a Stem-Cell Therapy"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Athersys"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Stem Cells"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2009-12-21T05:03:01+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/f4759e49-e4e3-50cb-a9ba-80eda1372412"", ""word_count"": 483, ""uri"": ""nyt://article/f4759e49-e4e3-50cb-a9ba-80eda1372412""}, {""abstract"": ""Pfizer said it was buying the rights to a somewhat controversial cell therapy from Athersys, a biotechnology company \u2014 a sign of big pharmaceutical companies\u2019 growing interest in stem cells."", ""web_url"": ""https://dealbook.nytimes.com/2009/12/21/pfizer-acquires-a-stem-cell-therapy/"", ""snippet"": ""Pfizer said it was buying the rights to a somewhat controversial cell therapy from Athersys, a biotechnology company \u2014 a sign of big pharmaceutical companies\u2019 growing interest in stem cells."", ""lead_paragraph"": ""Pfizer said Sunday that it was buying the rights to a somewhat controversial cell therapy from Athersys, a biotechnology company \u2014 a sign of big pharmaceutical companies\u2019 growing interest in stem cells, The New York Times\u2019s Andrew Pollack reported."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer Acquires a Stem-Cell Therapy"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Athersys"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}], ""pub_date"": ""2009-12-21T10:13:56+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/7f89cf35-b2dd-5dec-ac09-b550b64c48d3"", ""word_count"": 467, ""uri"": ""nyt://article/7f89cf35-b2dd-5dec-ac09-b550b64c48d3""}]"
2009-12-28,"{""abstract"": ""In part one of his 2009 year in review, the Deal Professor examines the general trends of what he predicts will be a flatter deal-making landscape for some time to come."", ""web_url"": ""https://dealbook.nytimes.com/2009/12/28/the-deal-professors-2009-in-review-part-i-no-exit/"", ""snippet"": ""In part one of his 2009 year in review, the Deal Professor examines the general trends of what he predicts will be a flatter deal-making landscape for some time to come."", ""lead_paragraph"": ""The mergers and acquisitions landscape circa 2010 isn\u2019t pretty. "", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""The Deal Professor\u2019s 2009 in Review, Part I: No Exit"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Banks and Banking"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Credit"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Private Equity"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Regulation and Deregulation of Industry"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Sovereign Wealth Funds"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""United States Economy"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""3Com Corporation"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AFFILIATED COMPUTER SERVICES INCORPORATED"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Agrium Incorporated"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Bank of America Corp"", ""rank"": 11, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Berkshire Hathaway Inc"", ""rank"": 12, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Brocade Communications Systems Inc"", ""rank"": 13, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Cerberus Capital Management"", ""rank"": 14, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Coca-Cola Co"", ""rank"": 15, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Dow Chemical Co"", ""rank"": 16, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Eastman Kodak Co"", ""rank"": 17, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Exxon Mobil Corp"", ""rank"": 18, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Finish Line Incorporated (The)"", ""rank"": 19, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Firstgold Corp"", ""rank"": 20, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Genesco Incorporated"", ""rank"": 21, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Hexion Specialty Chemicals"", ""rank"": 22, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Huawei Technologies"", ""rank"": 23, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Hummer Division of General Motors Corp"", ""rank"": 24, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Huntsman Chemical Corp"", ""rank"": 25, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""IMS Health Incorporated"", ""rank"": 26, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Kohlberg Kravis Roberts & Co"", ""rank"": 27, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""KRAFT FOODS"", ""rank"": 28, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""LANDRY'S RESTAURANTS INC"", ""rank"": 29, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merrill Lynch & Co"", ""rank"": 30, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Microsoft Corp"", ""rank"": 31, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Oracle Corp"", ""rank"": 32, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 33, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Sichuan Tengzhong Heavy Industrial Machinery Co"", ""rank"": 34, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Sun Microsystems Inc"", ""rank"": 35, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Terra Industries Incorporated"", ""rank"": 36, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""The Blackstone Group"", ""rank"": 37, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""TPG Capital"", ""rank"": 38, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""United Rentals Incorporated"", ""rank"": 39, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Virgin Galactic"", ""rank"": 40, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Wyeth"", ""rank"": 41, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""XTO Energy"", ""rank"": 42, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Yahoo! Inc"", ""rank"": 43, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""China"", ""rank"": 44, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Delaware"", ""rank"": 45, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Great Britain"", ""rank"": 46, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""United Arab Emirates"", ""rank"": 47, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""United States"", ""rank"": 48, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Wall Street (NYC)"", ""rank"": 49, ""major"": ""N""}], ""pub_date"": ""2009-12-28T17:16:31+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Steven Davidoff Solomon"", ""person"": [{""firstname"": ""Steven"", ""middlename"": ""Davidoff"", ""lastname"": ""Solomon"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/e7cbef59-a368-5be4-8ab0-b1d4630ff9b8"", ""word_count"": 2044, ""uri"": ""nyt://article/e7cbef59-a368-5be4-8ab0-b1d4630ff9b8""}"
2010-01-09,"{""abstract"": ""Why corporate apologies could mean a lot \u2014 for patients and for employees."", ""web_url"": ""https://www.nytimes.com/2010/01/10/business/10stream.html"", ""snippet"": ""Why corporate apologies could mean a lot \u2014 for patients and for employees."", ""lead_paragraph"": ""AH, the thorny and seemingly never-ending topic of employee error and corporate misconduct: How does your company handle it? Deny and defend? Disclose and apologize?"", ""print_section"": ""BU"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2010/01/10/business/10stream-span/articleLarge.jpg"", ""height"": 346, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2010/01/10/business/10stream-span/articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 346}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2010/01/10/business/10stream-span/thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2010/01/10/business/10stream-span/thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Is \u2018Sorry\u2019 the Hardest Word in Health Care?"", ""kicker"": ""Slipstream"", ""content_kicker"": null, ""print_headline"": ""Is \u2018Sorry\u2019 the Hardest Word in Health Care?"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Apologies"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Fines (Penalties)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Lilly, Eli, & Co"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Suits and Litigation"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2010-01-09T21:39:38+0000"", ""document_type"": ""article"", ""news_desk"": ""SundayBusiness"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Natasha Singer"", ""person"": [{""firstname"": ""Natasha"", ""middlename"": null, ""lastname"": ""Singer"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/7e35fac8-c611-580e-844b-655d36a369cf"", ""word_count"": 1015, ""uri"": ""nyt://article/7e35fac8-c611-580e-844b-655d36a369cf""}"
2010-01-11,"{""abstract"": ""With a $3 million grant, Stanford University is planning a continuing education program for doctors that is free of drug industry influence."", ""web_url"": ""https://www.nytimes.com/2010/01/11/business/11drug.html"", ""snippet"": ""With a $3 million grant, Stanford University is planning a continuing education program for doctors that is free of drug industry influence."", ""lead_paragraph"": ""Stanford University on Monday will announce plans to develop new continuing education programs for doctors that will be devoid of the drug industry influence that has often permeated such courses."", ""print_section"": ""B"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2010/01/11/business/11drug_CA0/thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2010/01/11/business/11drug_CA0/thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Using a Pfizer Grant, Courses Aim to Avoid Bias"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Using a Pfizer Grant, Courses Aim to Avoid Bias"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Conflicts of Interest"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Stanford University"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Grants (Corporate and Foundation)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Colleges and Universities"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2010-01-11T05:02:15+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Duff Wilson"", ""person"": [{""firstname"": ""Duff"", ""middlename"": null, ""lastname"": ""Wilson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/cb3fe48f-10e2-50b2-84ca-c277cb815fd0"", ""word_count"": 826, ""uri"": ""nyt://article/cb3fe48f-10e2-50b2-84ca-c277cb815fd0""}"
2010-01-15,"{""abstract"": ""Stocks advanced for a second day as technology shares climbed before Intel reported earnings. In addition, business inventories increased more than forecast, overshadowing an unexpected drop in retail sales."", ""web_url"": ""https://dealbook.nytimes.com/2010/01/15/technology-helps-lead-shares-higher-as-retailers-slip/"", ""snippet"": ""Stocks advanced for a second day as technology shares climbed before Intel reported earnings. In addition, business inventories increased more than forecast, overshadowing an unexpected drop in retail sales."", ""lead_paragraph"": ""Stocks advanced for a second day as technology shares climbed before Intel reported earnings. In addition, business inventories increased more than forecast, overshadowing an unexpected drop in retail sales."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Technology Helps Shares Higher as Retailers Slip"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Barclays PLC"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Credit Suisse Group"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Intel Corp"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Marriott International Incorporated"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Morgan Stanley"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""New York Stock Exchange"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Tyson Foods Incorporated"", ""rank"": 8, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Wall Street (NYC)"", ""rank"": 9, ""major"": ""N""}], ""pub_date"": ""2010-01-15T10:26:18+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/780b9ed0-cce8-5180-a4fb-cf5871e13cb6"", ""word_count"": 717, ""uri"": ""nyt://article/780b9ed0-cce8-5180-a4fb-cf5871e13cb6""}"
2010-02-01,"{""abstract"": ""The year started off exceptionally slow for mergers and acquisitions in the United States. There was only $34.2 billion worth of announced deals in January, according to Standard & Poor\u2019s Capital IQ, making it the slowest first month of the year since 2003."", ""web_url"": ""https://dealbook.nytimes.com/2010/02/01/big-chill-hit-the-deal-market-in-january/"", ""snippet"": ""The year started off exceptionally slow for mergers and acquisitions in the United States. There was only $34.2 billion worth of announced deals in January, according to Standard & Poor\u2019s Capital IQ, making it the slowest first month of the year s..."", ""lead_paragraph"": ""The year started off exceptionally slowly for mergers and acquisitions in the United States. There was only $34.2 billion worth of announced deals in January, according to Standard & Poor\u2019s Capital IQ, making it the slowest first month of the year since 2003."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Big Chill Hit the Deal Market in January"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Alcon Incorporated"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Williams Cos Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Wyeth"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2010-02-01T23:48:51+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Cyrus Sanati"", ""person"": [{""firstname"": ""Cyrus"", ""middlename"": null, ""lastname"": ""Sanati"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/8529e448-6ac9-5e60-b863-eafe7687bc94"", ""word_count"": 240, ""uri"": ""nyt://article/8529e448-6ac9-5e60-b863-eafe7687bc94""}"
2010-02-04,"[{""abstract"": ""The company\u2019s quarterly profit more than doubled but the results were hurt by costs associated with the purchase of Wyeth, a rival drug maker."", ""web_url"": ""https://www.nytimes.com/2010/02/04/business/04pfizer.html"", ""snippet"": ""The company\u2019s quarterly profit more than doubled but the results were hurt by costs associated with the purchase of Wyeth, a rival drug maker."", ""lead_paragraph"": ""Pfizer, the world\u2019s biggest drug maker, said fourth-quarter profit missed analysts\u2019 estimates on costs from its acquisition of Wyeth and projected lower-than-expected earnings in 2010."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2010/02/04/business/04pfizer_CA0/04pfizer_CA0-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2010/02/04/business/04pfizer_CA0/04pfizer_CA0-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Pfizer Misses Estimates, and Shares Slide"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer Misses Estimates, and Shares Slide"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Lipitor (Drug)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Company Reports"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2010-02-04T01:07:17+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Bloomberg News"", ""person"": [{""firstname"": ""Bloomberg"", ""middlename"": null, ""lastname"": ""News"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/5cfab7de-f798-5ba4-b758-f74a31c78ee2"", ""word_count"": 329, ""uri"": ""nyt://article/5cfab7de-f798-5ba4-b758-f74a31c78ee2""}, {""abstract"": ""Investors were cautious on Wednesday as concerns over high unemployment and the ability of businesses to bring in revenue resurfaced, tempering some of the zeal that had marked Wall Street earlier this week."", ""web_url"": ""https://dealbook.nytimes.com/2010/02/04/concerned-over-jobs-and-revenue-wall-st-wanders/"", ""snippet"": ""Investors were cautious on Wednesday as concerns over high unemployment and the ability of businesses to bring in revenue resurfaced, tempering some of the zeal that had marked Wall Street earlier this week."", ""lead_paragraph"": ""Investors were cautious on Wednesday as concerns over high unemployment and the ability of businesses to bring in revenue resurfaced, tempering some of the zeal that had marked Wall Street earlier this week."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Concerned Over Jobs and Revenue, Wall St. Wanders"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Labor Department"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""MetLife, Incorporated"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Toyota Motor Corp"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2010-02-04T09:06:36+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/f43aae95-546b-51db-b2ec-4e5bf4abe9c5"", ""word_count"": 579, ""uri"": ""nyt://article/f43aae95-546b-51db-b2ec-4e5bf4abe9c5""}]"
2010-02-05,"{""abstract"": ""Without the regulatory certainty stemming from the health care bill, drug companies face unpleasant surprises like a heavier tax on foreign income."", ""web_url"": ""https://www.nytimes.com/2010/02/05/business/05pharma.html"", ""snippet"": ""Without the regulatory certainty stemming from the health care bill, drug companies face unpleasant surprises like a heavier tax on foreign income."", ""lead_paragraph"": ""With the possible demise of health care legislation, getting back to business as usual may not be the best thing for the nation\u2019s drug makers. "", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Stalled Health Care Bill Leaves Drug Makers in Regulatory Limbo"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Stalled Health Care Bill Leaves Drug Makers in Regulatory Limbo"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Obama, Barack"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Johnson & Johnson Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Senate"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Reform and Reorganization"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Lilly, Eli, & Co"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Bristol-Myers Squibb Co"", ""rank"": 8, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Brown, Scott P"", ""rank"": 9, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Taxation"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""House of Representatives"", ""rank"": 11, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Health Insurance and Managed Care"", ""rank"": 12, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Sullivan, Martin A"", ""rank"": 13, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 14, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Kindler, Jeffrey B"", ""rank"": 15, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""United States Politics and Government"", ""rank"": 16, ""major"": ""N""}], ""pub_date"": ""2010-02-05T04:02:36+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Duff Wilson"", ""person"": [{""firstname"": ""Duff"", ""middlename"": null, ""lastname"": ""Wilson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/1ea98fb5-4ba7-57c6-a852-e90456569a32"", ""word_count"": 1184, ""uri"": ""nyt://article/1ea98fb5-4ba7-57c6-a852-e90456569a32""}"
2010-02-16,"{""abstract"": ""Drug makers are pursuing a consumer base in markets like Asia and Latin America, where many pay out of pocket for medicines but often cannot afford expensive brand-name drugs."", ""web_url"": ""https://www.nytimes.com/2010/02/16/business/16generic.html"", ""snippet"": ""Drug makers are pursuing a consumer base in markets like Asia and Latin America, where many pay out of pocket for medicines but often cannot afford expensive brand-name drugs."", ""lead_paragraph"": ""Some prestigious brand-name pharmaceutical companies that once looked askance at the high-volume, low-cost business of generic drugs are now becoming major purveyors of generic medicines."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2010/02/16/business/16generic_1/16generic_1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2010/02/16/business/16generic_1/16generic_1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Drug Firms Apply Brand to Generics"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Drug Firms Apply Brand To Generics"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Medley Pharmaceuticals"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Trademarks and Trade Names"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""GlaxoSmithKline PLC"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Sanofi-Aventis SA"", ""rank"": 8, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Generic and Brand Name Products"", ""rank"": 9, ""major"": ""N""}], ""pub_date"": ""2010-02-16T02:58:15+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Natasha Singer"", ""person"": [{""firstname"": ""Natasha"", ""middlename"": null, ""lastname"": ""Singer"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/b34aa206-d31c-5002-a9bd-64589049a273"", ""word_count"": 1220, ""uri"": ""nyt://article/b34aa206-d31c-5002-a9bd-64589049a273""}"
2010-02-17,"[{""abstract"": ""AstraZeneca waded into the competitive rheumatoid arthritis market on Tuesday by buying rights to Rigel Pharmaceuticals\u2019 next-generation drug R788 for up to $1.245 billion, Reuters reported."", ""web_url"": ""https://dealbook.nytimes.com/2010/02/17/astra-pays-up-to-1-2-billion-for-arthritis-drug/"", ""snippet"": ""AstraZeneca waded into the competitive rheumatoid arthritis market on Tuesday by buying rights to Rigel Pharmaceuticals\u2019 next-generation drug R788 for up to $1.245 billion, Reuters reported."", ""lead_paragraph"": ""AstraZeneca waded into the competitive rheumatoid arthritis market on Tuesday by buying rights to Rigel Pharmaceuticals\u2018 next-generation drug R788 for up to $1.245 billion, Reuters reported."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Astra Pays Up to $1.2 Billion for Arthritis Drug"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}], ""pub_date"": ""2010-02-17T08:59:28+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/a54bc8f1-211c-5747-9ba9-701d9e981852"", ""word_count"": 451, ""uri"": ""nyt://article/a54bc8f1-211c-5747-9ba9-701d9e981852""}, {""abstract"": ""Merck posted quarterly revenue above analysts\u2019 estimates on Tuesday, helped by strong sales of its diabetes and allergy drugs, Reuters reported."", ""web_url"": ""https://dealbook.nytimes.com/2010/02/17/in-wake-of-merger-merck-beats-forecasts/"", ""snippet"": ""Merck posted quarterly revenue above analysts\u2019 estimates on Tuesday, helped by strong sales of its diabetes and allergy drugs, Reuters reported."", ""lead_paragraph"": ""Merck posted quarterly revenue above analysts\u2019 estimates on Tuesday, helped by strong sales of its diabetes and allergy drugs, Reuters reported."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""In Wake of Merger, Merck Beats Forecasts"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Bristol-Myers Squibb Co"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Wyeth"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2010-02-17T09:56:18+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/2905d6ef-1339-5073-9fd9-192a48d86d7d"", ""word_count"": 293, ""uri"": ""nyt://article/2905d6ef-1339-5073-9fd9-192a48d86d7d""}]"
2010-02-18,"{""abstract"": ""Actavis has severed ties with Sweden\u2019s EQT in a bid for German drug maker Ratiopharm, Reuters reported."", ""web_url"": ""https://dealbook.nytimes.com/2010/02/18/actavis-relies-on-deutsche-for-ratiopharm-bid/"", ""snippet"": ""Actavis has severed ties with Sweden\u2019s EQT in a bid for German drug maker Ratiopharm, Reuters reported."", ""lead_paragraph"": ""Actavis has severed ties with Sweden\u2019s EQT in a bid for German drug maker Ratiopharm, Reuters reported."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Actavis Relies on Deutsche for Ratiopharm Bid"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Deutsche Bank AG"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Germany"", ""rank"": 3, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Iceland"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2010-02-18T12:30:55+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/1cb97094-f129-52c7-acba-f903a680dd92"", ""word_count"": 121, ""uri"": ""nyt://article/1cb97094-f129-52c7-acba-f903a680dd92""}"
2010-03-01,"{""abstract"": ""Mr. Gilgore, an opera lover, had roles in the advancement of drugs like Ambien and Celebrex."", ""web_url"": ""https://www.nytimes.com/2010/03/01/business/01gilgore.html"", ""snippet"": ""Mr. Gilgore, an opera lover, had roles in the advancement of drugs like Ambien and Celebrex."", ""lead_paragraph"": "" Dr. Sheldon G. Gilgore, a leader of two major pharmaceutical companies during decades of rapid change in the drug business, died Feb. 12 in his home in Naples, Fla. He was 77. "", ""print_section"": ""A"", ""print_page"": ""25"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2010/03/01/business/01gilgore_CA0/01gilgore_CA0-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2010/03/01/business/01gilgore_CA0/01gilgore_CA0-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Sheldon Gilgore, Physician Who Led Drug Giants Pfizer and Searle, Dies at 77"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Sheldon Gilgore, Physician Who Led Drug Giants Pfizer and Searle, Dies at 77"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Celebrex (Drug)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Research"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Deaths (Obituaries)"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2010-03-01T05:33:19+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Duff Wilson"", ""person"": [{""firstname"": ""Duff"", ""middlename"": null, ""lastname"": ""Wilson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""Obituary (Obit)"", ""_id"": ""nyt://article/7ea93e06-1eea-5aa6-bfa4-a49c660ea057"", ""word_count"": 852, ""uri"": ""nyt://article/7ea93e06-1eea-5aa6-bfa4-a49c660ea057""}"
2010-03-02,"[{""abstract"": ""Some big hedge funds are feeling the love for Pfizer, now that it has Wyeth\u2019s pipeline, Reuters reports."", ""web_url"": ""https://dealbook.nytimes.com/2010/03/02/hedge-funds-heart-pfizer/"", ""snippet"": ""Some big hedge funds are feeling the love for Pfizer, now that it has Wyeth\u2019s pipeline, Reuters reports."", ""lead_paragraph"": ""It seems that some hedge funds are feeling the love for Pfizer."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Hedge Funds Heart Pfizer"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Wyeth"", ""rank"": 2, ""major"": ""N""}], ""pub_date"": ""2010-03-02T12:00:51+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/52e354c4-2e0b-56c6-b86b-1d058e99b774"", ""word_count"": 139, ""uri"": ""nyt://article/52e354c4-2e0b-56c6-b86b-1d058e99b774""}, {""abstract"": ""Pfizer is reportedly gearing up this week to bid 3 million euro ($4.08 billion) for Ratiopharm, a generic drug maker based in Germany."", ""web_url"": ""https://dealbook.nytimes.com/2010/03/02/pfizer-said-to-set-sights-on-german-drug-maker/"", ""snippet"": ""Pfizer is reportedly gearing up this week to bid 3 million euro ($4.08 billion) for Ratiopharm, a generic drug maker based in Germany."", ""lead_paragraph"": ""Pfizer is reportedly gearing up this week to bid 3 billion euro ($4.08 billion) for Ratiopharm, a generic drug maker based in Germany, according to Bloomberg News, which cited two unidentified people with knowledge of the talks. The move would pit Pfizer, the world\u2019s largest drug maker, against Teva Pharmaceuticals Industries of Israel, the world\u2019s largest generic drug maker, and Actvis of Iceland, another big generic drug maker, both of which are said to be interested in Ratiopharm, according to Bloomberg."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer Said to Set Sights on German Drug Maker"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Generic and Brand Name Products"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Wyeth"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2010-03-02T23:50:12+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Cyrus Sanati"", ""person"": [{""firstname"": ""Cyrus"", ""middlename"": null, ""lastname"": ""Sanati"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/6bc49365-f986-5550-b766-787c45a21e93"", ""word_count"": 233, ""uri"": ""nyt://article/6bc49365-f986-5550-b766-787c45a21e93""}]"
2010-03-03,"[{""abstract"": ""Bristol-Myers Squibb, the drug maker, said Tuesday that its chief executive would retire in May and be succeeded by the chief operating officer."", ""web_url"": ""https://dealbook.nytimes.com/2010/03/03/management-shuffle-at-bristol-myers/"", ""snippet"": ""Bristol-Myers Squibb, the drug maker, said Tuesday that its chief executive would retire in May and be succeeded by the chief operating officer."", ""lead_paragraph"": ""The drug maker Bristol-Myers Squibb said on Tuesday that its chief executive would retire in May and be succeeded by the chief operating officer."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Management Shuffle at Bristol-Myers"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Bristol-Myers Squibb Co"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Medarex Incorporated"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}], ""pub_date"": ""2010-03-03T07:20:49+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Liza Klaussmann"", ""person"": [{""firstname"": ""Liza"", ""middlename"": null, ""lastname"": ""Klaussmann"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/3c987fae-e2f9-57cc-bd82-04c6498c43e9"", ""word_count"": 169, ""uri"": ""nyt://article/3c987fae-e2f9-57cc-bd82-04c6498c43e9""}, {""abstract"": ""The drug, called Dimebon, failed in its first late-stage clinical trial, dealing a blow to patients with Alzheimer\u2019s and the companies developing the treatment, Medivation and Pfizer."", ""web_url"": ""https://www.nytimes.com/2010/03/04/business/04drug.html"", ""snippet"": ""The drug, called Dimebon, failed in its first late-stage clinical trial, dealing a blow to patients with Alzheimer\u2019s and the companies developing the treatment, Medivation and Pfizer."", ""lead_paragraph"": ""It seemed somewhat unlikely, but in recent years an old Russian hay fever pill had become one of the world\u2019s best hopes for treating the growing epidemic of Alzheimer\u2019s disease. "", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Hopes for Alzheimer\u2019s Drug Are Dashed"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""As an Alzheimer\u2019s Drug Fails, Hopes Fall"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Clinical Trials"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Medivation, Incorporated"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Alzheimer's Disease"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2010-03-03T15:45:50+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/199d1b71-01ef-53be-a5af-3121080d7bc1"", ""word_count"": 645, ""uri"": ""nyt://article/199d1b71-01ef-53be-a5af-3121080d7bc1""}, {""abstract"": ""The Deal Professor examines how the structure of deals has changed and tightened in the wake of the financial crisis, when a number of transactions collapsed."", ""web_url"": ""https://dealbook.nytimes.com/2010/03/03/post-crisis-the-evolving-structure-of-deals/"", ""snippet"": ""The Deal Professor examines how the structure of deals has changed and tightened in the wake of the financial crisis, when a number of transactions collapsed."", ""lead_paragraph"": ""In the wake of the financial crisis, deal lawyers have been reconsidering the structure of acquisitions. The result has been a clash of wills between targets and acquirers. Targets have sought to bind acquirers as tightly as possible, seeking to avoid a deal collapse that destroys shares prices,\u00a0 similar to what happened to many targets amid the crisis."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Post-Crisis, the Evolving Structure of Deals"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""ACXIOM CORPORATION"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Dow Chemical Co"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Finish Line Incorporated (The)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Genesco Incorporated"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Mars Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""MSCI"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""RiskMetrics"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""United Rentals Incorporated"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Wyeth"", ""rank"": 10, ""major"": ""N""}], ""pub_date"": ""2010-03-03T16:17:13+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Steven Davidoff Solomon"", ""person"": [{""firstname"": ""Steven"", ""middlename"": ""Davidoff"", ""lastname"": ""Solomon"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/5ce44468-2341-5ca5-a4f8-eca04b0b04c2"", ""word_count"": 1588, ""uri"": ""nyt://article/5ce44468-2341-5ca5-a4f8-eca04b0b04c2""}]"
2010-03-08,"{""abstract"": ""Pfizer and two competitors with their eyes on global growth pursue a big maker of generics."", ""web_url"": ""https://www.nytimes.com/2010/03/09/business/09drug.html"", ""snippet"": ""Pfizer and two competitors with their eyes on global growth pursue a big maker of generics."", ""lead_paragraph"": ""The executives at some generic drug companies have a new catchphrase: There\u2019s no place like Ulm. There\u2019s no place like Ulm."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2010/03/09/business/09drug_CA0/09drug_CA0-articleLarge.jpg"", ""height"": 315, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2010/03/09/business/09drug_CA0/09drug_CA0-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 315}}], ""headline"": {""main"": ""Bidding War Pits Pfizer And Teva"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Bidding War Pits Pfizer And Teva"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Teva Pharmaceutical Industries Ltd"", ""rank"": 3, ""major"": ""N""}], ""pub_date"": ""2010-03-08T20:50:31+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Natasha Singer"", ""person"": [{""firstname"": ""Natasha"", ""middlename"": null, ""lastname"": ""Singer"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/eaa7c5e8-79fb-56c0-8e3d-39bd37fe44ee"", ""word_count"": 1061, ""uri"": ""nyt://article/eaa7c5e8-79fb-56c0-8e3d-39bd37fe44ee""}"
2010-03-09,"[{""abstract"": ""The Ratiopharm auction is riveting drug makers and analysts because it pits the world\u2019s biggest maker of brand-name drugs, the U.S. company Pfizer, against the global leader in generics, Israel\u2019s Teva Pharmaceutical Industries."", ""web_url"": ""https://dealbook.nytimes.com/2010/03/09/bidding-war-pits-pfizer-and-teva/"", ""snippet"": ""The Ratiopharm auction is riveting drug makers and analysts because it pits the world\u2019s biggest maker of brand-name drugs, the U.S. company Pfizer, against the global leader in generics, Israel\u2019s Teva Pharmaceutical Industries."", ""lead_paragraph"": ""The executives at some generic drug companies have a new catchphrase: There\u2019s no place like Ulm. There\u2019s no place like Ulm."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Bidding War Pits Pfizer Against Teva"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2010-03-09T07:41:58+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/d9a8cf1e-ffce-5fd5-bdc3-2bccb7f13f0e"", ""word_count"": 1034, ""uri"": ""nyt://article/d9a8cf1e-ffce-5fd5-bdc3-2bccb7f13f0e""}, {""abstract"": ""Lacking a clear consensus about the strength of the recovery, Wall Street fell into a seesaw pattern on Monday."", ""web_url"": ""https://dealbook.nytimes.com/2010/03/09/hesitation-on-wall-street-leaves-shares-flat/"", ""snippet"": ""Lacking a clear consensus about the strength of the recovery, Wall Street fell into a seesaw pattern on Monday."", ""lead_paragraph"": ""Lacking a clear consensus about the strength of the recovery, Wall Street fell into a seesaw pattern on Monday."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Hesitation on Wall Street Leaves Shares Flat"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""AMERICAN INTERNATIONAL GROUP"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Arrow Energy Limited"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Cisco Systems Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Health Net Incorporated"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ING Groep NV"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""MetLife Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""PetroChina Company Ltd"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Royal Dutch Shell Plc"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""UnitedHealth Group"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""WellPoint Inc"", ""rank"": 11, ""major"": ""N""}], ""pub_date"": ""2010-03-09T10:00:01+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/bfc2d99b-78cb-5b88-96b1-344d90099dba"", ""word_count"": 652, ""uri"": ""nyt://article/bfc2d99b-78cb-5b88-96b1-344d90099dba""}]"
2010-03-18,"{""abstract"": ""Teva Pharmaceutical Industries has won the bidding contest for German generic drug maker Ratiopharm, beating out Pfizer and Actavis, three people close to the matter told Reuters."", ""web_url"": ""https://dealbook.nytimes.com/2010/03/18/teva-to-take-over-ratiopharm-report-says/"", ""snippet"": ""Teva Pharmaceutical Industries has won the bidding contest for German generic drug maker Ratiopharm, beating out Pfizer and Actavis, three people close to the matter told Reuters."", ""lead_paragraph"": ""8:41 a.m. | Updated Teva Pharmaceutical Industries, the global leader in generic drugs, said Thursday that it had reached a deal to acquire the German generic drug maker Ratiopharm, ending a nine-month battle that had pitted it against at least two other bidders, Natasha Singer reports in The New York Times."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Teva to Acquire Ratiopharm for $5 Billion"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Ratiopharm"", ""rank"": 2, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Germany"", ""rank"": 3, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Israel"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2010-03-18T09:15:46+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/0df87a59-c9d2-5ad7-b577-521bae7b6352"", ""word_count"": 437, ""uri"": ""nyt://article/0df87a59-c9d2-5ad7-b577-521bae7b6352""}"
2010-03-23,"{""abstract"": ""The agreement, with Pfizer and GlaxoSmithKline, could save as many as 900,000 lives over the next five years."", ""web_url"": ""https://www.nytimes.com/2010/03/24/business/global/24vaccine.html"", ""snippet"": ""The agreement, with Pfizer and GlaxoSmithKline, could save as many as 900,000 lives over the next five years."", ""lead_paragraph"": ""Pfizer and GlaxoSmithKline will supply hundreds of millions of doses of their pneumonia vaccines to the world\u2019s poorest countries at heavily discounted prices under a novel agreement announced Tuesday."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Deal Provides Vaccines to Poor Nations at Lower Cost"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Deal Provides Vaccines to Poor Nations at Lower Cost"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Third World and Developing Countries"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Vaccination and Immunization"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Gates, Bill and Melinda, Foundation"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""GlaxoSmithKline PLC"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Prices (Fares, Fees and Rates)"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2010-03-23T16:14:44+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""Global Business"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/74938427-9e91-5f7d-a3b6-d8045e3e24cd"", ""word_count"": 703, ""uri"": ""nyt://article/74938427-9e91-5f7d-a3b6-d8045e3e24cd""}"
2010-03-27,"{""abstract"": ""About 80 percent of prescriptions for nitroglycerin are filled with unapproved, unvetted tablets, the agency said."", ""web_url"": ""https://www.nytimes.com/2010/03/27/business/27nitro.html"", ""snippet"": ""About 80 percent of prescriptions for nitroglycerin are filled with unapproved, unvetted tablets, the agency said."", ""lead_paragraph"": ""Doctors in the United States wrote more than four million prescriptions last year for nitroglycerin tablets, heart drugs placed under the tongue to reduce the chest pain angina or to stop a heart attack."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""F.D.A. Says Millions Got Unapproved Heart Pills"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""F.D.A. Says Millions Got Unapproved Heart Pills"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Heart"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Recalls and Bans of Products"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Generic and Brand Name Products"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2010-03-27T00:49:38+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Natasha Singer"", ""person"": [{""firstname"": ""Natasha"", ""middlename"": null, ""lastname"": ""Singer"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/5cd7a96c-84c6-5201-bc66-246661123336"", ""word_count"": 1158, ""uri"": ""nyt://article/5cd7a96c-84c6-5201-bc66-246661123336""}"
2010-03-31,"{""abstract"": ""The drug company said it paid about $20 million to 4,500 doctors and other professionals for consulting and speaking on its behalf."", ""web_url"": ""https://www.nytimes.com/2010/04/01/business/01payments.html"", ""snippet"": ""The drug company said it paid about $20 million to 4,500 doctors and other professionals for consulting and speaking on its behalf."", ""lead_paragraph"": "" Pfizer, the world\u2019s largest drug maker, said Wednesday that it paid about $20 million to 4,500 doctors and other medical professionals for consulting and speaking on its behalf in the last six months of 2009, its first public accounting of payments to the people who decide which drugs to recommend."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer Gives Details on Payments to Doctors"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer Gives Details on Payments to Doctors"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Doctors"", ""rank"": 3, ""major"": ""N""}], ""pub_date"": ""2010-03-31T18:40:51+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Duff Wilson"", ""person"": [{""firstname"": ""Duff"", ""middlename"": null, ""lastname"": ""Wilson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/d90cab0f-c46c-5883-bed9-3f4eae242188"", ""word_count"": 551, ""uri"": ""nyt://article/d90cab0f-c46c-5883-bed9-3f4eae242188""}"
2010-04-01,"{""abstract"": ""Producing new drugs and adjusting to the changing health care system are two of the tests facing the drug giant."", ""web_url"": ""https://www.nytimes.com/2010/04/01/business/01pfizer.html"", ""snippet"": ""Producing new drugs and adjusting to the changing health care system are two of the tests facing the drug giant."", ""lead_paragraph"": ""The world\u2019s largest drug company, Pfizer, has handled mergers badly, invented too few drugs and left its reputation in disrepair after two criminal cases."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2010/04/01/business/01pfizer_CA0/01pfizer_CA0-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2010/04/01/business/01pfizer_CA0/01pfizer_CA0-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Pfizer Chief Says Growth Is Imminent"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer Chief Says Growth Is Imminent"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Lipitor (Drug)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Warner-Lambert"", ""rank"": 6, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Kindler, Jeffrey B"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Wyeth"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2010-04-01T02:44:54+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Duff Wilson"", ""person"": [{""firstname"": ""Duff"", ""middlename"": null, ""lastname"": ""Wilson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/791b85fd-0f4d-511a-b023-efa45ac8d02f"", ""word_count"": 975, ""uri"": ""nyt://article/791b85fd-0f4d-511a-b023-efa45ac8d02f""}"
2010-04-03,"{""abstract"": ""A jury ruled that Pfizer violated laws protecting free speech and whistle-blowers by retaliating against a worker who said she was sickened by a genetically engineered virus at the company."", ""web_url"": ""https://www.nytimes.com/2010/04/03/business/03pfizer.html"", ""snippet"": ""A jury ruled that Pfizer violated laws protecting free speech and whistle-blowers by retaliating against a worker who said she was sickened by a genetically engineered virus at the company."", ""lead_paragraph"": ""A federal jury has awarded $1.37 million in damages to a former Pfizer scientist who claimed she was sickened by a genetically engineered virus at a company laboratory and then fired for raising safety concerns."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""A Pfizer Whistle-Blower Is Awarded $1.4 Million"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""A Pfizer Whistle-Blower Is Awarded $1.4 Million"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Michaels, David"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Occupational Safety and Health Administration"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Power, Elizabeth"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Decisions and Verdicts"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Whistle-Blowers"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2010-04-03T01:04:59+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack and Duff Wilson"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Duff"", ""middlename"": null, ""lastname"": ""Wilson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/93004d43-a9a2-5cb2-a0cf-4ac0e9ddc534"", ""word_count"": 609, ""uri"": ""nyt://article/93004d43-a9a2-5cb2-a0cf-4ac0e9ddc534""}"
2010-04-09,"{""abstract"": ""Another private equity firm has snapped up a high-profile former chief executive. The Carlyle Group announced that it had hired Wyeth\u2019s former chief, Robert Essner, as a senior adviser to its Global Healthcare group, Reuters reported."", ""web_url"": ""https://dealbook.nytimes.com/2010/04/09/carlyle-hires-former-wyeth-chief/"", ""snippet"": ""Another private equity firm has snapped up a high-profile former chief executive. The Carlyle Group announced that it had hired Wyeth\u2019s former chief, Robert Essner, as a senior adviser to its Global Healthcare group, Reuters reported."", ""lead_paragraph"": ""Another private equity firm has snapped up a high-profile former chief executive. The Carlyle Group announced that it had hired Wyeth\u2018s former chief, Robert Essner, as a senior adviser to its Global Healthcare group, Reuters reported."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Carlyle Hires Former Wyeth Chief"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Carlyle Group"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Wyeth"", ""rank"": 3, ""major"": ""N""}], ""pub_date"": ""2010-04-09T11:42:44+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/554fc5ee-8abc-5d32-a1a3-964131569258"", ""word_count"": 145, ""uri"": ""nyt://article/554fc5ee-8abc-5d32-a1a3-964131569258""}"
2010-04-12,"{""abstract"": ""Disclosure advocates say it is not easy enough to use the companies\u2019 Web sites to find out which doctors are getting the most money."", ""web_url"": ""https://www.nytimes.com/2010/04/13/business/13docpay.html"", ""snippet"": ""Disclosure advocates say it is not easy enough to use the companies\u2019 Web sites to find out which doctors are getting the most money."", ""lead_paragraph"": ""Pfizer recently became the latest big drug maker to start disclosing payments to doctors who act as consultants or speakers. But many followers of the pharmaceutical industry are still finding it far too difficult to follow the money."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Data on Fees to Doctors Is Called Hard to Parse"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Drug Makers Reveal Payments to Doctors, but Data Isn\u2019t Easy to Parse"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Conflicts of Interest"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""GlaxoSmithKline PLC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Doctors"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Prices (Fares, Fees and Rates)"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2010-04-12T19:59:47+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Duff Wilson"", ""person"": [{""firstname"": ""Duff"", ""middlename"": null, ""lastname"": ""Wilson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/e7a16730-fb51-53e4-b5af-c7c4fa526980"", ""word_count"": 1027, ""uri"": ""nyt://article/e7a16730-fb51-53e4-b5af-c7c4fa526980""}"
2010-05-21,"{""abstract"": ""Abbott Laboratories will pay $3.72 billion to acquire India\u2019s Piramal Healthcare\u2019s pharmaceutical solutions business, as global drugmakers look to boost their presence in emerging markets, Reuters reported."", ""web_url"": ""https://dealbook.nytimes.com/2010/05/21/abbott-in-3-7-billion-deal-for-piramal-unit-in-india/"", ""snippet"": ""Abbott Laboratories will pay $3.72 billion to acquire India\u2019s Piramal Healthcare\u2019s pharmaceutical solutions business, as global drugmakers look to boost their presence in emerging markets, Reuters reported."", ""lead_paragraph"": ""Abbott Laboratories will pay $3.72 billion to acquire India\u2019s Piramal Healthcare\u2018s pharmaceutical solutions business, as global drugmakers look to boost their presence in emerging markets, Reuters reported."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Abbott in $3.7 Billion Deal for Piramal Unit in India"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Abbott Laboratories"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""GlaxoSmithKline PLC"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Ranbaxy Laboratories"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Sanofi-Aventis SA"", ""rank"": 5, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""India"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2010-05-21T10:54:24+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/69661c7e-51a2-5c0c-9ad9-f69b86b1398e"", ""word_count"": 158, ""uri"": ""nyt://article/69661c7e-51a2-5c0c-9ad9-f69b86b1398e""}"
2010-05-27,"{""abstract"": ""Biotechnology labs are filled with imponderable hazards yet are subjected to fewer regulations than most factories."", ""web_url"": ""https://www.nytimes.com/2010/05/28/business/28hazard.html"", ""snippet"": ""Biotechnology labs are filled with imponderable hazards yet are subjected to fewer regulations than most factories."", ""lead_paragraph"": ""They are the highly trained, generally well-paid employees in the vanguard of American innovation: people who work in biotechnology labs. But the cutting edge can be a risky place to work. "", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2010/05/28/business/28HAZARD-SUB/28HAZARD-SUB-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2010/05/28/business/28HAZARD-SUB/28HAZARD-SUB-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Safety Rules Can\u2019t Keep Up With Biotech Industry"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Perils in the Biotech Frontier"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Laboratories and Scientific Equipment"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Occupational Safety and Health Administration"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Accidents and Safety"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Science and Technology"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Biotechnology"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2010-05-27T23:49:30+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack and Duff Wilson"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Duff"", ""middlename"": null, ""lastname"": ""Wilson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/b4d510b0-a037-5c95-b6fa-acc50eb2e58e"", ""word_count"": 1270, ""uri"": ""nyt://article/b4d510b0-a037-5c95-b6fa-acc50eb2e58e""}"
2010-07-06,"{""abstract"": ""Last week, Standard & Poor\u2019s lent its insight into European companies ripe for being acquired. This week, the firm\u2019s analysts are taking a look at who might do the buying."", ""web_url"": ""https://dealbook.nytimes.com/2010/07/06/a-look-at-american-companies-set-for-european-deals/"", ""snippet"": ""Last week, Standard & Poor\u2019s lent its insight into European companies ripe for being acquired. This week, the firm\u2019s analysts are taking a look at who might do the buying."", ""lead_paragraph"": ""5:00 p.m. | Updated Last week, Standard & Poor\u2019s lent its insight into European companies ripe for being acquired. This week, the firm\u2019s analysts are taking a look at who might do the buying."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""A Peek at U.S. Companies Set for European Deals"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Health Insurance and Managed Care"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""INVESTMENTS"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Disney, Walt, Co"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Motorola Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""News Corporation"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Northrop Grumman Corp"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Time Warner Inc"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Yahoo! Inc"", ""rank"": 10, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Europe"", ""rank"": 11, ""major"": ""N""}], ""pub_date"": ""2010-07-06T18:24:25+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Cyrus Sanati"", ""person"": [{""firstname"": ""Cyrus"", ""middlename"": null, ""lastname"": ""Sanati"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/4aebd43c-c79b-5cc0-b440-66ed96dc1336"", ""word_count"": 438, ""uri"": ""nyt://article/4aebd43c-c79b-5cc0-b440-66ed96dc1336""}"
2010-07-21,"{""abstract"": ""Stocks closed a lightly traded session higher Tuesday despite disappointing earnings from Goldman Sachs and Johnson & Johnson."", ""web_url"": ""https://dealbook.nytimes.com/2010/07/21/wall-street-ends-the-day-higher/"", ""snippet"": ""Stocks closed a lightly traded session higher Tuesday despite disappointing earnings from Goldman Sachs and Johnson & Johnson."", ""lead_paragraph"": ""Stocks closed a lightly traded session higher Tuesday despite disappointing earnings from Goldman Sachs and Johnson & Johnson."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Wall Street Ends the Day Higher"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Bank of America Corp"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Goldman Sachs Group"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""International Business Machines Corporation"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Morgan Stanley"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Prudential Financial Incorporated"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Texas Instruments Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Wells Fargo & Co"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2010-07-21T09:24:37+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/2a5baac0-0c48-57d5-ae22-3832aa255f9c"", ""word_count"": 621, ""uri"": ""nyt://article/2a5baac0-0c48-57d5-ae22-3832aa255f9c""}"
2010-07-22,"{""abstract"": ""A little more than a year after acquiring Genentech, Roche said Thursday that its profits for the first half of this year had risen by 37 percent from the same period a year before as exceptional costs associated with the merger had fallen."", ""web_url"": ""https://dealbook.nytimes.com/2010/07/22/roche-profit-up-on-genentech-synergies/"", ""snippet"": ""A little more than a year after acquiring Genentech, Roche said Thursday that its profits for the first half of this year had risen by 37 percent from the same period a year before as exceptional costs associated with the merger had fallen."", ""lead_paragraph"": ""A little more than a year after acquiring Genentech, Roche said Thursday that its profits for the first half of this year had risen by 37 percent from the same period a year before as exceptional costs associated with the merger had fallen."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Roche Profit Up on Genentech Synergies"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Schwan, Severin"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Genentech Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Roche Holding AG"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Wyeth"", ""rank"": 6, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""San Francisco (Calif)"", ""rank"": 7, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Switzerland"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2010-07-22T08:34:25+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chris V. Nicholson"", ""person"": [{""firstname"": ""Chris"", ""middlename"": ""V."", ""lastname"": ""Nicholson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/d3bbca8e-689d-5f68-8066-894ff8837a73"", ""word_count"": 232, ""uri"": ""nyt://article/d3bbca8e-689d-5f68-8066-894ff8837a73""}"
2010-09-04,"{""abstract"": ""Pfizer is pulling out of an agreement with Celldex Therapeutics to finance the development of an experimental brain tumor vaccine, Celldex said Friday."", ""web_url"": ""https://www.nytimes.com/2010/09/04/business/04bizbriefs-CELLDEXLOSES_BRF.html"", ""snippet"": ""Pfizer is pulling out of an agreement with Celldex Therapeutics to finance the development of an experimental brain tumor vaccine, Celldex said Friday."", ""lead_paragraph"": ""Pfizer is pulling out of an agreement with Celldex Therapeutics to finance the development of an experimental brain tumor vaccine, Celldex said Friday. The vaccine, called rindopepimut, is \u201cno longer a strategic priority of Pfizer,\u201d which will return the rights to the therapy to Celldex on Nov. 1, Celldex said. The treatment is in the second of three stages of testing generally required to win regulatory approval. Pfizer licensed rights to the product in 2008 from Celldex for as much as $440 million, plus royalties. If approved, the brain cancer vaccine could have $450 million in peak annual sales and come on the market in 2013, Joseph Pantginis, an analyst at Roth Capital, said in May. Celldex\u2019s chief executive, Anthony Marucci, said the company would need to raise more money to pay for late-stage testing but would not need another partner. Shares of Celldex, based in Needham Mass., fell $1.25, or 26 percent, to $3.53. "", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Celldex Loses a Partner in Brain Tumor Treatment"", ""kicker"": ""Business Briefing | Health"", ""content_kicker"": null, ""print_headline"": ""Celldex Loses a Partner In Brain Tumor Treatment"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Vaccination and Immunization"", ""rank"": 3, ""major"": ""N""}], ""pub_date"": ""2010-09-04T01:29:09+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Bloomberg News"", ""person"": [{""firstname"": ""Bloomberg"", ""middlename"": null, ""lastname"": ""News"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""Brief"", ""_id"": ""nyt://article/c79425c0-e9bd-5c22-ac9e-0510b185d19d"", ""word_count"": 155, ""uri"": ""nyt://article/c79425c0-e9bd-5c22-ac9e-0510b185d19d""}"
2010-09-22,"{""abstract"": ""The drug maker and its Wyeth unit are accused by two whistle-blowers of illegal off-label marketing of a drug used to prevent rejection of kidney transplants."", ""web_url"": ""https://www.nytimes.com/2010/09/22/business/22drug.html"", ""snippet"": ""The drug maker and its Wyeth unit are accused by two whistle-blowers of illegal off-label marketing of a drug used to prevent rejection of kidney transplants."", ""lead_paragraph"": ""The Justice Department on Tuesday joined a whistle-blower lawsuit against Pfizer and its subsidiary Wyeth Pharmaceuticals that accuses Wyeth of illegal off-label marketing of Rapamune, a drug used to prevent rejection of kidney transplants."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""U.S. Joins Pfizer Suit Over Drug\u2019s Marketing"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""U.S. Joins Pfizer Suit Over Drug\u2019s Marketing"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Wyeth"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Suits and Litigation"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Justice Department"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2010-09-22T00:12:09+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Duff Wilson"", ""person"": [{""firstname"": ""Duff"", ""middlename"": null, ""lastname"": ""Wilson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/bc08cbdc-22da-5c3c-bd65-bd3d608faeeb"", ""word_count"": 614, ""uri"": ""nyt://article/bc08cbdc-22da-5c3c-bd65-bd3d608faeeb""}"
2010-09-29,"{""abstract"": ""Markets in the United States on Tuesday erased most of their losses from Monday, as Walgreen led a rally in consumer staples and health companies Investors also speculated that the Federal Reserve would buy more debt to safeguard the economy."", ""web_url"": ""https://dealbook.nytimes.com/2010/09/29/healthcare-helps-wall-street-rebound-quickly/"", ""snippet"": ""Markets in the United States on Tuesday erased most of their losses from Monday, as Walgreen led a rally in consumer staples and health companies Investors also speculated that the Federal Reserve would buy more debt to safeguard the economy."", ""lead_paragraph"": ""Markets in the United States on Tuesday erased most of their losses from Monday, as Walgreen led a rally in consumer staples and health companies Investors also speculated that the Federal Reserve would buy more debt to safeguard the economy."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Healthcare Helps Wall Street Rebound Quickly"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Federal Reserve System"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Walgreen Co"", ""rank"": 3, ""major"": ""N""}], ""pub_date"": ""2010-09-29T05:25:32+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/88cbf506-5b47-535d-9ef1-6c252e11d9a8"", ""word_count"": 342, ""uri"": ""nyt://article/88cbf506-5b47-535d-9ef1-6c252e11d9a8""}"
2010-10-11,"{""abstract"": ""The Supreme Court\u2019s review of the no-fault system for vaccines could have an effect on hundreds of lawsuits over childhood vaccines and autism."", ""web_url"": ""https://www.nytimes.com/2010/10/12/health/12vaccine.html"", ""snippet"": ""The Supreme Court\u2019s review of the no-fault system for vaccines could have an effect on hundreds of lawsuits over childhood vaccines and autism."", ""lead_paragraph"": ""The safety of vaccines is at the heart of a case expected to be heard on Tuesday by the United States Supreme Court, one that could have implications for hundreds of lawsuits that contend there is a link between vaccines and autism."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2010/10/12/business/VACCINE/VACCINE-jumbo.jpg"", ""height"": 681, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2010/10/12/business/VACCINE/VACCINE-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2010/10/12/business/VACCINE/VACCINE-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Supreme Court to Consider Vaccine Case"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Vaccine Case To Be Heard By Justices"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Autism"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Vaccination and Immunization"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Children and Youth"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Supreme Court"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Suits and Litigation"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Wyeth"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2010-10-11T23:09:08+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Health"", ""byline"": {""original"": ""By Barry Meier"", ""person"": [{""firstname"": ""Barry"", ""middlename"": null, ""lastname"": ""Meier"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/8defc00f-7a16-59a4-9a97-f3271c973456"", ""word_count"": 846, ""uri"": ""nyt://article/8defc00f-7a16-59a4-9a97-f3271c973456""}"
2010-10-12,"{""abstract"": ""Pfizer agreed to buy the maker of pain medication for $3.6 billion in cash, in the giant drug maker\u2019s first major deal since its blockbuster purchase of Wyeth last year."", ""web_url"": ""https://dealbook.nytimes.com/2010/10/12/pfizer-to-buy-king-pharmaceuticals-for-3-6-billion/"", ""snippet"": ""Pfizer agreed to buy the maker of pain medication for $3.6 billion in cash, in the giant drug maker\u2019s first major deal since its blockbuster purchase of Wyeth last year."", ""lead_paragraph"": ""2:25 p.m. | Updated Pfizer stepped up the consolidation in the drug industry on Tuesday with a $3.6 billion deal to buy King Pharmaceuticals, a maker of pain medications."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer to Buy King Pharmaceuticals for $3.6 Billion"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""KING PHARMACEUTICALS INC"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}], ""pub_date"": ""2010-10-12T12:24:04+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/87762a3a-f8cc-54f8-bd7b-dd8845819eba"", ""word_count"": 558, ""uri"": ""nyt://article/87762a3a-f8cc-54f8-bd7b-dd8845819eba""}"
2010-10-15,"{""abstract"": ""The potential bids follow an announcement by Pfizer last week that it was considering selling the drug capsule business, Capsugel."", ""web_url"": ""https://dealbook.nytimes.com/2010/10/14/blackstone-and-bain-plan-bids-for-pfizer-capsule-unit/"", ""snippet"": ""The potential bids follow an announcement by Pfizer last week that it was considering selling the drug capsule business, Capsugel."", ""lead_paragraph"": ""Several private equity firms, including the Blackstone Group and Bain Capital, are preparing initial bids for Pfizer\u2018s Capsugel unit, people briefed on the matter told DealBook on Thursday. These people asked for anonymity because the talks are private and they are not authorized to discuss them."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Blackstone and Bain Plan Bids for Pfizer Capsule Unit"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Bain Capital"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Blackstone Group, The"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}], ""pub_date"": ""2010-10-15T01:38:06+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Michael J. de la Merced"", ""person"": [{""firstname"": ""Michael"", ""middlename"": ""J."", ""lastname"": ""de la Merced"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/ddb1da36-2385-5dd6-aa11-32ed31505fae"", ""word_count"": 254, ""uri"": ""nyt://article/ddb1da36-2385-5dd6-aa11-32ed31505fae""}"
2010-10-18,"{""abstract"": ""The Deal Professor examines 11 deals in the first half of October for signs of how the mergers and acquisition market will play out next year."", ""web_url"": ""https://dealbook.nytimes.com/2010/10/18/what-recent-deals-may-say-about-m-a-s-future/"", ""snippet"": ""The Deal Professor examines 11 deals in the first half of October for signs of how the mergers and acquisition market will play out next year."", ""lead_paragraph"": ""3:28 p.m. | Updated Where is the market for mergers and acquisitions going? After a summer of prominent deal announcements and increased M.&A. activity, investment bankers are speculating that the market will grow 15 percent to 30 percent in the next year. Bankers tend to talk their book, but this time it looks like the market is likely to support a modest upswing, albeit one not as big as the bankers hope for."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""What Recent Deals May Say About M.&A.\u2019s Future"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Private Equity"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Actel Corp"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Assa Abloy"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Bain Capital"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Blackstone Group, The"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Dynamex Incorporated"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Gymboree"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""KING PHARMACEUTICALS INC"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Microsemi Corporation"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 11, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Seagate Technology PLC"", ""rank"": 12, ""major"": ""N""}], ""pub_date"": ""2010-10-18T18:05:39+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Steven Davidoff Solomon"", ""person"": [{""firstname"": ""Steven"", ""middlename"": ""Davidoff"", ""lastname"": ""Solomon"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/dae4c142-5612-54ff-b385-aac435b9efe5"", ""word_count"": 2068, ""uri"": ""nyt://article/dae4c142-5612-54ff-b385-aac435b9efe5""}"
2010-11-25,"{""abstract"": ""Ireland plans to keep low rates that have attracted Microsoft, Intel and Pfizer but that other countries say distort competition."", ""web_url"": ""https://www.nytimes.com/2010/11/26/business/global/26tax.html"", ""snippet"": ""Ireland plans to keep low rates that have attracted Microsoft, Intel and Pfizer but that other countries say distort competition."", ""lead_paragraph"": ""DUBLIN \u2014 Cut Ireland\u2019s minimum wage? Check. Collect more in property taxes from beleaguered homeowners? Check. Raise the corporate tax rate, which could plug the gaping hole in Ireland\u2019s tattered balance sheets even faster? Well, no."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2010/11/26/business/TAX/TAX-articleLarge.jpg"", ""height"": 315, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2010/11/26/business/TAX/TAX-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 315}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2010/11/26/business/TAX/TAX-jumbo.jpg"", ""height"": 573, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}], ""headline"": {""main"": ""In Ireland, Low Corporate Taxes Go Untouched"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Much Fiscal Pain in Ireland, but Low Corporate Taxes Go Untouched"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Corporations"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Microsoft Corp"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Google Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Intel Corp"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Taxation"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""European Sovereign Debt Crisis (2010- )"", ""rank"": 7, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Ireland"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Hewlett-Packard Co"", ""rank"": 9, ""major"": ""N""}], ""pub_date"": ""2010-11-25T19:39:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""Global Business"", ""byline"": {""original"": ""By Liz Alderman"", ""person"": [{""firstname"": ""Liz"", ""middlename"": null, ""lastname"": ""Alderman"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/e1700a1c-a920-5eb4-82ca-73b0bd466da3"", ""word_count"": 1186, ""uri"": ""nyt://article/e1700a1c-a920-5eb4-82ca-73b0bd466da3""}"
2010-12-04,"{""abstract"": ""In a preliminary settlement agreement, Pfizer tries to address lawsuits accusing its board and top officials of failing to stop illegal marketing of its drugs."", ""web_url"": ""https://www.nytimes.com/2010/12/04/business/04drug.html"", ""snippet"": ""In a preliminary settlement agreement, Pfizer tries to address lawsuits accusing its board and top officials of failing to stop illegal marketing of its drugs."", ""lead_paragraph"": ""Pfizer has agreed to set up a $75 million fund and to create a new compliance committee to settle shareholders\u2019 lawsuits accusing the board and top officials of failing to stop illegal marketing of its drugs, according to a settlement agreement filed in United States District Court on Friday."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer Plans $75 Million Fund to Address Shareholder Suits"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer Plans $75 Million Fund To Address Shareholder Suits"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Suits and Litigation"", ""rank"": 3, ""major"": ""N""}], ""pub_date"": ""2010-12-04T01:49:31+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Duff Wilson"", ""person"": [{""firstname"": ""Duff"", ""middlename"": null, ""lastname"": ""Wilson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/a8396231-5a53-59ca-bf96-8131903fa3ab"", ""word_count"": 368, ""uri"": ""nyt://article/a8396231-5a53-59ca-bf96-8131903fa3ab""}"
2010-12-06,"[{""abstract"": ""Jeffrey B. Kindler\u2019s retirement comes almost two years after he led Pfizer\u2019s bid for Wyeth, the first major deal after the financial crisis."", ""web_url"": ""https://dealbook.nytimes.com/2010/12/05/pfizers-chief-architect-of-its-mega-merger-retires/"", ""snippet"": ""Jeffrey B. Kindler\u2019s retirement comes almost two years after he led Pfizer\u2019s bid for Wyeth, the first major deal after the financial crisis."", ""lead_paragraph"": ""Jeffrey B. Kindler announcing Pfizer\u2019s $68 billion deal for Wyeth in January 2009."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer Loses Man Behind Wyeth Deal"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Kindler, Jeffrey B"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}], ""pub_date"": ""2010-12-06T01:50:56+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Michael J. de la Merced"", ""person"": [{""firstname"": ""Michael"", ""middlename"": ""J."", ""lastname"": ""de la Merced"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/d3a1f39e-25a5-5f20-9106-0cc9ae69f012"", ""word_count"": 405, ""uri"": ""nyt://article/d3a1f39e-25a5-5f20-9106-0cc9ae69f012""}, {""abstract"": ""Jeffrey Kindler will be succeeded as chief executive by Ian Read, and the board will vote on a new chairman within two weeks."", ""web_url"": ""https://www.nytimes.com/2010/12/06/business/06drug.html"", ""snippet"": ""Jeffrey Kindler will be succeeded as chief executive by Ian Read, and the board will vote on a new chairman within two weeks."", ""lead_paragraph"": ""Jeffrey B. Kindler is retiring as chief executive and chairman of Pfizer, the world\u2019s largest pharmaceutical firm, the company said on Sunday evening in an unexpected announcement."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2010/12/06/business/drug/drug-jumbo.jpg"", ""height"": 1024, ""width"": 815, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2010/12/06/business/drug/drug-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2010/12/06/business/drug/drug-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Pfizer\u2019s Chairman and Chief Retires Unexpectedly"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer&#8217;s Chairman and Chief Retires Unexpectedly"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Kindler, Jeffrey B"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Appointments and Executive Changes"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2010-12-06T02:39:37+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Duff Wilson"", ""person"": [{""firstname"": ""Duff"", ""middlename"": null, ""lastname"": ""Wilson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/8fee1ca8-3f72-56a6-85ce-d8688ceeba8b"", ""word_count"": 590, ""uri"": ""nyt://article/8fee1ca8-3f72-56a6-85ce-d8688ceeba8b""}, {""abstract"": ""David Einhorn, the president of Greenlight Capital, tells CNBC he likes Sprint Nextel, Apple and Pfizer."", ""web_url"": ""https://dealbook.nytimes.com/2010/12/06/where-einhorn-is-investing-now/"", ""snippet"": ""David Einhorn, the president of Greenlight Capital, tells CNBC he likes Sprint Nextel, Apple and Pfizer."", ""lead_paragraph"": ""David Einhorn, president of Greenlight Capital, goes into detail with CNBC about his portfolio. Among the holdings: Sprint Nextel, Apple and Pfizer."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Where Einhorn Is Investing Now"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Einhorn, David"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""CNBC"", ""rank"": 2, ""major"": ""N""}], ""pub_date"": ""2010-12-06T20:46:43+0000"", ""document_type"": ""article"", ""news_desk"": """", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/4326a5e3-c268-5f2e-a793-d79f4488d1f0"", ""word_count"": 50, ""uri"": ""nyt://article/4326a5e3-c268-5f2e-a793-d79f4488d1f0""}]"
2010-12-07,"{""abstract"": ""Shareholders lost about 20 percent of their investment during Pfizer\u2019s chief executive, Jeffrey B. Kindler\u2019s four-and-a-half-year tenure."", ""web_url"": ""https://www.nytimes.com/2010/12/07/business/07views.html"", ""snippet"": ""Shareholders lost about 20 percent of their investment during Pfizer\u2019s chief executive, Jeffrey B. Kindler\u2019s four-and-a-half-year tenure."", ""lead_paragraph"": """", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2010/12/07/business/Views/Views-jumbo.jpg"", ""height"": 959, ""width"": 1009, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer\u2019s Falling Share Price Couldn\u2019t Be Cured"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer Chief Exits With Shares Down"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Gross Domestic Product"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Appointments and Executive Changes"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Stocks and Bonds"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Economic Conditions and Trends"", ""rank"": 6, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Hungary"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2010-12-07T00:45:17+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Robert Cyran and Ian Campbell"", ""person"": [{""firstname"": ""Robert"", ""middlename"": null, ""lastname"": ""Cyran"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Ian"", ""middlename"": null, ""lastname"": ""Campbell"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/614c8730-47a0-5fa8-b361-ef29f1203fe2"", ""word_count"": 723, ""uri"": ""nyt://article/614c8730-47a0-5fa8-b361-ef29f1203fe2""}"
2010-12-08,"{""abstract"": ""Johnson & Johnson made a formal offer on Wednesday for Crucell, a Dutch biotechnology company."", ""web_url"": ""https://dealbook.nytimes.com/2010/12/08/jj-bids-2-3-billion-for-crucell/"", ""snippet"": ""Johnson & Johnson made a formal offer on Wednesday for Crucell, a Dutch biotechnology company."", ""lead_paragraph"": ""The American health care giant Johnson & Johnson made a formal bid on Wednesday for Crucell, offering to pay 1.75 billion euros ($2.3 billion) for the rest of the Dutch biotechnology company."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""J.&J. Bids $2.3 Billion for Crucell"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Biotechnology"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Johnson & Johnson"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""United States"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2010-12-08T12:24:59+0000"", ""document_type"": ""article"", ""news_desk"": """", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chris V. Nicholson and Adrienne Carter"", ""person"": [{""firstname"": ""Chris"", ""middlename"": ""V."", ""lastname"": ""Nicholson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Adrienne"", ""middlename"": null, ""lastname"": ""Carter"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/e8884320-4b88-5255-9441-1a7c1e4584a3"", ""word_count"": 304, ""uri"": ""nyt://article/e8884320-4b88-5255-9441-1a7c1e4584a3""}"
2010-12-09,"{""abstract"": ""In total, Jeffrey B. Kindler, who resigned unexpectedly as chief executive and chairman, will receive $9.5 million in cash in addition to stock and retirement benefits."", ""web_url"": ""https://www.nytimes.com/2010/12/10/business/10pfizer.html"", ""snippet"": ""In total, Jeffrey B. Kindler, who resigned unexpectedly as chief executive and chairman, will receive $9.5 million in cash in addition to stock and retirement benefits."", ""lead_paragraph"": "" Pfizer, the world\u2019s largest pharmaceutical company, said in a regulatory filing on Thursday that it had agreed to give Jeffrey B. Kindler a $4.5 million severance payment after his sudden retirement on Sunday as chairman and chief executive."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2010/12/10/business/Pfizer/Pfizer-jumbo.jpg"", ""height"": 1024, ""width"": 737, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2010/12/10/business/Pfizer/Pfizer-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2010/12/10/business/Pfizer/Pfizer-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Pfizer to Pay Its Ex-Chief $4.5 Million in Severance"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer to Pay Its Ex-Chief $4.5 Million In Severance"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Kindler, Jeffrey B"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Suspensions, Dismissals and Resignations"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Executive Compensation"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2010-12-09T22:27:34+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Duff Wilson"", ""person"": [{""firstname"": ""Duff"", ""middlename"": null, ""lastname"": ""Wilson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/2b04a15b-a9b1-5db4-b4f1-61f5e4d9f163"", ""word_count"": 418, ""uri"": ""nyt://article/2b04a15b-a9b1-5db4-b4f1-61f5e4d9f163""}"
2010-12-10,"{""abstract"": ""Tor Myhren\u2019s promotion is the first time Grey New York will be led by its chief creative officer, a position he will keep."", ""web_url"": ""https://www.nytimes.com/2010/12/10/business/media/10adco.html"", ""snippet"": ""Tor Myhren\u2019s promotion is the first time Grey New York will be led by its chief creative officer, a position he will keep."", ""lead_paragraph"": ""GREY, long dismissed as being as creative as its name, is giving a creative executive the job of leading its New York office, the agency\u2019s largest, which produces campaigns for marketers like Canon, DirecTV, E*Trade, GlaxoSmithKline, Pfizer and Procter & Gamble."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2010/12/10/business/Adco/Adco-jumbo.jpg"", ""height"": 649, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2010/12/10/business/Adco/Adco-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2010/12/10/business/Adco/Adco-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Grey New York to Be Led by Its Chief Creative Officer"", ""kicker"": ""Advertising"", ""content_kicker"": null, ""print_headline"": ""Grey New York to Be Led by Its Chief Creative Officer"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Grey Group"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""ADVERTISING AND MARKETING"", ""rank"": 2, ""major"": ""N""}], ""pub_date"": ""2010-12-10T00:31:33+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""Media"", ""byline"": {""original"": ""By Stuart Elliott"", ""person"": [{""firstname"": ""Stuart"", ""middlename"": null, ""lastname"": ""Elliott"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/3046eacc-b3d1-5ecf-9eee-390c1f46804f"", ""word_count"": 864, ""uri"": ""nyt://article/3046eacc-b3d1-5ecf-9eee-390c1f46804f""}"
2010-12-11,"{""abstract"": ""A secret cable indicated that information about the Nigerian attorney general was spread through the media to publicly pressure him to drop lawsuits against Pfizer."", ""web_url"": ""https://www.nytimes.com/2010/12/11/business/11pfizer.html"", ""snippet"": ""A secret cable indicated that information about the Nigerian attorney general was spread through the media to publicly pressure him to drop lawsuits against Pfizer."", ""lead_paragraph"": ""Pfizer was accused of hiring investigators \u201cto uncover corruption links\u201d to Nigeria\u2019s former attorney general and apply pressure to drop lawsuits against the company over a controversial 1996 test of antibiotics on children with meningitis, according to a secret State Department cable that related a company official\u2019s account."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2010/12/11/business/Pfizer/Pfizer-jumbo.jpg"", ""height"": 1024, ""width"": 709, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2010/12/11/business/Pfizer/Pfizer-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2010/12/11/business/Pfizer/Pfizer-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Secret Cable Discusses Pfizer\u2019s Actions in Nigeria Case"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Secret Cable Discusses Pfizer\u2019s Actions in Nigeria Case"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Suits and Litigation"", ""rank"": 3, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Nigeria"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""WikiLeaks"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2010-12-11T01:11:32+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Duff Wilson"", ""person"": [{""firstname"": ""Duff"", ""middlename"": null, ""lastname"": ""Wilson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/cf1958ef-da16-567d-baca-2e15ea4c507e"", ""word_count"": 741, ""uri"": ""nyt://article/cf1958ef-da16-567d-baca-2e15ea4c507e""}"
2011-01-03,"{""abstract"": ""After a rise in the cigarette tax, demand for a Pfizer antismoking drug outstripped the supply."", ""web_url"": ""https://www.nytimes.com/2011/01/04/business/global/04smoke.html"", ""snippet"": ""After a rise in the cigarette tax, demand for a Pfizer antismoking drug outstripped the supply."", ""lead_paragraph"": ""TOKYO \u0097 When the Japanese government raised the tax on cigarettes on Oct. 1, it could have started a public health revolution in this land of heavy smokers. "", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2011/01/04/business/Smoke/Smoke-articleLarge.jpg"", ""height"": 315, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2011/01/04/business/Smoke/Smoke-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 315}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2011/01/04/business/Smoke/Smoke-jumbo.jpg"", ""height"": 651, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2011/01/04/business/Smoke/Smoke-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2011/01/04/business/Smoke/Smoke-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""In Japan, Pfizer Is Short of Drug to Help Smokers"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""In Japan, Pfizer Is Short of Drug To Help Smokers"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Japan"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Smoking and Tobacco"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Taxation"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2011-01-03T17:41:34+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""Global Business"", ""byline"": {""original"": ""By Hiroko Tabuchi"", ""person"": [{""firstname"": ""Hiroko"", ""middlename"": null, ""lastname"": ""Tabuchi"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/2a2f9916-6aee-5951-9859-4b7f759a8047"", ""word_count"": 1161, ""uri"": ""nyt://article/2a2f9916-6aee-5951-9859-4b7f759a8047""}"
2011-01-18,"{""abstract"": ""The deal, worth up to $632 million, is part of Pfizer\u2019s effort to keep up with rivals that are increasingly relying on biotechnology for products and profits."", ""web_url"": ""https://www.nytimes.com/2011/01/19/health/research/19pfizer.html"", ""snippet"": ""The deal, worth up to $632 million, is part of Pfizer\u2019s effort to keep up with rivals that are increasingly relying on biotechnology for products and profits."", ""lead_paragraph"": "" Pfizer, the world\u2019s largest drug company, has agreed to pay up to $632 million to Theraclone Sciences in a research collaboration on antibody drugs for cancer and infectious disease, the companies said Tuesday. "", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer in Deal With Theraclone for Antibody Drug Research"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer in Deal With Theraclone for Antibody Drug Research"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Research"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2011-01-18T22:09:05+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Health"", ""subsection_name"": ""Research"", ""byline"": {""original"": ""By Duff Wilson"", ""person"": [{""firstname"": ""Duff"", ""middlename"": null, ""lastname"": ""Wilson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/f43363a6-c642-565b-8e82-029047f06595"", ""word_count"": 535, ""uri"": ""nyt://article/f43363a6-c642-565b-8e82-029047f06595""}"
2011-01-29,"{""abstract"": ""A judge in Boston upheld a jury decision that Pfizer illegally promoted Neurontin for unapproved uses. Pfizer said it would appeal."", ""web_url"": ""https://www.nytimes.com/2011/01/29/business/29pfizer.html"", ""snippet"": ""A judge in Boston upheld a jury decision that Pfizer illegally promoted Neurontin for unapproved uses. Pfizer said it would appeal."", ""lead_paragraph"": ""Pfizer, the drug maker, has been ordered to pay a total of $142.1 million in damages for violating federal racketeering laws in the marketing of its epilepsy drug Neurontin."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer Told to Pay $142.1 Million Over Marketing of Epilepsy Drug"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer Told to Pay $142.1 Million Over Marketing of Epilepsy Drug"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Neurontin (Drug)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Decisions and Verdicts"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2011-01-29T01:08:32+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Bloomberg News"", ""person"": [{""firstname"": ""Bloomberg"", ""middlename"": null, ""lastname"": ""News"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/cfb3cce3-856a-5928-9bfd-a1d36a5a4e9f"", ""word_count"": 243, ""uri"": ""nyt://article/cfb3cce3-856a-5928-9bfd-a1d36a5a4e9f""}"
2011-02-01,"{""abstract"": ""Valeant Pharmaceuticals says it will acquire PharmaSwiss, a maker of generic drugs, for 350 million euros."", ""web_url"": ""https://dealbook.nytimes.com/2011/02/01/valeant-to-buy-pharmaswiss-for-481-million/"", ""snippet"": ""Valeant Pharmaceuticals says it will acquire PharmaSwiss, a maker of generic drugs, for 350 million euros."", ""lead_paragraph"": ""Valeant Pharmaceuticals said on Tuesday that it would acquire PharmaSwiss, the maker of generic drugs, for 350 million euros ($481 million). "", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Valeant to Buy PharmaSwiss for $481 Million"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""AMGEN INC"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2011-02-01T12:10:46+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chris V. Nicholson"", ""person"": [{""firstname"": ""Chris"", ""middlename"": ""V."", ""lastname"": ""Nicholson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/6baca220-a65a-524a-8faa-f8f4e63c371b"", ""word_count"": 161, ""uri"": ""nyt://article/6baca220-a65a-524a-8faa-f8f4e63c371b""}"
2011-02-02,"{""abstract"": ""Pfizer said it planned to close a facility in Britain, reduce research spending and invest in money-making drugs."", ""web_url"": ""https://www.nytimes.com/2011/02/02/health/02pfizer.html"", ""snippet"": ""Pfizer said it planned to close a facility in Britain, reduce research spending and invest in money-making drugs."", ""lead_paragraph"": "" Pfizer, the drug maker, announced plans Tuesday to slash its research spending by as much as $2.9 billion in the next two years, including closing the English labs that invented Viagra."", ""print_section"": ""B"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""New Chief Revises Goals and Spending for Pfizer"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""New Chief Revises Goals And Spending For Pfizer"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Company Reports"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Research"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Appointments and Executive Changes"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2011-02-02T01:11:16+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Health"", ""byline"": {""original"": ""By Duff Wilson"", ""person"": [{""firstname"": ""Duff"", ""middlename"": null, ""lastname"": ""Wilson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/9bd188d8-b117-5851-b27b-dc79afd23929"", ""word_count"": 494, ""uri"": ""nyt://article/9bd188d8-b117-5851-b27b-dc79afd23929""}"
2011-02-22,"{""abstract"": ""The Supreme Court ruled against the parents of a child who sued the drug maker Wyeth because of the health problems they say their daughter suffered from a vaccine."", ""web_url"": ""https://www.nytimes.com/2011/02/23/business/23bizcourt.html"", ""snippet"": ""The Supreme Court ruled against the parents of a child who sued the drug maker Wyeth because of the health problems they say their daughter suffered from a vaccine."", ""lead_paragraph"": ""WASHINGTON \u0097 People injured by vaccines that they say were improperly designed must rely solely on a compensation system created by a 1986 law and may not sue vaccine manufacturers, the Supreme Court ruled on Tuesday."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Justices Reject Suit Faulting a Vaccine"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Justices Reject Suit Faulting a Vaccine"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Vaccination and Immunization"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Supreme Court"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Decisions and Verdicts"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Suits and Litigation"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2011-02-22T19:21:10+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Adam Liptak"", ""person"": [{""firstname"": ""Adam"", ""middlename"": null, ""lastname"": ""Liptak"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/515d33f9-faa1-5234-a719-87c541003475"", ""word_count"": 710, ""uri"": ""nyt://article/515d33f9-faa1-5234-a719-87c541003475""}"
2011-03-07,"{""abstract"": ""The drug industry will lose control over more than 10 medicines with sales of nearly $50 billion this year, a reversal that highlights the problems drug companies now face."", ""web_url"": ""https://www.nytimes.com/2011/03/07/business/07drug.html"", ""snippet"": ""The drug industry will lose control over more than 10 medicines with sales of nearly $50 billion this year, a reversal that highlights the problems drug companies now face."", ""lead_paragraph"": ""At the end of November, Pfizer stands to lose a $10-billion-a-year revenue stream when the patent on its blockbuster cholesterol drug Lipitor expires and cheaper generics begin to cut into the company\u2019s huge sales."", ""print_section"": ""A"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2011/03/07/us/DRUG-1/DRUG-1-articleLarge.jpg"", ""height"": 350, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2011/03/07/us/DRUG-1/DRUG-1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 350}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2011/03/07/us/DRUG-1/DRUG-1-jumbo.jpg"", ""height"": 681, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2011/03/07/us/DRUG-1/DRUG-1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2011/03/07/us/DRUG-1/DRUG-1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Drug Firms Face Billions in Losses in \u201911 as Patents End"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Patent Woes Threatening Drug Firms"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Inventions and Patents"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Research"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Generic Brands and Products"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2011-03-07T01:48:48+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Duff Wilson"", ""person"": [{""firstname"": ""Duff"", ""middlename"": null, ""lastname"": ""Wilson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/55812ed7-1855-552b-b96f-bf70ddae26b7"", ""word_count"": 1521, ""uri"": ""nyt://article/55812ed7-1855-552b-b96f-bf70ddae26b7""}"
2011-04-04,"{""abstract"": ""The $2.375 billion deal may be a harbinger amid speculation that Pfizer will sell or spin off its nonpharmaceutical businesses."", ""web_url"": ""https://dealbook.nytimes.com/2011/04/04/pfizer-sells-capsule-unit-to-k-k-r/"", ""snippet"": ""The $2.375 billion deal may be a harbinger amid speculation that Pfizer will sell or spin off its nonpharmaceutical businesses."", ""lead_paragraph"": ""Pfizer said on Monday that it had agreed to sell its Capsugel unit, which makes a variety of capsules for drugs, to Kohlberg Kravis Roberts & Company for $2.375 billion in cash. "", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer Sells Capsule Unit to K.K.R."", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Kohlberg Kravis Roberts & Co"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}], ""pub_date"": ""2011-04-04T12:01:21+0000"", ""document_type"": ""article"", ""news_desk"": """", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/958c5c8c-de5a-55ce-9d45-a444a58353f5"", ""word_count"": 227, ""uri"": ""nyt://article/958c5c8c-de5a-55ce-9d45-a444a58353f5""}"
2011-04-13,"{""abstract"": ""The multibillion-dollar market is being driven by novel applications to compete with coming generics."", ""web_url"": ""https://www.nytimes.com/2011/04/14/health/14pills.html"", ""snippet"": ""The multibillion-dollar market is being driven by novel applications to compete with coming generics."", ""lead_paragraph"": ""Facing generic competition for its \u201clittle blue pill,\u201d Pfizer recently started selling a chewable form of Viagra in Mexico. It is called Viagra Jet, and Pfizer says it may also market it to other nations in the developing world, if not the United States."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2011/04/14/business/14PILLS/14PILLS-jumbo.jpg"", ""height"": 593, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2011/04/14/business/14PILLS/14PILLS-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2011/04/14/business/14PILLS/14PILLS-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""As Generics Near, Makers Tweak Erectile Drugs"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""As Generics Near, Makers Tweak Erectile Drugs"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Viagra (Drug)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Impotence"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cialis (Drug)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Levitra (Drug)"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Generic Brands and Products"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2011-04-13T23:01:41+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Health"", ""byline"": {""original"": ""By Duff Wilson"", ""person"": [{""firstname"": ""Duff"", ""middlename"": null, ""lastname"": ""Wilson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/36ea515c-4311-5deb-beb5-fbdf3922a86d"", ""word_count"": 1326, ""uri"": ""nyt://article/36ea515c-4311-5deb-beb5-fbdf3922a86d""}"
2011-06-09,"{""abstract"": ""Concerns about 3-Nitro have gotten the attention of the Food and Drug Administration."", ""web_url"": ""https://www.nytimes.com/2011/06/09/business/09arsenic.html"", ""snippet"": ""Concerns about 3-Nitro have gotten the attention of the Food and Drug Administration."", ""lead_paragraph"": ""WASHINGTON \u2014 Farmers have for decades fed chickens an arsenic-containing drug that promotes growth, but after a government study found trace amounts of this poisonous carcinogen in chickens, its maker will suspend its sales."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2011/06/09/business/Arsenic/Arsenic-jumbo.jpg"", ""height"": 584, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2011/06/09/business/Arsenic/Arsenic-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2011/06/09/business/Arsenic/Arsenic-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Pfizer Suspends Sales of Chicken Drug With Arsenic"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer Suspends Sales of Chicken Drug With Arsenic"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""ARSENIC"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""AGRICULTURE"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Recalls and Bans of Products"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Poultry"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2011-06-09T00:26:59+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Gardiner Harris and Denise Grady"", ""person"": [{""firstname"": ""Gardiner"", ""middlename"": null, ""lastname"": ""Harris"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Denise"", ""middlename"": null, ""lastname"": ""Grady"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/26b040a0-5fd7-5b59-a3d7-2e6ac537f0d5"", ""word_count"": 720, ""uri"": ""nyt://article/26b040a0-5fd7-5b59-a3d7-2e6ac537f0d5""}"
2011-06-23,"{""abstract"": ""The proposed medication, from Bristol-Myers Squibb and Pfizer, prevents more strokes with less bleeding risk than existing treatment. It needs F.D.A. approval."", ""web_url"": ""https://www.nytimes.com/2011/06/24/health/24drugs.html"", ""snippet"": ""The proposed medication, from Bristol-Myers Squibb and Pfizer, prevents more strokes with less bleeding risk than existing treatment. It needs F.D.A. approval."", ""lead_paragraph"": ""A proposed new anticlotting drug for people with irregular heartbeats has been shown to prevent more strokes with less bleeding risk than the existing treatment, the drug makers Bristol-Myers Squibb and Pfizer said late Wednesday. The announcement sent their stocks soaring on Thursday."", ""print_section"": ""B"", ""print_page"": ""7"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Anticlotting Drug Shows Promise to Displace a Longtime Standard"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Anticlotting Drug Shows Promise To Displace a Longtime Standard"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Bristol Myers Squibb Company"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Stroke"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2011-06-23T18:40:45+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Health"", ""byline"": {""original"": ""By Duff Wilson"", ""person"": [{""firstname"": ""Duff"", ""middlename"": null, ""lastname"": ""Wilson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/dd02fcf0-3ad2-5b44-b546-397f73dcc23f"", ""word_count"": 698, ""uri"": ""nyt://article/dd02fcf0-3ad2-5b44-b546-397f73dcc23f""}"
2011-07-04,"{""abstract"": ""Chantix was linked to an increased risk of a heart attack or other serious cardiovascular event for smokers without a history of heart disease."", ""web_url"": ""https://www.nytimes.com/2011/07/05/business/05smoke.html"", ""snippet"": ""Chantix was linked to an increased risk of a heart attack or other serious cardiovascular event for smokers without a history of heart disease."", ""lead_paragraph"": ""Chantix, the best-selling prescription drug for smoking cessation, was linked to an increased risk of a heart attack, stroke or other serious cardiovascular event for smokers without a history of heart disease compared with smokers who did not use the drug, according to a Canadian medical journal report released on \u00a0Monday. "", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Study Links Smoking Drug to Cardiovascular Problems"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Study Links Smoking Drug To Cardiovascular Problems"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Heart"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Smoking and Tobacco"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Canadian Medical Assn"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2011-07-04T16:02:09+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Duff Wilson"", ""person"": [{""firstname"": ""Duff"", ""middlename"": null, ""lastname"": ""Wilson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/5a1b5c24-128d-5e1c-b29b-66ad672a3f0a"", ""word_count"": 727, ""uri"": ""nyt://article/5a1b5c24-128d-5e1c-b29b-66ad672a3f0a""}"
2011-07-07,"{""abstract"": ""The drug maker steps up a streamlining effort to focus on its core business."", ""web_url"": ""https://dealbook.nytimes.com/2011/07/07/pfizer-puts-animal-health-and-nutrition-businesses-on-the-block/"", ""snippet"": ""The drug maker steps up a streamlining effort to focus on its core business."", ""lead_paragraph"": ""Pfizer is stepping up a streamlining effort to focus on drugs."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer Puts Nutrition and Animal Health Units on the Block"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Diet and Nutrition"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}], ""pub_date"": ""2011-07-07T13:57:23+0000"", ""document_type"": ""article"", ""news_desk"": """", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Kevin Roose"", ""person"": [{""firstname"": ""Kevin"", ""middlename"": null, ""lastname"": ""Roose"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/e4202547-998c-59b6-a13a-d10c319ec742"", ""word_count"": 231, ""uri"": ""nyt://article/e4202547-998c-59b6-a13a-d10c319ec742""}"
2011-08-02,"{""abstract"": ""Sales of the company\u2019s Lyrica pain pill and its Enbrel arthritis medicine topped analysts\u2019 predictions."", ""web_url"": ""https://www.nytimes.com/2011/08/03/business/sales-of-pain-drugs-help-lift-pfizer.html"", ""snippet"": ""Sales of the company\u2019s Lyrica pain pill and its Enbrel arthritis medicine topped analysts\u2019 predictions."", ""lead_paragraph"": ""Pfizer, the world\u2019s biggest drug maker, reported second-quarter profit that topped analysts\u2019 estimates as sales of pain medicines offset declining revenue from expired patents."", ""print_section"": ""B"", ""print_page"": ""7"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Sales of Pain Drugs Help Pfizer\u2019s Profit Beat Forecasts"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Sales of Pain Drugs Help Pfizer\u2019s Profit Beat Forecasts"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Company Reports"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Sales"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2011-08-02T20:37:08+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Bloomberg News"", ""person"": [{""firstname"": ""Bloomberg"", ""middlename"": null, ""lastname"": ""News"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/093f0ca9-2f70-5ed6-8151-dab752d86dc1"", ""word_count"": 422, ""uri"": ""nyt://article/093f0ca9-2f70-5ed6-8151-dab752d86dc1""}"
2011-08-04,"{""abstract"": ""Pfizer hopes to have an over-the-counter version of the world\u2019s best-selling drug after it loses patent protection."", ""web_url"": ""https://www.nytimes.com/2011/08/04/business/pfizer-is-said-to-be-pursuing-nonprescription-lipitor.html"", ""snippet"": ""Pfizer hopes to have an over-the-counter version of the world\u2019s best-selling drug after it loses patent protection."", ""lead_paragraph"": ""Pfizer hopes to introduce an over-the-counter version of Lipitor, the world\u2019s best-selling drug, after it loses patent protection in November, a person close to the situation said Wednesday. "", ""print_section"": ""B"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer Is Said to Pursue Nonprescription Lipitor"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer Is Said To Want New Lipitor Drug"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Lipitor (Drug)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Inventions and Patents"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2011-08-04T02:22:54+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/64c84ccb-5776-5c35-9518-3babb4ca7e78"", ""word_count"": 501, ""uri"": ""nyt://article/64c84ccb-5776-5c35-9518-3babb4ca7e78""}"
2011-11-12,"{""abstract"": ""Pfizer is offering to give discounts on Lipitor to pharmacists who keep filling prescriptions with the name-brand drug once generic competition begins."", ""web_url"": ""https://www.nytimes.com/2011/11/12/health/plan-would-delay-sales-of-generic-for-lipitor.html"", ""snippet"": ""Pfizer is offering to give discounts on Lipitor to pharmacists who keep filling prescriptions with the name-brand drug once generic competition begins."", ""lead_paragraph"": ""The biggest introduction of a generic drug in pharmaceutical history is being met with tough business strategies by Pfizer and pharmacy benefit companies, according to recent letters to pharmacists. "", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2011/11/12/business/Lipitor/Lipitor-jumbo.jpg"", ""height"": 1024, ""width"": 737, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}], ""headline"": {""main"": ""Plan Would Delay Sales of Generic for Lipitor"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Plan Would Delay Sales Of Generic For Lipitor"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugstores"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Lipitor (Drug)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cholesterol"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Generic Brands and Products"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2011-11-12T02:40:47+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Health"", ""byline"": {""original"": ""By Duff Wilson"", ""person"": [{""firstname"": ""Duff"", ""middlename"": null, ""lastname"": ""Wilson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/6fffd95c-280f-5848-a7f7-e216b965e404"", ""word_count"": 808, ""uri"": ""nyt://article/6fffd95c-280f-5848-a7f7-e216b965e404""}"
2011-11-22,"{""abstract"": ""As the nation seeks ways to create jobs, critics say many big companies are squandering resources on share repurchases at the expense of investing in future growth."", ""web_url"": ""https://www.nytimes.com/2011/11/22/business/rash-to-some-stock-buybacks-are-on-the-rise.html"", ""snippet"": ""As the nation seeks ways to create jobs, critics say many big companies are squandering resources on share repurchases at the expense of investing in future growth."", ""lead_paragraph"": ""When Pfizer cut its research budget this year and laid off 1,100 employees, it was not because the company needed to save money. "", ""print_section"": ""A"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2011/11/22/business/Buyback/Buyback-articleLarge.jpg"", ""height"": 380, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2011/11/22/business/Buyback/Buyback-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 380}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2011/11/22/business/Buyback/Buyback-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2011/11/22/business/Buyback/Buyback-thumbStandard-v2.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2011/11/22/business/Buyback/Buyback-thumbStandard-v2.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""As Layoffs Rise, Stock Buybacks Consume Cash"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""As Layoffs Rise, Stock Buybacks Consume Cash"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Unemployment"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Layoffs and Job Reductions"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Stocks and Bonds"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Executive Compensation"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2011-11-22T01:29:21+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Nelson D. Schwartz"", ""person"": [{""firstname"": ""Nelson"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/0a60401c-4575-562e-bd35-7db3aa8c6a34"", ""word_count"": 1273, ""uri"": ""nyt://article/0a60401c-4575-562e-bd35-7db3aa8c6a34""}"
2011-11-30,"{""abstract"": ""Pfizer\u2019s aggressive strategy may offer lessons for drug makers facing similar losses of patent protection for other blockbuster drugs over the next few years."", ""web_url"": ""https://www.nytimes.com/2011/11/30/health/generic-lipitor-sets-off-an-aggressive-push-by-pfizer.html"", ""snippet"": ""Pfizer\u2019s aggressive strategy may offer lessons for drug makers facing similar losses of patent protection for other blockbuster drugs over the next few years."", ""lead_paragraph"": ""For the last year, Pfizer has been laying the groundwork to combat the looming competition against Lipitor, forging deals with insurers, pharmacy benefit managers and patients to meet or beat the price of its generic replacements. "", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2011/11/30/business/LIPITOR/LIPITOR-jumbo.jpg"", ""height"": 622, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2011/11/30/business/LIPITOR/LIPITOR-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2011/11/30/business/LIPITOR/LIPITOR-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Facing Generic Lipitor Rivals, Pfizer Battles to Protect Its Cash Cow"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Facing Generic Lipitor Rivals, Pfizer Battles to Protect Its Cash Cow"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Watson Pharmaceuticals Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Ranbaxy Laboratories"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Lipitor (Drug)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Generic Brands and Products"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2011-11-30T01:55:05+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Health"", ""byline"": {""original"": ""By Duff Wilson"", ""person"": [{""firstname"": ""Duff"", ""middlename"": null, ""lastname"": ""Wilson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/f301b1ea-1b6c-532e-abe2-7ceade53cf76"", ""word_count"": 1288, ""uri"": ""nyt://article/f301b1ea-1b6c-532e-abe2-7ceade53cf76""}"
2011-12-01,"{""abstract"": ""Three senators asked Pfizer to detail their agreements to block prescriptions of generic versions of Lipitor, saying they were against the idea of drug makers manipulating the marketplace."", ""web_url"": ""https://www.nytimes.com/2011/12/01/health/senators-question-plan-to-stall-generic-lipitor.html"", ""snippet"": ""Three senators asked Pfizer to detail their agreements to block prescriptions of generic versions of Lipitor, saying they were against the idea of drug makers manipulating the marketplace."", ""lead_paragraph"": ""Three senators on Wednesday asked the drug maker Pfizer and five other health companies to detail their agreements to block prescriptions of generic versions of the cholesterol drug Lipitor and sell only the Pfizer brand-name version."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2011/12/01/business/SubDrug/SubDrug-jumbo.jpg"", ""height"": 1024, ""width"": 709, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}], ""headline"": {""main"": ""Senators Question Deals to Block Generic Lipitor"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Senators Question Deals to Block Generic Lipitor"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Lipitor (Drug)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cholesterol"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Kohl, Herbert H"", ""rank"": 5, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Grassley, Charles E"", ""rank"": 6, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Baucus, Max"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Generic Brands and Products"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2011-12-01T05:01:50+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Health"", ""byline"": {""original"": ""By Duff Wilson"", ""person"": [{""firstname"": ""Duff"", ""middlename"": null, ""lastname"": ""Wilson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/2325084d-4542-5d2f-bc5c-4e5beb1a2f6c"", ""word_count"": 489, ""uri"": ""nyt://article/2325084d-4542-5d2f-bc5c-4e5beb1a2f6c""}"
2011-12-10,"{""abstract"": ""Amy Schulman of Pfizer says that when conveying your management style to employees, it\u2019s always best to give real-life examples."", ""web_url"": ""https://www.nytimes.com/2011/12/11/business/amy-schulman-of-pfizer-on-demonstrating-leadership.html"", ""snippet"": ""Amy Schulman of Pfizer says that when conveying your management style to employees, it\u2019s always best to give real-life examples."", ""lead_paragraph"": ""This interview with  Amy Schulman, executive vice president, general counsel, and president of nutrition at Pfizer, was conducted and condensed by  Adam Bryant. "", ""print_section"": ""BU"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2011/12/11/business/11corner-pic/11corner-pic-jumbo.jpg"", ""height"": 290, ""width"": 190, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2011/12/11/business/11corner-pic/11corner-pic-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2011/12/11/business/11corner-pic/11corner-pic-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""A Blueprint for Leadership: Show, Don\u2019t Tell"", ""kicker"": ""Corner Office | Amy Schulman"", ""content_kicker"": null, ""print_headline"": ""A Blueprint for Leadership: Show, Don\u2019t Tell"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Hiring and Promotion"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Executives and Management (Theory)"", ""rank"": 3, ""major"": ""N""}], ""pub_date"": ""2011-12-10T18:52:22+0000"", ""document_type"": ""article"", ""news_desk"": ""NAT"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Adam Bryant"", ""person"": [{""firstname"": ""Adam"", ""middlename"": null, ""lastname"": ""Bryant"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""Question"", ""_id"": ""nyt://article/7aba93df-dfbe-59df-b4fe-4c384cdb4e25"", ""word_count"": 1768, ""uri"": ""nyt://article/7aba93df-dfbe-59df-b4fe-4c384cdb4e25""}"
2012-02-12,"{""abstract"": ""Mr. Aaron was one of the most notable deal-makers of his generation, having counseled a long list of blue-chip clients that included General Motors, Time Warner and Pfizer."", ""web_url"": ""https://dealbook.nytimes.com/2012/02/12/roger-s-aaron-top-deals-lawyer-dies-at-69/"", ""snippet"": ""Mr. Aaron was one of the most notable deal-makers of his generation, having counseled a long list of blue-chip clients that included General Motors, Time Warner and Pfizer."", ""lead_paragraph"": ""Roger S. Aaron, who as a longtime partner at the law firm Skadden, Arps, Slate, Meagher & Flom helped orchestrate some of the biggest mergers of the past several decades, notably the unions of Exxon and Mobil and Alcatel and Lucent, as well as Daimler\u2019s sale of Chrysler to Cerberus Capital Management, died on Saturday in Manhattan. He was 69."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Roger S. Aaron, Top Deal Lawyer, Dies at 69"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Skadden Arps Slate Meagher & Flom"", ""rank"": 1, ""major"": ""N""}], ""pub_date"": ""2012-02-12T21:39:53+0000"", ""document_type"": ""article"", ""news_desk"": """", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Michael J. de la Merced"", ""person"": [{""firstname"": ""Michael"", ""middlename"": ""J."", ""lastname"": ""de la Merced"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/06080c28-8b3c-5409-99c4-ea327bd6e20b"", ""word_count"": 615, ""uri"": ""nyt://article/06080c28-8b3c-5409-99c4-ea327bd6e20b""}"
2012-03-06,"{""abstract"": ""The proposed new drug would combine Merck\u2019s drug Zetia, which lowers \u201cbad\u201d cholesterol, with the generic version of Lipitor, the statin made by Pfizer."", ""web_url"": ""https://www.nytimes.com/2012/03/06/health/fda-rejects-mercks-application-for-combination-drug.html"", ""snippet"": ""The proposed new drug would combine Merck\u2019s drug Zetia, which lowers \u201cbad\u201d cholesterol, with the generic version of Lipitor, the statin made by Pfizer."", ""lead_paragraph"": ""The Food and Drug Administration on Monday rejected an application by Merck to combine a cholesterol-fighting pill with the generic version of Lipitor. "", ""print_section"": ""B"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""In Rejection, F.D.A. Wants More Data From Merck"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""In Rejection, F.D.A Wants More Data From Merck"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Vytorin (Drug)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Lipitor (Drug)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cholesterol"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Zetia (Drug)"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2012-03-06T00:20:13+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Health"", ""byline"": {""original"": ""By Katie Thomas"", ""person"": [{""firstname"": ""Katie"", ""middlename"": null, ""lastname"": ""Thomas"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/d71b3f6b-d035-520e-837d-13469c24ef1e"", ""word_count"": 474, ""uri"": ""nyt://article/d71b3f6b-d035-520e-837d-13469c24ef1e""}"
2012-03-28,"{""abstract"": ""The new owners of Pfizer\u2019s former factory in Williamsburg are bringing manufacturing jobs back to the borough in what was the pharmaceutical giant\u2019s original home."", ""web_url"": ""https://www.nytimes.com/2012/03/28/business/food-start-ups-flock-to-old-pfizer-factory-in-brooklyn.html"", ""snippet"": ""The new owners of Pfizer\u2019s former factory in Williamsburg are bringing manufacturing jobs back to the borough in what was the pharmaceutical giant\u2019s original home."", ""lead_paragraph"": ""The rise of artisanal food like small-batch pickles, basement-cured charcuterie and hand-churned ice cream has been a boon to Brooklyn\u2019s image. Now those products are helping the borough revive its manufacturing base, in a former pharmaceutical factory in South Williamsburg."", ""print_section"": ""B"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/03/28/business/Pfizer1/Pfizer1-jumbo.jpg"", ""height"": 628, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/03/28/business/Pfizer1/Pfizer1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2012/03/28/business/Pfizer1/Pfizer1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Food Start-Ups Find a Home in Brooklyn"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Food Start-Ups Find a Home in Brooklyn"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Factories and Manufacturing"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Food"", ""rank"": 3, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""New York City"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Real Estate (Commercial)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Williamsburg (NYC)"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Start-ups"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2012-03-28T01:29:44+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Ronda Kaysen"", ""person"": [{""firstname"": ""Ronda"", ""middlename"": null, ""lastname"": ""Kaysen"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/ad5148eb-a094-57f2-aec7-6edd079386f8"", ""word_count"": 1083, ""uri"": ""nyt://article/ad5148eb-a094-57f2-aec7-6edd079386f8""}"
2012-04-02,"{""abstract"": ""Through their holding company, Joh. A. Benckiser, the Reimanns own some of the world\u2019s most recognizable consumer brands, including Coty, Bally, Derek Lam, and the Reckitt Benckiser Group, a giant maker of household cleaning supplies."", ""web_url"": ""https://dealbook.nytimes.com/2012/04/02/the-billionaire-family-backing-the-avon-bid/"", ""snippet"": ""Through their holding company, Joh. A. Benckiser, the Reimanns own some of the world\u2019s most recognizable consumer brands, including Coty, Bally, Derek Lam, and the Reckitt Benckiser Group, a giant maker of household cleaning supplies."", ""lead_paragraph"": ""Behind Coty\u2019s $10 billion unsolicited offer for Avon Products is one of Europe\u2019s wealthiest and most private families: the Reimanns."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""The Billionaire Family Backing the Avon Bid"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Cosmetics and Toiletries"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Perfumes and Fragrances"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Jacobs, Marc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Lam, Derek"", ""rank"": 5, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Lopez, Jennifer"", ""rank"": 6, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Moss, Kate"", ""rank"": 7, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Wang, Vera"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Calvin Klein Inc"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Carlyle Group"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Choo, Jimmy, Ltd"", ""rank"": 11, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Coty Inc"", ""rank"": 12, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 13, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Reckitt Benckiser"", ""rank"": 14, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Germany"", ""rank"": 15, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Paris (France)"", ""rank"": 16, ""major"": ""N""}], ""pub_date"": ""2012-04-02T19:43:40+0000"", ""document_type"": ""article"", ""news_desk"": """", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Evelyn M. Rusli"", ""person"": [{""firstname"": ""Evelyn"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/ac738b1b-0ae3-56bd-9c06-6431fb723536"", ""word_count"": 576, ""uri"": ""nyt://article/ac738b1b-0ae3-56bd-9c06-6431fb723536""}"
2012-04-12,"{""abstract"": ""So-called specialty drugs for diseases like rheumatoid arthritis have a narrow use and high costs, leaving the most vulnerable patients with huge bills."", ""web_url"": ""https://www.nytimes.com/2012/04/13/health/states-seek-to-curb-exorbitant-drug-costs-incurred-by-patients.html"", ""snippet"": ""So-called specialty drugs for diseases like rheumatoid arthritis have a narrow use and high costs, leaving the most vulnerable patients with huge bills."", ""lead_paragraph"": ""The hemophilia drug that saves 7-year-old William Addison from uncontrolled bleeding costs $100,000 a year. His family\u2019s insurance pays virtually all of it. "", ""print_section"": ""A"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/04/12/business/copay/copay-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/04/12/business/copay/copay-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/04/12/business/copay/copay-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2012/04/12/business/copay/copay-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/04/12/business/copay/copay-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""States Seek Curb on Patient Bills for Costly Drugs"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""States Seek Curb On Patient Bills For Costly Drugs"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Reform and Reorganization"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Health Insurance and Managed Care"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""States (US)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Law and Legislation"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Prices (Fares, Fees and Rates)"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2012-04-12T21:15:04+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Health"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/18bd792e-7619-5099-bea1-22fdb5118c34"", ""word_count"": 1264, ""uri"": ""nyt://article/18bd792e-7619-5099-bea1-22fdb5118c34""}"
2012-04-18,"[{""abstract"": ""Pfizer, which has been selling off units to concentrate on development of medicines, may be ready to sell the nutrition unit to Nestl\u00e9."", ""web_url"": ""https://dealbook.nytimes.com/2012/04/17/pfizer-nears-sale-of-infant-nutrition-unit/"", ""snippet"": ""Pfizer, which has been selling off units to concentrate on development of medicines, may be ready to sell the nutrition unit to Nestl\u00e9."", ""lead_paragraph"": ""Pfizer is nearing a deal to sell its infant nutrition business, with a winning buyer that could be picked as soon as next week, people briefed on the matter said Tuesday."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer Nears Sale of Infant Nutrition Unit"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Nestle SA"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}], ""pub_date"": ""2012-04-18T03:33:02+0000"", ""document_type"": ""article"", ""news_desk"": """", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Michael J. de la Merced"", ""person"": [{""firstname"": ""Michael"", ""middlename"": ""J."", ""lastname"": ""de la Merced"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/5962fab7-2bb9-5add-b6f3-7d10d90828a3"", ""word_count"": 306, ""uri"": ""nyt://article/5962fab7-2bb9-5add-b6f3-7d10d90828a3""}, {""abstract"": ""Pfizer, which has been selling off units to concentrate on development of medicines, may be ready to sell the nutrition unit to Nestl\u00e9."", ""web_url"": ""https://www.nytimes.com/2012/04/18/business/pfizer-close-to-selling-its-infant-nutrition-unit.html"", ""snippet"": ""Pfizer, which has been selling off units to concentrate on development of medicines, may be ready to sell the nutrition unit to Nestl\u00e9."", ""lead_paragraph"": ""Pfizer is nearing a deal to sell its infant nutrition business, with a winning buyer that could be picked as soon as next week, people briefed on the matter said Tuesday."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer Close to Selling Another Unit"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer Close To Selling Another Unit"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}], ""pub_date"": ""2012-04-18T03:36:06+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Michael J. de la Merced"", ""person"": [{""firstname"": ""Michael"", ""middlename"": ""J."", ""lastname"": ""de la Merced"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/d2c54be1-3932-5c02-81f1-27b4230d2a4e"", ""word_count"": 315, ""uri"": ""nyt://article/d2c54be1-3932-5c02-81f1-27b4230d2a4e""}]"
2012-04-23,"[{""abstract"": ""Amid a weak merger market, drug makers are striking a flurry of deals, with Pfizer agreeing to sell its infant nutrition unit to Nestl\u00e9 for $11.9 billion on Monday."", ""web_url"": ""https://dealbook.nytimes.com/2012/04/23/a-hot-time-for-health-care-deals/"", ""snippet"": ""Amid a weak merger market, drug makers are striking a flurry of deals, with Pfizer agreeing to sell its infant nutrition unit to Nestl\u00e9 for $11.9 billion on Monday."", ""lead_paragraph"": ""If mergers activity rises this year, as ever-optimistic deal makers say will happen, health care transactions will help lead the way."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""A Hot Time for Health Care Deals"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""AMYLIN PHARMACEUTICALS INC"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Bristol Myers Squibb Company"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""GlaxoSmithKline PLC"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Human Genome Sciences Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Illumina Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Nestle SA"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Roche Holding AG"", ""rank"": 9, ""major"": ""N""}], ""pub_date"": ""2012-04-23T13:16:12+0000"", ""document_type"": ""article"", ""news_desk"": """", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Michael J. de la Merced"", ""person"": [{""firstname"": ""Michael"", ""middlename"": ""J."", ""lastname"": ""de la Merced"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/6dd373dc-93c7-540a-86a7-ae4c708372d5"", ""word_count"": 514, ""uri"": ""nyt://article/6dd373dc-93c7-540a-86a7-ae4c708372d5""}, {""abstract"": ""Adding to a flurry of health care deals announced on Monday, Thomson Reuters has sold its health care unit to an affiliate of Veritas Capital for $1.25 billion in cash."", ""web_url"": ""https://dealbook.nytimes.com/2012/04/23/thomson-reuters-sells-healthcare-business-for-1-25-billion/"", ""snippet"": ""Adding to a flurry of health care deals announced on Monday, Thomson Reuters has sold its health care unit to an affiliate of Veritas Capital for $1.25 billion in cash."", ""lead_paragraph"": ""On a rather active Merger Monday highlighted by two health care acquisitions \u2013 Nestl\u00e9\u2019s $11.9 billion purchase of the infant nutrition unit of Pfizer and AstraZeneca\u2019s $1.26 billion buyout of Ardea Biosciences \u2013 Thomson Reuters is adding one more deal to the mix."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Thomson Reuters Sells Health Care Business for $1.25 Billion"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2012-04-23T14:31:54+0000"", ""document_type"": ""article"", ""news_desk"": """", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Kevin Roose"", ""person"": [{""firstname"": ""Kevin"", ""middlename"": null, ""lastname"": ""Roose"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/93e7f9ed-834c-53f0-96ac-77af2d2c0661"", ""word_count"": 247, ""uri"": ""nyt://article/93e7f9ed-834c-53f0-96ac-77af2d2c0661""}, {""abstract"": ""By agreeing to acquire Pfizer\u2019s infant nutrition business for $11.9 billion, the Swiss food giant Nestl\u00e9 is paying a high premium to gain access to the baby food markets in emerging countries."", ""web_url"": ""https://dealbook.nytimes.com/2012/04/23/nestle-pays-a-high-price-for-pfizer-unit/"", ""snippet"": ""By agreeing to acquire Pfizer\u2019s infant nutrition business for $11.9 billion, the Swiss food giant Nestl\u00e9 is paying a high premium to gain access to the baby food markets in emerging countries."", ""lead_paragraph"": ""Nestl\u00e9 is throwing down its cash."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Nestle Pays a High Price for Pfizer Unit"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Baby Foods"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Nestle SA"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2012-04-23T17:30:49+0000"", ""document_type"": ""article"", ""news_desk"": """", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Mark Scott"", ""person"": [{""firstname"": ""Mark"", ""middlename"": null, ""lastname"": ""Scott"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/8fc1fc73-7c99-5db1-8f6b-bef8c5fd7ca6"", ""word_count"": 332, ""uri"": ""nyt://article/8fc1fc73-7c99-5db1-8f6b-bef8c5fd7ca6""}]"
2012-05-02,"{""abstract"": ""With its best-selling drugs losing patent protection, Pfizer is shedding money-making but noncore businesses to focus on pharmaceutical sciences."", ""web_url"": ""https://www.nytimes.com/2012/05/02/business/pfizer-profit-declines-19-after-loss-of-lipitor-patent.html"", ""snippet"": ""With its best-selling drugs losing patent protection, Pfizer is shedding money-making but noncore businesses to focus on pharmaceutical sciences."", ""lead_paragraph"": ""For years, drug companies have known that their days of plenty were numbered, that the moment would arrive when the best-selling drugs that had driven two decades\u2019 worth of profits would lose their patent protection and succumb to competition from generic alternatives. Without new blockbusters to replace them, profits would tumble."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/05/02/business/JP-PFIZER-2/JP-PFIZER-2-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/05/02/business/JP-PFIZER-2/JP-PFIZER-2-superJumbo.jpg"", ""height"": 1366, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/05/02/business/JP-PFIZER-2/JP-PFIZER-2-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2012/05/02/business/JP-PFIZER-2/JP-PFIZER-2-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/05/02/business/JP-PFIZER-2/JP-PFIZER-2-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer Races to Reinvent Itself"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer Profit Declines 19% On Slumping Lipitor Sales"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Company Reports"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Inventions and Patents"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Lipitor (Drug)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Budgets and Budgeting"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Research"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2012-05-02T01:37:09+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Katie Thomas"", ""person"": [{""firstname"": ""Katie"", ""middlename"": null, ""lastname"": ""Thomas"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/333f5fc9-1337-5b7e-8cea-0c814002304d"", ""word_count"": 1195, ""uri"": ""nyt://article/333f5fc9-1337-5b7e-8cea-0c814002304d""}"
2012-05-08,"{""abstract"": ""As an advisory panel prepared to consider whether to recommend federal approval of Pfizer\u2019s rheumatoid arthritis pill, F.D.A. documents raise safety questions."", ""web_url"": ""https://www.nytimes.com/2012/05/08/health/fda-staff-raises-concerns-about-arthritis-drug.html"", ""snippet"": ""As an advisory panel prepared to consider whether to recommend federal approval of Pfizer\u2019s rheumatoid arthritis pill, F.D.A. documents raise safety questions."", ""lead_paragraph"": ""Federal regulators said Monday that an experimental pill being developed by Pfizer to treat rheumatoid arthritis raised \u201cserious safety concerns\u201d and was linked to a higher risk for lymphoma, a form of cancer, and serious infections."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/05/08/business/Drug/Drug-jumbo.jpg"", ""height"": 1024, ""width"": 709, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/05/08/business/Drug/Drug-superJumbo.jpg"", ""height"": 2048, ""width"": 1418, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}], ""headline"": {""main"": ""F.D.A. Staff Raises Concerns About Arthritis Drug"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""F.D.A. Staff Raises Concerns About Arthritis Drug"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Rheumatoid Arthritis"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2012-05-08T01:40:05+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Health"", ""byline"": {""original"": ""By Katie Thomas"", ""person"": [{""firstname"": ""Katie"", ""middlename"": null, ""lastname"": ""Thomas"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/9d0b79e1-b49a-5310-9cae-9c0890f059ff"", ""word_count"": 546, ""uri"": ""nyt://article/9d0b79e1-b49a-5310-9cae-9c0890f059ff""}"
2012-05-09,"{""abstract"": ""A federal advisory panel recommended approval of a rheumatoid arthritis pill known as tofacitinib, but several members expressed concern about its safety."", ""web_url"": ""https://www.nytimes.com/2012/05/10/health/panel-supports-arthritis-pill.html"", ""snippet"": ""A federal advisory panel recommended approval of a rheumatoid arthritis pill known as tofacitinib, but several members expressed concern about its safety."", ""lead_paragraph"": ""A federal advisory panel recommended approval on Wednesday of a rheumatoid arthritis pill that could offer patients an alternative to the injectable medicines already on the market, but several members expressed concern about safety and urged the Food and Drug Administration to require rigorous follow-up studies."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Arthritis Pill From Pfizer Wins Support of U.S. Panel"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Arthritis Pill From Pfizer Wins Support Of U.S. Panel"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Accidents and Safety"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Rheumatoid Arthritis"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2012-05-09T21:37:20+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Health"", ""byline"": {""original"": ""By Katie Thomas"", ""person"": [{""firstname"": ""Katie"", ""middlename"": null, ""lastname"": ""Thomas"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/d9334e74-0af9-510f-8a94-24c705fee20e"", ""word_count"": 425, ""uri"": ""nyt://article/d9334e74-0af9-510f-8a94-24c705fee20e""}"
2012-06-01,"{""abstract"": ""Cavan M. Redmond, a senior executive at Pfizer, will become the chief executive of WebMD, which is under pressure to bolster its share price."", ""web_url"": ""https://dealbook.nytimes.com/2012/06/01/pfizer-executive-to-take-the-helm-of-webmd/"", ""snippet"": ""Cavan M. Redmond, a senior executive at Pfizer, will become the chief executive of WebMD, which is under pressure to bolster its share price."", ""lead_paragraph"": ""After months of searching, WebMD has found a new chief."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer Executive to Take the Helm of WebMD"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Appointments and Executive Changes"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""WebMD Health Corporation"", ""rank"": 3, ""major"": ""N""}], ""pub_date"": ""2012-06-01T04:01:07+0000"", ""document_type"": ""article"", ""news_desk"": """", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Michael J. de la Merced"", ""person"": [{""firstname"": ""Michael"", ""middlename"": ""J."", ""lastname"": ""de la Merced"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/7274fbe0-b891-517b-a0b4-1715a8702c46"", ""word_count"": 396, ""uri"": ""nyt://article/7274fbe0-b891-517b-a0b4-1715a8702c46""}"
2012-06-07,"{""abstract"": ""Shares in Pfizer were up slightly on Thursday after the drug maker announced that it planned to take its animal health unit public rather than sell it."", ""web_url"": ""https://dealbook.nytimes.com/2012/06/07/pfizer-confirms-spin-off-of-animal-health-unit/"", ""snippet"": ""Shares in Pfizer were up slightly on Thursday after the drug maker announced that it planned to take its animal health unit public rather than sell it."", ""lead_paragraph"": ""Shares in Pfizer were up slightly on Thursday after the drug maker made the entirely unsurprising announcement that it planned to take its animal health unit public rather than sell it to a potential buyer."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer Confirms Spinoff of Animal Health Unit"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}], ""pub_date"": ""2012-06-07T16:28:07+0000"", ""document_type"": ""article"", ""news_desk"": """", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Michael J. de la Merced"", ""person"": [{""firstname"": ""Michael"", ""middlename"": ""J."", ""lastname"": ""de la Merced"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/8ca4cc43-2c7b-566f-a12f-158a57451e4e"", ""word_count"": 282, ""uri"": ""nyt://article/8ca4cc43-2c7b-566f-a12f-158a57451e4e""}"
2012-06-25,"{""abstract"": ""Documents in a fraud case against Pfizer suggest that research officials were less than forthcoming about the safety of the arthritis drug Celebrex during an early trial study."", ""web_url"": ""https://www.nytimes.com/2012/06/25/health/in-documents-on-pain-drug-celebrex-signs-of-doubt-and-deception.html"", ""snippet"": ""Documents in a fraud case against Pfizer suggest that research officials were less than forthcoming about the safety of the arthritis drug Celebrex during an early trial study."", ""lead_paragraph"": ""A research director for Pfizer was positively buoyant after reading that an important medical conference had just featured a study claiming that the new arthritis drug Celebrex was safer on the stomach than more established drugs."", ""print_section"": ""A"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/06/25/business/jp-celebrex-1/jp-celebrex-1-articleLarge.jpg"", ""height"": 330, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2012/06/25/business/jp-celebrex-1/jp-celebrex-1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 330}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/06/25/business/jp-celebrex-1/jp-celebrex-1-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/06/25/business/jp-celebrex-1/jp-celebrex-1-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/06/25/business/jp-celebrex-1/jp-celebrex-1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2012/06/25/business/jp-celebrex-1/jp-celebrex-1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/06/25/business/jp-celebrex-1/jp-celebrex-1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""In Documents on Pain Drug, Signs of Doubt and Deception"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Signs of Doubt and Deception In Documents on a Pain Drug"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Heart"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""ARTHRITIS"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Celebrex (Drug)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2012-06-25T01:53:48+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Health"", ""byline"": {""original"": ""By Katie Thomas"", ""person"": [{""firstname"": ""Katie"", ""middlename"": null, ""lastname"": ""Thomas"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/47a59ebf-c865-58fa-bcc8-b4b7c3c6485b"", ""word_count"": 1465, ""uri"": ""nyt://article/47a59ebf-c865-58fa-bcc8-b4b7c3c6485b""}"
2012-06-26,"{""abstract"": ""The drug\u2019s makers said the agency had asked for more information on managing and verifying data from a large study that compared the drug, Eliquis, with warfarin."", ""web_url"": ""https://www.nytimes.com/2012/06/26/health/policy/fda-delays-action-on-eliquis-from-pfizer-and-bristol-myers.html"", ""snippet"": ""The drug\u2019s makers said the agency had asked for more information on managing and verifying data from a large study that compared the drug, Eliquis, with warfarin."", ""lead_paragraph"": ""In a move that came as a surprise to researchers and analysts, the Food and Drug Administration has decided not to approve \u2014 for now \u2014 the anticlotting drug Eliquis, viewed as the next blockbuster for its makers, Bristol-Myers Squibb and Pfizer."", ""print_section"": ""B"", ""print_page"": ""7"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""F.D.A. Unexpectedly Delays Move on Anticlotting Drug"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""F.D.A. Unexpectedly Delays Move on Anticlotting Drug"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Blood Clots"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Bristol Myers Squibb Company"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2012-06-26T00:39:09+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Health"", ""subsection_name"": ""Money & Policy"", ""byline"": {""original"": ""By Katie Thomas"", ""person"": [{""firstname"": ""Katie"", ""middlename"": null, ""lastname"": ""Thomas"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/bb48d9d6-70dc-522d-892d-47655c680233"", ""word_count"": 599, ""uri"": ""nyt://article/bb48d9d6-70dc-522d-892d-47655c680233""}"
2012-07-24,"{""abstract"": ""Pfizer, one of the three companies behind the drug, said it did not improve either cognition or daily functioning compared to a placebo."", ""web_url"": ""https://www.nytimes.com/2012/07/24/business/alzheimers-drug-fails-its-first-clinical-trial.html"", ""snippet"": ""Pfizer, one of the three companies behind the drug, said it did not improve either cognition or daily functioning compared to a placebo."", ""lead_paragraph"": ""The most closely watched experimental treatment for Alzheimer\u2019s disease proved ineffective in its first large clinical trial, dealing a blow to the field, to a theory about the cause of the disease, and to the three companies behind the drug."", ""print_section"": ""B"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Alzheimer\u2019s Drug Fails Its First Big Clinical Trial"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Alzheimer\u2019s Drug Fails First Big Clinical Trial"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Clinical Trials"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Alzheimer's Disease"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2012-07-24T01:23:30+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/3c443f8b-3d6a-5b4a-8583-c537807f92cc"", ""word_count"": 640, ""uri"": ""nyt://article/3c443f8b-3d6a-5b4a-8583-c537807f92cc""}"
2012-08-06,"{""abstract"": ""The companies developing the treatment, called bapineuzumab, said it did not improve cognition or daily functioning compared with a placebo."", ""web_url"": ""https://www.nytimes.com/2012/08/07/business/alzheimers-drug-trials-halted.html"", ""snippet"": ""The companies developing the treatment, called bapineuzumab, said it did not improve cognition or daily functioning compared with a placebo."", ""lead_paragraph"": ""Johnson & Johnson and Pfizer announced on Monday that they were halting development of a closely watched Alzheimer\u2019s drug after two clinical trials failed to show that it was effective in patients with mild to moderate forms of the disease."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Trials for Alzheimer\u2019s Drug Halted After Poor Results"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Trials for Alzheimer\u2019s Drug Halted After Poor Results"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Clinical Trials"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Johnson & Johnson"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Alzheimer's Disease"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2012-08-06T23:18:47+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Katie Thomas"", ""person"": [{""firstname"": ""Katie"", ""middlename"": null, ""lastname"": ""Thomas"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/eba6cc3e-ec90-54bc-a2cd-182b6931800f"", ""word_count"": 299, ""uri"": ""nyt://article/eba6cc3e-ec90-54bc-a2cd-182b6931800f""}"
2012-08-07,"{""abstract"": ""The pharmaceutical company and a subsidiary will pay a total of $60 million to resolve accusations that it paid doctors in several countries to prescribe its drugs."", ""web_url"": ""https://www.nytimes.com/2012/08/08/business/pfizer-settles-us-charges-of-overseas-bribery.html"", ""snippet"": ""The pharmaceutical company and a subsidiary will pay a total of $60 million to resolve accusations that it paid doctors in several countries to prescribe its drugs."", ""lead_paragraph"": ""The Securities and Exchange Commission announced on Tuesday that it had reached a $45 million settlement with Pfizer to resolve charges that subsidiaries of Pfizer and Wyeth, which it acquired in 2009, bribed overseas doctors and other health care workers to increase sales of their drugs."", ""print_section"": ""B"", ""print_page"": ""9"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer Settles U.S. Charges of Bribing Doctors Abroad"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer Settles U.S. Charges Of Bribing Doctors Abroad"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Bribery and Kickbacks"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Doctors"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2012-08-07T17:31:53+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Katie Thomas"", ""person"": [{""firstname"": ""Katie"", ""middlename"": null, ""lastname"": ""Thomas"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/8c997cd0-609c-5938-9b7c-4fb942a42641"", ""word_count"": 497, ""uri"": ""nyt://article/8c997cd0-609c-5938-9b7c-4fb942a42641""}"
2012-08-08,"{""abstract"": ""Jeffrey B. Kindler, who retired as Pfizer\u2019s chairman and chief executive at the end of 2011, has joined Lux Capital as a venture partner, the firm announced on Wednesday."", ""web_url"": ""https://dealbook.nytimes.com/2012/08/08/kindler-former-pfizer-chief-joins-lux-capital/"", ""snippet"": ""Jeffrey B. Kindler, who retired as Pfizer\u2019s chairman and chief executive at the end of 2011, has joined Lux Capital as a venture partner, the firm announced on Wednesday."", ""lead_paragraph"": ""Jeffrey B. Kindler, who retired as Pfizer\u2018s chairman and chief executive at the end of 2011, has joined Lux Capital as a venture partner, the firm announced on Wednesday."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Kindler, Former Pfizer Chief, Joins Lux Capital"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Kindler, Jeffrey B"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}], ""pub_date"": ""2012-08-08T19:31:55+0000"", ""document_type"": ""article"", ""news_desk"": """", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Michael J. de la Merced"", ""person"": [{""firstname"": ""Michael"", ""middlename"": ""J."", ""lastname"": ""de la Merced"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/2caf8974-aea4-574c-ae47-7dbb4a97e016"", ""word_count"": 277, ""uri"": ""nyt://article/2caf8974-aea4-574c-ae47-7dbb4a97e016""}"
2012-08-13,"{""abstract"": ""The company that will be spun off, to be called Zoetis, has about $4.2 billion in annual revenue and could be valued at $15 billion or more."", ""web_url"": ""https://dealbook.nytimes.com/2012/08/13/pfizer-animal-health-unit-files-for-i-p-o/"", ""snippet"": ""The company that will be spun off, to be called Zoetis, has about $4.2 billion in annual revenue and could be valued at $15 billion or more."", ""lead_paragraph"": ""Pfizer\u2018s animal health unit on Monday filed to sell a 20 percent stake to the public in an initial public offering. "", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer Animal Health Unit Files for I.P.O."", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Initial Public Offerings"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2012-08-13T18:28:25+0000"", ""document_type"": ""article"", ""news_desk"": """", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/d0014f41-3d6f-5a6a-85a3-ee1bb4a56acf"", ""word_count"": 282, ""uri"": ""nyt://article/d0014f41-3d6f-5a6a-85a3-ee1bb4a56acf""}"
2012-09-07,"{""abstract"": ""Mylan, the maker of the epinephrine injector EpiPen, is expanding its marketing efforts in the face of new, competing devices and the surging rates of allergies in children."", ""web_url"": ""https://www.nytimes.com/2012/09/08/business/mylan-invests-in-epipen-as-child-allergies-increase.html"", ""snippet"": ""Mylan, the maker of the epinephrine injector EpiPen, is expanding its marketing efforts in the face of new, competing devices and the surging rates of allergies in children."", ""lead_paragraph"": ""It has become an all-too-familiar story in schools across the country: a child eats a peanut or is stung by a bee and suffers an immediate, life-threatening allergic reaction known as anaphylaxis. "", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/09/08/business/08epipen/08epipen-articleLarge-v2.jpg"", ""height"": 375, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2012/09/08/business/08epipen/08epipen-articleLarge-v2.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 375}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/09/08/business/08epipen/08epipen-jumbo-v2.jpg"", ""height"": 681, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/09/08/business/08epipen/08epipen-superJumbo-v2.jpg"", ""height"": 1363, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/09/08/business/08epipen/08epipen-thumbStandard-v2.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2012/09/08/business/08epipen/08epipen-thumbStandard-v2.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/09/08/business/08epipen/08epipen-thumbLarge-v2.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Tiny Lifesaver for a Growing Worry"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Tiny Lifesaver for a Growing Worry"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medical Devices"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""ALLERGIES"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Epinephrine (Drug)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Mylan Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Anaphylactic Shock"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Children and Childhood"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2012-09-07T18:17:17+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Katie Thomas"", ""person"": [{""firstname"": ""Katie"", ""middlename"": null, ""lastname"": ""Thomas"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/1adca0d3-f72e-5de3-9dba-3a47ea12d21f"", ""word_count"": 1385, ""uri"": ""nyt://article/1adca0d3-f72e-5de3-9dba-3a47ea12d21f""}"
2012-11-06,"{""abstract"": ""In trials, use of the experimental drugs reduced so-called bad cholesterol by about 40 to 70 percent in a matter of weeks, equivalent to the reduction achieved by the most effective statins like Lipitor."", ""web_url"": ""https://www.nytimes.com/2012/11/06/business/new-drugs-for-lipids-set-off-race.html"", ""snippet"": ""In trials, use of the experimental drugs reduced so-called bad cholesterol by about 40 to 70 percent in a matter of weeks, equivalent to the reduction achieved by the most effective statins like Lipitor."", ""lead_paragraph"": ""LOS ANGELES \u2014 A new class of powerful cholesterol-reducing drugs is showing promising results, potentially offering a new option for people who do not respond to medication now on the market, according to studies presented at a conference of heart specialists here on Monday. "", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/11/06/technology/06drug-web/06drug-web-jumbo.jpg"", ""height"": 681, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/11/06/technology/06drug-web/06drug-web-superJumbo.jpg"", ""height"": 1363, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/11/06/technology/06drug-web/06drug-web-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2012/11/06/technology/06drug-web/06drug-web-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/11/06/technology/06drug-web/06drug-web-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""New Drugs for Lipids Set Off Race"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""New Drugs For Lipids Set Off Race"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Roche Holding A G"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Statins (Cholesterol-Lowering Drugs)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cholesterol"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Eli Lilly and Company"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AMGEN INC"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Regeneron Pharmaceuticals Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Sanofi-Aventis SA"", ""rank"": 8, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Clinical Trials"", ""rank"": 9, ""major"": ""N""}], ""pub_date"": ""2012-11-06T01:18:34+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/19ce99d4-a544-5484-b1cb-f1b9dfa7de13"", ""word_count"": 898, ""uri"": ""nyt://article/19ce99d4-a544-5484-b1cb-f1b9dfa7de13""}"
2012-12-29,"{""abstract"": ""Eliquis is the third anticlotting medicine to be approved recently and it is expected the backers will aggressively market their products."", ""web_url"": ""https://www.nytimes.com/2012/12/29/business/fda-approves-eliquis-from-bristol-and-pfizer.html"", ""snippet"": ""Eliquis is the third anticlotting medicine to be approved recently and it is expected the backers will aggressively market their products."", ""lead_paragraph"": ""The Food and Drug Administration on Friday approved Eliquis, an anticlotting drug that has been highly anticipated by cardiologists and is expected to be a blockbuster for Bristol-Myers Squibb, which will make the drug, and Pfizer, which will help market it."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/12/29/business/Blood/Blood-articleLarge.jpg"", ""height"": 480, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2012/12/29/business/Blood/Blood-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 480}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/12/29/business/Blood/Blood-jumbo.jpg"", ""height"": 819, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/12/29/business/Blood/Blood-superJumbo.jpg"", ""height"": 1639, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/12/29/business/Blood/Blood-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2012/12/29/business/Blood/Blood-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/12/29/business/Blood/Blood-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""F.D.A. Clears Anticlotting Drug by Bristol and Pfizer"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""F.D.A. Clears Anticlotting Drug by Bristol and Pfizer"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Eliquis (Drug)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Bristol Myers Squibb Company"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Blood Clots"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Blood"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2012-12-29T01:59:57+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Katie Thomas"", ""person"": [{""firstname"": ""Katie"", ""middlename"": null, ""lastname"": ""Thomas"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/f405252f-b263-5544-9e6c-f0e0cf46fa45"", ""word_count"": 645, ""uri"": ""nyt://article/f405252f-b263-5544-9e6c-f0e0cf46fa45""}"
2013-01-12,"{""abstract"": ""An Alabama court ruled that a patient could sue a brand-name company for failing to warn about a drug\u2019s risks even though he took a generic version."", ""web_url"": ""https://www.nytimes.com/2013/01/12/business/court-says-pfizer-can-be-sued-by-man-who-took-generic.html"", ""snippet"": ""An Alabama court ruled that a patient could sue a brand-name company for failing to warn about a drug\u2019s risks even though he took a generic version."", ""lead_paragraph"": ""The Alabama Supreme Court ruled on Friday that a patient could sue a brand-name company for failing to warn about a drug\u2019s risks even though he had taken a generic version of the product that the company did not make."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Man Taking Generic Drug Can Sue Branded Maker"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Man Taking Generic Drug Can Sue Branded Maker"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Thomas, Katie"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Generic Brands and Products"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Decisions and Verdicts"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Suits and Litigation"", ""rank"": 6, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""ALABAMA"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Gastroesophageal Reflux (Acid Reflux)"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Teva Pharmaceutical Industries Ltd"", ""rank"": 9, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Weeks, Danny"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Wyeth LLC"", ""rank"": 11, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Actavis Group"", ""rank"": 12, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 13, ""major"": ""N""}], ""pub_date"": ""2013-01-12T02:55:26+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Katie Thomas"", ""person"": [{""firstname"": ""Katie"", ""middlename"": null, ""lastname"": ""Thomas"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/8ec164e3-326b-574a-8e72-f63c885db345"", ""word_count"": 670, ""uri"": ""nyt://article/8ec164e3-326b-574a-8e72-f63c885db345""}"
2013-01-31,"{""abstract"": ""The Pfizer division, known as Zoetis, exceeded expectations by pricing its stock at $26 a share in an initial public offering that values the company at about $13 billion."", ""web_url"": ""https://dealbook.nytimes.com/2013/01/31/pfizer-spins-off-animal-health-unit-in-2-2-billion-i-p-o/"", ""snippet"": ""The Pfizer division, known as Zoetis, exceeded expectations by pricing its stock at $26 a share in an initial public offering that values the company at about $13 billion."", ""lead_paragraph"": ""Making medicines for livestock and pets may not seem to be as sexy a business as social networking, but Pfizer\u2019s animal health unit is poised to enjoy the biggest stock market debut since Facebook\u2019s offering last spring."", ""print_section"": ""B"", ""print_page"": ""7"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer Spins Off Animal Health Unit in $2.2 Billion I.P.O."", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Pfizer Spins Off Its Animal Health Unit in a $2.2 Billion I.P.O."", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Initial Public Offerings"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Stocks and Bonds"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Zoetis Inc"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2013-01-31T22:56:16+0000"", ""document_type"": ""article"", ""news_desk"": """", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Michael J. de la Merced"", ""person"": [{""firstname"": ""Michael"", ""middlename"": ""J."", ""lastname"": ""de la Merced"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/d9736bb5-0627-5865-853e-88930e67ad66"", ""word_count"": 673, ""uri"": ""nyt://article/d9736bb5-0627-5865-853e-88930e67ad66""}"
2013-02-01,"{""abstract"": ""Shares of the Pfizer animal health spinoff \u2014 the biggest initial public offering in the United States since Facebook\u2019s last spring \u2014 make an impressive market entrance."", ""web_url"": ""https://dealbook.nytimes.com/2013/02/01/shares-of-zoetis-surge-on-debut/"", ""snippet"": ""Shares of the Pfizer animal health spinoff \u2014 the biggest initial public offering in the United States since Facebook\u2019s last spring \u2014 make an impressive market entrance."", ""lead_paragraph"": ""4:32 p.m. | Updated "", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Shares of Zoetis Surge on Debut"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Shares Of Zoetis Climb In Its Initial Offering"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Initial Public Offerings"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Zoetis Inc"", ""rank"": 3, ""major"": ""N""}], ""pub_date"": ""2013-02-01T15:49:16+0000"", ""document_type"": ""article"", ""news_desk"": """", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Michael J. de la Merced"", ""person"": [{""firstname"": ""Michael"", ""middlename"": ""J."", ""lastname"": ""de la Merced"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/cc058bca-cc59-5d04-b36e-1fa538b4ef7b"", ""word_count"": 374, ""uri"": ""nyt://article/cc058bca-cc59-5d04-b36e-1fa538b4ef7b""}"
2013-03-19,"{""abstract"": ""Congress wants a second look at how private firms profit from public research after Pfizer and the National Institutes of Health developed a potentially lucrative new drug."", ""web_url"": ""https://www.nytimes.com/2013/03/19/business/questions-for-public-private-pact-that-led-to-xeljanz.html"", ""snippet"": ""Congress wants a second look at how private firms profit from public research after Pfizer and the National Institutes of Health developed a potentially lucrative new drug."", ""lead_paragraph"": ""WASHINGTON \u2014 With automatic spending cuts cascading through the government, lawmakers are calling for a review of federal policies they say have allowed businesses to profit on government research with limited return for taxpayers or consumers."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/03/19/business/Pharma3/Pharma3-jumbo.jpg"", ""height"": 660, ""width"": 336, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/03/19/business/Pharma3/Pharma3-superJumbo.jpg"", ""height"": 660, ""width"": 336, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/03/19/business/Pharma3/Pharma3-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2013/03/19/business/Pharma3/Pharma3-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/03/19/business/Pharma3/Pharma3-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Seeking Profit for Taxpayers in Potential of New Drug"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Seeking Profit For Taxpayers In Potential Of New Drug"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""National Institutes of Health"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""O'Shea, John J"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Federal Budget (US)"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Research"", ""rank"": 7, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Wyden, Ron"", ""rank"": 8, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""ARTHRITIS"", ""rank"": 9, ""major"": ""N""}], ""pub_date"": ""2013-03-19T00:38:01+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Jonathan Weisman"", ""person"": [{""firstname"": ""Jonathan"", ""middlename"": null, ""lastname"": ""Weisman"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/7ce59094-bd45-598f-b1f7-df8fa2580916"", ""word_count"": 1123, ""uri"": ""nyt://article/7ce59094-bd45-598f-b1f7-df8fa2580916""}"
2013-05-04,"{""abstract"": ""The drug pairs Merck\u2019s Zetia, which lowers low-density lipoprotein, with the generic version of Lipitor, the best-selling statin made by Pfizer that lost its patent protection in 2011."", ""web_url"": ""https://www.nytimes.com/2013/05/04/business/fda-approves-mercks-combination-drug-to-reduce-cholesterol.html"", ""snippet"": ""The drug pairs Merck\u2019s Zetia, which lowers low-density lipoprotein, with the generic version of Lipitor, the best-selling statin made by Pfizer that lost its patent protection in 2011."", ""lead_paragraph"": ""The Food and Drug Administration approved on Friday a combination drug developed by Merck that lowers a patient\u2019s cholesterol but has not been shown to reduce the risk of cardiovascular disease or death, the company said."", ""print_section"": ""B"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Drug to Cut Cholesterol Is Approved by the F.D.A."", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Drug to Cut Cholesterol Is Approved By the F.D.A."", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Thomas, Katie"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Zetia (Drug)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Lipitor (Drug)"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cholesterol"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2013-05-04T00:49:50+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Katie Thomas"", ""person"": [{""firstname"": ""Katie"", ""middlename"": null, ""lastname"": ""Thomas"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/652e5389-f054-5e72-9f42-f3488c008e93"", ""word_count"": 474, ""uri"": ""nyt://article/652e5389-f054-5e72-9f42-f3488c008e93""}"
2013-05-07,"{""abstract"": ""The drug maker is now selling its billion-dollar erectile dysfunction drug, among the world\u2019s most counterfeited, directly to men with a prescription."", ""web_url"": ""https://www.nytimes.com/2013/05/07/business/pfizer-begins-selling-viagra-online.html"", ""snippet"": ""The drug maker is now selling its billion-dollar erectile dysfunction drug, among the world\u2019s most counterfeited, directly to men with a prescription."", ""lead_paragraph"": ""Pfizer has taken the unusual step of selling its erectile dysfunction drug, Viagra, to consumers on its Web site, in an effort to establish a presence in the huge online market for the popular blue pill, considered to be one of the most counterfeited drugs in the world."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/05/07/business/Pfizer/Pfizer-articleLarge.jpg"", ""height"": 352, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2013/05/07/business/Pfizer/Pfizer-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 352}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/05/07/business/Pfizer/Pfizer-jumbo.jpg"", ""height"": 601, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/05/07/business/Pfizer/Pfizer-superJumbo.jpg"", ""height"": 1084, ""width"": 1847, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/05/07/business/Pfizer/Pfizer-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2013/05/07/business/Pfizer/Pfizer-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/05/07/business/Pfizer/Pfizer-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Facing Black Market, Pfizer Is Looking Online to Sell Viagra"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer Turning to Internet to Sell Viagra"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Thomas, Katie"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Viagra (Drug)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""E-Commerce"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Counterfeit Merchandise"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2013-05-07T01:06:20+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Katie Thomas"", ""person"": [{""firstname"": ""Katie"", ""middlename"": null, ""lastname"": ""Thomas"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/9821d004-7d90-5a48-b704-ad722c112e03"", ""word_count"": 911, ""uri"": ""nyt://article/9821d004-7d90-5a48-b704-ad722c112e03""}"
2013-07-31,"{""abstract"": ""The Justice Department announced that the drug maker would settle criminal and civil charges over illegal marketing of the kidney-transplant drug Rapamune."", ""web_url"": ""https://www.nytimes.com/2013/07/31/business/pfizer-settles-a-drug-marketing-case-for-491-million.html"", ""snippet"": ""The Justice Department announced that the drug maker would settle criminal and civil charges over illegal marketing of the kidney-transplant drug Rapamune."", ""lead_paragraph"": ""The drug maker Pfizer agreed to pay $491 million to settle criminal and civil charges over the illegal marketing of the kidney-transplant drug Rapamune, the Justice Department announced on Tuesday."", ""print_section"": ""B"", ""print_page"": ""8"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/07/31/business/PFIZER/PFIZER-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2013/07/31/business/PFIZER/PFIZER-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/07/31/business/PFIZER/PFIZER-jumbo.jpg"", ""height"": 682, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/07/31/business/PFIZER/PFIZER-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer Settles a Drug Marketing Case for $491 Million"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer Settles a Drug Marketing Case for $491 Million"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Thomas, Katie"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Wyeth LLC"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Suits and Litigation (Civil)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Justice Department"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Transplants"", ""rank"": 8, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Kidneys"", ""rank"": 9, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""ADVERTISING AND MARKETING"", ""rank"": 10, ""major"": ""N""}], ""pub_date"": ""2013-07-31T00:16:01+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Katie Thomas"", ""person"": [{""firstname"": ""Katie"", ""middlename"": null, ""lastname"": ""Thomas"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/0eea07d7-8666-5eee-8a76-dde090789329"", ""word_count"": 389, ""uri"": ""nyt://article/0eea07d7-8666-5eee-8a76-dde090789329""}"
2013-08-27,"{""abstract"": ""Tax policy experts are suspicious of tax holidays, and most experts question the effectiveness of attaching restrictions to such legislation. Many companies find a way around them."", ""web_url"": ""https://dealbook.nytimes.com/2013/08/27/a-holiday-from-taxes-and-often-from-the-strings-attached/"", ""snippet"": ""Tax policy experts are suspicious of tax holidays, and most experts question the effectiveness of attaching restrictions to such legislation. Many companies find a way around them."", ""lead_paragraph"": ""Large multinationals based in the United States \u2013 among them General Electric, Pfizer, Apple and Citigroup \u2013 have been hoarding record amounts of cash overseas, mainly because of the 35 percent tax they would have to pay if they brought it back to the United States. "", ""print_section"": ""B"", ""print_page"": ""7"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""A Holiday From Taxes, and Often From the Strings Attached"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Benefits, With Strings"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Law and Legislation"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tax Evasion"", ""rank"": 3, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""United States"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2013-08-27T15:31:05+0000"", ""document_type"": ""article"", ""news_desk"": """", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Victor Fleischer"", ""person"": [{""firstname"": ""Victor"", ""middlename"": null, ""lastname"": ""Fleischer"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/cb259132-e1fd-5f5e-ad2c-079c21a8774f"", ""word_count"": 703, ""uri"": ""nyt://article/cb259132-e1fd-5f5e-ad2c-079c21a8774f""}"
2013-10-12,"{""abstract"": ""The executives, ranging from the president of a beauty products company to the general counsel at Pfizer, shared their stories about headwinds they have navigated over the years and advice to women wanting to succeed at work."", ""web_url"": ""https://www.nytimes.com/interactive/2013/10/13/business/women-corner-office.html"", ""snippet"": ""The executives, ranging from the president of a beauty products company to the general counsel at Pfizer, shared their stories about headwinds they have navigated over the years and advice to women wanting to succeed at work."", ""lead_paragraph"": ""The executives, ranging from the president of a beauty products company to the general counsel at Pfizer, shared their stories about headwinds they have navigated over the years and advice to women wanting to succeed at work."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/10/13/business/13CORNERCOMBO/13CORNERCOMBO-articleLarge.jpg"", ""height"": 470, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2013/10/13/business/13CORNERCOMBO/13CORNERCOMBO-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 470}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/10/13/business/13CORNERCOMBO/13CORNERCOMBO-jumbo.jpg"", ""height"": 588, ""width"": 750, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/10/13/business/13CORNERCOMBO/13CORNERCOMBO-superJumbo.jpg"", ""height"": 588, ""width"": 750, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/10/13/business/13CORNERCOMBO/13CORNERCOMBO-thumbStandard-v2.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2013/10/13/business/13CORNERCOMBO/13CORNERCOMBO-thumbStandard-v2.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/10/13/business/13CORNERCOMBO/13CORNERCOMBO-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Four Executives on Succeeding in Business as a Woman"", ""kicker"": ""Corner Office"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Kaplan, Marjorie C"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Lorenzo, Doreen"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Price, Lisa"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Schulman, Amy W"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Women and Girls"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Careers and Professions"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Executives and Management (Theory)"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Carol's Daughter"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Quirky Inc"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ANIMAL PLANET"", ""rank"": 11, ""major"": ""N""}], ""pub_date"": ""2013-10-12T16:31:33+0000"", ""document_type"": ""multimedia"", ""news_desk"": ""Business Day"", ""section_name"": ""Business Day"", ""byline"": {""original"": """", ""person"": [], ""organization"": null}, ""type_of_material"": ""Interactive Feature"", ""_id"": ""nyt://interactive/7dcfb2e8-a8be-58e1-b098-adce187239ea"", ""word_count"": 0, ""uri"": ""nyt://interactive/7dcfb2e8-a8be-58e1-b098-adce187239ea""}"
2013-11-20,"{""abstract"": ""A proposal by Senator Max Baucus to revise international tax rules would help financial services firms that tend to have high effective tax rates, the author writes."", ""web_url"": ""https://dealbook.nytimes.com/2013/11/20/wall-street-could-benefit-from-tax-proposal/"", ""snippet"": ""A proposal by Senator Max Baucus to revise international tax rules would help financial services firms that tend to have high effective tax rates, the author writes."", ""lead_paragraph"": ""Changes to the tax code always create winners and losers. An ambitious plan to revise the system for taxing multinational corporations, released on Tuesday by the Senate Finance Committee chairman, Max Baucus, would hit technology companies and large pharmaceutical companies especially hard. Companies like Pfizer, Apple, Hewlett-Packard and Microsoft have become masters at reducing their tax liability in the United States by shifting income overseas."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/11/21/business/dbpix-baucus/dbpix-baucus-articleLarge.jpg"", ""height"": 406, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2013/11/21/business/dbpix-baucus/dbpix-baucus-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 406}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/11/21/business/dbpix-baucus/dbpix-baucus-jumbo.jpg"", ""height"": 693, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/11/21/business/dbpix-baucus/dbpix-baucus-superJumbo.jpg"", ""height"": 1386, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/11/21/business/dbpix-baucus/dbpix-baucus-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2013/11/21/business/dbpix-baucus/dbpix-baucus-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/11/21/business/dbpix-baucus/dbpix-baucus-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Wall Street Could Benefit From Tax Proposal"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Banking and Financial Institutions"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Law and Legislation"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Taxation"", ""rank"": 4, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Baucus, Max"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2013-11-20T17:41:43+0000"", ""document_type"": ""article"", ""news_desk"": """", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Victor Fleischer"", ""person"": [{""firstname"": ""Victor"", ""middlename"": null, ""lastname"": ""Fleischer"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/2bdb3b9d-8cc9-5602-a475-e7931971d8ac"", ""word_count"": 444, ""uri"": ""nyt://article/2bdb3b9d-8cc9-5602-a475-e7931971d8ac""}"
2013-12-31,"{""abstract"": ""Questions about Zilmax, a feed additive made by Merck, show the market dangers of an increasingly complicated global food chain, Kevin Allison of Reuters Breakingviews writes."", ""web_url"": ""https://dealbook.nytimes.com/2013/12/31/the-risks-of-investing-in-animal-medicine/"", ""snippet"": ""Questions about Zilmax, a feed additive made by Merck, show the market dangers of an increasingly complicated global food chain, Kevin Allison of Reuters Breakingviews writes."", ""lead_paragraph"": ""Animal medicine, whether for livestock or pets, is a booming business. Pfizer\u2019s recent spinoff, Zoetis, trades at a large valuation premium to traditional drug makers, for example."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""The Risks of Investing in Animal Medicine"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Cargill Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Tyson Foods Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Zoetis Inc"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2013-12-31T17:00:27+0000"", ""document_type"": ""article"", ""news_desk"": """", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Kevin Allison"", ""person"": [{""firstname"": ""Kevin"", ""middlename"": null, ""lastname"": ""Allison"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/97a577bf-5552-53fc-bdd3-c10bb8e3e0a4"", ""word_count"": 403, ""uri"": ""nyt://article/97a577bf-5552-53fc-bdd3-c10bb8e3e0a4""}"
2014-03-10,"{""abstract"": ""Minerals Technologies agreed to pay about $1.7 billion, beating out Imerys of France, after a spirited back-and-forth for Amcol, a producer of specialty minerals and materials based in Illinois."", ""web_url"": ""https://dealbook.nytimes.com/2014/03/10/minerals-technologies-wins-bidding-war-for-amcol-international/"", ""snippet"": ""Minerals Technologies agreed to pay about $1.7 billion, beating out Imerys of France, after a spirited back-and-forth for Amcol, a producer of specialty minerals and materials based in Illinois."", ""lead_paragraph"": ""LONDON \u2013 Minerals Technologies said on Monday that it had won a bidding war for Amcol International, agreeing to pay about $1.7 billion."", ""print_section"": ""B"", ""print_page"": ""7"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/03/10/business/dbpix-amcol/dbpix-amcol-jumbo.png"", ""height"": 246, ""width"": 354, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/03/10/business/dbpix-amcol/dbpix-amcol-superJumbo.png"", ""height"": 246, ""width"": 354, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/03/10/business/dbpix-amcol/dbpix-amcol-thumbStandard.png"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/03/10/business/dbpix-amcol/dbpix-amcol-thumbStandard.png"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/03/10/business/dbpix-amcol/dbpix-amcol-thumbLarge.png"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Minerals Technologies Wins Bidding War for Amcol International"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Top Suitor Wins"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Boards of Directors"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Amcol International"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Cravath Swaine & Moore"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Goldman Sachs Group Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Imerys SA"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""JPMorgan Chase & Company"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Kirkland & Ellis"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Lazard LLC"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Minerals Technologies Inc"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 11, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""France"", ""rank"": 12, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Illinois"", ""rank"": 13, ""major"": ""N""}], ""pub_date"": ""2014-03-10T15:36:21+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chad Bray"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/705d920e-2018-5190-ad74-0fa739b07a13"", ""word_count"": 378, ""uri"": ""nyt://article/705d920e-2018-5190-ad74-0fa739b07a13""}"
2014-04-06,"{""abstract"": ""Palbociclib, a drug being developed by Pfizer, sharply cut the risk that advanced cancer would worsen among patients taking part in a Phase 2 study, researchers said."", ""web_url"": ""https://www.nytimes.com/2014/04/07/business/breast-cancer-drug-shows-groundbreaking-results.html"", ""snippet"": ""Palbociclib, a drug being developed by Pfizer, sharply cut the risk that advanced cancer would worsen among patients taking part in a Phase 2 study, researchers said."", ""lead_paragraph"": ""SAN DIEGO \u2014 Researchers say that a new type of drug can help prevent advanced breast cancer from worsening, potentially providing an important new treatment option for women and a blockbuster product for Pfizer."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Guarded Optimism After Breast Cancer Drug Shows Promising Results"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Guarded Optimism After Breast Cancer Drug Shows Promising Results"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Breast Cancer"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Clinical Trials"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""American Assn for Cancer Research"", ""rank"": 6, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Finn, Richard S"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2014-04-06T14:31:02+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/54532b87-8972-538a-8d5b-b1599339099b"", ""word_count"": 973, ""uri"": ""nyt://article/54532b87-8972-538a-8d5b-b1599339099b""}"
2014-04-21,"{""abstract"": ""A deal with Pfizer would have been one of the biggest ever in the pharmaceutical industry. But whether such a deal makes sense is another matter."", ""web_url"": ""https://dealbook.nytimes.com/2014/04/21/spurning-merger-approaches-astrazeneca-pursues-own-path/"", ""snippet"": ""A deal with Pfizer would have been one of the biggest ever in the pharmaceutical industry. But whether such a deal makes sense is another matter."", ""lead_paragraph"": ""The British drug company AstraZeneca said no to a tie-up with Pfizer, turning down the possibility of one of the biggest drug mergers in recent history. "", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/22/business/dbpix-drug2/dbpix-drug2-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/04/22/business/dbpix-drug2/dbpix-drug2-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/22/business/dbpix-drug2/dbpix-drug2-jumbo.jpg"", ""height"": 682, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/22/business/dbpix-drug2/dbpix-drug2-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/22/business/dbpix-drug2/dbpix-drug2-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/04/22/business/dbpix-drug2/dbpix-drug2-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/22/business/dbpix-drug2/dbpix-drug2-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Spurning Merger Approaches, AstraZeneca Pursues Own Path"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Soriot, Pascal"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Roche Holding AG"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Warner-Lambert Co"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2014-04-21T17:17:13+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Michael J. de la Merced and Andrew Pollack"", ""person"": [{""firstname"": ""Michael"", ""middlename"": ""J."", ""lastname"": ""de la Merced"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/4ce50f9c-f4d3-55e9-ad7b-d1b50b6cd6c3"", ""word_count"": 976, ""uri"": ""nyt://article/4ce50f9c-f4d3-55e9-ad7b-d1b50b6cd6c3""}"
2014-04-22,"[{""abstract"": ""Novartis will buy GlaxoSmithKline\u2019s cancer drug business for as much as $16 billion, and Glaxo will buy Novartis\u2019s vaccine business for as much as $7.1 billion."", ""web_url"": ""https://dealbook.nytimes.com/2014/04/22/novartis-announces-major-restructuring/"", ""snippet"": ""Novartis will buy GlaxoSmithKline\u2019s cancer drug business for as much as $16 billion, and Glaxo will buy Novartis\u2019s vaccine business for as much as $7.1 billion."", ""lead_paragraph"": ""Updated, 8:18 p.m. | The Swiss pharmaceutical giant Novartis and its British rival GlaxoSmithKline announced on Tuesday that they would swap more than $20 billion in assets as they seek to sharpen the focus of their businesses."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Novartis and Glaxo Agree to Trade $20 Billion in Assets"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Novartis and Glaxo Agree to Trade $20 Billion in Assets"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Botox (Drug)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cancer"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Vaccination and Immunization"", ""rank"": 4, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Ackman, William A"", ""rank"": 5, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Jimenez, Joseph"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Eli Lilly and Company"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""GlaxoSmithKline PLC"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pershing Square Capital Management"", ""rank"": 11, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 12, ""major"": ""N""}], ""pub_date"": ""2014-04-22T06:18:35+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chad Bray and David Jolly"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Jolly"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/1516d147-6e27-5310-beaa-bc4982cb144f"", ""word_count"": 734, ""uri"": ""nyt://article/1516d147-6e27-5310-beaa-bc4982cb144f""}, {""abstract"": ""William A. Ackman and Valeant are bidding for Allergan, the maker of Botox. | Novartis announced a major overhaul. | AstraZeneca says no to a deal with Pfizer. | Barclays is set to exit its commodities business."", ""web_url"": ""https://dealbook.nytimes.com/2014/04/22/morning-agenda-ackmans-botox-ambitions/"", ""snippet"": ""William A. Ackman and Valeant are bidding for Allergan, the maker of Botox. | Novartis announced a major overhaul. | AstraZeneca says no to a deal with Pfizer. | Barclays is set to exit its commodities business."", ""lead_paragraph"": ""William A. Ackman, one of the brashest men on Wall Street, has come up with perhaps the boldest move yet for an activist: He has teamed up with the health care company Valeant to bid roughly $50 billion for Allergan, the maker of Botox, David Gelles, Michael J. de la Merced and Alexandra Stevenson write in DealBook. The offer by Valeant is expected to be announced Tuesday morning."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Ackman\u2019s Botox Ambitions"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2014-04-22T12:11:47+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Sydney Ember"", ""person"": [{""firstname"": ""Sydney"", ""middlename"": null, ""lastname"": ""Ember"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/4e027bef-017e-5f33-9c69-f72c49d464c2"", ""word_count"": 1946, ""uri"": ""nyt://article/4e027bef-017e-5f33-9c69-f72c49d464c2""}]"
2014-04-28,"[{""abstract"": ""Such a move would be aimed at putting pressure on the British drug maker, which has turned down a number of informal takeover approaches."", ""web_url"": ""https://dealbook.nytimes.com/2014/04/27/pfizer-said-to-pursue-astrazeneca/"", ""snippet"": ""Such a move would be aimed at putting pressure on the British drug maker, which has turned down a number of informal takeover approaches."", ""lead_paragraph"": ""Pfizer is close to publicly unveiling its interest in acquiring AstraZeneca of Britain, a person briefed on the matter said on Sunday, in what would be one of the biggest deals among drug makers."", ""print_section"": ""B"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/29/business/dbpix-astrazeneca1/dbpix-astrazeneca1-articleLarge.jpg"", ""height"": 440, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/04/29/business/dbpix-astrazeneca1/dbpix-astrazeneca1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 440}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/29/business/dbpix-astrazeneca1/dbpix-astrazeneca1-jumbo.jpg"", ""height"": 751, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/29/business/dbpix-astrazeneca1/dbpix-astrazeneca1-superJumbo.jpg"", ""height"": 1501, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/29/business/dbpix-astrazeneca1/dbpix-astrazeneca1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/04/29/business/dbpix-astrazeneca1/dbpix-astrazeneca1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/29/business/dbpix-astrazeneca1/dbpix-astrazeneca1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer Move for AstraZeneca Seen"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Pfizer Move for AstraZeneca Seen"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}], ""pub_date"": ""2014-04-28T02:37:44+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Michael J. de la Merced"", ""person"": [{""firstname"": ""Michael"", ""middlename"": ""J."", ""lastname"": ""de la Merced"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/4d906e1d-ead1-5449-b57a-6b03727752a2"", ""word_count"": 308, ""uri"": ""nyt://article/4d906e1d-ead1-5449-b57a-6b03727752a2""}, {""abstract"": ""The Swedish drug maker rejected an increased takeover offer from the generic pharmaceutical company based in Canonsburg, Pa."", ""web_url"": ""https://dealbook.nytimes.com/2014/04/28/meda-again-rejects-takeover-bid-by-mylan/"", ""snippet"": ""The Swedish drug maker rejected an increased takeover offer from the generic pharmaceutical company based in Canonsburg, Pa."", ""lead_paragraph"": ""LONDON \u2014 The Swedish drug maker Meda said on Monday that it had rejected an increased takeover offer from the generic pharmaceutical company Mylan."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/29/business/dbpix-meda/dbpix-meda-articleLarge.jpg"", ""height"": 157, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/04/29/business/dbpix-meda/dbpix-meda-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 157}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/29/business/dbpix-meda/dbpix-meda-jumbo.jpg"", ""height"": 269, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/29/business/dbpix-meda/dbpix-meda-superJumbo.jpg"", ""height"": 537, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/29/business/dbpix-meda/dbpix-meda-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/04/29/business/dbpix-meda/dbpix-meda-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/29/business/dbpix-meda/dbpix-meda-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Meda Again Rejects Takeover Bid by Mylan"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Stocks and Bonds"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Meda AB"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Mylan Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Pennsylvania"", ""rank"": 8, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Stockholm (Sweden)"", ""rank"": 9, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Sweden"", ""rank"": 10, ""major"": ""N""}], ""pub_date"": ""2014-04-28T08:19:35+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chad Bray"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/7e7b871d-0b39-5086-9b4f-1e7ceb83c76c"", ""word_count"": 328, ""uri"": ""nyt://article/7e7b871d-0b39-5086-9b4f-1e7ceb83c76c""}, {""abstract"": ""France puts the brakes on General Electric\u2019s bid for Alstom. | Investors are looking for other ways to profit from the aftermath of the housing crisis. | Pfizer continues its pursuit of AstraZeneca. | Elizabeth Warren seeks a level playing field."", ""web_url"": ""https://dealbook.nytimes.com/2014/04/28/morning-agenda-france-stalls-g-e-s-alstom-bid/"", ""snippet"": ""France puts the brakes on General Electric\u2019s bid for Alstom. | Investors are looking for other ways to profit from the aftermath of the housing crisis. | Pfizer continues its pursuit of AstraZeneca. | Elizabeth Warren seeks a level playing field."", ""lead_paragraph"": ""The French government on Sunday sought to discourage General Electric\u2019s bid for Alstom, one of the largest industrial companies in France, warning that economic sovereignty was at stake, David Jolly writes in DealBook. G.E. is looking to buy Alstom\u2019s energy business, and France\u2019s economic minister had been scheduled to meet on Sunday with Jeffrey R. Immelt, the chief executive of G.E."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""France Stalls G.E.\u2019s Alstom Bid"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2014-04-28T12:05:49+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Sydney Ember"", ""person"": [{""firstname"": ""Sydney"", ""middlename"": null, ""lastname"": ""Ember"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/7a5234a2-9d0b-5738-961a-15133ca018ba"", ""word_count"": 1785, ""uri"": ""nyt://article/7a5234a2-9d0b-5738-961a-15133ca018ba""}, {""abstract"": ""If the British drug company AstraZeneca cannot make Pfizer go away, it can certainly make it pay, Neil Unmack of Reuters Breakingviews contends."", ""web_url"": ""https://dealbook.nytimes.com/2014/04/28/why-pfizer-needs-to-do-more-to-win-astrazeneca/"", ""snippet"": ""If the British drug company AstraZeneca cannot make Pfizer go away, it can certainly make it pay, Neil Unmack of Reuters Breakingviews contends."", ""lead_paragraph"": ""Pfizer will need to pile on more pressure if it wants to buy AstraZeneca. Pfizer has confirmed that it made a $99 billion cash-and-stock approach in January for AstraZeneca, its British rival, and is now renewing its suit. AstraZeneca\u2019s chief executive, Pascal Soriot, may ultimately struggle to resist a takeover, but he ought to be able to extract a better proposal."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/29/business/dbpix-astrazeneca-nyse/dbpix-astrazeneca-nyse-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/04/29/business/dbpix-astrazeneca-nyse/dbpix-astrazeneca-nyse-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/29/business/dbpix-astrazeneca-nyse/dbpix-astrazeneca-nyse-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/29/business/dbpix-astrazeneca-nyse/dbpix-astrazeneca-nyse-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/29/business/dbpix-astrazeneca-nyse/dbpix-astrazeneca-nyse-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/04/29/business/dbpix-astrazeneca-nyse/dbpix-astrazeneca-nyse-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/29/business/dbpix-astrazeneca-nyse/dbpix-astrazeneca-nyse-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Why Pfizer Needs to Do More to Win AstraZeneca"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Soriot, Pascal"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2014-04-28T16:36:03+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Neil Unmack"", ""person"": [{""firstname"": ""Neil"", ""middlename"": null, ""lastname"": ""Unmack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/eab3f930-477d-5011-8cb8-5e5f305e5303"", ""word_count"": 446, ""uri"": ""nyt://article/eab3f930-477d-5011-8cb8-5e5f305e5303""}]"
2014-04-29,"[{""abstract"": ""Pfizer proposed a $99 billion acquisition of its British rival AstraZeneca that would allow it to reincorporate in Britain."", ""web_url"": ""https://dealbook.nytimes.com/2014/04/28/pfizer-proposes-a-marriage-and-a-move-to-britain-easing-taxes/"", ""snippet"": ""Pfizer proposed a $99 billion acquisition of its British rival AstraZeneca that would allow it to reincorporate in Britain."", ""lead_paragraph"": ""Pfizer, the maker of best-selling drugs like Lipitor and Viagra and a symbol of business prowess in the United States for more than a century, no longer wants to be an American company."", ""print_section"": ""A"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/29/business/subDrug/subDrug-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/04/29/business/subDrug/subDrug-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/29/business/subDrug/subDrug-jumbo.jpg"", ""height"": 682, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/29/business/subDrug/subDrug-superJumbo.jpg"", ""height"": 1332, ""width"": 2000, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/29/business/subDrug/subDrug-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/04/29/business/subDrug/subDrug-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/29/business/subDrug/subDrug-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer Proposes a Marriage With AstraZeneca, Easing Taxes in a Move to Britain"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Pfizer Proposes a Marriage and a Move to Britain, Easing Taxes"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2014-04-29T01:16:59+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By David Gelles and Michael J. de la Merced"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Gelles"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Michael"", ""middlename"": ""J."", ""lastname"": ""de la Merced"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/a01cb7f9-9fa5-5388-a92e-9bcc9c0807de"", ""word_count"": 1304, ""uri"": ""nyt://article/a01cb7f9-9fa5-5388-a92e-9bcc9c0807de""}, {""abstract"": ""Energy Future Holdings files for bankruptcy. | Pfizer makes a bid to move abroad with deal for AstraZeneca. | Bank of America\u2019s $4 billion accounting error. | France continues efforts to shield its economy."", ""web_url"": ""https://dealbook.nytimes.com/2014/04/29/morning-agenda-a-failure-in-texas/"", ""snippet"": ""Energy Future Holdings files for bankruptcy. | Pfizer makes a bid to move abroad with deal for AstraZeneca. | Bank of America\u2019s $4 billion accounting error. | France continues efforts to shield its economy."", ""lead_paragraph"": ""The troubled Texas utility Energy Future Holdings \u2012 which, as TXU, was private equity\u2019s biggest-ever buyout \u2012 filed for bankruptcy on Tuesday, Julie Creswell and Michael J. de la Merced write in DealBook. After months of on-again, off-again talks between the company, its owners and creditors, Energy Future Holdings went into Chapter 11 protection with a plan meant to avoid months in bankruptcy court in what will be one of the biggest Chapter 11 filings in history."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""A Failure in Texas"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2014-04-29T12:41:55+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Sydney Ember"", ""person"": [{""firstname"": ""Sydney"", ""middlename"": null, ""lastname"": ""Ember"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/c1be7834-cbba-556a-b8cf-09ddd30547fa"", ""word_count"": 1984, ""uri"": ""nyt://article/c1be7834-cbba-556a-b8cf-09ddd30547fa""}, {""abstract"": ""The biggest charm of Pfizer\u2019s offer for AstraZeneca lies in switching to a lower-tax domicile, a strategy that is sure to be duplicated, Robert Cyran writes for Reuters Breakingviews."", ""web_url"": ""https://dealbook.nytimes.com/2014/04/29/pfizer-most-likely-just-the-tip-of-the-tax-sword/"", ""snippet"": ""The biggest charm of Pfizer\u2019s offer for AstraZeneca lies in switching to a lower-tax domicile, a strategy that is sure to be duplicated, Robert Cyran writes for Reuters Breakingviews."", ""lead_paragraph"": ""Pfizer\u2019s $99 billion tax arbitrage bid will encourage copycats. The biggest charm of the United States drug giant\u2019s offer for AstraZeneca of Britain lies in switching to a lower-tax domicile. The latest and largest such deal to hit the headlines raises the odds Congress will tighten rules \u2013 but not yet."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/29/business/dealbook/dbpix-pfizer-tax/dbpix-pfizer-tax-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/04/29/business/dealbook/dbpix-pfizer-tax/dbpix-pfizer-tax-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/29/business/dealbook/dbpix-pfizer-tax/dbpix-pfizer-tax-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/29/business/dealbook/dbpix-pfizer-tax/dbpix-pfizer-tax-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/29/business/dealbook/dbpix-pfizer-tax/dbpix-pfizer-tax-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/04/29/business/dealbook/dbpix-pfizer-tax/dbpix-pfizer-tax-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/29/business/dealbook/dbpix-pfizer-tax/dbpix-pfizer-tax-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer Most Likely Just the Tip of the Tax Sword"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Relocation of Business"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2014-04-29T16:55:38+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Robert Cyran"", ""person"": [{""firstname"": ""Robert"", ""middlename"": null, ""lastname"": ""Cyran"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/82897b38-93c5-59ba-b409-2587a5ff6158"", ""word_count"": 416, ""uri"": ""nyt://article/82897b38-93c5-59ba-b409-2587a5ff6158""}, {""abstract"": ""We don\u2019t know if Pfizer is targeting a British rival because the combined firm will be more efficient or because of the tax savings, Victor Fleischer writes in his Standard Deduction column."", ""web_url"": ""https://dealbook.nytimes.com/2014/04/29/how-tax-laws-distort-the-pfizer-deal/"", ""snippet"": ""We don\u2019t know if Pfizer is targeting a British rival because the combined firm will be more efficient or because of the tax savings, Victor Fleischer writes in his Standard Deduction column."", ""lead_paragraph"": ""The United States tax code is fueling Pfizer Inc.\u2019s $98.7 billion bid to take over the London-based pharmaceutical company AstraZeneca. If the deal goes through as proposed, a new parent company in Britain would own the combined entity, making it easier for the new firm to strip income out of its American tax base. The deal is one of several recent transactions known as \u201cinversions,\u201d where a multinational company like Pfizer, based in New York, becomes an expatriate by acquiring a smaller foreign target."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/30/business/dbpix-viagra/dbpix-viagra-articleLarge.jpg"", ""height"": 407, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/04/30/business/dbpix-viagra/dbpix-viagra-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 407}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/30/business/dbpix-viagra/dbpix-viagra-jumbo.jpg"", ""height"": 695, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/30/business/dbpix-viagra/dbpix-viagra-superJumbo.jpg"", ""height"": 1254, ""width"": 1848, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/30/business/dbpix-viagra/dbpix-viagra-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/04/30/business/dbpix-viagra/dbpix-viagra-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/30/business/dbpix-viagra/dbpix-viagra-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""How Tax Laws Distort the Pfizer Deal"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2014-04-29T19:56:01+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Victor Fleischer"", ""person"": [{""firstname"": ""Victor"", ""middlename"": null, ""lastname"": ""Fleischer"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/521599db-1fca-597c-8642-46e84452abe8"", ""word_count"": 971, ""uri"": ""nyt://article/521599db-1fca-597c-8642-46e84452abe8""}]"
2014-05-01,"{""abstract"": ""Time is working against Pfizer in its pursuit of AstraZeneca and thus it will want a friendly deal completed as quickly as possible, Christopher Hughes and Neil Unmack write for Reuters Breakingviews."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/01/pfizer-looks-for-a-quick-strike-on-astrazeneca/"", ""snippet"": ""Time is working against Pfizer in its pursuit of AstraZeneca and thus it will want a friendly deal completed as quickly as possible, Christopher Hughes and Neil Unmack write for Reuters Breakingviews."", ""lead_paragraph"": ""Time often benefits bidders rather than targets\u00a0\u2014 that\u2019s why Kraft left its British rival Cadbury flailing for months after making a takeover approach. But the dynamics of Pfizer\u2019s interest in AstraZeneca are unusual. Pfizer has good reason to seek a quick negotiated deal."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/01/business/dealbook/dbpix-pfizer-astra/dbpix-pfizer-tax-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/01/business/dealbook/dbpix-pfizer-astra/dbpix-pfizer-tax-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/01/business/dealbook/dbpix-pfizer-astra/dbpix-pfizer-tax-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/01/business/dealbook/dbpix-pfizer-astra/dbpix-pfizer-tax-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/01/business/dealbook/dbpix-pfizer-astra/dbpix-pfizer-tax-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/01/business/dealbook/dbpix-pfizer-astra/dbpix-pfizer-tax-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/01/business/dealbook/dbpix-pfizer-astra/dbpix-pfizer-tax-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer Looks for a Quick Strike on AstraZeneca"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2014-05-01T19:22:23+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Christopher Hughes and Neil Unmack"", ""person"": [{""firstname"": ""Christopher"", ""middlename"": null, ""lastname"": ""Hughes"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Neil"", ""middlename"": null, ""lastname"": ""Unmack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/52ca2e11-1743-57fa-855b-982be2cccef9"", ""word_count"": 429, ""uri"": ""nyt://article/52ca2e11-1743-57fa-855b-982be2cccef9""}"
2014-05-02,"[{""abstract"": ""In a second bid for its British rival, the American drug giant Pfizer on Friday increased its offer by 7 percent. But AstraZeneca said the terms substantially undervalued the company."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/02/pfizer-raises-bid-for-astrazeneca-putting-pressure-on-drug-maker-to-make-deal/"", ""snippet"": ""In a second bid for its British rival, the American drug giant Pfizer on Friday increased its offer by 7 percent. But AstraZeneca said the terms substantially undervalued the company."", ""lead_paragraph"": ""The British drug maker AstraZeneca rejected an improved offer by its American rival Pfizer on Friday as political debate in Britain intensified over whether a foreign takeover of one of the country\u2019s largest pharmaceutical firms should be encouraged."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/03/business/SubPfizer1/SubPfizer1-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/03/business/SubPfizer1/SubPfizer1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/03/business/SubPfizer1/SubPfizer1-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/03/business/SubPfizer1/SubPfizer1-superJumbo.jpg"", ""height"": 1366, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/03/business/SubPfizer1/SubPfizer1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/03/business/SubPfizer1/SubPfizer1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/03/business/SubPfizer1/SubPfizer1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""AstraZeneca Rejects a Higher Bid From Pfizer"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""AstraZeneca Turns Down Higher Bid From Pfizer"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Stocks and Bonds"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Warner-Lambert Co"", ""rank"": 6, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Great Britain"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2014-05-02T06:37:11+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chad Bray and Stephen Castle"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Stephen"", ""middlename"": null, ""lastname"": ""Castle"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/081db4c0-b546-5458-9399-1c4fff4be721"", ""word_count"": 1010, ""uri"": ""nyt://article/081db4c0-b546-5458-9399-1c4fff4be721""}, {""abstract"": ""Federal authorities are looking into traders who traffic in Herbalife\u2019s stock. | AstraZeneca rejected a sweetened offer by Pfizer. | Ares is set to debut on the public market. | K.K.R. seeks to attract smaller investors."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/02/morning-agenda-scrutiny-for-traders-of-herbalife/"", ""snippet"": ""Federal authorities are looking into traders who traffic in Herbalife\u2019s stock. | AstraZeneca rejected a sweetened offer by Pfizer. | Ares is set to debut on the public market. | K.K.R. seeks to attract smaller investors."", ""lead_paragraph"": ""U.S. LOOKS INTO WAGERS ON HERBALIFE \u00a0|\u00a0 \u201cThree federal agencies and one billionaire hedge fund manager have placed Herbalife under the microscope, scrutinizing whether the diet supplements company is a pyramid scheme,\u201d Ben Protess and Alexandra Stevenson write in DealBook. \u201cBut Herbalife is not the only one under investigation. Some federal authorities are pursuing other inquiries that might expand the regulatory gaze from Herbalife to the traders who traffic in the company\u2019s stock.\u201d"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Morning Agenda: Scrutiny for Traders of Herbalife"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2014-05-02T11:54:06+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Sydney Ember"", ""person"": [{""firstname"": ""Sydney"", ""middlename"": null, ""lastname"": ""Ember"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/ac4795d9-71a2-5ba3-a967-ff0287c457c2"", ""word_count"": 1934, ""uri"": ""nyt://article/ac4795d9-71a2-5ba3-a967-ff0287c457c2""}, {""abstract"": ""Pfizer\u2019s latest offer for its rival seems cheap to shareholders who view AstraZeneca\u2019s turnaround as well advanced, Neil Unmack writes in Reuters Breakingviews."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/02/pfizer-has-yet-to-make-a-compelling-bid-to-astrazenecas-shareholders/"", ""snippet"": ""Pfizer\u2019s latest offer for its rival seems cheap to shareholders who view AstraZeneca\u2019s turnaround as well advanced, Neil Unmack writes in Reuters Breakingviews."", ""lead_paragraph"": ""Pfizer\u2019s courtship of AstraZeneca looks like a hate-hate relationship. In January, the British pharmaceutical firm AstraZeneca viewed its larger rival\u2019s takeover proposal of 46.61 pounds a share as too low on cash, too risky, and too cheap to even talk about. Pfizer\u2019s latest proposal, an effort to get AstraZeneca to begin friendly talks, hasn\u2019t moved the needle much."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/03/business/dbpix-ian-read/dbpix-ian-read-articleLarge.jpg"", ""height"": 444, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/03/business/dbpix-ian-read/dbpix-ian-read-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 444}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/03/business/dbpix-ian-read/dbpix-ian-read-jumbo.jpg"", ""height"": 758, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/03/business/dbpix-ian-read/dbpix-ian-read-superJumbo.jpg"", ""height"": 1516, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/03/business/dbpix-ian-read/dbpix-ian-read-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/03/business/dbpix-ian-read/dbpix-ian-read-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/03/business/dbpix-ian-read/dbpix-ian-read-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer Has Yet to Make a Compelling Bid to AstraZeneca\u2019s Shareholders"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Great Britain"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2014-05-02T17:00:17+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Neil Unmack"", ""person"": [{""firstname"": ""Neil"", ""middlename"": null, ""lastname"": ""Unmack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/ec8aaf84-5b1a-5c5f-9984-1ea85ce62151"", ""word_count"": 403, ""uri"": ""nyt://article/ec8aaf84-5b1a-5c5f-9984-1ea85ce62151""}]"
2014-05-05,"{""abstract"": ""Pfizer announced a 15 percent drop in earnings, and again pressed its suit for its rival, AstraZeneca."", ""web_url"": ""https://www.nytimes.com/2014/05/06/business/pfizer-profit-tumbles-15.html"", ""snippet"": ""Pfizer announced a 15 percent drop in earnings, and again pressed its suit for its rival, AstraZeneca."", ""lead_paragraph"": ""As the drug maker Pfizer announced a 15 percent drop in first-quarter earnings on Monday, its chief executive renewed his call for its British rival AstraZeneca to accept Pfizer\u2019s offer to buy it."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/06/business/Pfizer/Pfizer-articleLarge.jpg"", ""height"": 835, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/06/business/Pfizer/Pfizer-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 835}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/06/business/Pfizer/Pfizer-jumbo.jpg"", ""height"": 1024, ""width"": 736, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/06/business/Pfizer/Pfizer-superJumbo.jpg"", ""height"": 1038, ""width"": 746, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/06/business/Pfizer/Pfizer-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/06/business/Pfizer/Pfizer-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/06/business/Pfizer/Pfizer-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Profit Off, Pfizer Again Aims to Lure AstraZeneca"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Profits Off, Pfizer Again Aims to Lure AstraZeneca"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Thomas, Katie"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Company Reports"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2014-05-05T12:57:18+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Katie Thomas"", ""person"": [{""firstname"": ""Katie"", ""middlename"": null, ""lastname"": ""Thomas"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/264730d6-adaf-541f-8ab9-019d00864527"", ""word_count"": 592, ""uri"": ""nyt://article/264730d6-adaf-541f-8ab9-019d00864527""}"
2014-05-06,"{""abstract"": ""In presenting long-term financial estimates, AstraZeneca said it expected to achieve annual revenue of $45 billion by 2023, suggesting Pfizer\u2019s bid undervalued the company."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/06/astrazeneca-makes-case-against-pfizers-bid/"", ""snippet"": ""In presenting long-term financial estimates, AstraZeneca said it expected to achieve annual revenue of $45 billion by 2023, suggesting Pfizer\u2019s bid undervalued the company."", ""lead_paragraph"": ""Updated, 4:39 p.m. | AstraZeneca, the British drug maker, on Tuesday made an impassioned defense for itself as a stand-alone company, just a day after the American pharmaceutical giant Pfizer again pressed its case for a $106 billion takeover offer. "", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/07/business/dbpix-astrazeneca1/dbpix-astrazeneca1-articleLarge.jpg"", ""height"": 440, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/07/business/dbpix-astrazeneca1/dbpix-astrazeneca1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 440}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/07/business/dbpix-astrazeneca1/dbpix-astrazeneca1-jumbo.jpg"", ""height"": 751, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/07/business/dbpix-astrazeneca1/dbpix-astrazeneca1-superJumbo.jpg"", ""height"": 1501, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/07/business/dbpix-astrazeneca1/dbpix-astrazeneca1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/07/business/dbpix-astrazeneca1/dbpix-astrazeneca1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/07/business/dbpix-astrazeneca1/dbpix-astrazeneca1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""AstraZeneca Makes Its Case Against Pfizer\u2019s Takeover Bid"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Johansson, Leif"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Great Britain"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2014-05-06T12:02:52+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Jenny Anderson, David Gelles and Stephen Castle"", ""person"": [{""firstname"": ""Jenny"", ""middlename"": null, ""lastname"": ""Anderson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Gelles"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}, {""firstname"": ""Stephen"", ""middlename"": null, ""lastname"": ""Castle"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 3}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/0c623b11-bdea-5f49-9e0d-774d02f1951e"", ""word_count"": 1192, ""uri"": ""nyt://article/0c623b11-bdea-5f49-9e0d-774d02f1951e""}"
2014-05-07,"{""abstract"": ""Briggs Morrison, who oversees drug development for AstraZeneca, says the company would be better off without Pfizer. He bases that, in part, on having worked at Pfizer."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/07/a-scientists-defense-of-keeping-astrazeneca-independent/"", ""snippet"": ""Briggs Morrison, who oversees drug development for AstraZeneca, says the company would be better off without Pfizer. He bases that, in part, on having worked at Pfizer."", ""lead_paragraph"": ""Updated, 1:13 p.m. | LONDON \u2014 It is probably no surprise that Briggs Morrison, head of global drug development at AstraZeneca, has sided with his bosses in opposing the idea of the American giant Pfizer taking over the British company."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/08/business/dbpix-drug2/dbpix-drug2-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/08/business/dbpix-drug2/dbpix-drug2-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/08/business/dbpix-drug2/dbpix-drug2-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/08/business/dbpix-drug2/dbpix-drug2-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/08/business/dbpix-drug2/dbpix-drug2-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/08/business/dbpix-drug2/dbpix-drug2-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/08/business/dbpix-drug2/dbpix-drug2-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""A Scientist\u2019s Defense of Keeping AstraZeneca Independent"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2014-05-07T15:42:01+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Jenny Anderson"", ""person"": [{""firstname"": ""Jenny"", ""middlename"": null, ""lastname"": ""Anderson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/e6962748-39b1-5842-a4ed-a6e1df58ec31"", ""word_count"": 734, ""uri"": ""nyt://article/e6962748-39b1-5842-a4ed-a6e1df58ec31""}"
2014-05-08,"{""abstract"": ""AstraZeneca\u2019s board would do well to evaluate whether the company\u2019s progress will continue under Pfizer\u2019s management, Bill George, a professor at Harvard Business School, writes in the Another View column."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/08/a-case-for-rejecting-pfizers-bid-for-astrazeneca/"", ""snippet"": ""AstraZeneca\u2019s board would do well to evaluate whether the company\u2019s progress will continue under Pfizer\u2019s management, Bill George, a professor at Harvard Business School, writes in the Another View column."", ""lead_paragraph"": ""Bill George is professor of management practice at Harvard Business School, former chairman and chief executive of Medtronic and author of \u201cTrue North,\u201d a book about authentic leadership. He serves on the boards of ExxonMobil, Goldman Sachs and the Mayo Clinic. In the past two years, he has taught custom leadership programs at Harvard for AstraZeneca executives and consulted with the company in 2012-13. "", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/09/business/dbpix-pfizer1/dbpix-pfizer1-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/09/business/dbpix-pfizer1/dbpix-pfizer1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/09/business/dbpix-pfizer1/dbpix-pfizer1-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/09/business/dbpix-pfizer1/dbpix-pfizer1-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/09/business/dbpix-pfizer1/dbpix-pfizer1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/09/business/dbpix-pfizer1/dbpix-pfizer1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/09/business/dbpix-pfizer1/dbpix-pfizer1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""A Case for Rejecting Pfizer\u2019s Bid for AstraZeneca"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Read, Ian C"", ""rank"": 4, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Soriot, Pascal"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2014-05-08T19:35:49+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Bill George"", ""person"": [{""firstname"": ""Bill"", ""middlename"": null, ""lastname"": ""George"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/9d49b9ad-e7d8-5273-9522-c2705691b170"", ""word_count"": 906, ""uri"": ""nyt://article/9d49b9ad-e7d8-5273-9522-c2705691b170""}"
2014-05-09,"{""abstract"": ""Walgreen is already under pressure from hedge fund investors that want it to move across the Atlantic."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/08/pfizer-plan-to-go-to-london-spurs-other-companies-to-consider-moving-abroad/"", ""snippet"": ""Walgreen is already under pressure from hedge fund investors that want it to move across the Atlantic."", ""lead_paragraph"": ""Pfizer\u2019s attempt to escape the United States corporate tax rate by acquiring a British drug maker has set off a flurry of activity in other big companies across the country, at investment banks on Wall Street and in offices on Capitol Hill."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/09/business/Mergers/Mergers-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/09/business/Mergers/Mergers-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/09/business/Mergers/Mergers-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/09/business/Mergers/Mergers-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/09/business/Mergers/Mergers-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/09/business/Mergers/Mergers-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/09/business/Mergers/Mergers-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer\u2019s Plan to Go to London Spurs Other Companies to Consider Moving Abroad"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Pfizer\u2019s Plan to Go to London Spurs Other Companies to Consider Moving Abroad"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Relocation of Business"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Buffett, Warren E"", ""rank"": 4, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Levin, Carl M"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Walgreen Company"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2014-05-09T00:33:12+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By David Gelles"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Gelles"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/e0878883-cd0f-556f-bfec-a48be6cf7671"", ""word_count"": 977, ""uri"": ""nyt://article/e0878883-cd0f-556f-bfec-a48be6cf7671""}"
2014-05-10,"{""abstract"": ""In a series of videos posted online, Pfizer\u2019s chief executive tried to quell growing concern about the transaction."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/10/pfizer-continues-to-defend-takeover-bid-for-astrazeneca/"", ""snippet"": ""In a series of videos posted online, Pfizer\u2019s chief executive tried to quell growing concern about the transaction."", ""lead_paragraph"": ""Pfizer on Saturday continued to press its case for a $106 billion takeover of AstraZeneca, the British drug maker, in the face of mounting resistance on both sides of the Atlantic. "", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/11/business/dbpix-pfizer/dbpix-pfizer-articleLarge.jpg"", ""height"": 338, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/11/business/dbpix-pfizer/dbpix-pfizer-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 338}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/11/business/dbpix-pfizer/dbpix-pfizer-jumbo.jpg"", ""height"": 577, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/11/business/dbpix-pfizer/dbpix-pfizer-superJumbo.jpg"", ""height"": 620, ""width"": 1100, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/11/business/dbpix-pfizer/dbpix-pfizer-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/11/business/dbpix-pfizer/dbpix-pfizer-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/11/business/dbpix-pfizer/dbpix-pfizer-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer Continues to Defend Takeover Bid for AstraZeneca"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Read, Ian C"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2014-05-10T17:41:43+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By David Gelles"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Gelles"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/c2188814-8b16-5e82-9e94-1f6c4c063992"", ""word_count"": 509, ""uri"": ""nyt://article/c2188814-8b16-5e82-9e94-1f6c4c063992""}"
2014-05-12,"[{""abstract"": ""The American pharmaceutical giant is trying to convince British lawmakers that a Pfizer-AstraZeneca combination is viable."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/12/pfizer-and-astrazeneca-step-up-war-of-words-over-potential-merger/"", ""snippet"": ""The American pharmaceutical giant is trying to convince British lawmakers that a Pfizer-AstraZeneca combination is viable."", ""lead_paragraph"": ""Updated, 7:37 p.m. | LONDON \u2013 Pfizer pledged on Monday to keep jobs in Britain if it succeeds in taking over the British drug maker AstraZeneca, and it questioned whether AstraZeneca can stand on its own much longer."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/13/business/dbpix-drug2/dbpix-drug2-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/13/business/dbpix-drug2/dbpix-drug2-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/13/business/dbpix-drug2/dbpix-drug2-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/13/business/dbpix-drug2/dbpix-drug2-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/13/business/dbpix-drug2/dbpix-drug2-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/13/business/dbpix-drug2/dbpix-drug2-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/13/business/dbpix-drug2/dbpix-drug2-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pursuing AstraZeneca, Pfizer Pledges to Keep Jobs in Britain"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Pursuing AstraZeneca, Pfizer Pledges to Keep Jobs in Britain"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Read, Ian C"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2014-05-12T11:06:55+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chad Bray"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/a7094a9f-f819-585c-8e7f-257246efe413"", ""word_count"": 714, ""uri"": ""nyt://article/a7094a9f-f819-585c-8e7f-257246efe413""}, {""abstract"": ""BNP Paribas and Credit Suisse ask authorities in the United States to go easy. | Pfizer goes online to defend its bid for AstraZeneca. | Timothy F. Geithner\u2019s book, \u201cStress Test,\u201d comes out today. | Morgan Stanley is king in Silicon Valley."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/12/morning-agenda-2-banking-giants-ask-for-leniency/"", ""snippet"": ""BNP Paribas and Credit Suisse ask authorities in the United States to go easy. | Pfizer goes online to defend its bid for AstraZeneca. | Timothy F. Geithner\u2019s book, \u201cStress Test,\u201d comes out today. | Morgan Stanley is king in Silicon Valley."", ""lead_paragraph"": ""Facing the threat of criminal charges, BNP Paribas and Credit Suisse are imploring authorities in the United States for leniency, Ben Protess and Jessica Silver-Greenberg write in DealBook. To avoid fallout from pleading guilty, the banks are said to have made last-ditch appeals to prosecutors and regulators in recent weeks."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""BNP Paribas and Credit Suisse Seek Leniency"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2014-05-12T11:41:22+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Sydney Ember"", ""person"": [{""firstname"": ""Sydney"", ""middlename"": null, ""lastname"": ""Ember"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/c8028602-229a-53ca-a22b-f5aa54ebb5b6"", ""word_count"": 1839, ""uri"": ""nyt://article/c8028602-229a-53ca-a22b-f5aa54ebb5b6""}]"
2014-05-13,"[{""abstract"": ""The American drug maker continued its pursuit of its British competitor AstraZeneca, even as executives from both companies faced contentious questioning before Parliament over a possible takeover."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/13/pfizer-urges-astrazeneca-to-continue-talks-hinting-at-higher-offer/"", ""snippet"": ""The American drug maker continued its pursuit of its British competitor AstraZeneca, even as executives from both companies faced contentious questioning before Parliament over a possible takeover."", ""lead_paragraph"": ""LONDON \u2013 Pfizer opened the door on Tuesday to a possible higher offer for AstraZeneca, saying the deal remained compelling. It also urged AstraZeneca\u2019s board to engage in discussions that could result in \u201ca transaction that AstraZeneca can recommend.\u201d"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Lawmakers Mistrust a Marriage Offer Pfizer Won\u2019t Abandon"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Layoffs and Job Reductions"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Research"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Taxation"", ""rank"": 6, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Read, Ian C"", ""rank"": 7, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Soriot, Pascal"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 10, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Great Britain"", ""rank"": 11, ""major"": ""N""}], ""pub_date"": ""2014-05-13T12:59:02+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chad Bray"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/c1030112-0cdc-5b80-8efa-73d96660d4f9"", ""word_count"": 836, ""uri"": ""nyt://article/c1030112-0cdc-5b80-8efa-73d96660d4f9""}, {""abstract"": ""Investors are egging on companies to take on ever riskier transactions and are bidding up the shares of acquirers well beyond mathematical prudence, Rob Cox of Reuters Breakingviews writes."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/13/the-brewing-m-a-bubble/"", ""snippet"": ""Investors are egging on companies to take on ever riskier transactions and are bidding up the shares of acquirers well beyond mathematical prudence, Rob Cox of Reuters Breakingviews writes."", ""lead_paragraph"": ""Stop worrying about the tech bubble \u2013 there may be an even bigger one inflating beyond the confines of Silicon Valley. "", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/14/business/dbpix-merger-breakingviews/dbpix-merger-breakingviews-articleLarge.jpg"", ""height"": 332, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/14/business/dbpix-merger-breakingviews/dbpix-merger-breakingviews-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 332}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/14/business/dbpix-merger-breakingviews/dbpix-merger-breakingviews-jumbo.jpg"", ""height"": 567, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/14/business/dbpix-merger-breakingviews/dbpix-merger-breakingviews-superJumbo.jpg"", ""height"": 1060, ""width"": 1915, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/14/business/dbpix-merger-breakingviews/dbpix-merger-breakingviews-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/14/business/dbpix-merger-breakingviews/dbpix-merger-breakingviews-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/14/business/dbpix-merger-breakingviews/dbpix-merger-breakingviews-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""The Brewing M.&A. Bubble"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Stocks and Bonds"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALSTOM"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AT&T Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Biomet Incorporated"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Comcast Corporation"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""DirecTV"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""General Electric Company"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Time Warner Cable Inc"", ""rank"": 11, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Zimmer Holdings Inc"", ""rank"": 12, ""major"": ""N""}], ""pub_date"": ""2014-05-13T16:15:39+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Rob Cox"", ""person"": [{""firstname"": ""Rob"", ""middlename"": null, ""lastname"": ""Cox"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/9f49d369-8614-5af8-b2b6-b39ab6ea64ce"", ""word_count"": 882, ""uri"": ""nyt://article/9f49d369-8614-5af8-b2b6-b39ab6ea64ce""}, {""abstract"": ""One lesson for companies contemplating a big merger, Steven M. Davidoff writes in the Deal Professor column: Life is not a \u201cMad Men\u201d episode where ego and hubris triumph."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/13/lessons-from-the-breakup-of-an-advertising-merger/"", ""snippet"": ""One lesson for companies contemplating a big merger, Steven M. Davidoff writes in the Deal Professor column: Life is not a \u201cMad Men\u201d episode where ego and hubris triumph."", ""lead_paragraph"": ""\u201cOh, never mind.\u201d"", ""print_section"": ""B"", ""print_page"": ""9"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/14/business/dbpix-dealprof/dbpix-dealprof-articleLarge.jpg"", ""height"": 600, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/14/business/dbpix-dealprof/dbpix-dealprof-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 600}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/14/business/dbpix-dealprof/dbpix-dealprof-jumbo.jpg"", ""height"": 1024, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/14/business/dbpix-dealprof/dbpix-dealprof-superJumbo.jpg"", ""height"": 1190, ""width"": 1190, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/14/business/dbpix-dealprof/dbpix-dealprof-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/14/business/dbpix-dealprof/dbpix-dealprof-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/14/business/dbpix-dealprof/dbpix-dealprof-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""To Guide the Merger Giants, Strong Hands Are Needed"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""To Guide the Merger Giants, Strong Hands Are Needed"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Levy, Maurice"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Sorrell, Martin"", ""rank"": 4, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Wren, John D"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Omnicom Group Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Publicis Groupe"", ""rank"": 9, ""major"": ""N""}], ""pub_date"": ""2014-05-13T20:30:24+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Steven Davidoff Solomon"", ""person"": [{""firstname"": ""Steven"", ""middlename"": ""Davidoff"", ""lastname"": ""Solomon"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/a908a4f7-d0a5-570b-be71-8c30b993165a"", ""word_count"": 1144, ""uri"": ""nyt://article/a908a4f7-d0a5-570b-be71-8c30b993165a""}]"
2014-05-15,"{""abstract"": ""A new Reuters Breakingviews calculator shows why investors seem to believe that a $100 billion-plus acquisition by Pfizer will probably happen."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/15/the-right-price-for-astrazenecas-stock/"", ""snippet"": ""A new Reuters Breakingviews calculator shows why investors seem to believe that a $100 billion-plus acquisition by Pfizer will probably happen."", ""lead_paragraph"": ""Investors are putting a lot of faith in Pfizer succeeding in its $100 billion-plus quest to acquire British pharmaceuticals rival AstraZeneca. The right price for the target\u2019s share price can be seen as the weighted average of two possible outcomes \u2013 a sale to Pfizer or a standalone future. A new Breakingviews calculator shows why the market seems to think a transaction will probably happen."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/17/business/dbpix-astrazeneca/dbpix-astrazeneca-articleLarge.jpg"", ""height"": 900, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/17/business/dbpix-astrazeneca/dbpix-astrazeneca-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 900}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/17/business/dbpix-astrazeneca/dbpix-astrazeneca-jumbo.jpg"", ""height"": 1024, ""width"": 683, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/17/business/dbpix-astrazeneca/dbpix-astrazeneca-superJumbo.jpg"", ""height"": 2048, ""width"": 1366, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/17/business/dbpix-astrazeneca/dbpix-astrazeneca-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/17/business/dbpix-astrazeneca/dbpix-astrazeneca-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/17/business/dbpix-astrazeneca/dbpix-astrazeneca-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""The Right Price for AstraZeneca\u2019s Stock"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Stocks and Bonds"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2014-05-15T18:54:48+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Christopher Hughes"", ""person"": [{""firstname"": ""Christopher"", ""middlename"": null, ""lastname"": ""Hughes"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/d87bc7ef-a7d0-577b-869b-6b268df07149"", ""word_count"": 360, ""uri"": ""nyt://article/d87bc7ef-a7d0-577b-869b-6b268df07149""}"
2014-05-18,"{""abstract"": ""The American drug giant Pfizer has made an offer worth $119 billion in what it said was a final effort to bring the British drug maker AstraZeneca to the table for deal talks."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/18/pfizer-raises-bid-for-astrazeneca/"", ""snippet"": ""The American drug giant Pfizer has made an offer worth $119 billion in what it said was a final effort to bring the British drug maker AstraZeneca to the table for deal talks."", ""lead_paragraph"": ""Pfizer has again raised its offer for AstraZeneca, making what it said was a final effort to bring the giant British drug maker to the negotiating table."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/19/business/drug/drug-articleLarge.jpg"", ""height"": 441, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/19/business/drug/drug-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 441}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/19/business/drug/drug-jumbo.jpg"", ""height"": 752, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/19/business/drug/drug-superJumbo.jpg"", ""height"": 1255, ""width"": 1709, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/19/business/drug/drug-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/19/business/drug/drug-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/19/business/drug/drug-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""In Last-Ditch Bid, Pfizer Offers $119 Billion for AstraZeneca"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""In Last-Ditch Bid, Pfizer Offers $119 Billion for AstraZeneca"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Levin, Carl M"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Read, Ian C"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Great Britain"", ""rank"": 7, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""United States"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2014-05-18T21:19:58+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By David Gelles"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Gelles"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/3e9310a1-1019-5221-9d44-12265822d3ee"", ""word_count"": 848, ""uri"": ""nyt://article/3e9310a1-1019-5221-9d44-12265822d3ee""}"
2014-05-19,"[{""abstract"": ""AstraZeneca said the $119 billion offer undervalued the company, and its latest rebuff may mean the end of Pfizer\u2019s pursuit of a merger."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/19/astrazeneca-rejects-final-offer-by-pfizer/"", ""snippet"": ""AstraZeneca said the $119 billion offer undervalued the company, and its latest rebuff may mean the end of Pfizer\u2019s pursuit of a merger."", ""lead_paragraph"": ""Updated, 10:36 p.m. | LONDON \u2014\u00a0AstraZeneca has to hope it can deliver on its vaunted drug pipeline."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""AstraZeneca Snubs Pfizer Once More"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""AstraZeneca Snubs Pfizer Once More"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Johansson, Leif"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2014-05-19T07:23:42+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chad Bray"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/b6ebe4f6-1549-5fb4-92e3-f825cab8d602"", ""word_count"": 1198, ""uri"": ""nyt://article/b6ebe4f6-1549-5fb4-92e3-f825cab8d602""}, {""abstract"": ""Leif Johansson, the chairman of the British pharmaceutical company AstraZeneca, explained why the board rejected the $119 billion takeover offer from the American drug maker Pfizer."", ""web_url"": ""https://www.nytimes.com/video/business/100000002888664/astrazeneca-chairman-on-pfizers-bid.html"", ""snippet"": ""Leif Johansson, the chairman of the British pharmaceutical company AstraZeneca, explained why the board rejected the $119 billion takeover offer from the American drug maker Pfizer."", ""lead_paragraph"": ""Leif Johansson, the chairman of the British pharmaceutical company AstraZeneca, explained why the board rejected the $119 billion takeover offer from the American drug maker Pfizer."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/19/business/drug-astrazeneca-chairman/drug-astrazeneca-chairman-articleLarge.jpg"", ""height"": 339, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/19/business/drug-astrazeneca-chairman/drug-astrazeneca-chairman-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 339}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/19/business/drug-astrazeneca-chairman/drug-astrazeneca-chairman-jumbo.jpg"", ""height"": 577, ""width"": 1022, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/19/business/drug-astrazeneca-chairman/drug-astrazeneca-chairman-superJumbo.jpg"", ""height"": 577, ""width"": 1022, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/19/business/drug-astrazeneca-chairman/drug-astrazeneca-chairman-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/19/business/drug-astrazeneca-chairman/drug-astrazeneca-chairman-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/19/business/drug-astrazeneca-chairman/drug-astrazeneca-chairman-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""AstraZeneca\u2019s Chairman on Pfizer\u2019s Bid"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc (PFE/NYSE)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Johansson, Leif"", ""rank"": 5, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Great Britain"", ""rank"": 6, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""United States"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2014-05-19T14:31:51+0000"", ""document_type"": ""multimedia"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""Associated Press"", ""person"": [], ""organization"": ""Associated Press""}, ""type_of_material"": ""Video"", ""_id"": ""nyt://video/27155709-509f-5af1-a681-cc7c42b2a228"", ""word_count"": 0, ""uri"": ""nyt://video/27155709-509f-5af1-a681-cc7c42b2a228""}, {""abstract"": ""Britain does not have as many takeover defenses as the United States, so it is puzzling why Pfizer did not make a full-fledged hostile bid for AstraZeneca, Steven M. Davidoff writes in the Deal Professor column."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/19/the-curious-incident-of-pfizers-final-offer-for-astrazeneca/"", ""snippet"": ""Britain does not have as many takeover defenses as the United States, so it is puzzling why Pfizer did not make a full-fledged hostile bid for AstraZeneca, Steven M. Davidoff writes in the Deal Professor column."", ""lead_paragraph"": ""In its bid for AstraZeneca, Pfizer is finding out that some merger offers need to be sweet enough for everyone."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/20/business/dbpix-dealprof/dbpix-dealprof-articleLarge.jpg"", ""height"": 600, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/20/business/dbpix-dealprof/dbpix-dealprof-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 600}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/20/business/dbpix-dealprof/dbpix-dealprof-jumbo.jpg"", ""height"": 970, ""width"": 970, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/20/business/dbpix-dealprof/dbpix-dealprof-superJumbo.jpg"", ""height"": 970, ""width"": 970, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/20/business/dbpix-dealprof/dbpix-dealprof-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/20/business/dbpix-dealprof/dbpix-dealprof-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/20/business/dbpix-dealprof/dbpix-dealprof-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""The Curious Incident of Pfizer\u2019s \u2018Final\u2019 Offer for AstraZeneca"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Federal Taxes (US)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Taxation"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Great Britain"", ""rank"": 7, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""United States"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2014-05-19T16:09:20+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Steven Davidoff Solomon"", ""person"": [{""firstname"": ""Steven"", ""middlename"": ""Davidoff"", ""lastname"": ""Solomon"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/1a3cf152-03f0-5760-95f1-ff900aae6975"", ""word_count"": 884, ""uri"": ""nyt://article/1a3cf152-03f0-5760-95f1-ff900aae6975""}]"
2014-05-20,"[{""abstract"": ""The company\u2019s rejection of Pfizer\u2019s latest offer disappointed some investors, while others said the deal was not in AstraZeneca\u2019s best interest."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/20/large-shareholder-urges-astrazeneca-to-continue-talks-with-pfizer/"", ""snippet"": ""The company\u2019s rejection of Pfizer\u2019s latest offer disappointed some investors, while others said the deal was not in AstraZeneca\u2019s best interest."", ""lead_paragraph"": ""Updated, 7:20 p.m. LONDON \u2014 Some of AstraZeneca\u2019s largest shareholders were publicly split Tuesday on whether the company should continue merger discussions with Pfizer."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/21/business/ASTRA/ASTRA-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/21/business/ASTRA/ASTRA-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/21/business/ASTRA/ASTRA-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/21/business/ASTRA/ASTRA-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/21/business/ASTRA/ASTRA-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/21/business/ASTRA/ASTRA-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/21/business/ASTRA/ASTRA-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer\u2019s Latest Offer Divides Some of Largest Shareholders in AstraZeneca"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Pfizer\u2019s Latest Offer Divides Some of Largest Shareholders in AstraZeneca "", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Stocks and Bonds"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Great Britain"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2014-05-20T13:47:42+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chad Bray"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/e5541058-536a-5534-bfe8-40fbce2e567e"", ""word_count"": 684, ""uri"": ""nyt://article/e5541058-536a-5534-bfe8-40fbce2e567e""}, {""abstract"": ""An apparent loophole in Britain\u2019s takeover code means Pfizer could offer a higher price for AstraZeneca, even after declaring that its earlier pitch was \u201cfinal,\u201d says Christopher Hughes of Reuters Breakingviews."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/20/loophole-offers-pfizer-a-risky-way-back-into-a-deal/"", ""snippet"": ""An apparent loophole in Britain\u2019s takeover code means Pfizer could offer a higher price for AstraZeneca, even after declaring that its earlier pitch was \u201cfinal,\u201d says Christopher Hughes of Reuters Breakingviews."", ""lead_paragraph"": ""Pfizer has a risky way back into a deal with AstraZeneca. An apparent loophole in Britain\u2019s takeover code means that the American pharmaceutical giant could offer the 58.85 pounds-a-share demanded by Astra for a recommendation, even after declaring that the earlier \u00a355-a-share pitch was \u201cfinal.\u201d"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-articleLarge.jpg"", ""height"": 900, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 900}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-jumbo.jpg"", ""height"": 1024, ""width"": 683, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-superJumbo.jpg"", ""height"": 2048, ""width"": 1366, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Loophole Offers Pfizer a Risky Way Back Into a Deal"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2014-05-20T17:29:07+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Christopher Hughes"", ""person"": [{""firstname"": ""Christopher"", ""middlename"": null, ""lastname"": ""Hughes"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/c88d558c-9fc7-54c8-8fac-f4ce5d8dc5bd"", ""word_count"": 339, ""uri"": ""nyt://article/c88d558c-9fc7-54c8-8fac-f4ce5d8dc5bd""}]"
2014-05-21,"[{""abstract"": ""If a merger with Pfizer really makes sense, AstraZeneca\u2019s decision is not now or never, Christopher Hughes of Reuters Breakingviews writes."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/21/a-giant-drug-deal-first-needs-a-rest-and-then-a-fresh-start/"", ""snippet"": ""If a merger with Pfizer really makes sense, AstraZeneca\u2019s decision is not now or never, Christopher Hughes of Reuters Breakingviews writes."", ""lead_paragraph"": ""AstraZeneca should not re-engage with Pfizer in the dying days of the takeover timetable. Talks now would either be fruitless or delay a proper restart later."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-articleLarge.jpg"", ""height"": 900, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 900}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-jumbo.jpg"", ""height"": 1024, ""width"": 683, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-superJumbo.jpg"", ""height"": 2048, ""width"": 1366, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer-AstraZeneca Talks Need a Rest and Then a Fresh Start"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Great Britain"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2014-05-21T16:18:13+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Christopher Hughes"", ""person"": [{""firstname"": ""Christopher"", ""middlename"": null, ""lastname"": ""Hughes"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/3c2d92e0-83b8-5332-883d-4fd27cf6d7ab"", ""word_count"": 519, ""uri"": ""nyt://article/3c2d92e0-83b8-5332-883d-4fd27cf6d7ab""}, {""abstract"": ""The fragmented response offers a glimmer of hope to Pfizer, but AstraZeneca also contends that under British takeover law, its hands are tied unless a third part steps in with a competing bid."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/21/astrazenecas-shareholders-remain-sharply-divided-over-talks-with-pfizer/"", ""snippet"": ""The fragmented response offers a glimmer of hope to Pfizer, but AstraZeneca also contends that under British takeover law, its hands are tied unless a third part steps in with a competing bid."", ""lead_paragraph"": ""LONDON \u2013 AstraZeneca\u2019s decision not to pursue merger talks with Pfizer\u00a0 has caused a split among the British-Swedish drug maker\u2019s shareholders, \u00a0with several large shareholders publicly and privately voicing opposing views on Wednesday on the potential tie-up."", ""print_section"": ""B"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/22/business/dbpix-drug1/dbpix-drug1-articleLarge.jpg"", ""height"": 366, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/22/business/dbpix-drug1/dbpix-drug1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 366}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/22/business/dbpix-drug1/dbpix-drug1-jumbo.jpg"", ""height"": 625, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/22/business/dbpix-drug1/dbpix-drug1-superJumbo.jpg"", ""height"": 1250, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/22/business/dbpix-drug1/dbpix-drug1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/22/business/dbpix-drug1/dbpix-drug1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/22/business/dbpix-drug1/dbpix-drug1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""AstraZeneca\u2019s Shareholders Remain Sharply Divided Over Talks With Pfizer"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Shareholders Divided"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Axa SA"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2014-05-21T17:42:54+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chad Bray"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/4e0d2234-1084-5b9f-bc10-6e74820978f1"", ""word_count"": 607, ""uri"": ""nyt://article/4e0d2234-1084-5b9f-bc10-6e74820978f1""}]"
2014-05-22,"{""abstract"": ""BlackRock, AstraZeneca\u2019s largest shareholder, is said to prefer that the drug firm engage in talks with Pfizer later on rather than accept Pfizer\u2019s most recent offer."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/22/blackrock-encourages-astrazeneca-to-renew-pfizer-talks-at-later-date/"", ""snippet"": ""BlackRock, AstraZeneca\u2019s largest shareholder, is said to prefer that the drug firm engage in talks with Pfizer later on rather than accept Pfizer\u2019s most recent offer."", ""lead_paragraph"": ""LONDON \u2013 AstraZeneca\u2019s largest shareholder, BlackRock, wants the drugmaker to renew its talks with Pfizer about a potential deal at a later date, according to a person familiar with the discussions."", ""print_section"": ""B"", ""print_page"": ""7"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/22/business/dbpix-drug1/dbpix-drug1-articleLarge.jpg"", ""height"": 366, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/22/business/dbpix-drug1/dbpix-drug1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 366}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/22/business/dbpix-drug1/dbpix-drug1-jumbo.jpg"", ""height"": 625, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/22/business/dbpix-drug1/dbpix-drug1-superJumbo.jpg"", ""height"": 1250, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/22/business/dbpix-drug1/dbpix-drug1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/22/business/dbpix-drug1/dbpix-drug1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/22/business/dbpix-drug1/dbpix-drug1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""BlackRock Encourages AstraZeneca to Renew Pfizer Talks at Later Date"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Early Retirement"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""BlackRock Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2014-05-22T16:55:43+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chad Bray"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/4b7bfb0e-2516-5e1f-8a67-068b09a7e309"", ""word_count"": 450, ""uri"": ""nyt://article/4b7bfb0e-2516-5e1f-8a67-068b09a7e309""}"
2014-05-26,"[{""abstract"": ""The European Central Bank is hosting a forum in Portugal, and American figures on consumer confidence, home prices and first-quarter growth are due."", ""web_url"": ""https://www.nytimes.com/2014/05/26/business/a-banking-forum-in-europe-and-a-raft-of-us-economic-data.html"", ""snippet"": ""The European Central Bank is hosting a forum in Portugal, and American figures on consumer confidence, home prices and first-quarter growth are due."", ""lead_paragraph"": ""EUROPEAN CENTRAL BANK TO HOLD GLOBAL FORUM"", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/26/business/ahead/ahead-articleLarge.jpg"", ""height"": 419, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/26/business/ahead/ahead-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 419}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/26/business/ahead/ahead-jumbo.jpg"", ""height"": 714, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/26/business/ahead/ahead-superJumbo.jpg"", ""height"": 1429, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/26/business/ahead/ahead-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/26/business/ahead/ahead-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/26/business/ahead/ahead-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""A Banking Forum in Europe and a Raft of U.S. Economic Data"", ""kicker"": ""The Week Ahead"", ""content_kicker"": null, ""print_headline"": ""A Banking Forum in Europe and a Raft of U.S. Economic Data"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""United States Economy"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Real Estate and Housing (Residential)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Alternative and Renewable Energy"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Wind Power"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Solar Energy"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Banking and Financial Institutions"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Interest Rates"", ""rank"": 8, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Energy and Power"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""European Monetary Union"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Conference Board"", ""rank"": 11, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""American Legislative Exchange Council"", ""rank"": 12, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Commerce Department"", ""rank"": 13, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 14, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""European Central Bank"", ""rank"": 15, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 16, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Sintra (Portugal)"", ""rank"": 17, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""United States"", ""rank"": 18, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Portugal"", ""rank"": 19, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Europe"", ""rank"": 20, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Jackson Hole (Wyo)"", ""rank"": 21, ""major"": ""N""}], ""pub_date"": ""2014-05-26T00:52:46+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By The New York Times"", ""person"": [], ""organization"": ""The New York Times""}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/27571d5a-2c73-5dfe-bc01-ed73c07698c2"", ""word_count"": 735, ""uri"": ""nyt://article/27571d5a-2c73-5dfe-bc01-ed73c07698c2""}, {""abstract"": ""Pfizer said it \u201cdoes not intend to make an offer for AstraZeneca\u201d in the wake of AstraZeneca\u2019s rejection of a $119 billion bid."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/26/pfizers-says-its-bid-for-astrazeneca-is-dead/"", ""snippet"": ""Pfizer said it \u201cdoes not intend to make an offer for AstraZeneca\u201d in the wake of AstraZeneca\u2019s rejection of a $119 billion bid."", ""lead_paragraph"": ""Updated, 9:36 p.m. | On the final day for Pfizer to decide whether to abandon the plan, it said it did not intend to make an offer for AstraZeneca. Last week, the British company rejected what Pfizer had called its final offer. The cash-and-stock bid, which valued AstraZeneca at about $119 billion, would have created the world\u2019s largest drug company."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/26/business/26dbpix-astrazeneca/26dbpix-astrazeneca-articleLarge.jpg"", ""height"": 366, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/26/business/26dbpix-astrazeneca/26dbpix-astrazeneca-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 366}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/26/business/26dbpix-astrazeneca/26dbpix-astrazeneca-jumbo.jpg"", ""height"": 625, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/26/business/26dbpix-astrazeneca/26dbpix-astrazeneca-superJumbo.jpg"", ""height"": 1250, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/26/business/26dbpix-astrazeneca/26dbpix-astrazeneca-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/26/business/26dbpix-astrazeneca/26dbpix-astrazeneca-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/26/business/26dbpix-astrazeneca/26dbpix-astrazeneca-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer Abandons Bid for AstraZeneca"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Pfizer Abandons Bid for AstraZeneca"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Read, Ian C"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2014-05-26T14:39:52+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Jenny Anderson"", ""person"": [{""firstname"": ""Jenny"", ""middlename"": null, ""lastname"": ""Anderson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/73fdd200-9ca2-5913-be04-69d619de876a"", ""word_count"": 630, ""uri"": ""nyt://article/73fdd200-9ca2-5913-be04-69d619de876a""}]"
2014-05-27,"[{""abstract"": ""Pfizer has abandoned its bid for AstraZeneca. | N.Y.U.\u2019s trustees are tied to the university\u2019s crisis in Abu Dhabi. | The S.E.C. and private equity. | Bill Gates has cut the pace of his own giving to his foundation."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/27/morning-agenda-pfizer-lets-astrazeneca-go/"", ""snippet"": ""Pfizer has abandoned its bid for AstraZeneca. | N.Y.U.\u2019s trustees are tied to the university\u2019s crisis in Abu Dhabi. | The S.E.C. and private equity. | Bill Gates has cut the pace of his own giving to his foundation."", ""lead_paragraph"": ""Pfizer said on Monday that it had abandoned its bid for AstraZeneca, bringing an end to a monthslong takeover effort that would have created the world\u2019s largest drug company, Jenny Anderson writes in DealBook. The decision \u2012 made on the final day for Pfizer to decide whether to abandon the deal \u2012 came in the wake of AstraZeneca\u2019s rejection of what Pfizer called its final offer earlier this month. The cash-and-stock bid valued AstraZeneca at about $119 billion."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer Lets AstraZeneca Go"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2014-05-27T12:03:57+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Sydney Ember"", ""person"": [{""firstname"": ""Sydney"", ""middlename"": null, ""lastname"": ""Ember"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/4c56c105-9ece-55ad-97b0-d7eff25d9cd3"", ""word_count"": 1997, ""uri"": ""nyt://article/4c56c105-9ece-55ad-97b0-d7eff25d9cd3""}, {""abstract"": ""Pfizer looks foolish for the way it handled a $119 billion bid, yet it is AstraZeneca that remains under pressure, Christopher Hughes of Reuters Breakingviews writes."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/27/the-lessons-of-a-failed-drug-deal/"", ""snippet"": ""Pfizer looks foolish for the way it handled a $119 billion bid, yet it is AstraZeneca that remains under pressure, Christopher Hughes of Reuters Breakingviews writes."", ""lead_paragraph"": ""The failure of Pfizer\u2019s $119 billion bid for AstraZeneca leaves the frustrated buyer no worse off. But AstraZeneca has much to prove. Some of its shareholders welcomed a possible takeover \u2013 and could again."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-articleLarge.jpg"", ""height"": 900, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 900}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-jumbo.jpg"", ""height"": 1024, ""width"": 683, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-superJumbo.jpg"", ""height"": 2048, ""width"": 1366, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""The Lessons of a Drug Maker\u2019s Failed Deal"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Great Britain"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2014-05-27T15:49:36+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Christopher Hughes"", ""person"": [{""firstname"": ""Christopher"", ""middlename"": null, ""lastname"": ""Hughes"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/673a4161-a3dd-5c7c-b644-091be9e918ff"", ""word_count"": 343, ""uri"": ""nyt://article/673a4161-a3dd-5c7c-b644-091be9e918ff""}]"
2014-05-29,"[{""abstract"": ""Marcato Capital Management said combining the Intercontinental Hotels Group\u2019s Holiday Inn and Crowne Plaza brands with a larger hotel operator \u201crepresents a unique opportunity to reshape the global hospitality industry.\u201d"", ""web_url"": ""https://dealbook.nytimes.com/2014/05/29/marcato-capital-urges-intercontinental-hotels-to-pursue-merger/"", ""snippet"": ""Marcato Capital Management said combining the Intercontinental Hotels Group\u2019s Holiday Inn and Crowne Plaza brands with a larger hotel operator \u201crepresents a unique opportunity to reshape the global hospitality industry.\u201d"", ""lead_paragraph"": ""LONDON \u2013 The hedge fund Marcato Capital Management urged the Intercontinental Hotels Group on Thursday to pursue a merger after media reports in Britain this week that it had turned down an unknown American bidder."", ""print_section"": ""B"", ""print_page"": ""5"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/30/business/dbpix-hotel/dbpix-hotel-articleLarge.jpg"", ""height"": 396, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/30/business/dbpix-hotel/dbpix-hotel-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 396}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/30/business/dbpix-hotel/dbpix-hotel-jumbo.jpg"", ""height"": 677, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/30/business/dbpix-hotel/dbpix-hotel-superJumbo.jpg"", ""height"": 1019, ""width"": 1542, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/30/business/dbpix-hotel/dbpix-hotel-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/30/business/dbpix-hotel/dbpix-hotel-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/30/business/dbpix-hotel/dbpix-hotel-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Marcato Capital Urges Intercontinental Hotels to Pursue Merger"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Calling for a Merger"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Federal Taxes (US)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Hedge Funds"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Hotels and Travel Lodgings"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Holiday Inn"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Great Britain"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2014-05-29T12:42:12+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chad Bray"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/488ff37d-d7eb-5a95-8b05-4483a00ba8dd"", ""word_count"": 258, ""uri"": ""nyt://article/488ff37d-d7eb-5a95-8b05-4483a00ba8dd""}, {""abstract"": ""The government says the national health service suffered losses from the drug companies\u2019 efforts to restrict competition in ophthalmic drugs."", ""web_url"": ""https://www.nytimes.com/2014/05/30/business/international/italy-seeks-1-6-billion-in-damages-from-roche-and-novartis.html"", ""snippet"": ""The government says the national health service suffered losses from the drug companies\u2019 efforts to restrict competition in ophthalmic drugs."", ""lead_paragraph"": ""PARIS \u2014 The Italian government is seeking $1.6 billion in damages from two of the world\u2019s biggest drug companies \u2014 Novartis and Roche \u2014 for losses that it says the national health service incurred from the companies\u2019 efforts to restrict competition in ophthalmic drugs."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Italy Seeks $1.6 Billion in Damages From Roche and Novartis"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Novartis and Roche Face Fines in Italy"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Jolly, David"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Pianigiani, Gaia"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Antitrust Laws and Competition Issues"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 6, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Italy"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2014-05-29T16:26:04+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""International Business"", ""byline"": {""original"": ""By David Jolly and Gaia Pianigiani"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Jolly"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Gaia"", ""middlename"": null, ""lastname"": ""Pianigiani"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/99050c46-617e-5a06-9a52-08fd3ecde0c8"", ""word_count"": 449, ""uri"": ""nyt://article/99050c46-617e-5a06-9a52-08fd3ecde0c8""}]"
2014-06-16,"[{""abstract"": ""Stents and sutures are not an obvious fit, Jeffrey Goldfarb and Robert Cyran of Reuters Breakingviews write, and the savings and benefits from such a merger do not appear to justify a premium of nearly $10 billion."", ""web_url"": ""https://dealbook.nytimes.com/2014/06/16/medtronic-covidien-deal-is-a-marriage-of-convenience/"", ""snippet"": ""Stents and sutures are not an obvious fit, Jeffrey Goldfarb and Robert Cyran of Reuters Breakingviews write, and the savings and benefits from such a merger do not appear to justify a premium of nearly $10 billion."", ""lead_paragraph"": ""The marriage of Medtronic and Covidien looks to be one of convenience. The $42.9 billion deal includes a premium that exceeds the estimated cost savings. Stents and sutures are not an obvious fit. And moving Medtronic\u2019s headquarters from Minneapolis to Covidien\u2019s Dublin base will not obviously cut the American company\u2019s tax bill. Freeing up overseas cash is too shallow a reason to tie the knot."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Medtronic-Covidien Deal Is a Marriage of Convenience"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medical Devices"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Covidien plc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Medtronic Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2014-06-16T15:53:11+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Jeffrey Goldfarb and Robert Cyran"", ""person"": [{""firstname"": ""Jeffrey"", ""middlename"": null, ""lastname"": ""Goldfarb"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Robert"", ""middlename"": null, ""lastname"": ""Cyran"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/31a419a6-83ae-5883-99dd-a8456f274a4d"", ""word_count"": 393, ""uri"": ""nyt://article/31a419a6-83ae-5883-99dd-a8456f274a4d""}, {""abstract"": ""Bill George, a former chief executive of Medtronic, opposed Pfizer\u2019s proposed deal to acquire an overseas competitor and reincorporate abroad, but he is all in favor of his former employer making a similar deal."", ""web_url"": ""https://dealbook.nytimes.com/2014/06/16/former-medtronic-c-e-o-defends-inversion-deal/"", ""snippet"": ""Bill George, a former chief executive of Medtronic, opposed Pfizer\u2019s proposed deal to acquire an overseas competitor and reincorporate abroad, but he is all in favor of his former employer making a similar deal."", ""lead_paragraph"": ""Bill George, a former chief executive of the medical device maker Medtronic, came out last month against Pfizer\u2019s proposed inversion \u2013 a deal to acquire an overseas competitor and reincorporate abroad, lowering tax rates and freeing up overseas cash."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/17/business/dbpix-george/dbpix-george-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/06/17/business/dbpix-george/dbpix-george-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/17/business/dbpix-george/dbpix-george-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/17/business/dbpix-george/dbpix-george-superJumbo.jpg"", ""height"": 1367, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/17/business/dbpix-george/dbpix-george-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/06/17/business/dbpix-george/dbpix-george-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/17/business/dbpix-george/dbpix-george-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Former Medtronic C.E.O. Defends Inversion Deal"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tax Shelters"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""George, William W"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Covidien plc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Medtronic Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 8, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Ireland"", ""rank"": 9, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""United States"", ""rank"": 10, ""major"": ""N""}], ""pub_date"": ""2014-06-16T16:13:27+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By David Gelles"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Gelles"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/b4212ed8-0a2e-507e-8049-3d8fc41fd2e3"", ""word_count"": 483, ""uri"": ""nyt://article/b4212ed8-0a2e-507e-8049-3d8fc41fd2e3""}]"
2014-06-24,"{""abstract"": ""Two BNP Paribas analysts said in a research note that a sweetened offer of about $127.7 billion by Pfizer for its British rival would still make \u201ceconomic sense.\u201d"", ""web_url"": ""https://dealbook.nytimes.com/2014/06/24/bank-analysts-say-pfizer-astrazeneca-merger-still-makes-sense/"", ""snippet"": ""Two BNP Paribas analysts said in a research note that a sweetened offer of about $127.7 billion by Pfizer for its British rival would still make \u201ceconomic sense.\u201d"", ""lead_paragraph"": ""LONDON \u2014 Analysts at BNP Paribas think a potential merger between AstraZeneca and Pfizer may not be dead despite AstraZeneca\u2019s repeated rejections of a deal between the drug makers."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/25/business/dbpix-pfizer1/dbpix-pfizer1-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/06/25/business/dbpix-pfizer1/dbpix-pfizer1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/25/business/dbpix-pfizer1/dbpix-pfizer1-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/25/business/dbpix-pfizer1/dbpix-pfizer1-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/25/business/dbpix-pfizer1/dbpix-pfizer1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/06/25/business/dbpix-pfizer1/dbpix-pfizer1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/25/business/dbpix-pfizer1/dbpix-pfizer1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Bank Analysts Say Pfizer-AstraZeneca Merger Still Makes Sense"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Federal Taxes (US)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Stocks and Bonds"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""BNP Paribas"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""GlaxoSmithKline PLC"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 8, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Great Britain"", ""rank"": 9, ""major"": ""N""}], ""pub_date"": ""2014-06-24T11:37:42+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chad Bray"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/114d6261-f048-5372-8f79-d548f29de11a"", ""word_count"": 286, ""uri"": ""nyt://article/114d6261-f048-5372-8f79-d548f29de11a""}"
2014-06-25,"{""abstract"": ""Though AbbVie, based in Chicago, stopped short of raising its $46 billion takeover offer, its presentation and investor call on Wednesday made the case for a deal with Shire."", ""web_url"": ""https://dealbook.nytimes.com/2014/06/25/abbvie-signals-it-will-continue-to-pursue-irish-drug-maker-shire/"", ""snippet"": ""Though AbbVie, based in Chicago, stopped short of raising its $46 billion takeover offer, its presentation and investor call on Wednesday made the case for a deal with Shire."", ""lead_paragraph"": ""Updated, 2:28 p.m. | "", ""print_section"": ""B"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/26/business/dbpix-shire/dbpix-shire-articleLarge.jpg"", ""height"": 419, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/06/26/business/dbpix-shire/dbpix-shire-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 419}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/26/business/dbpix-shire/dbpix-shire-jumbo.jpg"", ""height"": 419, ""width"": 600, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/26/business/dbpix-shire/dbpix-shire-superJumbo.jpg"", ""height"": 419, ""width"": 600, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/26/business/dbpix-shire/dbpix-shire-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/06/26/business/dbpix-shire/dbpix-shire-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/26/business/dbpix-shire/dbpix-shire-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""AbbVie Signals It Will Continue to Pursue Irish Drug Maker Shire"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Defending Its Offer"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Gonzalez, Richard"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Goldman Sachs Group Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Shire PLC"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2014-06-25T13:06:34+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By David Gelles"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Gelles"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/6f8402b9-2f2e-55f8-9167-a229e3f030ab"", ""word_count"": 804, ""uri"": ""nyt://article/6f8402b9-2f2e-55f8-9167-a229e3f030ab""}"
2014-06-26,"{""abstract"": ""Auxilium Pharmaceuticals, based in Pennsylvania, agreed to acquire QLT of Canada in one of the smallest inversions in recent years."", ""web_url"": ""https://dealbook.nytimes.com/2014/06/26/auxilium-buys-qlt-as-a-small-player-does-an-inversion-too/"", ""snippet"": ""Auxilium Pharmaceuticals, based in Pennsylvania, agreed to acquire QLT of Canada in one of the smallest inversions in recent years."", ""lead_paragraph"": ""Most of the corporate inversions that have grabbed headlines recently have been attempted by multibillion-dollar stalwarts of United States industry like Pfizer, Chiquita and Medtronic. But smaller companies can benefit from striking deals to move abroad, too. "", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Auxilium, a Small Player, Buys QLT and Does an Inversion, Too"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2014-06-26T16:23:08+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By David Gelles"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Gelles"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/068e3bf7-cc07-5b21-80ae-8362769e458e"", ""word_count"": 357, ""uri"": ""nyt://article/068e3bf7-cc07-5b21-80ae-8362769e458e""}"
2014-07-02,"{""abstract"": ""As more companies seek to relocate by mergers \u2014 so-called inversions \u2014 it is more likely the law will change, Robert Cyran of Reuters Breakingviews writes."", ""web_url"": ""https://dealbook.nytimes.com/2014/07/02/the-fleeting-benefits-of-overseas-corporate-marriages/"", ""snippet"": ""As more companies seek to relocate by mergers \u2014 so-called inversions \u2014 it is more likely the law will change, Robert Cyran of Reuters Breakingviews writes."", ""lead_paragraph"": ""Tax-arbitrage mergers and acquisitions require a deep discount. American companies seeking to relocate by mergers in a bid to slash how much they pay Uncle Sam were a big part of the $1.8 trillion first-half deal boom. The benefits of such ill-conceived combinations will be fleeting, though. The more so-called inversions there are, the more likely the law is to change."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/03/business/dbpix-medtronic/dbpix-medtronic-articleLarge.jpg"", ""height"": 246, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/07/03/business/dbpix-medtronic/dbpix-medtronic-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 246}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/03/business/dbpix-medtronic/dbpix-medtronic-jumbo.jpg"", ""height"": 420, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/03/business/dbpix-medtronic/dbpix-medtronic-superJumbo.jpg"", ""height"": 839, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/03/business/dbpix-medtronic/dbpix-medtronic-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/07/03/business/dbpix-medtronic/dbpix-medtronic-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/03/business/dbpix-medtronic/dbpix-medtronic-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""The Fleeting Benefits of Overseas Corporate Marriages"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Law and Legislation"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Taxation"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Covidien plc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Medtronic Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2014-07-02T17:01:54+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Robert Cyran"", ""person"": [{""firstname"": ""Robert"", ""middlename"": null, ""lastname"": ""Cyran"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/76cd9ae5-b1b5-57dd-b0ba-d7bf9fbbb4e7"", ""word_count"": 384, ""uri"": ""nyt://article/76cd9ae5-b1b5-57dd-b0ba-d7bf9fbbb4e7""}"
2014-07-14,"{""abstract"": ""Vince Cable, the British business secretary, wants to eliminate the \u201cwiggle room\u201d in commitments made by foreign suitors for British companies."", ""web_url"": ""https://dealbook.nytimes.com/2014/07/14/government-official-calls-for-stricter-takeover-rules-in-britain/"", ""snippet"": ""Vince Cable, the British business secretary, wants to eliminate the \u201cwiggle room\u201d in commitments made by foreign suitors for British companies."", ""lead_paragraph"": ""LONDON \u2013 Vince Cable, the British business secretary, is calling for stricter rules to regulate acquisitions of British companies by overseas competitors."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/15/business/dbpix-vince-cable/dbpix-vince-cable-articleLarge.jpg"", ""height"": 463, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/07/15/business/dbpix-vince-cable/dbpix-vince-cable-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 463}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/15/business/dbpix-vince-cable/dbpix-vince-cable-jumbo.jpg"", ""height"": 791, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/15/business/dbpix-vince-cable/dbpix-vince-cable-superJumbo.jpg"", ""height"": 1582, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/15/business/dbpix-vince-cable/dbpix-vince-cable-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/07/15/business/dbpix-vince-cable/dbpix-vince-cable-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/15/business/dbpix-vince-cable/dbpix-vince-cable-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""A Call for Stricter Takeover Rules in Britain"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Cable, Vince"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Great Britain"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2014-07-14T10:45:08+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chad Bray"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/9c36040f-86c8-5232-acc2-ecf880071553"", ""word_count"": 364, ""uri"": ""nyt://article/9c36040f-86c8-5232-acc2-ecf880071553""}"
2014-07-15,"{""abstract"": ""The pharmaceutical company is hoping to bring a new acronym into the vernacular with FOGO, or fear of getting old."", ""web_url"": ""https://www.nytimes.com/2014/07/16/business/media/pfizer-to-inject-youth-into-the-aging-process.html"", ""snippet"": ""The pharmaceutical company is hoping to bring a new acronym into the vernacular with FOGO, or fear of getting old."", ""lead_paragraph"": ""Acronyms seem to be growing more prevalent in the vernacular, among them BOGO, for buy one, get one; YOLO, you only live once; and FOMO, fear of missing out. To that list, the pharmaceutical giant Pfizer hopes to add FOGO, a.k.a. fear of getting old."", ""print_section"": ""B"", ""print_page"": ""9"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/16/business/Adco/Adco-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/07/16/business/Adco/Adco-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/16/business/Adco/Adco-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/16/business/Adco/Adco-superJumbo.jpg"", ""height"": 1234, ""width"": 1851, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/16/business/Adco/Adco-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/07/16/business/Adco/Adco-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/16/business/Adco/Adco-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer to Inject Youth Into the Aging Process"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer to Inject Youth Into the Aging Process"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Elliott, Stuart"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Elderly"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""ADVERTISING AND MARKETING"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2014-07-15T23:56:29+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""Media"", ""byline"": {""original"": ""By Stuart Elliott"", ""person"": [{""firstname"": ""Stuart"", ""middlename"": null, ""lastname"": ""Elliott"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/86c5472e-483f-5fd4-9442-b44f707523c4"", ""word_count"": 890, ""uri"": ""nyt://article/86c5472e-483f-5fd4-9442-b44f707523c4""}"
2014-07-24,"{""abstract"": ""Allergan, the target of a $52 billion hostile bid, is linking stock and option grants to lofty profit goals. It is a bold tactic that should become a norm in M.&A., contends Robert Cyran of Reuters Breakingviews."", ""web_url"": ""https://dealbook.nytimes.com/2014/07/24/allergans-bosses-put-money-on-where-their-mouths-are/"", ""snippet"": ""Allergan, the target of a $52 billion hostile bid, is linking stock and option grants to lofty profit goals. It is a bold tactic that should become a norm in M.&A., contends Robert Cyran of Reuters Breakingviews."", ""lead_paragraph"": ""Allergan\u2018s bosses have put money where their mouths are."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/25/business/dbpix-allergan1/dbpix-allergan1-articleLarge.jpg"", ""height"": 444, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/07/25/business/dbpix-allergan1/dbpix-allergan1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 444}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/25/business/dbpix-allergan1/dbpix-allergan1-jumbo.jpg"", ""height"": 757, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/25/business/dbpix-allergan1/dbpix-allergan1-superJumbo.jpg"", ""height"": 1036, ""width"": 1401, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/25/business/dbpix-allergan1/dbpix-allergan1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/07/25/business/dbpix-allergan1/dbpix-allergan1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/25/business/dbpix-allergan1/dbpix-allergan1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Botox Maker\u2019s Bosses Put Money Where Their Mouths Are"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Executive Compensation"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Valeant Pharmaceuticals International Inc"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2014-07-24T16:04:36+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Robert Cyran"", ""person"": [{""firstname"": ""Robert"", ""middlename"": null, ""lastname"": ""Cyran"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/7c1279c1-aa77-511a-8b4f-49a8ae1e1532"", ""word_count"": 385, ""uri"": ""nyt://article/7c1279c1-aa77-511a-8b4f-49a8ae1e1532""}"
2014-07-25,"{""abstract"": ""How AbbVie came to win Shire demonstrates that even in the middle of a new boom in mergers and acquisitions, a hefty premium is no guarantee of success."", ""web_url"": ""https://dealbook.nytimes.com/2014/07/24/to-woo-shire-abbvie-trod-cautiously-in-takeover-bid/"", ""snippet"": ""How AbbVie came to win Shire demonstrates that even in the middle of a new boom in mergers and acquisitions, a hefty premium is no guarantee of success."", ""lead_paragraph"": ""Susan Kilsby had not been chairwoman of the drug maker Shire for even a week when she received an office call that would set off a frenzied trans-Atlantic courtship."", ""print_section"": ""B"", ""print_page"": ""6"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/25/business/Drug/Drug-articleLarge.jpg"", ""height"": 394, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/07/25/business/Drug/Drug-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 394}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/25/business/Drug/Drug-jumbo.jpg"", ""height"": 673, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/25/business/Drug/Drug-superJumbo.jpg"", ""height"": 1345, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/25/business/Drug/Drug-thumbStandard-v2.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/07/25/business/Drug/Drug-thumbStandard-v2.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/25/business/Drug/Drug-thumbLarge-v2.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""To Woo Drug Maker Shire, AbbVie Trod Cautiously in Tax Inversion Bid"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""To Woo Shire, AbbVie Trod Cautiously in Takeover Bid"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Abbott Laboratories"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""JPMorgan Chase & Company"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Shire PLC"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2014-07-25T00:31:39+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By David Gelles"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Gelles"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/cbf63f2d-f877-5c94-9bd6-9fd139d09c84"", ""word_count"": 1129, ""uri"": ""nyt://article/cbf63f2d-f877-5c94-9bd6-9fd139d09c84""}"
2014-07-30,"{""abstract"": ""The British drug maker said it would initially pay $875 million for the rights to the drugs, and up to $1.22 billion more if development and sales milestones are met."", ""web_url"": ""https://dealbook.nytimes.com/2014/07/30/astrazeneca-to-pay-up-to-2-1-billion-for-respiratory-drugs/"", ""snippet"": ""The British drug maker said it would initially pay $875 million for the rights to the drugs, and up to $1.22 billion more if development and sales milestones are met."", ""lead_paragraph"": ""Updated, 9:30 a.m. | LONDON \u2013 AstraZeneca of Britain said on Wednesday that it had agreed to pay up to $2.1 billion for a slate of respiratory drugs from the Spanish drug maker Almirall."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/31/business/dbpix-astrazeneca/dbpix-astrazeneca-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/07/31/business/dbpix-astrazeneca/dbpix-astrazeneca-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/31/business/dbpix-astrazeneca/dbpix-astrazeneca-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/31/business/dbpix-astrazeneca/dbpix-astrazeneca-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/31/business/dbpix-astrazeneca/dbpix-astrazeneca-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/07/31/business/dbpix-astrazeneca/dbpix-astrazeneca-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/31/business/dbpix-astrazeneca/dbpix-astrazeneca-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""AstraZeneca to Pay Almirall Up to $2.1 Billion for Respiratory Drugs"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Chronic Obstructive Pulmonary Disease"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Respiratory Diseases"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Almirall SA"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Baxter International"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""GlaxoSmithKline PLC"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 10, ""major"": ""N""}], ""pub_date"": ""2014-07-30T09:20:13+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chad Bray"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/3500a053-4cec-5aee-b1d3-88db49252df6"", ""word_count"": 356, ""uri"": ""nyt://article/3500a053-4cec-5aee-b1d3-88db49252df6""}"
2014-09-02,"{""abstract"": ""Public pension funds have major stakes in American companies moving overseas to cut their tax bills. But they are saying little about the strategy, which could hurt the nation\u2019s tax base."", ""web_url"": ""https://dealbook.nytimes.com/2014/09/01/public-pension-funds-stay-mum-on-corporate-expats/"", ""snippet"": ""Public pension funds have major stakes in American companies moving overseas to cut their tax bills. But they are saying little about the strategy, which could hurt the nation\u2019s tax base."", ""lead_paragraph"": ""In the outcry about the recent merger mania to take advantage of the tax avoidance transactions known as inversions, certain key players have been notably silent: public pension funds."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/01/business/dealbook/dbpix-simpson/dbpix-simpson-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/09/01/business/dealbook/dbpix-simpson/dbpix-simpson-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/01/business/dealbook/dbpix-simpson/dbpix-simpson-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/01/business/dealbook/dbpix-simpson/dbpix-simpson-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/01/business/dealbook/dbpix-simpson/dbpix-simpson-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/09/01/business/dealbook/dbpix-simpson/dbpix-simpson-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/01/business/dealbook/dbpix-simpson/dbpix-simpson-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Public Pension Funds Stay Mum on Corporate Expats"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Staying Mum on Corporate Expats"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Pensions and Retirement Plans"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tax Shelters"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Burger King Corp"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Covidien plc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Medtronic Inc"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Shire PLC"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Tim Hortons"", ""rank"": 11, ""major"": ""N""}], ""pub_date"": ""2014-09-02T01:05:36+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Ross Sorkin"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": ""Ross"", ""lastname"": ""Sorkin"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/aeace868-deae-52b3-84a2-f22a8cfd25ee"", ""word_count"": 1192, ""uri"": ""nyt://article/aeace868-deae-52b3-84a2-f22a8cfd25ee""}"
2014-09-23,"{""abstract"": ""Some American-led transactions may survive on strategic logic. But pure tax-avoiding combinations look tricky, Neil Unmack and Robert Cyran of Reuters Breakingviews write."", ""web_url"": ""https://dealbook.nytimes.com/2014/09/23/u-s-curbs-on-inversions-may-deter-some-pharmaceutical-deals/"", ""snippet"": ""Some American-led transactions may survive on strategic logic. But pure tax-avoiding combinations look tricky, Neil Unmack and Robert Cyran of Reuters Breakingviews write."", ""lead_paragraph"": ""The clampdown by the United States on tax-driven cross-border mergers and acquisitions should deter half-baked pharmaceutical deals. Some American-led transactions, like AbbVie\u2019s recent agreement to buy its British rival Shire, may survive on strategic logic. But pure tax-avoiding combinations look tricky."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/24/business/dbpix-shire/dbpix-shire-articleLarge.jpg"", ""height"": 382, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/09/24/business/dbpix-shire/dbpix-shire-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 382}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/24/business/dbpix-shire/dbpix-shire-jumbo.jpg"", ""height"": 653, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/24/business/dbpix-shire/dbpix-shire-superJumbo.jpg"", ""height"": 1305, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/24/business/dbpix-shire/dbpix-shire-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/09/24/business/dbpix-shire/dbpix-shire-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/24/business/dbpix-shire/dbpix-shire-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""U.S. Curbs on Inversions May Deter Some Pharmaceutical Deals"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Taxation"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Covidien plc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Medtronic Inc"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Shire PLC"", ""rank"": 10, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""United States"", ""rank"": 11, ""major"": ""N""}], ""pub_date"": ""2014-09-23T19:16:58+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Neil Unmack and Robert Cyran"", ""person"": [{""firstname"": ""Neil"", ""middlename"": null, ""lastname"": ""Unmack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Robert"", ""middlename"": null, ""lastname"": ""Cyran"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/969361d7-4dca-50d8-863c-77f15acebf4e"", ""word_count"": 383, ""uri"": ""nyt://article/969361d7-4dca-50d8-863c-77f15acebf4e""}"
2014-10-04,"{""abstract"": ""Companies like Allergan, Valeant, Salix, Actavis and Medtronic are riding a wave of cheap debt and pent-up demand in a slew of recent acquisitions or attempted acquisitions."", ""web_url"": ""https://dealbook.nytimes.com/2014/10/03/a-scramble-to-acquire-for-drug-companies/"", ""snippet"": ""Companies like Allergan, Valeant, Salix, Actavis and Medtronic are riding a wave of cheap debt and pent-up demand in a slew of recent acquisitions or attempted acquisitions."", ""lead_paragraph"": ""A chain reaction of deal-making and acquisition talks is continuing to reshape the pharmaceutical industry, with a handful of big companies jostling to outmaneuver their competitors."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/04/business/04drug-jp/04drug-jp-articleLarge-v2.jpg"", ""height"": 399, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/10/04/business/04drug-jp/04drug-jp-articleLarge-v2.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 399}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/04/business/04drug-jp/04drug-jp-jumbo-v2.jpg"", ""height"": 682, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/04/business/04drug-jp/04drug-jp-superJumbo-v2.jpg"", ""height"": 1363, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/04/business/04drug-jp/04drug-jp-thumbStandard-v2.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/10/04/business/04drug-jp/04drug-jp-thumbStandard-v2.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/04/business/04drug-jp/04drug-jp-thumbLarge-v2.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""A Scramble to Acquire for Drug Companies"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""A Scramble to Acquire for Drug Companies"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Covidien plc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Medtronic Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pershing Square Capital Management"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Salix Pharmaceuticals Ltd"", ""rank"": 9, ""major"": ""N""}], ""pub_date"": ""2014-10-04T01:23:52+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By David Gelles"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Gelles"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/04e4e168-9d4b-5331-93ea-3d30f5dda513"", ""word_count"": 845, ""uri"": ""nyt://article/04e4e168-9d4b-5331-93ea-3d30f5dda513""}"
2014-10-14,"{""abstract"": ""Already, 2014 ranks as the busiest year for failed mergers since 2008, data from Thomson Reuters shows."", ""web_url"": ""https://dealbook.nytimes.com/2014/10/14/an-ill-fated-bid-for-t-mobile-is-the-latest-in-a-year-of-failed-deals/"", ""snippet"": ""Already, 2014 ranks as the busiest year for failed mergers since 2008, data from Thomson Reuters shows."", ""lead_paragraph"": ""Bankers who advise on mergers and acquisitions have had plenty of assignments this year. It\u2019s just that a large portion of their advice is being spent on deals that fail to materialize."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/14/business/dbpix-mobile2/dbpix-mobile2-articleLarge.jpg"", ""height"": 385, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/10/14/business/dbpix-mobile2/dbpix-mobile2-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 385}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/14/business/dbpix-mobile2/dbpix-mobile2-jumbo.jpg"", ""height"": 658, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/14/business/dbpix-mobile2/dbpix-mobile2-superJumbo.jpg"", ""height"": 1315, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/14/business/dbpix-mobile2/dbpix-mobile2-thumbStandard-v2.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/10/14/business/dbpix-mobile2/dbpix-mobile2-thumbStandard-v2.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/14/business/dbpix-mobile2/dbpix-mobile2-thumbLarge-v2.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""An Ill-Fated Bid for T-Mobile US is the Latest in a Year of Failed Deals"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Telephones and Telecommunications"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Wireless Communications"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Iliad SA"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""T-Mobile US Inc"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Thomson Reuters Corporation"", ""rank"": 9, ""major"": ""N""}], ""pub_date"": ""2014-10-14T15:56:42+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By William Alden"", ""person"": [{""firstname"": ""William"", ""middlename"": null, ""lastname"": ""Alden"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/bbcbf985-3738-59dc-8717-5f434754cd6b"", ""word_count"": 335, ""uri"": ""nyt://article/bbcbf985-3738-59dc-8717-5f434754cd6b""}"
2014-10-15,"[{""abstract"": ""Shares of Shire tumble in London trading amid fears that a $54 billion deal \u2014 the biggest takeover this year \u2014 is in trouble."", ""web_url"": ""https://dealbook.nytimes.com/2014/10/15/shire-urges-abbvie-to-pursue-merger-despite-new-inversion-rules/"", ""snippet"": ""Shares of Shire tumble in London trading amid fears that a $54 billion deal \u2014 the biggest takeover this year \u2014 is in trouble."", ""lead_paragraph"": ""LONDON\u00a0\u2014 A day after the American drug maker\u00a0AbbVie disclosed that it was having second thoughts about its planned acquisition of Shire,\u00a0the Irish drug maker urged it to pursue the $54 billion deal."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/16/business/dbpix-abbvie1b/dbpix-abbvie1b-articleLarge-v2.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/10/16/business/dbpix-abbvie1b/dbpix-abbvie1b-articleLarge-v2.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/16/business/dbpix-abbvie1b/dbpix-abbvie1b-jumbo-v2.jpg"", ""height"": 682, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/16/business/dbpix-abbvie1b/dbpix-abbvie1b-superJumbo-v2.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/16/business/dbpix-abbvie1b/dbpix-abbvie1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/10/16/business/dbpix-abbvie1b/dbpix-abbvie1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/16/business/dbpix-abbvie1b/dbpix-abbvie1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Shire Urges AbbVie to Pursue Merger Despite New Inversion Rules"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Lew, Jacob J"", ""rank"": 4, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Obama, Barack"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Abbott Laboratories"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Covidien plc"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Medtronic Inc"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 11, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Salix Pharmaceuticals Ltd"", ""rank"": 12, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Shire PLC"", ""rank"": 13, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Steris Corporation"", ""rank"": 14, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Treasury Department"", ""rank"": 15, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Chicago (Ill)"", ""rank"": 16, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Ireland"", ""rank"": 17, ""major"": ""N""}], ""pub_date"": ""2014-10-15T09:05:01+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chad Bray"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/d371a12d-3e0f-5a4b-8a5b-771563f40bc5"", ""word_count"": 536, ""uri"": ""nyt://article/d371a12d-3e0f-5a4b-8a5b-771563f40bc5""}, {""abstract"": ""The American drug company\u2019s retreat, writes Neil Unmack of Reuters Breakingviews, will make it difficult for the board of any European company to approve an inversion bid in the future."", ""web_url"": ""https://dealbook.nytimes.com/2014/10/15/abbvies-u-turn-shows-shire-deal-was-driven-by-taxes/"", ""snippet"": ""The American drug company\u2019s retreat, writes Neil Unmack of Reuters Breakingviews, will make it difficult for the board of any European company to approve an inversion bid in the future."", ""lead_paragraph"": ""AbbVie\u2019s U-turn shows its Shire deal was mostly about tax breaks, after all."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/16/business/dbpix-abbvie-tablets/dbpix-abbvie-tablets-articleLarge.jpg"", ""height"": 360, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/10/16/business/dbpix-abbvie-tablets/dbpix-abbvie-tablets-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 360}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/16/business/dbpix-abbvie-tablets/dbpix-abbvie-tablets-jumbo.jpg"", ""height"": 614, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/16/business/dbpix-abbvie-tablets/dbpix-abbvie-tablets-superJumbo.jpg"", ""height"": 1200, ""width"": 2000, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/16/business/dbpix-abbvie-tablets/dbpix-abbvie-tablets-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/10/16/business/dbpix-abbvie-tablets/dbpix-abbvie-tablets-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/16/business/dbpix-abbvie-tablets/dbpix-abbvie-tablets-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""AbbVie\u2019s U-Turn Shows Shire Deal Was Driven by Taxes"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Shire PLC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Treasury Department"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2014-10-15T15:59:18+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Neil Unmack"", ""person"": [{""firstname"": ""Neil"", ""middlename"": null, ""lastname"": ""Unmack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/c1e1c3fc-3338-5e8f-a5dc-ca3ab37a8520"", ""word_count"": 378, ""uri"": ""nyt://article/c1e1c3fc-3338-5e8f-a5dc-ca3ab37a8520""}]"
2014-10-29,"{""abstract"": ""The strain, known as serogroup B meningitis, infected students at Princeton and the University of California, Santa Barbara last year."", ""web_url"": ""https://www.nytimes.com/2014/10/30/business/fda-approves-vaccine-for-rare-meningitis.html"", ""snippet"": ""The strain, known as serogroup B meningitis, infected students at Princeton and the University of California, Santa Barbara last year."", ""lead_paragraph"": ""The Food and Drug Administration said on Wednesday that it had approved a vaccine for a dangerous strain of meningitis that caused outbreaks last year at Princeton and the University of California, Santa Barbara."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""F.D.A. Approves Pfizer\u2019s Trumenba, a Vaccine for a Rare Meningitis"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""F.D.A. Approves Vaccine for Rare Meningitis"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Meningitis"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Thomas, Katie"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Vaccination and Immunization"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2014-10-29T22:34:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Katie Thomas"", ""person"": [{""firstname"": ""Katie"", ""middlename"": null, ""lastname"": ""Thomas"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/307873ee-28e7-5ff8-8574-c85c23d4d8d6"", ""word_count"": 464, ""uri"": ""nyt://article/307873ee-28e7-5ff8-8574-c85c23d4d8d6""}"
2014-11-11,"{""abstract"": ""The activist investor William A. Ackman has acquired an 8.5 percent economic interest in the former animal health arm of Pfizer."", ""web_url"": ""https://dealbook.nytimes.com/2014/11/11/zoetis-an-animal-health-company-says-ackman-has-taken-a-stake/"", ""snippet"": ""The activist investor William A. Ackman has acquired an 8.5 percent economic interest in the former animal health arm of Pfizer."", ""lead_paragraph"": ""The activist investor William A. Ackman appears to have found yet another target for his hedge fund in the health care industry: Zoetis, the former animal health arm of Pfizer that is now a $21.8 billion publicly traded company."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/11/12/business/dbpix-zoetis3/dbpix-zoetis3-articleLarge.png"", ""height"": 720, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/11/12/business/dbpix-zoetis3/dbpix-zoetis3-articleLarge.png"", ""xlargewidth"": 600, ""xlargeheight"": 720}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/11/12/business/dbpix-zoetis3/dbpix-zoetis3-jumbo.png"", ""height"": 1024, ""width"": 854, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/11/12/business/dbpix-zoetis3/dbpix-zoetis3-superJumbo.png"", ""height"": 1249, ""width"": 1041, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/11/12/business/dbpix-zoetis3/dbpix-zoetis3-thumbStandard.png"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/11/12/business/dbpix-zoetis3/dbpix-zoetis3-thumbStandard.png"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/11/12/business/dbpix-zoetis3/dbpix-zoetis3-thumbLarge.png"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Zoetis, an Animal Health Company, Says Ackman Has Taken a Stake"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Ackman, William A"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pershing Square Capital Management"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Sachem Head Capital Management"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Zoetis Inc"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2014-11-11T22:28:54+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Michael J. de la Merced"", ""person"": [{""firstname"": ""Michael"", ""middlename"": ""J."", ""lastname"": ""de la Merced"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/2244ab10-52dc-57ee-9e96-0c68f182a801"", ""word_count"": 307, ""uri"": ""nyt://article/2244ab10-52dc-57ee-9e96-0c68f182a801""}"
2014-11-13,"{""abstract"": ""Groups including the Bill & Melinda Gates Foundation aim to help bring an easier-to-inject form of Depo-Provera to 69 countries."", ""web_url"": ""https://www.nytimes.com/2014/11/14/business/pfizer-and-aid-groups-team-up-on-depo-provera-for-developing-world.html"", ""snippet"": ""Groups including the Bill & Melinda Gates Foundation aim to help bring an easier-to-inject form of Depo-Provera to 69 countries."", ""lead_paragraph"": ""Depo-Provera, an injectable contraceptive given once every three months, is already a popular choice of women in developing countries, who value the convenience and discretion of not having to take a daily birth control pill."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/11/14/business/Pfizer/Pfizer-articleLarge.jpg"", ""height"": 403, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/11/14/business/Pfizer/Pfizer-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 403}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/11/14/business/Pfizer/Pfizer-jumbo.jpg"", ""height"": 688, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/11/14/business/Pfizer/Pfizer-superJumbo.jpg"", ""height"": 1376, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/11/14/business/Pfizer/Pfizer-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/11/14/business/Pfizer/Pfizer-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/11/14/business/Pfizer/Pfizer-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer and Aid Groups Team Up on Contraceptive for Developing World"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer and Aid Groups Team Up on Contraceptive for Developing World"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Thomas, Katie"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Birth Control and Family Planning"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Third World and Developing Countries"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Gates, Bill and Melinda, Foundation"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2014-11-13T15:01:08+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Katie Thomas"", ""person"": [{""firstname"": ""Katie"", ""middlename"": null, ""lastname"": ""Thomas"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/730b9e57-68da-5ff9-b895-136d23058aee"", ""word_count"": 600, ""uri"": ""nyt://article/730b9e57-68da-5ff9-b895-136d23058aee""}"
2014-11-17,"{""abstract"": ""The alliance between the American and German companies is expected to strengthen Merck\u2019s oncology business in several important markets, including the United States."", ""web_url"": ""https://dealbook.nytimes.com/2014/11/17/pfizer-to-pay-up-to-2-9-billion-in-cancer-drug-deal-with-merck-of-germany/"", ""snippet"": ""The alliance between the American and German companies is expected to strengthen Merck\u2019s oncology business in several important markets, including the United States."", ""lead_paragraph"": ""LONDON \u2014 Merck of Germany said on Monday that the American drug giant Pfizer had agreed to pay $850 million upfront and as much as $2 billion later in a deal to jointly develop one of Merck\u2019s cancer drugs."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer to Pay up to $2.9 Billion in Cancer Drug Deal With Merck of Germany"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Cancer"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck of Germany"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Germany"", ""rank"": 7, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""United States"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2014-11-17T10:32:21+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chad Bray"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/33223746-b95c-55ec-8365-355da0986132"", ""word_count"": 415, ""uri"": ""nyt://article/33223746-b95c-55ec-8365-355da0986132""}"
2014-12-08,"{""abstract"": ""The deal will give Merck, the second-largest American drug maker after Pfizer, control of the largest antibiotics company, and deepen its ties with hospitals."", ""web_url"": ""https://dealbook.nytimes.com/2014/12/08/merck-agrees-to-acquire-drug-maker-cubist-for-9-5-billion/"", ""snippet"": ""The deal will give Merck, the second-largest American drug maker after Pfizer, control of the largest antibiotics company, and deepen its ties with hospitals."", ""lead_paragraph"": ""Deal making in the health care industry has been booming all year, with medical technology companies and cosmetic drug makers changing hands at rich premiums."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/09/business/Drug/Drug-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/12/09/business/Drug/Drug-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/09/business/Drug/Drug-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/09/business/Drug/Drug-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/09/business/Drug/Drug-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/12/09/business/Drug/Drug-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/09/business/Drug/Drug-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Merck in $8.4 Billion Deal for Cubist, Big Maker of Antibiotics"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Merck in Deal for Big Maker of Antibiotics"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Biotechnology and Bioengineering"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Cubist Pharmaceuticals Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2014-12-08T12:53:59+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By David Gelles"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Gelles"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/d7ab937e-c988-5d8e-a3ba-2a9d72be2698"", ""word_count"": 970, ""uri"": ""nyt://article/d7ab937e-c988-5d8e-a3ba-2a9d72be2698""}"
2015-01-09,"{""abstract"": ""In search of an alternative to hearing aids or implants, some report success in early trials for drugs to improve hearing or silence tinnitus."", ""web_url"": ""https://www.nytimes.com/2015/01/10/business/ear-disorders-long-neglected-attract-drug-makers-attention-.html"", ""snippet"": ""In search of an alternative to hearing aids or implants, some report success in early trials for drugs to improve hearing or silence tinnitus."", ""lead_paragraph"": ""Driving to a meeting in 2008, Jay Lichter, a venture capitalist, suddenly became so dizzy he had to pull over and call a friend to take him to the emergency room."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/01/10/business/10ear-web1/10ear-web1-articleLarge-v2.jpg"", ""height"": 411, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/01/10/business/10ear-web1/10ear-web1-articleLarge-v2.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 411}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/01/10/business/10ear-web1/10ear-web1-jumbo-v2.jpg"", ""height"": 702, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/01/10/business/10ear-web1/10ear-web1-superJumbo-v2.jpg"", ""height"": 1405, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/01/10/business/10ear-web1/10ear-web1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/01/10/business/10ear-web1/10ear-web1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/01/10/business/10ear-web1/10ear-web1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""From Vertigo to Tinnitus, Ear Ailments Are New Focus for Drugs  "", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Music to the Ears"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Ears and Hearing"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Otonomy Inc."", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Auris Medical Holding A.G."", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Clinical Trials"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Start-ups"", ""rank"": 8, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tinnitus"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Roche Holding AG"", ""rank"": 11, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""GlaxoSmithKline PLC"", ""rank"": 12, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Avalon Ventures Limited"", ""rank"": 13, ""major"": ""N""}], ""pub_date"": ""2015-01-09T20:31:58+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/77297f1a-2dbd-57a9-a2e9-8e4a55b021e0"", ""word_count"": 1501, ""uri"": ""nyt://article/77297f1a-2dbd-57a9-a2e9-8e4a55b021e0""}"
2015-02-05,"[{""abstract"": ""In its offer to buy Hospira, Pfizer is paying richly for what it believes will be a lucrative source of future revenue, drugs known as biosimilars."", ""web_url"": ""https://dealbook.nytimes.com/2015/02/05/pfizer-to-buy-hospira-a-drug-maker-for-15-2-billion-in-cash/"", ""snippet"": ""In its offer to buy Hospira, Pfizer is paying richly for what it believes will be a lucrative source of future revenue, drugs known as biosimilars."", ""lead_paragraph"": ""Pfizer is making a $15.2 billion bet on the drug industry\u2019s new, more elite class of generics: costly, complex copies of already expensive biotech drugs."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/02/06/business/06DRUG/06DRUG-articleLarge.jpg"", ""height"": 415, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/02/06/business/06DRUG/06DRUG-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 415}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/02/06/business/06DRUG/06DRUG-jumbo.jpg"", ""height"": 708, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/02/06/business/06DRUG/06DRUG-superJumbo.jpg"", ""height"": 1417, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/02/06/business/06DRUG/06DRUG-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/02/06/business/06DRUG/06DRUG-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/02/06/business/06DRUG/06DRUG-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer Bets $15 Billion on New Class of Generic Drugs"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Pfizer Bets $15 Billion on New Sort of Generics"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Biotechnology and Bioengineering"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Generic Brands and Products"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Hospira Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2015-02-05T12:24:35+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By David Gelles and Katie Thomas"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Gelles"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Katie"", ""middlename"": null, ""lastname"": ""Thomas"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/57e135c7-12dd-5648-bf61-1c5c50c8908a"", ""word_count"": 1188, ""uri"": ""nyt://article/57e135c7-12dd-5648-bf61-1c5c50c8908a""}, {""abstract"": ""The pharmaceutical giant\u2019s $15 billion purchase of Hospira should bolster Pfizer\u2019s own generics unit \u2013 and open the way for spinning it off, says Robert Cyran of Reuters Breakingviews."", ""web_url"": ""https://dealbook.nytimes.com/2015/02/05/a-deal-that-could-reverse-pfizers-history-of-value-destroying-acquisitions/"", ""snippet"": ""The pharmaceutical giant\u2019s $15 billion purchase of Hospira should bolster Pfizer\u2019s own generics unit \u2013 and open the way for spinning it off, says Robert Cyran of Reuters Breakingviews."", ""lead_paragraph"": ""Pfizer has made more than its share of value-destroying acquisitions. The pharmaceutical giant\u2019s $15.2 billion purchase of Hospira could reverse that history. The injectable-drug maker\u2019s strength in non-branded medications should bolster Pfizer\u2019s own generics unit \u2013 and open the way for spinning it off."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/02/06/business/dbpix-drug-hospira1/dbpix-drug-hospira1-articleLarge.jpg"", ""height"": 800, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/02/06/business/dbpix-drug-hospira1/dbpix-drug-hospira1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 800}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/02/06/business/dbpix-drug-hospira1/dbpix-drug-hospira1-jumbo.jpg"", ""height"": 1024, ""width"": 768, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/02/06/business/dbpix-drug-hospira1/dbpix-drug-hospira1-superJumbo.jpg"", ""height"": 2048, ""width"": 1536, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/02/06/business/dbpix-drug-hospira1/dbpix-drug-hospira1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/02/06/business/dbpix-drug-hospira1/dbpix-drug-hospira1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/02/06/business/dbpix-drug-hospira1/dbpix-drug-hospira1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""A Deal That Could Reverse Pfizer\u2019s History of Value-Destroying Acquisitions"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Biotechnology and Bioengineering"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Read, Ian C"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Hospira Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Warner-Lambert Co"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2015-02-05T19:10:05+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Robert Cyran"", ""person"": [{""firstname"": ""Robert"", ""middlename"": null, ""lastname"": ""Cyran"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/cd398e20-7b2f-5253-bf0a-cf664131cecc"", ""word_count"": 383, ""uri"": ""nyt://article/cd398e20-7b2f-5253-bf0a-cf664131cecc""}, {""abstract"": ""In what might be called \u201ctransaction Thursday,\u201d some $25.7 billion of deals were recorded, according to Thomson Reuters, including Pfizer\u2019s purchase of Hospira and BT\u2019s acquisition of the mobile carrier EE."", ""web_url"": ""https://dealbook.nytimes.com/2015/02/05/pfizer-deal-and-other-mergers-show-a-case-of-the-mondays-on-a-thursday/"", ""snippet"": ""In what might be called \u201ctransaction Thursday,\u201d some $25.7 billion of deals were recorded, according to Thomson Reuters, including Pfizer\u2019s purchase of Hospira and BT\u2019s acquisition of the mobile carrier EE."", ""lead_paragraph"": ""Wall Street has a late-in-the-week case of the Mondays."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/02/06/business/dbpix-drug-thursday1/dbpix-drug-thursday1-articleLarge.jpg"", ""height"": 435, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/02/06/business/dbpix-drug-thursday1/dbpix-drug-thursday1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 435}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/02/06/business/dbpix-drug-thursday1/dbpix-drug-thursday1-jumbo.jpg"", ""height"": 743, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/02/06/business/dbpix-drug-thursday1/dbpix-drug-thursday1-superJumbo.jpg"", ""height"": 1486, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/02/06/business/dbpix-drug-thursday1/dbpix-drug-thursday1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/02/06/business/dbpix-drug-thursday1/dbpix-drug-thursday1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/02/06/business/dbpix-drug-thursday1/dbpix-drug-thursday1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer Deal and Other Mergers Show a Case of the Mondays, on a Thursday"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Ball Corporation"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""BT Group PLC"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""EE Ltd"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Hospira Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2015-02-05T19:12:34+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By William Alden"", ""person"": [{""firstname"": ""William"", ""middlename"": null, ""lastname"": ""Alden"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/4169eb8b-d302-52f9-b45d-4cb565c28e98"", ""word_count"": 351, ""uri"": ""nyt://article/4169eb8b-d302-52f9-b45d-4cb565c28e98""}]"
2015-02-06,"{""abstract"": ""RadioShack files for bankruptcy. | Ally Financial is looking to ramp up performance. | Pfizer makes a big bet on a new class of generics. | Dysfunction continues at GFI."", ""web_url"": ""https://dealbook.nytimes.com/2015/02/06/morning-agenda-radioshacks-bankruptcy-filing/"", ""snippet"": ""RadioShack files for bankruptcy. | Ally Financial is looking to ramp up performance. | Pfizer makes a big bet on a new class of generics. | Dysfunction continues at GFI."", ""lead_paragraph"": ""RADIOSHACK FILES FOR BANKRUPTCY | RadioShack has filed for bankruptcy, but is poised to live on in a diminished form, Rebecca R. Ruiz and Michael J. de la Merced report in DealBook. The Chapter 11 filing, in federal bankruptcy court in Delaware on Thursday, had long been expected for the 94-year-old electronics retailer, which has not been profitable since 2011. "", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Morning Agenda: RadioShack\u2019s Bankruptcy Filing"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2015-02-06T12:11:02+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Sydney Ember"", ""person"": [{""firstname"": ""Sydney"", ""middlename"": null, ""lastname"": ""Ember"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/de94c176-70e0-58d8-ab49-469dee2e3227"", ""word_count"": 2141, ""uri"": ""nyt://article/de94c176-70e0-58d8-ab49-469dee2e3227""}"
2015-03-20,"{""abstract"": ""The drug, developed by Biogen Idec, could achieve sales of billions of dollars a year if the results from the small trial are replicated in larger trials."", ""web_url"": ""https://www.nytimes.com/2015/03/21/business/alzheimers-drug-trial-shows-cognitive-decline-sharply-slowed.html"", ""snippet"": ""The drug, developed by Biogen Idec, could achieve sales of billions of dollars a year if the results from the small trial are replicated in larger trials."", ""lead_paragraph"": ""An experimental drug for Alzheimer\u2019s disease sharply slowed the decline in mental function in a small clinical trial, researchers reported Friday, reviving hopes for an approach to therapy that until now has experienced repeated failures."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Biogen Reports Its Alzheimer\u2019s Drug Sharply Slowed Cognitive Decline"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Alzheimer\u2019s Drug Shows Promise in a Trial"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Alzheimer's Disease"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Biogen Idec Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Clinical Trials"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Dementia"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Eli Lilly and Company"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Johnson & Johnson"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Roche Holding AG"", ""rank"": 10, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Nice (France)"", ""rank"": 11, ""major"": ""N""}], ""pub_date"": ""2015-03-20T09:34:55+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/c8a818a6-fb97-57ec-b941-e937035b4b44"", ""word_count"": 999, ""uri"": ""nyt://article/c8a818a6-fb97-57ec-b941-e937035b4b44""}"
2015-04-27,"{""abstract"": ""Swedish Orphan Biovitrum, which makes the ReFacto AF treatment for hemophilia for Pfizer, received a preliminary offer from an undisclosed suitor."", ""web_url"": ""https://www.nytimes.com/2015/04/28/business/dealbook/swedish-orphan-biovitrum-deal.html"", ""snippet"": ""Swedish Orphan Biovitrum, which makes the ReFacto AF treatment for hemophilia for Pfizer, received a preliminary offer from an undisclosed suitor."", ""lead_paragraph"": ""LONDON \u2014 The biopharmaceutical maker Swedish Orphan Biovitrum said on Monday that it had received a preliminary takeover offer from an unnamed suitor."", ""print_section"": ""B"", ""print_page"": ""5"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Sobi, Swedish Maker of Drugs for Rare Diseases, Receives Takeover Bid"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Sobi Gets Offer"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Swedish Orphan Biovitrum AB (Sobi)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Bray, Chad"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2015-04-27T11:09:03+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Chad Bray"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/82fd7f59-5516-5686-86da-a8553865661c"", ""word_count"": 200, ""uri"": ""nyt://article/82fd7f59-5516-5686-86da-a8553865661c""}"
2015-06-02,"{""abstract"": ""If companies are going to fight activist investors who call for breakups or spinoffs, they should also be more honest about downsides of mergers."", ""web_url"": ""https://www.nytimes.com/2015/06/03/business/dealbook/breaking-up-companies-creates-extensive-costs-too.html"", ""snippet"": ""If companies are going to fight activist investors who call for breakups or spinoffs, they should also be more honest about downsides of mergers."", ""lead_paragraph"": ""Acquisitive corporate chieftains love to talk about \u201csynergies\u201d from the deals they\u2019re planning while they de-emphasize costs. On the flip side, managers who are trying to resist pressure to split their companies may overstate the \u201cdis-synergies\u201d such moves would create, but such costs are still real."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Breaking Up Companies Creates Extensive Costs, Too"", ""kicker"": ""Breakingviews"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""JPMorgan Chase & Company"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}], ""pub_date"": ""2015-06-02T18:11:54+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Robert Cyran and Richard Beales"", ""person"": [{""firstname"": ""Robert"", ""middlename"": null, ""lastname"": ""Cyran"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Richard"", ""middlename"": null, ""lastname"": ""Beales"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/1a6c5508-6c52-531b-add0-4c306893a29a"", ""word_count"": 371, ""uri"": ""nyt://article/1a6c5508-6c52-531b-add0-4c306893a29a""}"
2015-07-01,"{""abstract"": ""Four executives of leading health care organizations are members of the board of the U.S. Chamber of Commerce, which is engaged in a worldwide campaign to thwart antismoking laws."", ""web_url"": ""https://www.nytimes.com/2015/07/02/business/international/many-board-members-fight-smoking-even-as-chamber-opposes-tobacco-laws.html"", ""snippet"": ""Four executives of leading health care organizations are members of the board of the U.S. Chamber of Commerce, which is engaged in a worldwide campaign to thwart antismoking laws."", ""lead_paragraph"": ""Anthem, one of the nation\u2019s largest health insurers, wants its members to stop smoking."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/07/02/business/02smoke-web/02smoke-web-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/07/02/business/02smoke-web/02smoke-web-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/07/02/business/02smoke-web/02smoke-web-jumbo.jpg"", ""height"": 682, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/07/02/business/02smoke-web/02smoke-web-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/07/02/business/02smoke-web/02smoke-web-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/07/02/business/02smoke-web/02smoke-web-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/07/02/business/02smoke-web/02smoke-web-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""U.S. Chamber Fights Smoking Laws While Hospitals and Insurers Sit on Its Board"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Dissonance in Mission of Chamber on Tobacco"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Hakim, Danny"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Smoking and Tobacco"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""United States Chamber of Commerce"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Health Insurance and Managed Care"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Hospitals"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Lobbying and Lobbyists"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Burson-Marsteller Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALTRIA GROUP INC"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Philip Morris Companies Inc"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 10, ""major"": ""N""}], ""pub_date"": ""2015-07-01T09:00:07+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""International Business"", ""byline"": {""original"": ""By Danny Hakim"", ""person"": [{""firstname"": ""Danny"", ""middlename"": null, ""lastname"": ""Hakim"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/4402a9a6-9e32-5d5b-966e-2b676a3f06de"", ""word_count"": 1560, ""uri"": ""nyt://article/4402a9a6-9e32-5d5b-966e-2b676a3f06de""}"
2015-10-14,"{""abstract"": ""The Pfizer chemist helped create the antidepressant that has been used to treat more than 100 million people and has generated sales of more than $3 billion."", ""web_url"": ""https://www.nytimes.com/2015/10/14/business/kenneth-koe-co-inventor-behind-zoloft-dies-at-90.html"", ""snippet"": ""The Pfizer chemist helped create the antidepressant that has been used to treat more than 100 million people and has generated sales of more than $3 billion."", ""lead_paragraph"": ""Kenneth Koe, an inventor of Zoloft, the antidepressant that has helped tens of millions of people since it was introduced a quarter-century ago, died on Oct. 7 in Shrewsbury, Mass. He was 90."", ""print_section"": ""A"", ""print_page"": ""22"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/10/14/business/11KOE-OBIT/11KOE-OBIT-articleLarge.jpg"", ""height"": 413, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/10/14/business/11KOE-OBIT/11KOE-OBIT-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 413}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/10/14/business/11KOE-OBIT/11KOE-OBIT-jumbo.jpg"", ""height"": 705, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/10/14/business/11KOE-OBIT/11KOE-OBIT-superJumbo.jpg"", ""height"": 1409, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/10/14/business/11KOE-OBIT/11KOE-OBIT-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/10/14/business/11KOE-OBIT/11KOE-OBIT-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/10/14/business/11KOE-OBIT/11KOE-OBIT-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Kenneth Koe, an Inventor Behind Zoloft, Dies at 90"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Kenneth Koe, an Inventor Behind Zoloft, Dies at 90"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Deaths (Obituaries)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Fox, Margalit"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Zoloft (Drug)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Koe, Kenneth (1925-2015)"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2015-10-14T02:29:53+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Margalit Fox"", ""person"": [{""firstname"": ""Margalit"", ""middlename"": null, ""lastname"": ""Fox"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""Obituary (Obit)"", ""_id"": ""nyt://article/b8bcbe00-0de6-5369-aa77-89d929a68936"", ""word_count"": 555, ""uri"": ""nyt://article/b8bcbe00-0de6-5369-aa77-89d929a68936""}"
2015-10-29,"[{""abstract"": ""Pfizer, one of America\u2019s oldest drug makers, is again looking to renounce its corporate citizenship by buying a foreign rival."", ""web_url"": ""https://www.nytimes.com/2015/10/30/business/dealbook/allergan-pfizer-deal.html"", ""snippet"": ""Pfizer, one of America\u2019s oldest drug makers, is again looking to renounce its corporate citizenship by buying a foreign rival."", ""lead_paragraph"": ""Pfizer has long played an important role in United States history over its 166 years, including producing painkillers during the Civil War and penicillin in World War II."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/10/30/business/db-drug-web2/db-drug-web2-articleLarge.jpg"", ""height"": 401, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/10/30/business/db-drug-web2/db-drug-web2-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 401}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/10/30/business/db-drug-web2/db-drug-web2-jumbo.jpg"", ""height"": 684, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/10/30/business/db-drug-web2/db-drug-web2-superJumbo.jpg"", ""height"": 1368, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/10/30/business/db-drug-web2/db-drug-web2-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/10/30/business/db-drug-web2/db-drug-web2-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/10/30/business/db-drug-web2/db-drug-web2-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer Bid for Allergan Has Its Eyes on Ireland"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer Bid for Allergan Has Its Eyes on Ireland"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Picker, Leslie"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""de la Merced, Michael J"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2015-10-29T14:05:25+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Michael J. de la Merced and Leslie Picker"", ""person"": [{""firstname"": ""Michael"", ""middlename"": ""J."", ""lastname"": ""de la Merced"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Leslie"", ""middlename"": null, ""lastname"": ""Picker"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/140b7e0c-9df8-5f60-9f7c-bb8e752a476d"", ""word_count"": 1090, ""uri"": ""nyt://article/140b7e0c-9df8-5f60-9f7c-bb8e752a476d""}, {""abstract"": ""Allergan can hold out for a good price. But if Pfizer puts up a premium of more than 25 percent, it will risk paying away the benefits of a deal."", ""web_url"": ""https://www.nytimes.com/2015/10/30/business/dealbook/pfizer-faces-challenges-in-pursuing-deal-for-a-lower-tax-rate.html"", ""snippet"": ""Allergan can hold out for a good price. But if Pfizer puts up a premium of more than 25 percent, it will risk paying away the benefits of a deal."", ""lead_paragraph"": ""There\u2019s no easy cure for tax."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/10/30/business/db-drug-web1/db-drug-web1-articleLarge.jpg"", ""height"": 508, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/10/30/business/db-drug-web1/db-drug-web1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 508}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/10/30/business/db-drug-web1/db-drug-web1-jumbo.jpg"", ""height"": 867, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/10/30/business/db-drug-web1/db-drug-web1-superJumbo.jpg"", ""height"": 1253, ""width"": 1480, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/10/30/business/db-drug-web1/db-drug-web1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/10/30/business/db-drug-web1/db-drug-web1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/10/30/business/db-drug-web1/db-drug-web1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer Faces Challenges in Pursuing Deal for a Lower Tax Rate"", ""kicker"": ""Breakingviews"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Federal Taxes (US)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""GlaxoSmithKline PLC"", ""rank"": 8, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Read, Ian C"", ""rank"": 9, ""major"": ""N""}], ""pub_date"": ""2015-10-29T16:43:38+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By John Foley"", ""person"": [{""firstname"": ""John"", ""middlename"": null, ""lastname"": ""Foley"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/4de024c5-722c-52a2-8e12-bdb90b4efdc4"", ""word_count"": 401, ""uri"": ""nyt://article/4de024c5-722c-52a2-8e12-bdb90b4efdc4""}, {""abstract"": ""Cheap capital, low interest rates and the challenges posed by the Affordable Care Act are driving health companies of all kinds, not just hospitals, to combine."", ""web_url"": ""https://www.nytimes.com/2015/10/30/business/dealbook/health-care-companies-in-merger-frenzy.html"", ""snippet"": ""Cheap capital, low interest rates and the challenges posed by the Affordable Care Act are driving health companies of all kinds, not just hospitals, to combine."", ""lead_paragraph"": ""In a fast-paced financial version of musical chairs, health care companies of all kinds \u2014 drug makers, hospital groups and insurers \u2014 have been frantically circling to be sure they are not left out of the latest frenzy of deal making. Mergers and acquisitions worth about $270 billion have been announced in the first nine months of 2015 in the United States, easily outpacing the activity in recent years, according to a tally by Mergermarket."", ""print_section"": ""B"", ""print_page"": ""6"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/10/30/business/db-drug-web1/db-drug-web1-articleLarge.jpg"", ""height"": 508, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/10/30/business/db-drug-web1/db-drug-web1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 508}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/10/30/business/db-drug-web1/db-drug-web1-jumbo.jpg"", ""height"": 867, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/10/30/business/db-drug-web1/db-drug-web1-superJumbo.jpg"", ""height"": 1253, ""width"": 1480, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/10/30/business/db-drug-web1/db-drug-web1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/10/30/business/db-drug-web1/db-drug-web1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/10/30/business/db-drug-web1/db-drug-web1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Health Care Companies in Merger Frenzy"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Health Care Companies, Seeking Scale, Are Caught Up in a Merger Frenzy"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Abelson, Reed"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Health Insurance and Managed Care"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Patient Protection and Affordable Care Act (2010)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Hospitals"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2015-10-29T20:25:03+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Reed Abelson"", ""person"": [{""firstname"": ""Reed"", ""middlename"": null, ""lastname"": ""Abelson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/41d2a068-c7af-51e7-9203-2c8b0ce83a4d"", ""word_count"": 1301, ""uri"": ""nyt://article/41d2a068-c7af-51e7-9203-2c8b0ce83a4d""}]"
2015-11-04,"{""abstract"": ""In response Mylan\u2019s move to the Netherlands, the Securities and Exchange Commission now requires shareholder votes for each governance change from such deals."", ""web_url"": ""https://www.nytimes.com/2015/11/04/business/dealbook/regulators-unbundle-some-attractions-of-mergers.html"", ""snippet"": ""In response Mylan\u2019s move to the Netherlands, the Securities and Exchange Commission now requires shareholder votes for each governance change from such deals."", ""lead_paragraph"": ""The Securities and Exchange Commission has quietly taken a stand against corporate inversions. "", ""print_section"": ""B"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/04/business/04DEALPROF/04DEALPROF-articleLarge.jpg"", ""height"": 600, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/11/04/business/04DEALPROF/04DEALPROF-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 600}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/04/business/04DEALPROF/04DEALPROF-jumbo.jpg"", ""height"": 1023, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/04/business/04DEALPROF/04DEALPROF-superJumbo.jpg"", ""height"": 1413, ""width"": 1414, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/04/business/04DEALPROF/04DEALPROF-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/11/04/business/04DEALPROF/04DEALPROF-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/04/business/04DEALPROF/04DEALPROF-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Regulators Unbundle Some Attractions of Mergers"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Regulators Unbundle Some Attractions of Mergers"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Mylan Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Securities and Exchange Commission"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Shareholder Rights and Activism"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Perrigo Company"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Chiquita Brands International Inc"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Medtronic Inc"", ""rank"": 11, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 12, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Teva Pharmaceutical Industries Ltd"", ""rank"": 13, ""major"": ""N""}], ""pub_date"": ""2015-11-04T01:37:14+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Steven Davidoff Solomon"", ""person"": [{""firstname"": ""Steven"", ""middlename"": ""Davidoff"", ""lastname"": ""Solomon"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/da7da8d8-a9df-5016-92fe-0503e4d5f00b"", ""word_count"": 1016, ""uri"": ""nyt://article/da7da8d8-a9df-5016-92fe-0503e4d5f00b""}"
2015-11-06,"{""abstract"": ""The transaction is expected to improve the British drug maker\u2019s pipeline of treatments for cardiovascular and metabolic diseases."", ""web_url"": ""https://www.nytimes.com/2015/11/07/business/dealbook/astrazeneca-agrees-to-buy-zs-pharma-for-2-7-billion.html"", ""snippet"": ""The transaction is expected to improve the British drug maker\u2019s pipeline of treatments for cardiovascular and metabolic diseases."", ""lead_paragraph"": ""LONDON \u2014 The British drug maker AstraZeneca said on Friday that it had agreed to acquire ZS Pharma, a California-based biopharmaceutical company, for $2.7 billion in cash."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""AstraZeneca Agrees to Buy ZS Pharma for $2.7 Billion"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Business Briefing; AstraZeneca Agrees to Buy ZS Pharma for $2.7 Billion"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Bray, Chad"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ZS Pharma Inc."", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 6, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Great Britain"", ""rank"": 7, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""California"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 9, ""major"": ""N""}], ""pub_date"": ""2015-11-06T09:17:50+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Chad Bray"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/8d30b7db-d7c6-5830-bba0-cb07a8de7dc7"", ""word_count"": 346, ""uri"": ""nyt://article/8d30b7db-d7c6-5830-bba0-cb07a8de7dc7""}"
2015-11-19,"[{""abstract"": ""A merger would create a drug giant with nearly $53 billion in annual sales and give Pfizer a long-sought foreign headquarters for tax purposes."", ""web_url"": ""https://www.nytimes.com/2015/11/19/business/dealbook/pfizer-allergan-deal-for-up-to-150-billion-is-said-to-be-close-to-complete.html"", ""snippet"": ""A merger would create a drug giant with nearly $53 billion in annual sales and give Pfizer a long-sought foreign headquarters for tax purposes."", ""lead_paragraph"": ""Pfizer is nearing a deal to buy Allergan, a rival drug maker that has its headquarters in Ireland, for as much as $150 billion, potentially helping the company move its corporate citizenship abroad and reduce its tax bill, a person briefed on the matter said on Wednesday."", ""print_section"": ""B"", ""print_page"": ""6"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/20/business/db-drug-web1/db-drug-web1-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/11/20/business/db-drug-web1/db-drug-web1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/20/business/db-drug-web1/db-drug-web1-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/20/business/db-drug-web1/db-drug-web1-superJumbo.jpg"", ""height"": 1366, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/20/business/db-drug-web1/db-drug-web1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/11/20/business/db-drug-web1/db-drug-web1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/20/business/db-drug-web1/db-drug-web1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer and Allergan Said to Be Near Merger for Up to $150 Billion"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer and Allergan Said to Be Close to $150 Billion Merger"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""de la Merced, Michael J"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tax Shelters"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2015-11-19T01:50:50+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Michael J. de la Merced"", ""person"": [{""firstname"": ""Michael"", ""middlename"": ""J."", ""lastname"": ""de la Merced"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/f9b5103b-f147-5063-9b41-e845f7b9ea56"", ""word_count"": 580, ""uri"": ""nyt://article/f9b5103b-f147-5063-9b41-e845f7b9ea56""}, {""abstract"": ""Buying Allergan would give the drug giant a low-tax domicile in Ireland and one good drug, Botox. But Allergan would accrue nearly all of the upside."", ""web_url"": ""https://www.nytimes.com/2015/11/20/business/dealbook/high-risk-and-low-benefit-in-pfizers-pursuit-of-allergan.html"", ""snippet"": ""Buying Allergan would give the drug giant a low-tax domicile in Ireland and one good drug, Botox. But Allergan would accrue nearly all of the upside."", ""lead_paragraph"": ""Pfizer\u2019s $150 billion Botox gamble is a high-risk, low-benefit deal."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""High Risk and Low Benefit in Pfizer\u2019s Pursuit of Allergan"", ""kicker"": ""Breakingviews"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Federal Taxes (US)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Read, Ian C"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2015-11-19T19:12:32+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Robert Cyran"", ""person"": [{""firstname"": ""Robert"", ""middlename"": null, ""lastname"": ""Cyran"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/09141cb3-72e2-5666-a4f6-4d41be980422"", ""word_count"": 389, ""uri"": ""nyt://article/09141cb3-72e2-5666-a4f6-4d41be980422""}]"
2015-11-22,"{""abstract"": ""The deal, to be announced Monday, would create a huge new pharmaceutical giant and could potentially help Pfizer lower its American tax rate."", ""web_url"": ""https://www.nytimes.com/2015/11/23/business/dealbook/pfizer-and-allergan-reach-150-billion-merger-deal.html"", ""snippet"": ""The deal, to be announced Monday, would create a huge new pharmaceutical giant and could potentially help Pfizer lower its American tax rate."", ""lead_paragraph"": ""Pfizer has clinched a blockbuster merger with a fellow drug maker, one worth more than $150 billion, that can best be described in superlatives."", ""print_section"": ""A"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/23/business/23db-drug-web2/23db-drug-web2-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/11/23/business/23db-drug-web2/23db-drug-web2-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/23/business/23db-drug-web2/23db-drug-web2-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/23/business/23db-drug-web2/23db-drug-web2-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/23/business/23db-drug-web2/23db-drug-web2-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/11/23/business/23db-drug-web2/23db-drug-web2-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/23/business/23db-drug-web2/23db-drug-web2-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer and Allergan Reach $150 Billion Merger Deal"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer Reaches Takeover Deal With Allergan "", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""de la Merced, Michael J"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tax Shelters"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Botox (Drug)"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 8, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Relocation of Business"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Treasury Department"", ""rank"": 10, ""major"": ""N""}], ""pub_date"": ""2015-11-22T19:39:52+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Michael J. de la Merced"", ""person"": [{""firstname"": ""Michael"", ""middlename"": ""J."", ""lastname"": ""de la Merced"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/e9d80199-98dc-58ff-a205-1ecae9ca9842"", ""word_count"": 1113, ""uri"": ""nyt://article/e9d80199-98dc-58ff-a205-1ecae9ca9842""}"
2015-11-23,"[{""abstract"": ""The agreement would be the latest, and largest, aimed at helping an American company lower its taxes by reincorporating overseas, a tactic known as corporate inversion."", ""web_url"": ""https://www.nytimes.com/2015/11/24/business/dealbook/pfizer-allergan-merger-inversion.html"", ""snippet"": ""The agreement would be the latest, and largest, aimed at helping an American company lower its taxes by reincorporating overseas, a tactic known as corporate inversion."", ""lead_paragraph"": ""In phone calls to Washington lawmakers and Obama administration officials, the chief executive of the largest drug maker in the nation had a surprising message: A deal that would allow the company to move its headquarters to Ireland was actually good for the United States."", ""print_section"": ""A"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/24-pfizer-web1/24-pfizer-web1-articleLarge.jpg"", ""height"": 332, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/11/24/business/24-pfizer-web1/24-pfizer-web1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 332}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/24-pfizer-web1/24-pfizer-web1-jumbo.jpg"", ""height"": 567, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/24-pfizer-web1/24-pfizer-web1-superJumbo.jpg"", ""height"": 1134, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/24-pfizer-web1/24-pfizer-web1-thumbStandard-v3.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/11/24/business/24-pfizer-web1/24-pfizer-web1-thumbStandard-v3.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/24-pfizer-web1/24-pfizer-web1-thumbLarge-v3.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer Chief Defends Merger With Allergan as Good for U.S."", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Chief of Pfizer Defends Merger as Good for U.S."", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Picker, Leslie"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Gelles, David"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""de la Merced, Michael J"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tax Shelters"", ""rank"": 8, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Ireland"", ""rank"": 9, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Read, Ian C"", ""rank"": 10, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Relocation of Business"", ""rank"": 11, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Botox (Drug)"", ""rank"": 12, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 13, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Dublin (Ireland)"", ""rank"": 14, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 15, ""major"": ""N""}], ""pub_date"": ""2015-11-23T12:29:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Michael J. de la Merced, David Gelles and Leslie Picker"", ""person"": [{""firstname"": ""Michael"", ""middlename"": ""J."", ""lastname"": ""de la Merced"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Gelles"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}, {""firstname"": ""Leslie"", ""middlename"": null, ""lastname"": ""Picker"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 3}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/dbb15e51-ccdc-549e-9017-35ea94baf612"", ""word_count"": 1485, ""uri"": ""nyt://article/dbb15e51-ccdc-549e-9017-35ea94baf612""}, {""abstract"": ""The deal will bring hefty tax and cost savings worth slightly more than the $30 billion premium being offered, but the structure will upset lawmakers."", ""web_url"": ""https://www.nytimes.com/2015/11/24/business/dealbook/pfizers-huge-deal-could-work-but-with-adverse-effects.html"", ""snippet"": ""The deal will bring hefty tax and cost savings worth slightly more than the $30 billion premium being offered, but the structure will upset lawmakers."", ""lead_paragraph"": ""Pfizer\u2019s $160 billion opus of financial engineering theoretically could pay off."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/db-pfizerviews-web1/db-pfizerviews-web1-articleLarge.jpg"", ""height"": 443, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/11/24/business/db-pfizerviews-web1/db-pfizerviews-web1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 443}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/db-pfizerviews-web1/db-pfizerviews-web1-jumbo.jpg"", ""height"": 757, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/db-pfizerviews-web1/db-pfizerviews-web1-superJumbo.jpg"", ""height"": 1478, ""width"": 2000, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/db-pfizerviews-web1/db-pfizerviews-web1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/11/24/business/db-pfizerviews-web1/db-pfizerviews-web1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/db-pfizerviews-web1/db-pfizerviews-web1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer\u2019s Huge Deal Could Work, but With Adverse Effects"", ""kicker"": ""Breakingviews"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Federal Taxes (US)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Treasury Department"", ""rank"": 5, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Read, Ian C"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2015-11-23T15:30:59+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Robert Cyran"", ""person"": [{""firstname"": ""Robert"", ""middlename"": null, ""lastname"": ""Cyran"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/b642cca6-ce47-5e5d-8a9d-193dc7b47b8d"", ""word_count"": 386, ""uri"": ""nyt://article/b642cca6-ce47-5e5d-8a9d-193dc7b47b8d""}, {""abstract"": ""While not technically structured as an inversion, the huge drug merger spurs calls for change."", ""web_url"": ""https://www.nytimes.com/2015/11/24/business/dealbook/pfizer-deal-stokes-washington-concerns-over-tax-policy.html"", ""snippet"": ""While not technically structured as an inversion, the huge drug merger spurs calls for change."", ""lead_paragraph"": ""Despite growing pressure in Washington to curb a tax-saving strategy used by American companies, recent proposals by the Treasury Department would not have affected the Pfizer-Allergan merger."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/db-react-web1/db-react-web1-articleLarge.jpg"", ""height"": 399, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/11/24/business/db-react-web1/db-react-web1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 399}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/db-react-web1/db-react-web1-jumbo.jpg"", ""height"": 681, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/db-react-web1/db-react-web1-superJumbo.jpg"", ""height"": 1362, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/db-react-web1/db-react-web1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/11/24/business/db-react-web1/db-react-web1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/db-react-web1/db-react-web1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer Deal Stokes Washington Concerns Over Tax Policy"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Taxation"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""United States Politics and Government"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Federal Taxes (US)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 6, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Hatch, Orrin G"", ""rank"": 7, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Levin, Sander M"", ""rank"": 8, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Lew, Jacob J"", ""rank"": 9, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Sanders, Bernard"", ""rank"": 10, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Obama, Barack"", ""rank"": 11, ""major"": ""N""}], ""pub_date"": ""2015-11-23T18:31:13+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Liz Moyer"", ""person"": [{""firstname"": ""Liz"", ""middlename"": null, ""lastname"": ""Moyer"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/a074a2c8-fbfd-5c28-97fa-ed09eba60359"", ""word_count"": 940, ""uri"": ""nyt://article/a074a2c8-fbfd-5c28-97fa-ed09eba60359""}, {""abstract"": ""With an equity value of $152 billion, the merger is the largest since the heady days of 2000."", ""web_url"": ""https://www.nytimes.com/2015/11/24/business/dealbook/how-the-pfizer-allergan-deal-ranks.html"", ""snippet"": ""With an equity value of $152 billion, the merger is the largest since the heady days of 2000."", ""lead_paragraph"": ""The huge price tag accorded to the deal between Allergan and Pfizer \u2014 $160 billion in total enterprise value \u2014 is one of the largest in history and the biggest ever among pharmaceutical companies."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/24db-deal-web1/24db-deal-web1-articleLarge.jpg"", ""height"": 393, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/11/24/business/24db-deal-web1/24db-deal-web1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 393}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/24db-deal-web1/24db-deal-web1-jumbo.jpg"", ""height"": 671, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/24db-deal-web1/24db-deal-web1-superJumbo.jpg"", ""height"": 1342, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/24db-deal-web1/24db-deal-web1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/11/24/business/24db-deal-web1/24db-deal-web1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/24db-deal-web1/24db-deal-web1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""How the Pfizer-Allergan Deal Ranks"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Vodafone Group Plc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Mannesmann AG"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Time Warner Inc"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2015-11-23T18:49:32+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Leslie Picker"", ""person"": [{""firstname"": ""Leslie"", ""middlename"": null, ""lastname"": ""Picker"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/47ec9b96-e47c-517c-9f8b-df52fc507d92"", ""word_count"": 275, ""uri"": ""nyt://article/47ec9b96-e47c-517c-9f8b-df52fc507d92""}]"
2015-11-24,"[{""abstract"": ""The blockbuster pharmaceutical merger has put new pressure on Congress and the White House to overhaul the corporate tax code."", ""web_url"": ""https://www.nytimes.com/2015/11/24/business/drug-merger-reignites-tax-reform-discussion.html"", ""snippet"": ""The blockbuster pharmaceutical merger has put new pressure on Congress and the White House to overhaul the corporate tax code."", ""lead_paragraph"": ""WASHINGTON \u2014 For almost four years, Congress and the White House have done little to make their long-promised overhaul of the corporate tax code a reality. Now the blockbuster pharmaceutical merger of Pfizer and Allergan has put new pressure on all sides to act."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/24corptax-web1/24corptax-web1-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/11/24/business/24corptax-web1/24corptax-web1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/24corptax-web1/24corptax-web1-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/24corptax-web1/24corptax-web1-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/24corptax-web1/24corptax-web1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/11/24/business/24corptax-web1/24corptax-web1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/24corptax-web1/24corptax-web1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer-Allergan Merger Reignites Tax Reform Discussion"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Drug Merger Reignites Tax Reform Discussion"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Calmes, Jackie"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tax Shelters"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""United States Politics and Government"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Relocation of Business"", ""rank"": 8, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 9, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Federal Taxes (US)"", ""rank"": 10, ""major"": ""N""}], ""pub_date"": ""2015-11-24T02:20:32+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Jackie Calmes"", ""person"": [{""firstname"": ""Jackie"", ""middlename"": null, ""lastname"": ""Calmes"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/92d72a39-66e0-5992-b462-0b735f834bd4"", ""word_count"": 1051, ""uri"": ""nyt://article/92d72a39-66e0-5992-b462-0b735f834bd4""}, {""abstract"": ""The United States approach has been a failure, and a $152 billion drug merger could nudge tax-writing committees in Washington into action."", ""web_url"": ""https://www.nytimes.com/2015/11/25/business/dealbook/why-pfizers-deal-may-change-the-system-oftaxing-multinationals.html"", ""snippet"": ""The United States approach has been a failure, and a $152 billion drug merger could nudge tax-writing committees in Washington into action."", ""lead_paragraph"": ""Pfizer\u2019s proposed merger with Allergan is a blockbuster deal in the pharmaceutical industry. History may remember the deal instead for finally killing off the United States\u2019 outdated approach to taxing multinational corporations."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/25/business/db-deduction-web1/db-deduction-web1-articleLarge.jpg"", ""height"": 395, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/11/25/business/db-deduction-web1/db-deduction-web1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 395}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/25/business/db-deduction-web1/db-deduction-web1-jumbo.jpg"", ""height"": 674, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/25/business/db-deduction-web1/db-deduction-web1-superJumbo.jpg"", ""height"": 1348, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/25/business/db-deduction-web1/db-deduction-web1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/11/25/business/db-deduction-web1/db-deduction-web1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/25/business/db-deduction-web1/db-deduction-web1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Why Pfizer\u2019s Deal May Change the System of\u00a0Taxing Multinationals"", ""kicker"": ""Standard Deduction"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Law and Legislation"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2015-11-24T15:10:41+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Victor Fleischer"", ""person"": [{""firstname"": ""Victor"", ""middlename"": null, ""lastname"": ""Fleischer"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/df2d37a0-8ad2-5245-aed0-c690132aa819"", ""word_count"": 917, ""uri"": ""nyt://article/df2d37a0-8ad2-5245-aed0-c690132aa819""}, {""abstract"": ""The deal with Allergan will cut taxes and add solid assets, but it is also prompting Pfizer to defer a decision on splitting up until 2018."", ""web_url"": ""https://www.nytimes.com/2015/11/25/business/dealbook/pfizers-desire-to-split-has-faded.html"", ""snippet"": ""The deal with Allergan will cut taxes and add solid assets, but it is also prompting Pfizer to defer a decision on splitting up until 2018."", ""lead_paragraph"": ""Pfizer\u2019s huge deal for Allergan will lower the drugmaker\u2019s taxes, add solid assets such as Botox and reduce leverage. But it has also created a material adverse event. Pfizer is delaying a decision on whether to split the company by two years."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/24DB-PFIZERjp1/24DB-PFIZERjp1-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/11/24/business/24DB-PFIZERjp1/24DB-PFIZERjp1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/24DB-PFIZERjp1/24DB-PFIZERjp1-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/24DB-PFIZERjp1/24DB-PFIZERjp1-superJumbo.jpg"", ""height"": 1366, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/24DB-PFIZERjp1/24DB-PFIZERjp1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/11/24/business/24DB-PFIZERjp1/24DB-PFIZERjp1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/24DB-PFIZERjp1/24DB-PFIZERjp1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer\u2019s Desire to Split Has Faded"", ""kicker"": ""Breakingviews"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Read, Ian C"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2015-11-24T17:05:17+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Robert Cyran"", ""person"": [{""firstname"": ""Robert"", ""middlename"": null, ""lastname"": ""Cyran"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/bd5db93b-0027-56de-ac34-f020cfc98ed5"", ""word_count"": 353, ""uri"": ""nyt://article/bd5db93b-0027-56de-ac34-f020cfc98ed5""}, {""abstract"": ""The two companies have outlined the various termination fees they will pay each other in the event the $152 billion merger collapses."", ""web_url"": ""https://www.nytimes.com/2015/11/25/business/dealbook/pfizer-and-allergan-deal-comes-with-an-extensive-prenup.html"", ""snippet"": ""The two companies have outlined the various termination fees they will pay each other in the event the $152 billion merger collapses."", ""lead_paragraph"": ""Pfizer and Allergan thought up several situations where their blockbuster $152 billion merger agreement could meet resistance, including from shareholders, regulators and lawmakers, and even rival suitors."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/24DB-PFIZERjp2/24DB-PFIZERjp2-articleLarge.jpg"", ""height"": 395, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/11/24/business/24DB-PFIZERjp2/24DB-PFIZERjp2-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 395}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/24DB-PFIZERjp2/24DB-PFIZERjp2-jumbo.jpg"", ""height"": 674, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/24DB-PFIZERjp2/24DB-PFIZERjp2-superJumbo.jpg"", ""height"": 1349, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/24DB-PFIZERjp2/24DB-PFIZERjp2-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/11/24/business/24DB-PFIZERjp2/24DB-PFIZERjp2-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/24DB-PFIZERjp2/24DB-PFIZERjp2-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer and Allergan Deal Comes With an Extensive Prenup"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""House of Representatives"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Encounter (Magazine)"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Senate"", ""rank"": 7, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Franken, Al"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2015-11-24T22:36:21+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Liz Moyer"", ""person"": [{""firstname"": ""Liz"", ""middlename"": null, ""lastname"": ""Moyer"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/6eb50ab5-1ef8-50bf-899a-ba279e013691"", ""word_count"": 577, ""uri"": ""nyt://article/6eb50ab5-1ef8-50bf-899a-ba279e013691""}]"
2015-11-25,"[{""abstract"": ""Recent deals show that normally sober-minded business executives seem to have thrown over sound decision-making for flights of fancy."", ""web_url"": ""https://www.nytimes.com/2015/11/25/business/dealbook/telltale-signs-that-deal-makers-swallowed-the-silly-pills.html"", ""snippet"": ""Recent deals show that normally sober-minded business executives seem to have thrown over sound decision-making for flights of fancy."", ""lead_paragraph"": ""Even in these grim times, deal makers have descended into silliness."", ""print_section"": ""B"", ""print_page"": ""5"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/25/business/25DEALPROF/25DEALPROF-articleLarge.jpg"", ""height"": 600, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/11/25/business/25DEALPROF/25DEALPROF-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 600}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/25/business/25DEALPROF/25DEALPROF-jumbo.jpg"", ""height"": 1024, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/25/business/25DEALPROF/25DEALPROF-superJumbo.jpg"", ""height"": 1196, ""width"": 1196, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/25/business/25DEALPROF/25DEALPROF-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/11/25/business/25DEALPROF/25DEALPROF-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/25/business/25DEALPROF/25DEALPROF-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer-Allergan Merger Is Latest Sign of Deal Makers\u2019 Silly Pills"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Telltale Signs That Deal Makers Swallowed the Silly Pills "", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Mylan Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Perrigo Company"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pershing Square Capital Management"", ""rank"": 7, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Ackman, William A"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Valeant Pharmaceuticals International Inc"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Herbalife Ltd"", ""rank"": 10, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Taxation"", ""rank"": 11, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 12, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Coury, Robert J"", ""rank"": 13, ""major"": ""N""}], ""pub_date"": ""2015-11-25T00:54:37+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Steven Davidoff Solomon"", ""person"": [{""firstname"": ""Steven"", ""middlename"": ""Davidoff"", ""lastname"": ""Solomon"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/3ad0ef27-5f51-5570-8649-56dddee4f1b5"", ""word_count"": 1201, ""uri"": ""nyt://article/3ad0ef27-5f51-5570-8649-56dddee4f1b5""}, {""abstract"": ""An offshore tax address means there\u2019s no reason to keep over $60 billion of cash on its balance sheet. That\u2019s a lot of financial firepower to buy back shares and fuel more acquisitions."", ""web_url"": ""https://www.nytimes.com/2015/11/26/business/dealbook/how-allergan-deal-will-rebuild-pfizers-war-chest.html"", ""snippet"": ""An offshore tax address means there\u2019s no reason to keep over $60 billion of cash on its balance sheet. That\u2019s a lot of financial firepower to buy back shares and fuel more acquisitions."", ""lead_paragraph"": ""It sounds counterintuitive, but Pfizer\u2019s $152 billion takeover of Allergan will rebuild the acquisitive drug giant\u2019s war chest to do even more deals. Because it was structured as a merger, allowing it to flip its tax liabilities overseas, most of what Pfizer is paying comes in the form of stock. That means the pharma mega-beast will be flush with cash and eager to put it to work."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/24DB-PFIZERjp2/24DB-PFIZERjp2-articleLarge.jpg"", ""height"": 395, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/11/24/business/24DB-PFIZERjp2/24DB-PFIZERjp2-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 395}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/24DB-PFIZERjp2/24DB-PFIZERjp2-jumbo.jpg"", ""height"": 674, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/24DB-PFIZERjp2/24DB-PFIZERjp2-superJumbo.jpg"", ""height"": 1349, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/24DB-PFIZERjp2/24DB-PFIZERjp2-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/11/24/business/24DB-PFIZERjp2/24DB-PFIZERjp2-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/24DB-PFIZERjp2/24DB-PFIZERjp2-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""How Allergan Deal Will Rebuild Pfizer\u2019s War Chest"", ""kicker"": ""Breakingviews"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Federal Taxes (US)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Taxation"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Read, Ian C"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2015-11-25T18:21:43+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Robert Cyran"", ""person"": [{""firstname"": ""Robert"", ""middlename"": null, ""lastname"": ""Cyran"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/c7d78ab7-327e-5b0f-81c7-dad490a47c89"", ""word_count"": 369, ""uri"": ""nyt://article/c7d78ab7-327e-5b0f-81c7-dad490a47c89""}, {""abstract"": ""The Pfizer-Allergan merger has been criticized because of a planned headquarters move to Ireland, but such strategies are not necessary to avoid taxes."", ""web_url"": ""https://www.nytimes.com/2015/11/29/business/dealbook/pfizer-didnt-need-an-inversion-to-avoid-paying-us-taxes.html"", ""snippet"": ""The Pfizer-Allergan merger has been criticized because of a planned headquarters move to Ireland, but such strategies are not necessary to avoid taxes."", ""lead_paragraph"": ""Pfizer\u2019s declaration that it intends to merge with Allergan and cut taxes by moving its tax home to Dublin from New York City has set off something of a furor."", ""print_section"": ""BU"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/29/business/29-STRA/29-STRA-articleLarge-v2.jpg"", ""height"": 473, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/11/29/business/29-STRA/29-STRA-articleLarge-v2.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 473}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/29/business/29-STRA/29-STRA-jumbo-v2.jpg"", ""height"": 808, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/29/business/29-STRA/29-STRA-superJumbo-v2.jpg"", ""height"": 1615, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/29/business/29-STRA/29-STRA-thumbStandard-v2.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/11/29/business/29-STRA/29-STRA-thumbStandard-v2.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/29/business/29-STRA/29-STRA-thumbLarge-v2.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer Didn\u2019t Need an Inversion to Avoid Paying U.S. Taxes"", ""kicker"": ""Strategies"", ""content_kicker"": null, ""print_headline"": ""The Benefits of Keeping Earnings in Exile"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tax Shelters"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2015-11-25T19:04:50+0000"", ""document_type"": ""article"", ""news_desk"": ""SundayBusiness"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Jeff Sommer"", ""person"": [{""firstname"": ""Jeff"", ""middlename"": null, ""lastname"": ""Sommer"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/83a0c8a3-2469-57ec-8a11-409f77e8169f"", ""word_count"": 1127, ""uri"": ""nyt://article/83a0c8a3-2469-57ec-8a11-409f77e8169f""}]"
2015-12-01,"[{""abstract"": ""Pfizer, which plans to enjoy a lower tax rate in Ireland after a merger with Allergan, has long employed various tax avoidance strategies."", ""web_url"": ""https://www.nytimes.com/2015/12/01/business/dealbook/pfizers-long-war-on-taxation.html"", ""snippet"": ""Pfizer, which plans to enjoy a lower tax rate in Ireland after a merger with Allergan, has long employed various tax avoidance strategies."", ""lead_paragraph"": ""Long before Pfizer conceived of merging with Allergan in a $150 billion deal to rid itself of what its chief executive called an \u201can uncompetitive tax rate\u201d in the United States, the company was deploying various tax avoidance strategies dating back to at least 1976."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/12/01/business/subDB-SORKIN/subDB-SORKIN-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/12/01/business/subDB-SORKIN/subDB-SORKIN-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/12/01/business/subDB-SORKIN/subDB-SORKIN-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/12/01/business/subDB-SORKIN/subDB-SORKIN-superJumbo.jpg"", ""height"": 1366, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/12/01/business/subDB-SORKIN/subDB-SORKIN-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/12/01/business/subDB-SORKIN/subDB-SORKIN-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/12/01/business/subDB-SORKIN/subDB-SORKIN-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer\u2019s Long War on Taxation"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer\u2019s Long War on Taxation"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Sorkin, Andrew Ross"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tax Shelters"", ""rank"": 4, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Puerto Rico"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tax Credits, Deductions and Exemptions"", ""rank"": 7, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Ireland"", ""rank"": 8, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""International Trade and World Market"", ""rank"": 9, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Lew, Jacob J"", ""rank"": 10, ""major"": ""N""}], ""pub_date"": ""2015-12-01T02:02:20+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Andrew Ross Sorkin"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": ""Ross"", ""lastname"": ""Sorkin"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/8943e688-5628-5a51-b3c3-4fe62c6bfb19"", ""word_count"": 855, ""uri"": ""nyt://article/8943e688-5628-5a51-b3c3-4fe62c6bfb19""}, {""abstract"": ""That this high-water mark is justified by its tax workaround is a sign that the two-year boom of extraordinary corporate deals is reaching its conclusion."", ""web_url"": ""https://www.nytimes.com/2015/12/02/business/dealbook/pfizers-deal-for-allergan-is-a-dubious-milestone.html"", ""snippet"": ""That this high-water mark is justified by its tax workaround is a sign that the two-year boom of extraordinary corporate deals is reaching its conclusion."", ""lead_paragraph"": ""Pfizer\u2019s $160 billion takeover of Allergan reached a few milestones in the mergers and acquisitions trade."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/db-pfizerviews-web1/db-pfizerviews-web1-articleLarge.jpg"", ""height"": 443, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/11/24/business/db-pfizerviews-web1/db-pfizerviews-web1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 443}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/db-pfizerviews-web1/db-pfizerviews-web1-jumbo.jpg"", ""height"": 757, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/db-pfizerviews-web1/db-pfizerviews-web1-superJumbo.jpg"", ""height"": 1478, ""width"": 2000, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/db-pfizerviews-web1/db-pfizerviews-web1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/11/24/business/db-pfizerviews-web1/db-pfizerviews-web1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/db-pfizerviews-web1/db-pfizerviews-web1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer\u2019s Deal for Allergan Is a Dubious Milestone"", ""kicker"": ""Breakingviews"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2015-12-01T21:20:35+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Rob Cox"", ""person"": [{""firstname"": ""Rob"", ""middlename"": null, ""lastname"": ""Cox"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/508d18bc-31f1-59bb-99d4-174ac9e1ffe9"", ""word_count"": 875, ""uri"": ""nyt://article/508d18bc-31f1-59bb-99d4-174ac9e1ffe9""}]"
2015-12-15,"{""abstract"": ""The exchange of business units would make Sanofi one of the world\u2019s largest manufacturers of nonprescription medicines."", ""web_url"": ""https://www.nytimes.com/2015/12/16/business/dealbook/sanofi-boehringer-asset-swap.html"", ""snippet"": ""The exchange of business units would make Sanofi one of the world\u2019s largest manufacturers of nonprescription medicines."", ""lead_paragraph"": ""LONDON \u2014 The French pharmaceutical company Sanofi and the German drug maker Boehringer Ingelheim said on Tuesday that they were in \u201cexclusive negotiations\u201d on a potential asset swap that would make Sanofi one of the world\u2019s largest manufacturers of nonprescription medicines."", ""print_section"": ""B"", ""print_page"": ""5"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/12/16/business/16DB-Sanofi/16DB-Sanofi-articleLarge.jpg"", ""height"": 337, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/12/16/business/16DB-Sanofi/16DB-Sanofi-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 337}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/12/16/business/16DB-Sanofi/16DB-Sanofi-jumbo.jpg"", ""height"": 574, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/12/16/business/16DB-Sanofi/16DB-Sanofi-superJumbo.jpg"", ""height"": 1149, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/12/16/business/16DB-Sanofi/16DB-Sanofi-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/12/16/business/16DB-Sanofi/16DB-Sanofi-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/12/16/business/16DB-Sanofi/16DB-Sanofi-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""European Drug Makers Sanofi and Boehringer Ingelheim in Talks"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Two European Drug Makers in Talks About Asset Swaps"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Sanofi SA"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Bray, Chad"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Boehringer Ingelheim GmbH"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merial Animal Health"", ""rank"": 6, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Brandicourt, Olivier"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Zoetis Inc"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 9, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""France"", ""rank"": 10, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Germany"", ""rank"": 11, ""major"": ""N""}], ""pub_date"": ""2015-12-15T10:18:18+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Chad Bray"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/f40f6462-6b90-5091-ba69-d52bcfb464cb"", ""word_count"": 465, ""uri"": ""nyt://article/f40f6462-6b90-5091-ba69-d52bcfb464cb""}"
2015-12-17,"{""abstract"": ""The deal would be the latest by a pharmaceutical company in what has been a record year for mergers and acquisitions, driven in part by transactions in the health care sector."", ""web_url"": ""https://www.nytimes.com/2015/12/18/business/dealbook/astrazeneca-to-acquire-majority-stake-in-acerta-pharma.html"", ""snippet"": ""The deal would be the latest by a pharmaceutical company in what has been a record year for mergers and acquisitions, driven in part by transactions in the health care sector."", ""lead_paragraph"": ""LONDON \u2014 The British drug maker AstraZeneca said on Thursday that it had agreed to acquire a majority stake in Acerta Pharma, a privately-held cancer drug developer with operations in the Netherlands and in California, for $4 billion."", ""print_section"": ""B"", ""print_page"": ""5"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/12/18/world/18db-Astrazeneca-web/18db-Astrazeneca-web-articleLarge.jpg"", ""height"": 376, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/12/18/world/18db-Astrazeneca-web/18db-Astrazeneca-web-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 376}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/12/18/world/18db-Astrazeneca-web/18db-Astrazeneca-web-jumbo.jpg"", ""height"": 642, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/12/18/world/18db-Astrazeneca-web/18db-Astrazeneca-web-superJumbo.jpg"", ""height"": 1283, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/12/18/world/18db-Astrazeneca-web/18db-Astrazeneca-web-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/12/18/world/18db-Astrazeneca-web/18db-Astrazeneca-web-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/12/18/world/18db-Astrazeneca-web/18db-Astrazeneca-web-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""AstraZeneca to Acquire Majority Stake in Acerta Pharma"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""AstraZeneca to Acquire Control of a Cancer Drug Developer"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Acerta Pharma BV"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Bray, Chad"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 6, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Great Britain"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2015-12-17T09:37:53+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Chad Bray"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/abafa742-a66a-5faf-87c6-4b36c0e7c7c7"", ""word_count"": 393, ""uri"": ""nyt://article/abafa742-a66a-5faf-87c6-4b36c0e7c7c7""}"
2015-12-18,"{""abstract"": ""The British drug maker plans to acquire treatments at various stages of research in a deal with Bristol-Myers Squibb of New York that could be worth $1.46 billion."", ""web_url"": ""https://www.nytimes.com/2015/12/19/business/dealbook/gsk-bristol-myers-hiv.html"", ""snippet"": ""The British drug maker plans to acquire treatments at various stages of research in a deal with Bristol-Myers Squibb of New York that could be worth $1.46 billion."", ""lead_paragraph"": ""LONDON \u2014 GlaxoSmithKline said on Friday that it had agreed to acquire a pipeline of H.I.V. drugs in development from Bristol-Myers Squibb, in two deals that could be worth as much as $1.46 billion."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""GlaxoSmithKline to Buy Raft of H.I.V. Drugs in Development"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Acquired Immune Deficiency Syndrome"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Bristol Myers Squibb Company"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""GlaxoSmithKline PLC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""London (England)"", ""rank"": 7, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Japan"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2015-12-18T11:50:51+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Chad Bray"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/80e0e999-d0dd-5ac1-b4c8-0a58e01b5ab6"", ""word_count"": 204, ""uri"": ""nyt://article/80e0e999-d0dd-5ac1-b4c8-0a58e01b5ab6""}"
2015-12-22,"{""abstract"": ""The merger market is on track for a $4 trillion-plus year, and deal makers are no doubt celebrating, but this is also a time for reflection."", ""web_url"": ""https://www.nytimes.com/2015/12/23/business/dealbook/in-a-record-year-for-deals-success-and-a-few-missteps.html"", ""snippet"": ""The merger market is on track for a $4 trillion-plus year, and deal makers are no doubt celebrating, but this is also a time for reflection."", ""lead_paragraph"": ""It\u2019s time once again to hand out grades to the year\u2019s deals and deal makers."", ""print_section"": ""B"", ""print_page"": ""5"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/12/23/business/23dealprof-illo/23dealprof-illo-articleLarge.jpg"", ""height"": 600, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/12/23/business/23dealprof-illo/23dealprof-illo-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 600}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/12/23/business/23dealprof-illo/23dealprof-illo-jumbo.jpg"", ""height"": 1024, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/12/23/business/23dealprof-illo/23dealprof-illo-superJumbo.jpg"", ""height"": 1179, ""width"": 1179, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/12/23/business/23dealprof-illo/23dealprof-illo-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/12/23/business/23dealprof-illo/23dealprof-illo-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/12/23/business/23dealprof-illo/23dealprof-illo-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""In a Record Year for Deals, Success and a Few Missteps"", ""kicker"": ""Deal Professor"", ""content_kicker"": null, ""print_headline"": ""In a Record Year for Deals, Success and a Few Missteps"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Shareholder Rights and Activism"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Boards of Directors"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Law and Legislation"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""BGC Partners Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Sysco Corporation"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""GFI Group Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""House of Representatives"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Perrigo Company"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""CIGNA Corporation"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AETNA INC"", ""rank"": 11, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Mylan Inc"", ""rank"": 12, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Royal Bank of Canada"", ""rank"": 13, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AIRGAS INC"", ""rank"": 14, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Office Depot Inc."", ""rank"": 15, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Staples Inc"", ""rank"": 16, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Senate"", ""rank"": 17, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 18, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Goldman Sachs Group Inc"", ""rank"": 19, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Federal Communications Commission"", ""rank"": 20, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Hudson City Bancorp Inc"", ""rank"": 21, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AIR LIQUIDE SA"", ""rank"": 22, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pershing Square Capital Management"", ""rank"": 23, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Olive Garden Italian Restaurants"", ""rank"": 24, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Federal Trade Commission"", ""rank"": 25, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""CME Group Inc"", ""rank"": 26, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 27, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""DuPont Co"", ""rank"": 28, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""CBS Corporation"", ""rank"": 29, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Humana Inc"", ""rank"": 30, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Comcast Corporation"", ""rank"": 31, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Starboard Value LP"", ""rank"": 32, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Square Inc"", ""rank"": 33, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Time Warner Cable Inc"", ""rank"": 34, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""US Foods Inc"", ""rank"": 35, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Valeant Pharmaceuticals International Inc"", ""rank"": 36, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Viacom Inc"", ""rank"": 37, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Ackman, William A"", ""rank"": 38, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Dorsey, Jack"", ""rank"": 39, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Gooch, Michael A"", ""rank"": 40, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Icahn, Carl C"", ""rank"": 41, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Redstone, Sumner M"", ""rank"": 42, ""major"": ""N""}], ""pub_date"": ""2015-12-22T20:29:06+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Steven Davidoff Solomon"", ""person"": [{""firstname"": ""Steven"", ""middlename"": ""Davidoff"", ""lastname"": ""Solomon"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/ffe960da-0cc2-519f-9911-c97b81fcc96e"", ""word_count"": 1382, ""uri"": ""nyt://article/ffe960da-0cc2-519f-9911-c97b81fcc96e""}"
2016-01-05,"{""abstract"": ""The insulin, called Afrezza, has had poor sales since being approved by the F.D.A. in 2014. Shares in its maker, MannKind, fell 48 percent."", ""web_url"": ""https://www.nytimes.com/2016/01/06/business/sanofi-ends-marketing-deal-with-developer-of-inhaled-insulin.html"", ""snippet"": ""The insulin, called Afrezza, has had poor sales since being approved by the F.D.A. in 2014. Shares in its maker, MannKind, fell 48 percent."", ""lead_paragraph"": ""An inhaled insulin championed by a billionaire medical entrepreneur suffered a big setback on Tuesday when it was abandoned by the company with the rights to market it."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/06/business/06Insulin/06Insulin-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/01/06/business/06Insulin/06Insulin-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/06/business/06Insulin/06Insulin-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/06/business/06Insulin/06Insulin-superJumbo.jpg"", ""height"": 1367, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/06/business/06Insulin/06Insulin-thumbStandard-v2.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/01/06/business/06Insulin/06Insulin-thumbStandard-v2.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/06/business/06Insulin/06Insulin-thumbLarge-v2.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Sanofi Ends Marketing Deal With Developer of Inhaled Insulin"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Shares of Inhaled Insulin Maker Plummet 48% as Big Marketing Partner Pulls Out"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Sanofi SA"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""MannKind Corporation"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Mann, Alfred E"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Diabetes"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2016-01-05T18:05:34+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/1f3fccb0-77a0-591c-af2e-ccbebd991606"", ""word_count"": 914, ""uri"": ""nyt://article/1f3fccb0-77a0-591c-af2e-ccbebd991606""}"
2016-01-11,"{""abstract"": ""Some pharmaceutical companies will form the National Immunotherapy Coalition to rapidly test various combinations of promising new types of cancer drugs."", ""web_url"": ""https://www.nytimes.com/2016/01/12/business/drug-companies-to-try-a-unified-front-against-cancer.html"", ""snippet"": ""Some pharmaceutical companies will form the National Immunotherapy Coalition to rapidly test various combinations of promising new types of cancer drugs."", ""lead_paragraph"": ""SAN FRANCISCO \u2014 Some leading pharmaceutical companies are joining forces in an effort to speed the testing of new types of cancer drugs that harness the body\u2019s immune system to battle tumors."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/12/business/12cancer-web1/12cancer-web1-articleLarge.jpg"", ""height"": 419, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/01/12/business/12cancer-web1/12cancer-web1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 419}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/12/business/12cancer-web1/12cancer-web1-jumbo.jpg"", ""height"": 716, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/12/business/12cancer-web1/12cancer-web1-superJumbo.jpg"", ""height"": 1432, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/12/business/12cancer-web1/12cancer-web1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/01/12/business/12cancer-web1/12cancer-web1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/12/business/12cancer-web1/12cancer-web1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Drug Companies to Try a Unified Front Against Cancer"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Cancer"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Clinical Trials"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Soon-Shiong, Patrick"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AMGEN INC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Celgene Corporation"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""GlaxoSmithKline PLC"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 9, ""major"": ""N""}], ""pub_date"": ""2016-01-11T15:46:36+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/e37fcae4-ae54-52e9-923d-774b4b8ee48f"", ""word_count"": 505, ""uri"": ""nyt://article/e37fcae4-ae54-52e9-923d-774b4b8ee48f""}"
2016-01-13,"{""abstract"": ""When hemophiliacs make their living by selling lucrative hemophilia drugs, patient advocates say it creates a dangerous conflict of interest."", ""web_url"": ""https://www.nytimes.com/2016/01/14/business/hemophilia-patient-or-drug-seller-dual-role-creates-ethical-quandary.html"", ""snippet"": ""When hemophiliacs make their living by selling lucrative hemophilia drugs, patient advocates say it creates a dangerous conflict of interest."", ""lead_paragraph"": ""LaQuenta Caldwell-Moody considered it improper when a pharmacy sales representative tried to take her teenage son, when he was still a minor, to dinner without her."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/14/business/14hemophilia-web1/14hemophilia-web1-articleLarge.jpg"", ""height"": 398, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/01/14/business/14hemophilia-web1/14hemophilia-web1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 398}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/14/business/14hemophilia-web1/14hemophilia-web1-jumbo.jpg"", ""height"": 680, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/14/business/14hemophilia-web1/14hemophilia-web1-superJumbo.jpg"", ""height"": 1360, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/14/business/14hemophilia-web1/14hemophilia-web1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/01/14/business/14hemophilia-web1/14hemophilia-web1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/14/business/14hemophilia-web1/14hemophilia-web1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Hemophilia Patient or Drug Seller? Dual Role Creates Ethical Quandary"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""The Patient&#8217;s Sales Pitch "", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Hemophilia"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Conflicts of Interest"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Blood"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Ethics and Official Misconduct"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Hemophilia of North Carolina"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""National Hemophilia Foundation"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""MedfusionRx LLC"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Bayer AG"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 11, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novo Nordisk A/S"", ""rank"": 12, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Baxalta Inc."", ""rank"": 13, ""major"": ""N""}], ""pub_date"": ""2016-01-13T18:17:24+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/9b1396b3-f5a4-506f-9b88-5c157864f836"", ""word_count"": 1254, ""uri"": ""nyt://article/9b1396b3-f5a4-506f-9b88-5c157864f836""}"
2016-01-26,"{""abstract"": ""Johnson Controls is just the latest corporation to flee America for greener, lower-tax pastures. And until lawmakers reform the tax code, the exodus will continue."", ""web_url"": ""https://www.nytimes.com/2016/01/26/business/dealbook/a-tidal-wave-of-corporate-migrants-seeking-tax-shelter.html"", ""snippet"": ""Johnson Controls is just the latest corporation to flee America for greener, lower-tax pastures. And until lawmakers reform the tax code, the exodus will continue."", ""lead_paragraph"": ""In the fall of 2008, with General Motors and Chrysler on the precipice of bankruptcy, executives at the car parts supplier Johnson Controls flew to Washington. The company\u2019s president testified before a Senate panel and implored lawmakers to bail out the auto industry."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/26/business/26subSORKIN/26subSORKIN-articleLarge.jpg"", ""height"": 417, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/01/26/business/26subSORKIN/26subSORKIN-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 417}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/26/business/26subSORKIN/26subSORKIN-jumbo.jpg"", ""height"": 711, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/26/business/26subSORKIN/26subSORKIN-superJumbo.jpg"", ""height"": 1329, ""width"": 1913, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/26/business/26subSORKIN/26subSORKIN-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/01/26/business/26subSORKIN/26subSORKIN-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/26/business/26subSORKIN/26subSORKIN-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""A Tidal Wave of Corporate Migrants Seeking (Tax) Shelter"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""A Tidal Wave of Corporate Migrants Seeking (Tax) Shelter"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Sorkin, Andrew Ross"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tax Shelters"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Johnson Controls Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Corporations"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""United States Politics and Government"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Law and Legislation"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Federal Taxes (US)"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Tyco International Co"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Medtronic Inc"", ""rank"": 11, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Coca-Cola Company"", ""rank"": 12, ""major"": ""N""}], ""pub_date"": ""2016-01-26T01:23:09+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Andrew Ross Sorkin"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": ""Ross"", ""lastname"": ""Sorkin"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/26bf6a9f-690b-5deb-bc0c-2ac27d1367cd"", ""word_count"": 833, ""uri"": ""nyt://article/26bf6a9f-690b-5deb-bc0c-2ac27d1367cd""}"
2016-02-10,"{""abstract"": ""The bigger benefit to corporations fleeing American tax bills \u2014 and the bigger loss to American taxpayers \u2014 is a maneuver called earnings stripping."", ""web_url"": ""https://www.nytimes.com/2016/02/10/business/dealbook/corporate-inversions-arent-the-half-of-it.html"", ""snippet"": ""The bigger benefit to corporations fleeing American tax bills \u2014 and the bigger loss to American taxpayers \u2014 is a maneuver called earnings stripping."", ""lead_paragraph"": ""If you thought there was a problem with inversions \u2014 deals that allow American companies to relocate their headquarters to lower their tax bills \u2014 wait until you hear about the real secret to avoiding corporate taxes. It\u2019s called earnings stripping, and it is a technique that the Obama administration has so far failed to stop."", ""print_section"": ""B"", ""print_page"": ""5"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/02/10/business/10DEALPROF/10DEALPROF-articleLarge.jpg"", ""height"": 602, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/02/10/business/10DEALPROF/10DEALPROF-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 602}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/02/10/business/10DEALPROF/10DEALPROF-jumbo.jpg"", ""height"": 1024, ""width"": 1022, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/02/10/business/10DEALPROF/10DEALPROF-superJumbo.jpg"", ""height"": 1194, ""width"": 1191, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/02/10/business/10DEALPROF/10DEALPROF-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/02/10/business/10DEALPROF/10DEALPROF-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/02/10/business/10DEALPROF/10DEALPROF-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Corporate Inversions Aren\u2019t the Half of It"", ""kicker"": ""Deal Professor"", ""content_kicker"": null, ""print_headline"": ""If You Think Corporate Inversions Are Bad, Brace Yourself"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tax Shelters"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Federal Taxes (US)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""United States Politics and Government"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Internal Revenue Service"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2016-02-10T00:40:40+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Steven Davidoff Solomon"", ""person"": [{""firstname"": ""Steven"", ""middlename"": ""Davidoff"", ""lastname"": ""Solomon"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/544f37bf-7ed2-5d53-b69c-1e9d6472fda5"", ""word_count"": 1068, ""uri"": ""nyt://article/544f37bf-7ed2-5d53-b69c-1e9d6472fda5""}"
2016-02-19,"{""abstract"": ""If Burger King and Pfizer can lower their tax rates with inversions, why can\u2019t I?"", ""web_url"": ""https://www.nytimes.com/2016/02/21/business/yourtaxes/just-send-the-tax-bill-to-my-personal-irish-subsidiary.html"", ""snippet"": ""If Burger King and Pfizer can lower their tax rates with inversions, why can\u2019t I?"", ""lead_paragraph"": ""I want to lower my taxes. It\u2019s one of my dreams, along with becoming taller. And younger. And much, much richer."", ""print_section"": ""BU"", ""print_page"": ""9"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/02/21/business/21ESSAY/21ESSAY-articleLarge.jpg"", ""height"": 466, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/02/21/business/21ESSAY/21ESSAY-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 466}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/02/21/business/21ESSAY/21ESSAY-jumbo.jpg"", ""height"": 796, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/02/21/business/21ESSAY/21ESSAY-superJumbo.jpg"", ""height"": 1592, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/02/21/business/21ESSAY/21ESSAY-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/02/21/business/21ESSAY/21ESSAY-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/02/21/business/21ESSAY/21ESSAY-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Just Send the Tax Bill to My Personal Irish Subsidiary"", ""kicker"": ""2016 Taxes | Essay"", ""content_kicker"": null, ""print_headline"": ""Just Send the Tax Bill to My Personal Irish Subsidiary  "", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Income Tax"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tax Credits, Deductions and Exemptions"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tax Shelters"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Taxation"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Internal Revenue Service"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2016-02-19T21:16:56+0000"", ""document_type"": ""article"", ""news_desk"": ""SundayBusiness"", ""section_name"": ""Business Day"", ""subsection_name"": ""Your Taxes"", ""byline"": {""original"": ""By John Schwartz"", ""person"": [{""firstname"": ""John"", ""middlename"": null, ""lastname"": ""Schwartz"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""An Analysis"", ""_id"": ""nyt://article/e587fc2f-52bb-5bfd-88f8-632544549a02"", ""word_count"": 1168, ""uri"": ""nyt://article/e587fc2f-52bb-5bfd-88f8-632544549a02""}"
2016-04-05,"[{""abstract"": ""The new rules take particular aim at companies that have completed multiple acquisitions of American companies in a short period."", ""web_url"": ""https://www.nytimes.com/2016/04/05/business/dealbook/us-acts-to-end-use-of-foreign-acquisitions-to-dodge-taxes.html"", ""snippet"": ""The new rules take particular aim at companies that have completed multiple acquisitions of American companies in a short period."", ""lead_paragraph"": ""The Treasury Department took new steps on Monday to further curtail a popular type of merger in which an American company buys a foreign counterpart, then moves abroad to lower its tax bill."", ""print_section"": ""B"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/05/business/db-inversions2/db-inversions2-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/04/05/business/db-inversions2/db-inversions2-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/05/business/db-inversions2/db-inversions2-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/05/business/db-inversions2/db-inversions2-superJumbo.jpg"", ""height"": 1366, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/05/business/db-inversions2/db-inversions2-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/04/05/business/db-inversions2/db-inversions2-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/05/business/db-inversions2/db-inversions2-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""U.S. Moves to Thwart Use of Foreign Inversions as Tax Dodge"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""U.S. Moves to Thwart Mergers Done as Tax Dodge"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""de la Merced, Michael J"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Picker, Leslie"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tax Shelters"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Internal Revenue Service"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Treasury Department"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""United States Politics and Government"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 10, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Dublin (Ireland)"", ""rank"": 11, ""major"": ""N""}], ""pub_date"": ""2016-04-05T00:50:26+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Leslie Picker and Michael J. de la Merced"", ""person"": [{""firstname"": ""Leslie"", ""middlename"": null, ""lastname"": ""Picker"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Michael"", ""middlename"": ""J."", ""lastname"": ""de la Merced"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/d9002428-124f-57b7-89ef-7c7124c4134f"", ""word_count"": 621, ""uri"": ""nyt://article/d9002428-124f-57b7-89ef-7c7124c4134f""}, {""abstract"": ""The proposed regulations are more aggressive and expansive than the administration\u2019s earlier volleys, but they may face a legal challenge."", ""web_url"": ""https://www.nytimes.com/2016/04/06/business/dealbook/on-inversions-the-treasury-department-drops-the-gloves.html"", ""snippet"": ""The proposed regulations are more aggressive and expansive than the administration\u2019s earlier volleys, but they may face a legal challenge."", ""lead_paragraph"": ""Tax lawyers at the Treasury Department have grappled in recent years with the many corporations finding ways to merge with overseas \u201cinversion\u201d partners and, as a result of the merger or acquisition, move their legal residence offshore to reduce tax payments."", ""print_section"": ""B"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/06/business/db-standard1/db-standard1-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/04/06/business/db-standard1/db-standard1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/06/business/db-standard1/db-standard1-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/06/business/db-standard1/db-standard1-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/06/business/db-standard1/db-standard1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/04/06/business/db-standard1/db-standard1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/06/business/db-standard1/db-standard1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""On Inversions, the Treasury Department Drops the Gloves"", ""kicker"": ""Standard Deduction"", ""content_kicker"": null, ""print_headline"": ""Treasury Department Takes Off the Gloves on Corporate Inversions"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Fleischer, Victor"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tax Shelters"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Treasury Department"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2016-04-05T15:39:39+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Victor Fleischer"", ""person"": [{""firstname"": ""Victor"", ""middlename"": null, ""lastname"": ""Fleischer"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/045948c2-b2f5-5167-a29c-275b7043654f"", ""word_count"": 785, ""uri"": ""nyt://article/045948c2-b2f5-5167-a29c-275b7043654f""}, {""abstract"": ""The broader reach of regulations, intended to keep companies from cutting deals to move income overseas, appears to have caught many by surprise."", ""web_url"": ""https://www.nytimes.com/2016/04/06/business/dealbook/tax-inversion-obama-treasury.html"", ""snippet"": ""The broader reach of regulations, intended to keep companies from cutting deals to move income overseas, appears to have caught many by surprise."", ""lead_paragraph"": ""Pfizer plans to abandon its $152 billion merger with Allergan \u2014 the largest deal yet aimed at helping an American company shed its United States corporate citizenship for a lower tax bill \u2014 just days after the Obama administration introduced new tax rules, a person briefed on the matter said late Tuesday."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer and Allergan Are Said to End Merger as Tax Rules Tighten"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer and Allergan Said to End Merger as Tax Rules Tighten"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Picker, Leslie"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""de la Merced, Michael J"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tax Shelters"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 7, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Obama, Barack"", ""rank"": 8, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Law and Legislation"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 10, ""major"": ""N""}], ""pub_date"": ""2016-04-05T17:06:05+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Michael J. de la Merced and Leslie Picker"", ""person"": [{""firstname"": ""Michael"", ""middlename"": ""J."", ""lastname"": ""de la Merced"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Leslie"", ""middlename"": null, ""lastname"": ""Picker"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/3e04673c-6e25-5bc3-880a-50110b786db6"", ""word_count"": 1458, ""uri"": ""nyt://article/3e04673c-6e25-5bc3-880a-50110b786db6""}]"
2016-04-06,"[{""abstract"": ""The company has been growing steadily, but investors are certain to start agitating again to complete a bold move in order to push growth higher."", ""web_url"": ""https://www.nytimes.com/2016/04/07/business/dealbook/pfizer-allergan-merger.html"", ""snippet"": ""The company has been growing steadily, but investors are certain to start agitating again to complete a bold move in order to push growth higher."", ""lead_paragraph"": ""Pfizer needs a Plan C."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/07/business/db-pfizer2/db-pfizer2-articleLarge.jpg"", ""height"": 407, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/04/07/business/db-pfizer2/db-pfizer2-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 407}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/07/business/db-pfizer2/db-pfizer2-jumbo.jpg"", ""height"": 695, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/07/business/db-pfizer2/db-pfizer2-superJumbo.jpg"", ""height"": 1254, ""width"": 1848, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/07/business/db-pfizer2/db-pfizer2-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/04/07/business/db-pfizer2/db-pfizer2-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/07/business/db-pfizer2/db-pfizer2-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer Faces Limited Options After Its Dead Deal With Allergan"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer Weighs Split as Allergan Deal Collapses"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Bray, Chad"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Allergan Inc (ALL CAPS)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Thomas, Katie"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 9, ""major"": ""N""}], ""pub_date"": ""2016-04-06T11:21:45+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Katie Thomas and Chad Bray"", ""person"": [{""firstname"": ""Katie"", ""middlename"": null, ""lastname"": ""Thomas"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/b82fed4d-90ed-5116-af2e-b52ed86af37b"", ""word_count"": 929, ""uri"": ""nyt://article/b82fed4d-90ed-5116-af2e-b52ed86af37b""}, {""abstract"": ""Now that the merger between the pharmaceutical giants is dead, their bankers will receive about 10 percent of their fees, according to estimates."", ""web_url"": ""https://www.nytimes.com/2016/04/07/business/dealbook/pfizer-and-allergan-advisers-lose-out-on-200-million-in-fees.html"", ""snippet"": ""Now that the merger between the pharmaceutical giants is dead, their bankers will receive about 10 percent of their fees, according to estimates."", ""lead_paragraph"": ""A collective sigh \u2014 and most likely some profanity \u2014 echoed across Wall Street on Wednesday after Pfizer and Allergan terminated the biggest deal in 15 years and federal regulators sought to break up another large deal on antitrust grounds."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/07/business/07db-fees/07db-fees-articleLarge.jpg"", ""height"": 401, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/04/07/business/07db-fees/07db-fees-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 401}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/07/business/07db-fees/07db-fees-jumbo.jpg"", ""height"": 684, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/07/business/07db-fees/07db-fees-superJumbo.jpg"", ""height"": 1368, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/07/business/07db-fees/07db-fees-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/04/07/business/07db-fees/07db-fees-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/07/business/07db-fees/07db-fees-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer and Allergan Advisers Lose Out on $200 Million in Fees"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Banking and Financial Institutions"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Antitrust Laws and Competition Issues"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Regulation and Deregulation of Industry"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Halliburton Company"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Baker Hughes Inc"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2016-04-06T18:36:39+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Leslie Picker"", ""person"": [{""firstname"": ""Leslie"", ""middlename"": null, ""lastname"": ""Picker"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/2ced1210-ae8a-5b58-954c-8a05285c2f53"", ""word_count"": 468, ""uri"": ""nyt://article/2ced1210-ae8a-5b58-954c-8a05285c2f53""}, {""abstract"": ""In the abandoned merger with Allergan, lawmakers, the Treasury Department and Pfizer itself bear some responsibility."", ""web_url"": ""https://www.nytimes.com/2016/04/07/business/dealbook/finger-pointing-abounds-in-failed-pfizer-deal.html"", ""snippet"": ""In the abandoned merger with Allergan, lawmakers, the Treasury Department and Pfizer itself bear some responsibility."", ""lead_paragraph"": ""Pfizer\u2019s abandoned deal leaves all sides tainted."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Finger-Pointing Abounds in Failed Pfizer Deal"", ""kicker"": ""Breakingviews"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Treasury Department"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Read, Ian C"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Taxation"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2016-04-06T19:19:15+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Robert Cyran"", ""person"": [{""firstname"": ""Robert"", ""middlename"": null, ""lastname"": ""Cyran"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/db227162-6882-5514-8d8d-3286bb786631"", ""word_count"": 366, ""uri"": ""nyt://article/db227162-6882-5514-8d8d-3286bb786631""}]"
2016-04-07,"[{""abstract"": ""The Obama administration took on two possible deals this week, and claimed a victory with one."", ""web_url"": ""https://www.nytimes.com/2016/04/07/business/dealbook/megamergers-face-deterrents-in-the-united-states.html"", ""snippet"": ""The Obama administration took on two possible deals this week, and claimed a victory with one."", ""lead_paragraph"": ""The drug giant Pfizer wanted to cut its taxes through a $152 billion takeover of the Dublin-based maker of Botox. And Halliburton sought to buy a major rival in the business of selling equipment to oil drillers for nearly $35 billion."", ""print_section"": ""A"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/07/business/07DB-DEALBREAKER/07DB-DEALBREAKER-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/04/07/business/07DB-DEALBREAKER/07DB-DEALBREAKER-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/07/business/07DB-DEALBREAKER/07DB-DEALBREAKER-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/07/business/07DB-DEALBREAKER/07DB-DEALBREAKER-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/07/business/07DB-DEALBREAKER/07DB-DEALBREAKER-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/04/07/business/07DB-DEALBREAKER/07DB-DEALBREAKER-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/07/business/07DB-DEALBREAKER/07DB-DEALBREAKER-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Megamergers Face Deterrents in the United States"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Giant Mergers Face Deterrents From the U.S."", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Picker, Leslie"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Antitrust Laws and Competition Issues"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""de la Merced, Michael J"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Allergan Inc (ALL CAPS)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Halliburton Company"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Baker Hughes Inc"", ""rank"": 8, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Obama, Barack"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 10, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 11, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 12, ""major"": ""N""}], ""pub_date"": ""2016-04-07T00:26:55+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Michael J. de la Merced and Leslie Picker"", ""person"": [{""firstname"": ""Michael"", ""middlename"": ""J."", ""lastname"": ""de la Merced"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Leslie"", ""middlename"": null, ""lastname"": ""Picker"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/fd943920-3ab4-54be-ae5a-291a3ce5ad04"", ""word_count"": 1261, ""uri"": ""nyt://article/fd943920-3ab4-54be-ae5a-291a3ce5ad04""}, {""abstract"": ""The government\u2019s crackdown on inversions and two lawsuits it filed this week offer some things for advisers, companies and shareholders to think about."", ""web_url"": ""https://www.nytimes.com/2016/04/08/business/dealbook/lessons-in-a-busy-week-of-deal-busting.html"", ""snippet"": ""The government\u2019s crackdown on inversions and two lawsuits it filed this week offer some things for advisers, companies and shareholders to think about."", ""lead_paragraph"": ""Corporate America fought the law and the law won."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/03/29/business/0329dealprofjpg/0329dealprofjpg-articleLarge.jpg"", ""height"": 608, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/03/29/business/0329dealprofjpg/0329dealprofjpg-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 608}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/03/29/business/0329dealprofjpg/0329dealprofjpg-jumbo.jpg"", ""height"": 1024, ""width"": 1011, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/03/29/business/0329dealprofjpg/0329dealprofjpg-superJumbo.jpg"", ""height"": 1225, ""width"": 1209, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/03/29/business/0329dealprofjpg/0329dealprofjpg-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/03/29/business/0329dealprofjpg/0329dealprofjpg-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/03/29/business/0329dealprofjpg/0329dealprofjpg-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Lessons in a Busy Week of Deal Busting"", ""kicker"": ""Deal Professor"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Antitrust Laws and Competition Issues"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Halliburton Company"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Baker Hughes Inc"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2016-04-07T21:29:18+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Steven Davidoff Solomon"", ""person"": [{""firstname"": ""Steven"", ""middlename"": ""Davidoff"", ""lastname"": ""Solomon"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/87d505c0-28f1-56d0-b494-9dbf5e2878e0"", ""word_count"": 1106, ""uri"": ""nyt://article/87d505c0-28f1-56d0-b494-9dbf5e2878e0""}]"
2016-04-14,"{""abstract"": ""Companies are abandoning the biggest mergers, largely out of concern over how the government might react in an election year."", ""web_url"": ""https://www.nytimes.com/2016/04/15/business/dealbook/the-winds-from-washington-chill-wall-streets-deal-making.html"", ""snippet"": ""Companies are abandoning the biggest mergers, largely out of concern over how the government might react in an election year."", ""lead_paragraph"": ""On Wall Street, the phones have been a little quieter. The workload has been a little lighter. The happy hours have been starting earlier."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/15/business/15db-mergers/15db-mergers-articleLarge.jpg"", ""height"": 401, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/04/15/business/15db-mergers/15db-mergers-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 401}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/15/business/15db-mergers/15db-mergers-jumbo.jpg"", ""height"": 684, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/15/business/15db-mergers/15db-mergers-superJumbo.jpg"", ""height"": 1368, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/15/business/15db-mergers/15db-mergers-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/04/15/business/15db-mergers/15db-mergers-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/15/business/15db-mergers/15db-mergers-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""The Winds From Washington Chill Wall Street\u2019s Deal Making"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Winds From Washington Chill the Biggest Deals of Wall Street\u2019s Making"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Picker, Leslie"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Treasury Department"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Justice Department"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2016-04-14T19:58:08+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Leslie Picker"", ""person"": [{""firstname"": ""Leslie"", ""middlename"": null, ""lastname"": ""Picker"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/a33bbc92-a853-5cca-bd09-063689768d9a"", ""word_count"": 872, ""uri"": ""nyt://article/a33bbc92-a853-5cca-bd09-063689768d9a""}"
2016-05-05,"{""abstract"": ""As the drug-giant weighs its options, setting a strategy would be better than keeping all doors open."", ""web_url"": ""https://www.nytimes.com/2016/05/06/business/dealbook/pfizer-needs-clearer-goals.html"", ""snippet"": ""As the drug-giant weighs its options, setting a strategy would be better than keeping all doors open."", ""lead_paragraph"": ""Pfizer\u2019s record with mergers hardly inspires confidence. The drug giant\u2019s last two huge acquisition attempts failed. It could try another merger to cut its tax rate, it could enter one or more potentially heated auctions or it could split up. If it wants to succeed at deal making, the company needs clearer goals."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-jumbo.jpg"", ""height"": 682, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer Needs Clearer Goals"", ""kicker"": ""Breakingviews"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Read, Ian C"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2016-05-05T17:19:21+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Robert Cyran"", ""person"": [{""firstname"": ""Robert"", ""middlename"": null, ""lastname"": ""Cyran"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/8935f33d-0066-5e18-af7a-a4c46773c744"", ""word_count"": 324, ""uri"": ""nyt://article/8935f33d-0066-5e18-af7a-a4c46773c744""}"
2016-05-10,"{""abstract"": ""The recent actions of Zoetis and Allergan suggest a more subdued approach to deals."", ""web_url"": ""https://www.nytimes.com/2016/05/11/business/dealbook/change-is-in-the-air-for-pharmaceutical-mergers.html"", ""snippet"": ""The recent actions of Zoetis and Allergan suggest a more subdued approach to deals."", ""lead_paragraph"": ""The pharmaceuticals merger mind-set may be changing. Allergan, the $87 billion maker of Botox, will devote capital to stock buybacks and paying down debt."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Change Is in the Air for Pharmaceutical Mergers"", ""kicker"": ""Breakingviews"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Zoetis Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Ackman, William A"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2016-05-10T23:01:50+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Robert Cyran"", ""person"": [{""firstname"": ""Robert"", ""middlename"": null, ""lastname"": ""Cyran"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/cc677553-4c1d-5703-b5df-7df222697f8a"", ""word_count"": 386, ""uri"": ""nyt://article/cc677553-4c1d-5703-b5df-7df222697f8a""}"
2016-05-12,"{""abstract"": ""Since the beginning of January, $400 billion worth of corporate mergers have fallen apart in the United States, creating anxiety in those who bet on them."", ""web_url"": ""https://www.nytimes.com/2016/05/12/business/dealbook/hedge-funds-look-for-hard-hats-in-a-year-of-collapsing-mergers.html"", ""snippet"": ""Since the beginning of January, $400 billion worth of corporate mergers have fallen apart in the United States, creating anxiety in those who bet on them."", ""lead_paragraph"": ""While last year set a record for the amount of money spent on corporate mergers \u2014 $4.7 trillion \u2014 this year is so far setting a very different record: the dollar amount of deals that have come undone."", ""print_section"": ""A"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/05/12/business/11DB-ARBS/11DB-ARBS-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/05/12/business/11DB-ARBS/11DB-ARBS-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/05/12/business/11DB-ARBS/11DB-ARBS-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/05/12/business/11DB-ARBS/11DB-ARBS-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/05/12/business/11DB-ARBS/11DB-ARBS-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/05/12/business/11DB-ARBS/11DB-ARBS-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/05/12/business/11DB-ARBS/11DB-ARBS-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Hedge Funds Look for Hard Hats in a Year of Collapsing Mergers"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": "" Hedge Funds Reach for Hard Hats in Year of Collapsing Mergers"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Picker, Leslie"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Hedge Funds"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Dealogic PLC"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Antitrust Laws and Competition Issues"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Office Depot Inc."", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Staples Inc"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Halliburton Company"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Baker Hughes Inc"", ""rank"": 11, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 12, ""major"": ""N""}], ""pub_date"": ""2016-05-12T00:52:29+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Leslie Picker"", ""person"": [{""firstname"": ""Leslie"", ""middlename"": null, ""lastname"": ""Picker"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/c773f09f-15e2-558b-8d18-91023d22370f"", ""word_count"": 1275, ""uri"": ""nyt://article/c773f09f-15e2-558b-8d18-91023d22370f""}"
2016-05-16,"[{""abstract"": ""After terminating deals with AstraZeneca and most recently, Allergan, Pfizer has turned to relatively smaller biotech companies for acquisitions."", ""web_url"": ""https://www.nytimes.com/2016/05/17/business/dealbook/pfizer-to-acquire-anacor-pharmaceuticals-for-5-2-billion.html"", ""snippet"": ""After terminating deals with AstraZeneca and most recently, Allergan, Pfizer has turned to relatively smaller biotech companies for acquisitions."", ""lead_paragraph"": ""Pfizer has signed its first acquisition since terminating its $152 billion merger with Allergan about a month ago."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/05/17/business/db-pfizer1/db-pfizer1-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/05/17/business/db-pfizer1/db-pfizer1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/05/17/business/db-pfizer1/db-pfizer1-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/05/17/business/db-pfizer1/db-pfizer1-superJumbo.jpg"", ""height"": 1366, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/05/17/business/db-pfizer1/db-pfizer1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/05/17/business/db-pfizer1/db-pfizer1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/05/17/business/db-pfizer1/db-pfizer1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer to Acquire Anacor Pharmaceuticals for $5.2 Billion"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer Refocuses, Scooping Up a Smaller Biotech Company"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Anacor Pharmaceuticals Inc"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2016-05-16T12:19:36+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Leslie Picker"", ""person"": [{""firstname"": ""Leslie"", ""middlename"": null, ""lastname"": ""Picker"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/c34ad3ea-9ee9-5ead-b554-2cf14936d3a6"", ""word_count"": 303, ""uri"": ""nyt://article/c34ad3ea-9ee9-5ead-b554-2cf14936d3a6""}, {""abstract"": ""The more important question for shareholders, though, is whether Pfizer\u2019s chief executive, Ian C. Read, will break up Pfizer."", ""web_url"": ""https://www.nytimes.com/2016/05/17/business/dealbook/pfizer-could-get-its-moneys-worth-out-of-anacor-deal.html"", ""snippet"": ""The more important question for shareholders, though, is whether Pfizer\u2019s chief executive, Ian C. Read, will break up Pfizer."", ""lead_paragraph"": ""Pfizer\u2019s $5.2 billion offer for Anacor Pharmaceuticals, announced on Monday, dodges the drug giant\u2019s bigger issue. The company may have made a good deal for Anacor, the maker of eczema and toenail-fungus remedies, even though it\u2019s paying a 55 percent premium. The more important question for shareholders, though, is whether Pfizer\u2019s chief executive, Ian C. Read, will break up Pfizer."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer Could Get Its Money\u2019s Worth Out of Anacor Deal"", ""kicker"": ""Breakingviews"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Read, Ian C"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Anacor Pharmaceuticals Inc"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2016-05-16T18:31:45+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Antony Currie"", ""person"": [{""firstname"": ""Antony"", ""middlename"": null, ""lastname"": ""Currie"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/307a3087-4b66-530a-a45b-c061a6c892e5"", ""word_count"": 363, ""uri"": ""nyt://article/307a3087-4b66-530a-a45b-c061a6c892e5""}]"
2016-05-31,"{""abstract"": ""Months ago, Mr. Icahn criticized Pfizer\u2019s proposed takeover of Allergan; now he is buying part of the company."", ""web_url"": ""https://www.nytimes.com/2016/06/01/business/dealbook/carl-icahn-takes-stake-in-allergan.html"", ""snippet"": ""Months ago, Mr. Icahn criticized Pfizer\u2019s proposed takeover of Allergan; now he is buying part of the company."", ""lead_paragraph"": ""Five months ago, Carl C. Icahn deplored Pfizer\u2019s proposed takeover of the Ireland-based drug maker Allergan as a \u201ctravesty\u201d meant to help one of America\u2019s biggest companies lower its tax bill by moving abroad."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/06/01/business/01db-allergen/01db-allergen-articleLarge.jpg"", ""height"": 399, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/06/01/business/01db-allergen/01db-allergen-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 399}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/06/01/business/01db-allergen/01db-allergen-jumbo.jpg"", ""height"": 682, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/06/01/business/01db-allergen/01db-allergen-superJumbo.jpg"", ""height"": 1363, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/06/01/business/01db-allergen/01db-allergen-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/06/01/business/01db-allergen/01db-allergen-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/06/01/business/01db-allergen/01db-allergen-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Carl Icahn Takes Stake in Allergan"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""After Blasting Pfizer\u2019s Plan, Icahn Buys Allergan Stake"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""de la Merced, Michael J"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Icahn, Carl C"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Forest Laboratories Inc"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2016-05-31T20:17:39+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Michael J. de la Merced"", ""person"": [{""firstname"": ""Michael"", ""middlename"": ""J."", ""lastname"": ""de la Merced"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/dae93f6c-dc91-5a43-aa7a-ca8286ae0350"", ""word_count"": 388, ""uri"": ""nyt://article/dae93f6c-dc91-5a43-aa7a-ca8286ae0350""}"
2016-07-07,"{""abstract"": ""The Treasury Department wants to curb a practice called earnings stripping, but its efforts could hurt normal funding practices."", ""web_url"": ""https://www.nytimes.com/2016/07/08/business/dealbook/plan-to-curb-tax-inversion-deals-could-go-too-far.html"", ""snippet"": ""The Treasury Department wants to curb a practice called earnings stripping, but its efforts could hurt normal funding practices."", ""lead_paragraph"": ""There\u2019s a harmful flip side to the push against tax-inversion deals in the United States. The Treasury Department\u2019s latest plan to curb tax-motivated overseas mergers takes aim at inter-company loans. It is a good idea to curb this so-called earnings stripping. The proposed rule is broad, however, and could hurt normal funding practices."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Plan to Curb Tax-Inversion Deals Could Go Too Far"", ""kicker"": ""Breakingviews"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Treasury Department"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2016-07-07T17:48:08+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Gina Chon"", ""person"": [{""firstname"": ""Gina"", ""middlename"": null, ""lastname"": ""Chon"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/9f4729c2-8ab1-53cf-99a1-a3e32e328fc4"", ""word_count"": 403, ""uri"": ""nyt://article/9f4729c2-8ab1-53cf-99a1-a3e32e328fc4""}"
2016-08-04,"{""abstract"": ""The Chamber is leading a legal fight in Texas to overturn Treasury rules aimed at curbing mergers done for tax reasons."", ""web_url"": ""https://www.nytimes.com/2016/08/05/business/dealbook/tax-avoiding-mergers-find-champion-in-us-chamber-of-commerce.html"", ""snippet"": ""The Chamber is leading a legal fight in Texas to overturn Treasury rules aimed at curbing mergers done for tax reasons."", ""lead_paragraph"": ""The U.S. Chamber of Commerce filed a lawsuit on Thursday to block new rules issued by the Obama administration that prevent American corporations from merging with foreign-based companies and moving their headquarters abroad to save on taxes."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/08/05/business/05DB-INVERSIONS/05DB-INVERSIONS-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/08/05/business/05DB-INVERSIONS/05DB-INVERSIONS-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/08/05/business/05DB-INVERSIONS/05DB-INVERSIONS-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/08/05/business/05DB-INVERSIONS/05DB-INVERSIONS-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/08/05/business/05DB-INVERSIONS/05DB-INVERSIONS-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/08/05/business/05DB-INVERSIONS/05DB-INVERSIONS-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/08/05/business/05DB-INVERSIONS/05DB-INVERSIONS-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}], ""headline"": {""main"": ""Tax-Avoiding Mergers Find Champion in U.S. Chamber of Commerce"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Texas Suit Would Keep Tax Strategy Deals Legal"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""United States Chamber of Commerce"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Picker, Leslie"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Moyer, Liz"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Suits and Litigation (Civil)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Regulation and Deregulation of Industry"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Treasury Department"", ""rank"": 10, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tax Shelters"", ""rank"": 11, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Internal Revenue Service"", ""rank"": 12, ""major"": ""N""}], ""pub_date"": ""2016-08-04T23:35:19+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Liz Moyer and Leslie Picker"", ""person"": [{""firstname"": ""Liz"", ""middlename"": null, ""lastname"": ""Moyer"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Leslie"", ""middlename"": null, ""lastname"": ""Picker"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/b9b359f8-dde7-5f46-adab-e67ad6e68c40"", ""word_count"": 689, ""uri"": ""nyt://article/b9b359f8-dde7-5f46-adab-e67ad6e68c40""}"
2016-08-22,"[{""abstract"": ""If you pay rent to a property management company with the aim of eventually owning the place, are you a renter or a homeowner? Some companies are blurring that line."", ""web_url"": ""https://www.nytimes.com/2016/08/22/business/dealbook/landlords-tenants-pfizer-medivation-private-equity-pace.html"", ""snippet"": ""If you pay rent to a property management company with the aim of eventually owning the place, are you a renter or a homeowner? Some companies are blurring that line."", ""lead_paragraph"": ""If you pay rent to a property management company with the aim of eventually owning the place, are you a renter or a homeowner? Some companies are blurring that line."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Morning Agenda: Tenants Struggle in Win-Win Contracts for Landlords"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Renting and Leasing (Real Estate)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Medivation Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Elder Care"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicare"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Private Equity"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2016-08-22T09:58:53+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Amie Tsang"", ""person"": [{""firstname"": ""Amie"", ""middlename"": null, ""lastname"": ""Tsang"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/03ba9b4b-0d9e-5ae7-9b33-6bc98aaa1d1f"", ""word_count"": 569, ""uri"": ""nyt://article/03ba9b4b-0d9e-5ae7-9b33-6bc98aaa1d1f""}, {""abstract"": ""The frenzy over Medivation, which makes treatments for prostate and breast cancers, shows what pharmaceutical companies are willing to pay for oncology deals."", ""web_url"": ""https://www.nytimes.com/2016/08/23/business/dealbook/medivation-pfizer-14-billion-deal.html"", ""snippet"": ""The frenzy over Medivation, which makes treatments for prostate and breast cancers, shows what pharmaceutical companies are willing to pay for oncology deals."", ""lead_paragraph"": ""Medivation, which makes the big-selling drug Xtandi to treat prostate cancer, has finally found its buyer in a fellow American drug maker, Pfizer."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/08/23/business/23DB-MEDIVATION2/23DB-MEDIVATION-1471896501249-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/08/23/business/23DB-MEDIVATION2/23DB-MEDIVATION-1471896501249-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/08/23/business/23DB-MEDIVATION2/23DB-MEDIVATION-1471896501249-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/08/23/business/23DB-MEDIVATION2/23DB-MEDIVATION-1471896501249-articleLarge.jpg"", ""height"": 366, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/08/23/business/23DB-MEDIVATION2/23DB-MEDIVATION-1471896501249-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 366}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/08/23/business/23DB-MEDIVATION2/23DB-MEDIVATION-1471896501249-jumbo.jpg"", ""height"": 625, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/08/23/business/23DB-MEDIVATION2/23DB-MEDIVATION-1471896501249-superJumbo.jpg"", ""height"": 1251, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer to Buy Cancer Drug Maker in $14 Billion Deal"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer Pays $14 Billion to Expand in Oncology"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Medivation Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Picker, Leslie"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2016-08-22T12:03:13+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Andrew Pollack and Leslie Picker"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Leslie"", ""middlename"": null, ""lastname"": ""Picker"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/dcd0f2b8-e2ac-5b6b-9b61-410ffd022292"", ""word_count"": 1244, ""uri"": ""nyt://article/dcd0f2b8-e2ac-5b6b-9b61-410ffd022292""}, {""abstract"": ""A heated auction and back-of-the-envelope math hint that the buyer is overpaying."", ""web_url"": ""https://www.nytimes.com/2016/08/23/business/dealbook/the-flaws-in-pfizers-plan-to-acquire-medivation.html"", ""snippet"": ""A heated auction and back-of-the-envelope math hint that the buyer is overpaying."", ""lead_paragraph"": ""Pfizer seems to know something others do not about the biotech company Medivation."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""The Flaws in Pfizer\u2019s Plan to Acquire Medivation"", ""kicker"": ""Breakingviews"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Medivation Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Astellas Pharma"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2016-08-22T20:05:15+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Robert Cyran"", ""person"": [{""firstname"": ""Robert"", ""middlename"": null, ""lastname"": ""Cyran"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/dcca7dbf-9072-50c6-a62d-162fd6851b1b"", ""word_count"": 376, ""uri"": ""nyt://article/dcca7dbf-9072-50c6-a62d-162fd6851b1b""}]"
2016-08-23,"{""abstract"": ""Collapsing oil prices are one thing, but oil refineries must now contend with the soaring cost of renewable energy credits."", ""web_url"": ""https://www.nytimes.com/2016/08/23/business/dealbook/oil-refinery-pfizer-medivation-viacom.html"", ""snippet"": ""Collapsing oil prices are one thing, but oil refineries must now contend with the soaring cost of renewable energy credits."", ""lead_paragraph"": ""\u201cIt\u2019s a black pool of speculation that could cause bankruptcies in our sector.\u201d"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/08/23/business/23db-newsletter/23db-newsletter-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/08/23/business/23db-newsletter/23db-newsletter-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/08/23/business/23db-newsletter/23db-newsletter-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/08/23/business/23db-newsletter/23db-newsletter-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/08/23/business/23db-newsletter/23db-newsletter-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/08/23/business/23db-newsletter/23db-newsletter-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/08/23/business/23db-newsletter/23db-newsletter-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Morning Agenda: Prices of Ethanol Credits Surge, Hurting Oil Refiners"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Oil (Petroleum) and Gasoline"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Alternative and Renewable Energy"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Viacom Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Medivation Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Redstone, Sumner M"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2016-08-23T10:00:12+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Amie Tsang"", ""person"": [{""firstname"": ""Amie"", ""middlename"": null, ""lastname"": ""Tsang"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/8680ef31-789a-5474-a5e3-fdac07bc01c7"", ""word_count"": 546, ""uri"": ""nyt://article/8680ef31-789a-5474-a5e3-fdac07bc01c7""}"
2016-09-26,"{""abstract"": ""Wall Street has given Pfizer the benefit of the doubt, but investors do not universally love the decision not to break up."", ""web_url"": ""https://www.nytimes.com/2016/09/27/business/dealbook/pfizer-remains-whole-but-the-option-to-split-could-return.html"", ""snippet"": ""Wall Street has given Pfizer the benefit of the doubt, but investors do not universally love the decision not to break up."", ""lead_paragraph"": ""Pfizer has finally admitted that there is no rabbit in its breakup hat."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-jumbo.jpg"", ""height"": 682, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer Remains Whole, but the Option to Split Could Return"", ""kicker"": ""Breakingviews"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Read, Ian C"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2016-09-26T17:44:24+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Robert Cyran"", ""person"": [{""firstname"": ""Robert"", ""middlename"": null, ""lastname"": ""Cyran"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/598f42d1-4e8a-56c9-9783-fba1887a4624"", ""word_count"": 396, ""uri"": ""nyt://article/598f42d1-4e8a-56c9-9783-fba1887a4624""}"
2016-10-13,"{""abstract"": ""Part of the Treasury\u2019s goal was to clamp down on earnings stripping. But many multinationals with no history of inversions were affected by the rules as well."", ""web_url"": ""https://www.nytimes.com/2016/10/14/business/dealbook/exemptions-made-to-treasurys-tax-saving-restriction-rules.html"", ""snippet"": ""Part of the Treasury\u2019s goal was to clamp down on earnings stripping. But many multinationals with no history of inversions were affected by the rules as well."", ""lead_paragraph"": ""After the Treasury Department announced new rules in April restricting companies from using certain tax-reduction strategies, the protests rang out loudly. Business lobbying groups, executives, tax experts and lawmakers argued that they went too far."", ""print_section"": ""B"", ""print_page"": ""6"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Companies Hurt by Treasury Crackdown Win Exemptions"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Firms Hurt by Crackdown by Treasury Win Pardons"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Picker, Leslie"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tax Credits, Deductions and Exemptions"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Business Roundtable"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""United States Chamber of Commerce"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Treasury Department"", ""rank"": 7, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Lew, Jacob J"", ""rank"": 8, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 9, ""major"": ""N""}], ""pub_date"": ""2016-10-13T23:49:49+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Leslie Picker"", ""person"": [{""firstname"": ""Leslie"", ""middlename"": null, ""lastname"": ""Picker"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/608169b2-de99-58d4-a2f4-b439f24852b5"", ""word_count"": 507, ""uri"": ""nyt://article/608169b2-de99-58d4-a2f4-b439f24852b5""}"
2016-11-06,"{""abstract"": ""Proposition 56 would tax e-cigarettes in the state for the first time, despite evidence suggesting e-cigarettes are less harmful and may help people quit smoking."", ""web_url"": ""https://www.nytimes.com/2016/11/07/business/debate-over-risk-of-e-cigarettes-plays-out-on-california-ballot.html"", ""snippet"": ""Proposition 56 would tax e-cigarettes in the state for the first time, despite evidence suggesting e-cigarettes are less harmful and may help people quit smoking."", ""lead_paragraph"": ""Wearing a white lab coat, the doctor looks straight at the camera and explains why Californians should vote against higher taxes on tobacco products."", ""print_section"": ""B"", ""print_page"": ""5"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/11/05/business/00ECIG2-sub/00ECIG2-sub-thumbStandard-v4.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/11/05/business/00ECIG2-sub/00ECIG2-sub-thumbStandard-v4.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/11/05/business/00ECIG2-sub/00ECIG2-sub-thumbLarge-v4.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/11/05/business/00ECIG2-sub/00ECIG2-sub-articleLarge-v3.jpg"", ""height"": 389, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/11/05/business/00ECIG2-sub/00ECIG2-sub-articleLarge-v3.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 389}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/11/05/business/00ECIG2-sub/00ECIG2-sub-jumbo-v3.jpg"", ""height"": 664, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/11/05/business/00ECIG2-sub/00ECIG2-sub-superJumbo-v3.jpg"", ""height"": 1327, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}], ""headline"": {""main"": ""Who Wins if California Voters Tax E-Cigarettes?"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""California Voters to Have a Say on an E-Cigarette Tax"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Smoking and Tobacco"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""E-Cigarettes"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Referendums"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Taxation"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALTRIA GROUP INC"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Reynolds, R J, Tobacco Co"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Philip Morris Companies Inc"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AMERICAN LUNG ASSN"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 11, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Glantz, Stanton A"", ""rank"": 12, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""California"", ""rank"": 13, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Sales and Excise Taxes"", ""rank"": 14, ""major"": ""N""}], ""pub_date"": ""2016-11-06T21:29:24+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Rachel Abrams"", ""person"": [{""firstname"": ""Rachel"", ""middlename"": null, ""lastname"": ""Abrams"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/12f2a597-c57e-526f-bf4f-eaf6190ad0f5"", ""word_count"": 1106, ""uri"": ""nyt://article/12f2a597-c57e-526f-bf4f-eaf6190ad0f5""}"
2016-12-15,"{""abstract"": ""MSCI\u2019s social index business grows as big pensions and other investors pour money into funds that focus on more than just corporate balance sheets."", ""web_url"": ""https://www.nytimes.com/2016/12/14/business/dealbook/investors-social-environmental-corporate-governance.html"", ""snippet"": ""MSCI\u2019s social index business grows as big pensions and other investors pour money into funds that focus on more than just corporate balance sheets."", ""lead_paragraph"": ""Pfizer stock was riding high in June 2015, up 128 percent in five years, making it the second-most valuable American drug maker. Nine out of 10 Wall Street research analysts recommended that investors hold it in their portfolio, if not buy more."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/12/14/business/14DB-SOCIAL/14DB-SOCIAL-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/12/14/business/14DB-SOCIAL/14DB-SOCIAL-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/12/14/business/14DB-SOCIAL/14DB-SOCIAL-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/12/14/business/14DB-SOCIAL/14DB-SOCIAL-articleLarge.jpg"", ""height"": 474, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/12/14/business/14DB-SOCIAL/14DB-SOCIAL-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 474}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/12/14/business/14DB-SOCIAL/14DB-SOCIAL-jumbo.jpg"", ""height"": 810, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/12/14/business/14DB-SOCIAL/14DB-SOCIAL-superJumbo.jpg"", ""height"": 1619, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}], ""headline"": {""main"": ""Investors Sharpen Focus on Social and Environmental Risks to Stocks"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Investor Demand Leads Analysts to Focus on Stocks\u2019 Social and Environmental Risks"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""MSCI Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Stocks and Bonds"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Research"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Environment"", ""rank"": 6, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Monks, Robert A G"", ""rank"": 8, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Corporate Social Responsibility"", ""rank"": 9, ""major"": ""N""}], ""pub_date"": ""2016-12-15T01:15:43+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Randall Smith"", ""person"": [{""firstname"": ""Randall"", ""middlename"": null, ""lastname"": ""Smith"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/aec807e7-8260-55c1-a5d9-59ef3ff41459"", ""word_count"": 1229, ""uri"": ""nyt://article/aec807e7-8260-55c1-a5d9-59ef3ff41459""}"
2016-12-26,"{""abstract"": ""Big takeovers by the likes of the pharmaceutical giant Pfizer, the Oreos maker Mondelez and the office supply retailer Staples were all consigned to the scrap heap."", ""web_url"": ""https://www.nytimes.com/2016/12/26/business/dealbook/more-than-1000-deals-were-abandoned-in-2016.html"", ""snippet"": ""Big takeovers by the likes of the pharmaceutical giant Pfizer, the Oreos maker Mondelez and the office supply retailer Staples were all consigned to the scrap heap."", ""lead_paragraph"": ""It may not have been a banner year for striking deals, but 2016 was a healthy time for breaking them."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""2016 Was a Year for Undoing Major Deals"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Two Thousand Sixteen"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Honeywell International Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Monsanto Company"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Antitrust Laws and Competition Issues"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""United Technologies Corporation"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Energy Transfer Equity LP"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Williams Companies Inc"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Halliburton Company"", ""rank"": 11, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Baker Hughes Inc"", ""rank"": 12, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Mondelez International Inc"", ""rank"": 13, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Hershey Foods Corp"", ""rank"": 14, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Anbang Insurance Group Co"", ""rank"": 15, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Starwood Hotels & Resorts Worldwide Inc"", ""rank"": 16, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Staples Inc"", ""rank"": 17, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Office Depot Inc."", ""rank"": 18, ""major"": ""N""}], ""pub_date"": ""2016-12-26T20:03:50+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Michael J. de la Merced"", ""person"": [{""firstname"": ""Michael"", ""middlename"": ""J."", ""lastname"": ""de la Merced"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/85b6d2d9-fd58-5c73-8a78-7c70431c1e83"", ""word_count"": 1012, ""uri"": ""nyt://article/85b6d2d9-fd58-5c73-8a78-7c70431c1e83""}"
